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Abstract 
Ciprofloxacin Therapy for Neonates and Young Infants:  
A Clinical Pharmacological Perspective including Pharmacokinetics (PK) and 
Pharmacodynamics (PD).  
Severe infection due to Gram-negative bacteraemia increases mortality and long term 
consequences of morbidity. In Liverpool Women’s NHS FT neonatal unit mortality 
increased from 20% for the more premature babies to 44%. Ciprofloxacin is a 
synthetic fluoroquinolone prescribed for suspected or proven Gram-negative infection 
in many neonatal units throughout Europe (25%). At present this drug is not 
authorised for this population and is prescribed off label. The optimal drug regimen is 
unknown resulting in a wide range of regimens (5 to 60 mg/kg/day) prescribed 
internationally. The TINN Consortium ‘Treat Infection in Neonates’ were funded by a 
European Union FP7 grant to develop a Paediatric Investigation Plan in line with the 
EU Paediatric Regulations and European Medicines Agency requirements. This 
thesis describes a prospective population PK clinical trial as part of the work of TINN, 
a retrospective clinical outcome study in neonates and infants with late onset Gram-
negative sepsis and a framework to facilitate PK-PD research.  
The pharmacokinetic (PK) clinical trial of ciprofloxacin recruited 64 babies including a 
minimum of seven recruits representing every four weeks of development. The 
median post menstrual age in weeks was 35.7 (6.5) (range 24.9 - 47.9). Blood 
samples (n = 265) were collected at pre-defined informative time points in addition to 
165 samples scavenged from clinically indicated blood tests, in total 430. A two 
compartment model with first-order elimination fitted the data. PK parameters 
included maximum concentration, clearance, area under the curve (0-tau), apparent 
volume of distribution and half-life and selected covariates with their inter-individual 
variability (CV%). Based on adult PD targets the minimum area under the curve 
/minimum inhibitory concentration (AUC/MIC) ratio 125 was achieved by 85% of this 
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population. Higher AUC24 hour/MIC targets >250 may be required for serious infections 
yet few (42%) of this population achieved this. The optimal AUC/MIC ratio for 
neonates is unknown. Clearance increased with post-natal age yet the combined 
effect of PMA at birth and corrected gestational age had a greater effect on clearance. 
Clearance reduced by 29% with co-administration of inotropes associated with 
underlying renal compromise. Monte Carlo simulation demonstrated that the 
AUC24/MIC 125 was achieved by 90% of neonates <34 weeks PMA administered 7.5 
mg/kg/day and 84% of those ≥34 PMA administered 12.5 mg/kg/day. Ciprofloxacin is 
lipophilic and has good tissue penetration. CSF concentrations achieved a ratio of 
0.33 of the serum plasma concentrations.  
Pharmacodynamic data included a retrospective cohort study over a six year period 
of neonates with confirmed Gram-negative organisms in blood cultures. Organisms 
retrieved from the clinical laboratory (n=88) were re-cultured and the MIC ciprofloxacin 
determined using an E Test. A sub-group were administered ciprofloxacin (n=33); 
each organism’s MIC was compared with the same neonate’s clinical outcome. 
Relatively higher MICs within the susceptible range were associated with a greater 
risk of treatment failure. These data were not statistically significant due to the low 
incidence of confirmed Gram-negative bacteraemia (1.3%). The clinical implications 
are that more intensive dosage regimens may be required or a lower clinical 
breakpoint subject to further PD and safety data. Too few organisms were available 
to determine if the MIC increased annually but the incidence of ciprofloxacin 
resistance in surveillance surface swabs was no higher than for gentamicin.    
To prepare for a future pharmacogenomic study, DNA scavenged from clinical blood 
samples were compared to a buccal scrape to evaluate whether this less invasive 
method is reliable. A substantially larger quantity and higher quality of DNA was 
obtained from scavenged blood. A sub-group were transfused with leukocyte depleted 
products for their clinical care prior to DNA sampling. The genotyping of allelic 
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polymorphisms were not affected by the donor’s blood sufficiently to affect the genetic 
fingerprint. This indicates that prior blood transfusions should not be a contra-
indication to scavenging blood for pharmacogenetic purposes. 
The challenges of PK/PD trials in this vulnerable population were explored. The 
majority were recruited in intensive care and had comorbidity and extreme 
prematurity. Due to the complexity of critical illness there are limitations to interpreting 
clinical outcome or safety data from a PK clinical trial design. There were no 
suspected unexpected serious adverse reactions. Arthralgia was not reported but is 
difficult to assess in non-weight bearing non-vocal neonates and young infants.  A 
proportionate regulatory model of neonatal PK clinical trials was developed with the 
Medicines and Health Care Products Regulatory Agency. A framework for 
pharmacovigilance reporting during critical illness which avoided nuisance reporting 
was developed.  The impact was assessed by an observational case study and review 
of discharge letters to illustrate the challenge of attributing causality.  
Individualised therapy may be required in critical illness. The correct dose of an 
antimicrobial may change daily during the sepsis episode. The inter- and intra-
individual variability in parameters is associated with dynamic changes during 
neonatal development and the effects of critical illness. Further outcome and safety 
data are required to determine the optimal AUC24/MIC ratio. Paediatric clinical 
breakpoints specific to each sub-age group of children are required. Individualised 
therapy may be required to optimise clinical outcome and minimise resistance.              
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Introduction  
Chapter 1 Introduction  
1.1 Neonatal Infection  
Every year, an estimated four million babies die in the first-four weeks of life [1]. More 
than 80% of all newborn deaths result from three preventable and treatable 
conditions: infection, complications due to prematurity and intrapartum-related deaths 
(including birth asphyxia) [2]. In the UK the neonatal mortality rate has reduced over 
the last 30 years from 7.7 per 1000 live births (1980) to 2.9 per 1000 live births in 
2010 [3]. The average global neonatal mortality rate is 20 deaths per 1000 live births 
but rises in developing countries to 30 per 1000 live births [2]. Inequalities in health 
care are evident but also suggest that improvements in neonatal care can improve 
mortality.   
The United Nation’s Millennium Development Goals aimed to reduce child mortality 
by two-thirds, between 1990 and 2015 [4]. Mortality for the sub-group of neonates is 
reducing at a slower rate than the broad group of under-five-year-olds. Neonates  
accounts for 44% of mortality in children under five years old [4] Figure 1-1. Infectious 
diseases account for more than four million deaths a year in children (58%) [4]. An 
action plan to end preventable deaths ‘Every Newborn’ by WHO and UNICEF in 2014 
set a target to reduce the neonatal mortality rate to ten or fewer newborn deaths per 
1000 live births by 2035 [2]. Infection is an ever-present threat in this highly vulnerable 
population and these recent reports suggest an increasing need for effective 
treatment. As neonatal mortality improves, the surviving babies are at increased risk 
of morbidity increasing the burden of infection [5]. 
There remains considerable uncertainty about the optimal way to use antibiotics in 
neonates, particularly the optimal regimens to improve clinical outcomes and prevent 
the emergence of resistant organisms. Optimising the use of existing antibiotics is 
important particularly due to the decline in new antibiotics [6]. 
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Figure 1-1 Causes of deaths in children under 5 years age  2012                    
 
WHO Global Health Observatory Data 2014   (accessed 2015) 
http://apps.who.int/gho/data/node.wrapper.MORT-  
 
Fourteen classes of antibiotic were developed for human use between 1935 and 1968 
but subsequently only five have been introduced to clinical practice  
Figure 1-2 http://antibiotic-action.com/aa-resources/ (accessed August 2013). 
Equally, there is a growing gap between the availability of new antibiotics and the 
increasing incidence of infections caused by multi-resistant bacteria [6]. 
In Europe, the human and economic burden on healthcare of antibiotic-resistant 
Gram-negative organisms is predicted to outweigh that of MRSA especially for E.coli  
[6]. To suppress the emergence of resistant organisms it is important to identify 
optimal regimens with pharmacodynamic modelling that result in effective clinical and 
microbiological outcomes [6, 7].  The impact of infection can be reduced by 
antimicrobial stewardship [6]. However the treatment of sepsis does not always 
protect infants from subsequent long-term neurodevelopmental impairment. The best 
strategy is to prevent rather than to treat late onset sepsis (LOS) [8]. 
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Figure 1-2 Discovery of new classes of antibiotics  
 
Adapted from ECDC Report The bacterial challenge : time to react [6] 
 
Three main goals of antimicrobial therapy are relevant to neonatal infection [7]. Firstly, 
the antimicrobial agent(s) must be initiated as soon as possible after the onset of 
sepsis [9]. The protocol in the neonatal unit at Liverpool Women’s NHS Foundation 
Trust (FT) requires administration within 30 minutes of the decision to treat suspected 
sepsis. Secondly, the antimicrobial spectrum of the agent should be broad enough to 
cover the potential causative microorganisms [10]. Therefore, empiric antimicrobial 
therapy is often administered before the causative pathogen is known [11, 12]. Finally, 
an appropriate antimicrobial dosing regimens is required to maximize microbial killing, 
minimize the development of multidrug antimicrobial resistance, and avoid 
concentration-related adverse drug reactions [13, 14]. The success of each step is 
dependent on pharmacokinetic and pharmacodynamic (PK-PD) relationships specific 
to the neonatal population.  
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1.1.1 The Clinical Impact 
Suspected sepsis is one of the most common diagnoses made in the neonatal 
intensive care unit. It is difficult to diagnose as the signs of sepsis are nonspecific, 
and inflammatory syndromes of non-infectious origin often mimic those of neonatal 
sepsis [15, 16]. In most cases a diagnosis is based on clinical suspicion which has a  
reasonably reliable a positive predictive value of approximately 70% [17]. Infection 
that occurs in the days after birth is defined as early onset. This is thought to be due 
to organisms acquired before, or during birth including those that ascend from the 
birth canal. Late onset is more likely to be nosocomially acquired [16, 18]. The cut-off 
for early vs. late neonatal infection has not been defined and definitions vary between 
48 hours and 6 days [11]. One-third of the late onset neonatal infections in developed 
countries are associated with Gram-negative organisms [18, 19].  
Since the clinical presentation of sepsis is non-specific, many neonates are 
empirically treated. Few neonates treated for sepsis have culture proven sepsis, 
although the incidence increases from 2% for early onset infection to 25% for late 
onset infection [18].  Stoll et al. reported half of their cohort of neonates with suspected 
sepsis received antibiotics but only 21% had a positive blood culture [18]. Blood 
cultures may be falsely negative as the sensitivity is dependent on the bacterial 
burden in the blood and obtaining a sufficient blood volume [20, 21].  
To make the diagnosis of neonatal sepsis even more challenging, bacteraemia may 
occur in the absence of clinical signs. The subtlety of these signs also makes it difficult 
to determine when to discontinue antimicrobial therapy [16].  Thus diagnostic 
uncertainty results in the over-use of antibiotics and “spiralling empiricism” [22]. 
Prolonged empiric antibiotic therapy in premature babies has been associated with 
the combination of late onset sepsis, necrotising enterocolitis (NEC), and death (OR, 
2.66, 95% CI 1.12-6.3) [23]. Rapid identification of causative organisms may reduce 
the use of broad spectrum antibiotics but is not readily available at present.    
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Rates of neonatal infection are inversely related to birth weight and gestational age 
[18]. A higher proportion of very premature neonates (36.3%) GA <28 weeks had at 
least one episode of late onset sepsis when compared with 29.6% of moderately 
preterm (GA 29–32 weeks) and 16.5% term infants [24]. Gram-negative neonatal 
sepsis is a significant problem especially among VLBW infants [25, 26]. 
The Expert Meeting on Neonatal and Paediatric Sepsis European Medicines Agency 
2010 [27]  defined  neonatal sepsis as the presence of at least two clinical symptoms 
and at least two laboratory signs in the presence of or as a result of suspected or 
proven infection (positive culture, microscopy or polymerase chain reaction)  Table 
1-1. Other definitions include ‘a clinical syndrome characterised by systemic signs of 
infection accompanied by bacteraemia in the first month of life’ [28].  Sepsis in children 
was defined by the International Consensus Conference on Paediatric Sepsis and 
Organ Dysfunction (2002) [29] as “a systemic inflammatory response syndrome 
(SIRS) in the presence of, or as a result of, suspected or proven infection” requiring a 
minimum of two symptoms one of which must be either: 
 an abnormal temperature and/or leukocyte count  
 or both tachycardia and altered respiratory rate  
They excluded neonates from their definition of sepsis in children because of the 
complexities of diagnosis [29].   
As the survival of critically ill neonates increases, the period of hospitalisation is 
prolonged with an inevitable increase in infection and associated morbidity. A study 
monitoring the outcome of babies with septic shock found that only 28% were alive 
and considered normal at 18 months follow up [30].  Post-natal infection is an 
important risk factor for subsequent morbidity including neurodevelopmental 
abnormalities [31]. Recurrent postnatal infection may be detrimental to early brain 
development. The brains of premature and VLBW infants in particular may be affected 
directly (e.g. meningitis) or as a result of inflammatory injury, [32-34]. Inflammation is 
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associated with progressive white matter injury in premature infants that has been 
attributed to the susceptibility of oligodendrocyte precursors to inflammation, hypoxia, 
and ischemia [19]. Neurodevelopmental sequelae (e.g. cognitive and psychomotor 
impairment, cerebral palsy, and visual impairment) are independent of the inciting 
pathogen [34].  
Mortality caused by Gram-negative infection is significantly higher than that of Gram-
positive infections at all ages of sepsis onset [25]. Mortality from Gram-negative late 
onset sepsis is approximately 36% which is higher than estimated for other infections 
(18%) and the overall mortality of VLBW babies without sepsis (7%) [18].  Fulminant 
late-onset sepsis (i.e. lethal within 48 hours) is more likely to be caused by Gram-
negative organisms [35, 36]. There are important differences in mortality as a function 
of the invading pathogen. Gram-negative bacteria produce endotoxin that incites a 
systemic inflammatory response [37]. Higher mortality rates are associated with 
Pseudomonas (74.4%) compared with other members of Enterobacteriaceae (e.g. E. 
coli (34%), Serratia marcesens (35.9%), Klebsiella spp. (22.6%) and Enterobacter 
spp. (26.8%) [34]. 
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Table 1-1 Clinical results and signs of sepsis in neonates (<44 weeks PMA)  
 
Modified Body Temperature 
Body temperature >38.5 0C or <36 OC  
AND/OR  
Temperature instability 
 Haematological and Biochemical 
White Blood Cells      <4000 x109 cells /L  
                           or     >20 000 x 109 cells/L  
Immature to total neutrophil ratio (IT) >0.2 
Cardiovascular Instability 
Bradycardia (mean HR <10th percentile for age  
in the absence of external vagal stimulus,  
beta-blocker or congenital heart disease  
OR  
otherwise unexplained persistent depression 
over a 0.5 h time period)  
OR 
Tachycardia (mean HR >2 SD above normal 
for age in the absence of external stimulus 
chronic drugs and painful stimuli or otherwise 
unexplained persistent elevation over a 0.5 h to  
4 h time period  
AND/OR 
Rhythm instability 
Reduced urine output (<1mL/kg/h)  
  
Platelet count            >100000 x109 cells/L 
C Reactive Protein    >15mg/L OR 
Procalcitonin              ≥ 21 ng/mL 
 
Glucose intolerance confirmed  
at least 2 times 
Hyperglycaemia         >10 mMol/L 
Hypoglycaemia*         <2.5 mMol/L 
 
Metabolic acidosis 
Base Excess BE        < -10 mEq/L    
Or  
Serum Lactate            > 2 mMol/L 
Hypotension (mean arterial pressure <5th  
percentile for age) 
Mottled skin 
Impaired peripheral perfusion 
 Gastrointestinal  
Feeding intolerance  
Poor sucking 
Abdominal distension 
Respiratory Instability 
Apnoea episodes OR 
Tachypnoea episodes  
Mean respiratory rate > 2 SD above normal for 
age 
Or increased oxygen requirements  
Or requirements for ventilation support  
 Non-specific 
Irritability  
Lethargy 
Hypotonia  
Skin and subcutaneous lesions 
Petechial rash / sclerema 
   
*when receiving age specific normal range of glucose  
Adapted from EMA report on the Expert meeting of Neonatal and Paediatric Sepsis 
2010 [27] 
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1.1.2 Microbiology   
 
The range of organisms causing late onset sepsis includes Gram-positive or negative 
bacteria and fungi  [38]. Gram-negative bacteria account for one third of late onset 
sepsis primarily Enterobacteriaceae [18, 34]. Gram-negative organisms belong to two 
broad groups. Enterobacteriaceae known as lactose fermenting coliforms includes 
e.g. E.coli, Enterobacter spp., Hafnia, Klebsiella spp., Serratia and Citrobacter. These 
are all late fermenters. The other group includes non-lactose fermenting e.g. 
Pseudomonas aeruginosa, Burkholderia cepacia, Acinetobacter spp., 
Stenotrophomonas and Haemophilus influenzae [25]. Currently, the most common 
Gram-negative organisms isolated in cases of neonatal sepsis are E.coli, Klebsiella  
spp. and Pseudomonas spp. [11, 18, 25, 26, 39, 40] Figure 1-3.   
  
Figure 1-3 Major causative pathogens of neonatal late-onset sepsis globally  
 
Adapted from Dong et al (BMJ Publishing Group) [11].  
 
A recent survey in the UK, found bacteria isolated from neonatal blood cultures 
between  2006 and 2008 were mainly Gram-positive (80%) of which the main 
organism was Coagulase-negative staphylococci (CoNS) (45.1%); the main Gram-
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negative organisms (19.3%) including  Enterobacteriaceae (9%), E.coli (6.8%) and 
Pseudomonas spp. (1.9%) [12]. CoNS have emerged as the predominant pathogens 
of late onset sepsis, accounting for 53.2%–77.9% of late onset sepsis in industrialised 
countries and 35.5%–47.4% in some developing regions [11]. The ARPEC survey in 
European found the most common Gram-negative isolates from infants under one 
year were Escherichia coli 27.9%, Klebsiella pneumoniae 13.2 and Pseudomonas 
aeruginosa 6.1[41]. 
Neonates are colonised by three main types of bacteria: 1) beneficial (lactobacilli and 
bifidobacteria), 2) potentially pathogenic (Enterobacter spp., Enterococci and 
bacteroides) 3) pathogenic (Clostridia, Staphylococci, Klebsiella spp. and 
Pseudomonas spp.) [42]. Colonisation of the gut in intensive care is altered by 
delayed feeding and antibiotic administration [42, 43]. Meconium is not sterile and the 
neonatal gut may be colonised with potentially pathogenic Gram-negative bacteria 
including E.coli and Pseudomonas spp. within two days of birth [43-45]. 
Antibiotics may supress the growth of susceptible organisms leaving other bacteria to 
dominate then translocate across the gut leading to sepsis with significant morbidity 
and mortality [46, 47]. The use of broad spectrum antibiotics causes a less diverse 
gut flora that is associated with late onset sepsis [43].  This is a particular concern for 
inpatients. Pathogens acquired within a hospital are more likely to have previous 
antibiotic exposure therefore at greater risk of harbouring established resistance 
mechanisms [48]. 
  Mechanism of resistance  
Fluoroquinolones are novel among antimicrobial agents as they directly inhibit DNA 
synthesis. Ciprofloxacin’s pharmacological action is that it binds to the 
topoisomerases; these are essential enzymes for replication of bacteria DNA, they 
target two of the four topoisomerases enzymes DNA gyrase II and IV [49, 50]. Both 
are large complex enzymes composed of two pairs of subunits gyrA and gyrB that 
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work together in the replication, transcription, recombination and repair of DNA [51]. 
The topoisomerase structure has two subunits coded by parC and parE genes [52]. 
Until recently the mutations that prevented it from binding were the most important 
mechanisms of ciprofloxacin resistance [50, 53]. In Gram-negative bacteria gyrase II 
is more susceptible to inhibition by quinolones whereas Gram-positive bacteria 
topoisomerase IV is the target and their gyrase is intrinsically less susceptible. 
Consequently, resistant mutations occur first in gyrA in Gram-negative bacteria and 
in parC in Gram-positive bacteria [51]. A single mutation in gyrA will produce only 
modest increments of resistance so bacteria would still be clinically susceptible, a 
second mutation or mutation in parC would be required for clinical resistance to be 
reached [51].  
Isolates with decreased ciprofloxacin susceptibility, emerged in the 1990s and usually 
had single point mutations in the quinolone resistance determining region (QRDR) of 
the gyrA gene [54, 55]. One mutation may exhibit elevated MICs which are difficult to 
distinguish from the wild-type MIC distributions [56].  Multiple mutations generally lead 
to resistance to all active substances within the class  [52]. However, in some species 
that are inherently less susceptible to fluoroquinolones it has been suggested that 
only one mutation is needed for clinically relevant resistance to occur [57]. In vitro 
investigations have shown that resistance to ciprofloxacin is commonly acquired by a 
stepwise process by target site mutations [53, 56]. Cross-resistance between 
fluoroquinolones may occur when the mechanism of resistance is due to mutations in 
bacterial gyrases. 
 
Impermeability and/or drug efflux pump mechanisms that are reverse transport 
systems pumping the drug out of the cell may have a variable effect on susceptibility 
to fluoroquinolones. This depends on the physicochemical properties of the various 
drugs within the class and the affinity of transport systems for each drug. [53]. Low 
concentration  resistance mechanisms include increased activity of efflux pumps  [58] 
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where antibiotics enter the bacterial cell via a porin channel but are then ejected [50, 
57, 59]. Efflux pumps have been found in Stenotrophomonas maltophilia (intrinsically 
resistant), P.aeruginosa and Acinetobacter baumannii [60, 61]. Mechanisms of 
resistance to quinolones include plasmids that protect cells from the lethal effects of 
quinolones [49]. Fluoroquinolones are small allowing them to cross the outer 
membrane through porin proteins therefore resistance is associated with a reduction 
in porins [62]. 
The mechanisms of ciprofloxacin resistance identified a quinolone resistance protein, 
this plasmid-mediated quinolone resistance gene  named ‘Qnr’ is known as plasmid-
mediated quinolone resistance (PMQR) that is capable of modifying ciprofloxacin to 
reduce its activity [51] [50]. The genetic transfer via a plasmid-encoding quinolone 
(Qnr A) resistance pentapeptide protein is capable of protecting the DNA gyrase from 
quinolones and inactivating enzymes [56, 63]. Horizontal gene transfer is a concern 
as DNA mutations can be transferred to either individual bacteria or different genus 
or species, whereas vertical transfer limits resistance to the same species. Martinez 
et al found a Klebsiella pneumoniae isolate transferred low level quinolone resistance 
to E coli and other Gram-negative bacteria [64]. Since then this has been identified 
worldwide in the US,  Europe and Asia [50]. Another concern is that the basal level of 
resistance in wild type strains was low, but plasmid mediated resistance allows the 
bacterial population to reach a concentration at which secondary mutations to high 
resistance can occur. Ultimately, this may hasten the widespread loss of susceptibility 
of fluoroquinolones to many Gram-negative bacteria [64]. Robicsek et al reported that 
the mechanisms and spread of these plasmids into apparently susceptible organisms 
have led to four to eight fold higher MICs for ciprofloxacin [50]. Robicsek et al. advise 
a more cautious approach to quinolone use is required and raises concerns about the 
appropriateness of current quinolone breakpoints [50, 65].  
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Subtle changes in MIC may predispose to sub–clinical resistance and possibly lead 
to a reduced effectiveness of fluoroquinolones over time [52, 66-68]. Higher drug 
concentrations may provide some protection against resistance; lower rates of 
fluoroquinolone resistance in vitro and in vivo have been found with higher AUC24/MIC 
ranges [69]. A change in MIC over the period of treatment with an antibiotic may 
indicate that ciprofloxacin resistance has occurred. Subtle changes in the MIC are 
more easily detected by testing against the lower class quinolone nalidixic acid [63]. 
Time to kill studies have shown that when the dose was double the MIC or higher than 
the mutant prevention concentration (MPC), resistant mutants did not arise [63]. 
 Prevalence of Gram-negative resistance   
Antimicrobial resistance surveillance in Europe 2014 restated that the situation for 
gram-negative bacteria is especially worrying but varies throughout Europe influenced 
by prescribing practices. Within the UK fluoroquinolone resistance is lower than the 
European mean 22.4% (95% CI 22 to 24) and has decreased between 2011 and 2014 
from 17.5% (17-19) 16.8 % (16-18) [70] Table 1-2. In neonatal late onset sepsis Gram-
negative bacteraemia reported to the UK Health Protection Agency (HPA) between 
2006 and 2008 found higher resistance to cefotaxime monotherapy (23%) compared 
to combination therapy with flucloxacillin and gentamicin (4%), amoxicillin and 
cefotaxime (15%) or amoxicillin and gentamicin (7%)[71]. As few as 26 Gram negative 
bacteraemia isolates are reported per month for neonates as reporting to the HPA is 
not compulsory neonatal data for clinical trials or clinical breakpoints is limited [71]. A 
prevalence report by  Antibiotic Resistance and Prescribing in European Children 
(ARPEC) found Gram-negative resistance in infants less than one year of age was 
less than older children and adults reported by European Antimicrobial Resistance 
Surveillance Network (EARS-Net) between 2011 and 2012 [41]. In particular, 
aminoglycoside resistance is increasingly alarming as this is considerably higher in 
children older than one year age compared to younger neonates, infants or adults 
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Table 1-3. There is a lower rate of resistance in neonatal intensive care but the 
authors suggest the burden of resistance could still be highest in this group due to the 
higher incidence of blood stream infections [41]. Third generation cephalosporins in 
Klebsiella pneumoniae and Escherichia coli increased significantly between 2011 and 
2014 in Europe. This was increasingly seen in combination with fluoroquinolone and 
aminoglycoside resistance from 16.7 % in 2011 to 19.6 % in 2014 [70].  
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Table 1-2 Percentage of Resistance comparing the UK with Europe  
(adapted from ECDC report 2014 [70])  
 
Organism  Antimicrobial                 Resistance % 
UK Europe 2014 
*Population weighted mean 
except for median* 
(95% CI) 
2011 2014 
Acinetobacter Aminopenicillin - - - - 
 Aminogylcoside - 10 38 * (22-56) 
 Carbapenem 1 2 26 * (13-44) 
 3rd Generation Cephalosporins -  - - - 
 Fluoroquinolone  11 41 * (25-59) 
 
Escherichia  coli 
 
Aminopenicillin 
 
63 
 
63 
 
57  
 
(56-58) 
 Aminogylcoside 8 9 10 (9-11) 
 Carbapenem <1 <1 <1 <1 
 3rd Generation Cephalosporins 10 10 12 (11-13) 
 Fluoroquinolone 18 17 22 (21-24) 
 
Klebsiella 
 
Aminopenicillin 
 
- 
 
- 
 
- 
 
- 
 Aminogylcoside 4 6 23 (21-25) 
 Carbapenem <1 1 7.3 (6-9) 
 3rd Generation Cephalosporins 5 9 28 (25-30) 
 Fluoroquinolone  8 27 (26-30) 
 
Pseudomonas 
aeruginosa 
 
Piperacillin/ Tazobactam 
 
5 
 
5 
 
17 
 
(14-21) 
Aminogylcoside 3 2 14.8 (12-18) 
 Carbapenem 6 6 18.3 (15-21) 
 3rd Generation Cephalosporins 
(Ceftazidime) 
5 5 13 (10-16) 
 Fluoroquinolone  5 19 (16-22) 
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Table 1-3 Antimicrobial resistance of Gram-negative pathogens comparing adults and 
infants between 2011 and 2012  
(adapted from ARPEC and EARS – NET data [41]  
 
Gram-negative 
Pathogen  
Antibiotic Resistance % 
Adult  Children >1 year age 
(95% CI) 
Infants  <1 year  
age (95% CI) 
Escherichia coli Aminoglycosides 
Carbapenems 
3rd Generation cephalosporins 
Fluoroquinolones 
 
11.3 
0.1 
11.9 
 
23 
 
16.7 (9.9-23.4) 
1.7   (0.2-5.9) 
17.0 (10.2-24.0) 
 
22.5 (14.9-30.1) 
13.5 (9.0 -18) 
0 (0-1.7) 
10.7 (6.6 -14.8) 
 
8.5 ( 4.8 -12.2) 
Klebsiella 
pneumoniae 
Aminoglycosides 
Carbapenems 
3rd Generation cephalosporins 
Fluoroquinolones 
 
27.6 
13.5 
31.6 
30.7 
41.2 (29.0 – 54.4) 
14.4 (6.7-25.4) 
37.1 (25.2-50.3) 
35.5 (23.7-48.7) 
26.2 (18.1 - 35.6) 
1.9   (0.2 - 6.7) 
29.9 (21.4 - 39.5) 
7.5   (3.3 - 14.3) 
Pseudomonas 
aeruginosa 
Aminoglycosides 
Carbapenems 
Ceftazidime 
Fluoroquinolones 
 
19.3 
20.5 
14.8 
23.1 
35.4 (25.0-47.0) 
36.7 (26.1-48.3) 
34.3 (23.8-45.7) 
27.8 (18.3-39.1) 
14.3 (5.9 -27.2) 
26.1 (14.3 - 41.1) 
12.2 (4.6 - 24.8 
16.2 (7.3 - 29.7) 
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1.1.3 Neonatal Pharmacology  
Variability in drug response among patients is multifactorial, including environmental, 
genetic and disease determinants that affect the disposition of a given drug. The 
interplay of these factors determines the profile of the plasma concentration over time 
and pharmacological effect at the site of infection [72].  
To guide drug therapy the regulatory process ensures that a medicinal product 
undergoes extensive studies to ensure that it is safe, manufactured to high quality 
standards to be authorised specifically for use in the target population [73]. 
Unmonitored off label use of medicines in children extrapolated from adult data has 
resulted in significant morbidity and mortality; due to toxicity and under-dosage which 
results in ineffective treatment. The lack of data required for a Marketing Authorisation 
with the European Medicines Agency (EMA) prevents children from benefiting from 
therapeutic advances [73, 74]. To obtain a Marketing Authorisation for a drug for 
children the EMA require a Paediatric Investigation Plan (PIP) that outlines drug 
development specific to the population that may include pharmacokinetic, 
pharmacodynamic and pharmacogenomic studies[73]:  
 Pharmacokinetics (PK) - how the body handles the drug. The changes in 
drug concentration in the different body fluids and tissues in the dynamic 
system of liberation, absorption, distribution, body storage binding metabolism 
and excretion [75].  
 Pharmacodynamics (PD) - the action of the drug in the body, i.e. what the 
drug does to the body [76].   
 Pharmacogenetics – the individual variation in DNA sequence related to drug 
absorption and distribution (pharmacokinetics) or drug action 
(pharmacodynamics) [75]  
The application of these general principles of antibiotic development to neonates 
faces many challenges. At present there are no authorised medicinal products for the 
treatment of sepsis in neonates or children [27]. Some antibiotics are authorised for 
infections in specific sites. As recently as 1999 most neonates (90%) surveyed had 
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received at least one off label drug during their admission [77]. In Europe the 
paediatric drug development climate has changed dramatically. The EU Paediatric 
Regulations (2006) recognise that drug development specific to the population is 
required and aim to ensure medicines are authorised specifically for children [73].  
It is widely accepted that the developmental changes in the spectrum of premature 
and term neonates influence the response to therapy [78-80]. The absorption, 
distribution, metabolism and elimination (ADME) of drugs by neonates is different not 
only to adults but to sub-groups of children.  Previous attempts to scale adult dosages 
to children have failed as age associated changes in body composition and organ 
function are not linear per kilogram [78, 81]. As a result of this the EMA require 
neonatal trials to be stratified representing the changes for each four week period of 
development [79, 80].  
1.1.4 Pathophysiology of Critical Illness 
In critical illness many factors influence the PK/PD of drugs including changes in 
physiology due to the clinical condition and the disease influence on organ function 
Figure 1-4. The key influence of ciprofloxacin in neonates is yet to be determined but 
the following factors are considered and included in the case report form as potential 
covariates for the PK clinical trial. Physiology may be altered within hours by systemic 
inflammatory response, multi system organ failure, drug interactions that occur during 
poly-therapy, instability of renal function or interventions such as extracorporeal 
circulation or dialysis [82]. This may result in decreased attainment of PD targets or 
development of toxicity. In addition, the effect of other medicines that are administered 
simultaneously may affect the PK parameters of the investigational medicine. 
Clinical interventions that provide organ support including ventilation ECMO 
/cardiopulmonary bypass dialysis/haemofiltration may influence drug disposition [83]. 
Positive pressure ventilation has been shown to influence the clearance of 
vancomycin in neonates perhaps via decreased atrial natriuretic peptide and 
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increased anti-diuretic hormone production [84]. This may be attributable to right atrial 
pressure receptors that are influenced by altered thoracic pressures during positive 
pressure ventilation. Factors specific to renal replacement therapy may even include 
differences in the type of haemofiltration filter and ultra-filtration rate [85].   
Ongoing evaluation of illness severity allows timely adjustment of antibacterial dosing 
to minimise antibacterial resistance Figure 1-4 [86]. Antimicrobial Resistance (AMR) 
has been shown to increase with suboptimal drug exposure [87]. Regular monitoring 
of drug concentrations may be required for drugs with a narrow therapeutic index. 
 
Figure 1-4 Pathophysiology during critical illness and PK effects  
Reproduced from Roberts et al 2006 Springer Publications [86] 
 
 
Hypoalbuminaemia occurs frequently in critical illness due to a leaky endothelium, 
fluid overload, malnutrition and fluid extravasation. The effect of hypoalbuminaemia 
is that less of the drug binds to albumin; the increase in the free fraction of drugs may 
increase the volume of distribution but also facilitates elimination (see 1.1.5.2.2)  [88, 
89]. The inflammatory response to sepsis leads to capillary leak. Fleck et al. found a 
200% increase in trans-capillary leak from intravascular to extravascular space during 
the first 2 days of admission in critically ill adults with a mean serum albumin of 25g/L 
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[90]. Severe hypoalbuminaemia (22 ± 6.1 g/L) resulted in a substantial increase in the 
volume of distribution of ceftriaxone and almost doubled drug clearance (41.3 ± 11.7 
vs 19.8 ± 2.5 mL/min) compared to healthy volunteers with normal renal function [91]. 
A significant covariate for amikacin interindividual variability was hypoalbuminaemia 
that increased the Vd to the extent that a loading dose 1.6 fold higher was required 
[92]. A low albumin may result in the unbound drug being distributed into a larger 
extravascular compartment faster resulting in low concentrations in the distribution 
phase [89]. Conversely, when protein concentrations are high the drug concentration 
retained in the plasma space will be greater [75]. Even if clearance remains constant, 
the half-life (T1/2) may increase with implications on the frequency of administration of 
the drug [93]. As capillary leak resolves, the half-life may then increase when the drug 
is redistributed from the tissues back into the blood [89].  
In summary clearance of ciprofloxacin is primarily renal and the effect of sepsis or 
immaturity on renal function are expected to be significant. Ciprofloxacin it is only 
moderately bound to protein 20-40% therefore changes in albumin may have less 
effect on  concentrations than other drugs [53]. As ciprofloxacin is lipophilic 
concentrations are less likely to respond to the fluctuating effect of changes in fluid 
volume due to capillary leak or fluid resuscitation throughout the sepsis episode. 
Similarly, these factors are associated with developmental changes discussed in 
more details in the ontogeny section.     
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Figure 1-5 Pathophysiological changes during sepsis affecting concentration 
This illustrates pathophysiological changes during sepsis that affect distribution and 
elimination of antimicrobials. Reproduced from Pea et al 2005 Springer Publications   [88] 
 
1.1.5 Ontogeny  
 
Ontogeny is the study of the development of an organism [94]. Changes in body 
composition, and organs influence drug disposition [78]. These developmental 
changes influence metabolic capacity, distribution of total body water, extracellular 
water, body fat and renal function illustrated by Figure 1-5.  The Liberation, 
Absorption, Distribution, Metabolism, Elimination and Response referred to as 
“LADMER” describes the relationship between a dose and the ultimate effect [75]. 
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Figure 1-6 Developmental changes and physiologic factors influencing the  disposition 
of intravenous drugs 
Adapted from: Factors that Influence Drug Disposition in Infants, Children, and Adolescents. 
Reproduced with permission from Massachusetts Medical Society [78].  
Image of infant reproduced with permission from Science Picture.Co 
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 Absorption 
In neonatal sepsis antibiotics are administered intravenously [75]. Due to the high 
mortality and morbidity associated with neonatal sepsis other routes of drug 
administration are not reliable. There is a risk of reduced bioavailability caused by 
delayed gastric emptying and possible differences in intramuscular blood flow 
following intramuscular administration [79, 93].   
 Distribution  
The distribution of drugs in neonates differs to older children depending on their 
developmental stage Figure 1-7. The anatomical distribution of the drug is influenced 
by the proportion of body water in the physiological spaces, the high surface area to 
weight ratio, and protein or fat content [95].  Also, there are changes in 
haemodynamics, cardiac output, regional blood flow and membrane permeability that 
influence the distribution of a drug [80, 84].  
During the first year of life there is a sharp decrease in the total body water (TBW) 
that varies inversely with the amount of fat tissue in the body. The TBW constitutes 
85% of the body weight in the preterm neonate, 78.4 % in term neonates reducing to 
approximately 60% at five months [96]. The proportion of extracellular water 
decreases during the first year of life from 40% in the newborn to 25% at one year; 
intracellular water increases during the first three months from 34% to 43% [96]. In 
the 3-month foetus the total body water is 92% of which extracellular fluid is 65% and 
intracellular 25% [97]. Neonates, young infants and children have a higher relative 
extracellular and total-body water spaces and higher water to fat ratio. The clinical 
relevance of this gradual reduction in body water in extracellular compartments with 
age is that higher doses of drugs per kilogram are required to achieve comparable 
plasma and tissue concentrations for drugs that distribute into the extracellular fluid 
[98].  The relatively larger extracellular and total body water spaces, and adipose 
stores in babies results in lower plasma concentrations of drugs when administered 
 
23 
Introduction  
in a weight-based fashion [78]. Conversely, when calculated as a percentage of litres 
per square meter TBW increases from 12.38 L/m2 to 12.9 at 12 months [96]. This 
distribution may influence the selection of allometric methods of dosing based on 
weight or surface area [99]. 
The volume of distribution (Vd) is a reflection of the drugs concentration in the 
extracellular (particularly intravascular) compartment [96].  A change in body water 
can result in a higher volume of distribution of soluble drugs in childhood with a longer 
half-life than in the adult [93]. The apparent volume of distribution (Vd) describes the 
relationship between the amount of drug in the body and it’s plasma concentration 
[100]. V is simply a theoretical volume representing the total amount of drug in the 
body store required to achieve the same concentration in plasma when distributed 
throughout the body [100].    
V = D/Co 
Volume of distribution (V) = Dose (D) administered (total drug in the body) 
Initial plasma concentration (Co) of the drug 
 
The higher total body water of a newborn baby, results in a higher volume of 
distribution compared with an adult and alters the pharmacokinetics Figure 1-7 [93]. 
An increase in blood volume, fluid retention due to renal failure or an altered fraction 
of unbound drug in the blood may result in an increased volume of distribution [84].  
Table 1-4 Developmental aspects of fluid compartments as % of body weight  
 
Post  
Menstrual Age 
%  
Total Body Water 
 
%  
Extra Cellular Fluid 
%  
Intracellular 
Fluid  
<3 month fetus 92 65 25 
Term 75 35- 44 33 
4-6 months 60 23 37 
12 months - 26-30 - 
Puberty 60 20 40 
Adult 50-60 20 40 
 
Cited from Reed M  1996 Sage Publications  [101]  
 
24 
Introduction  
 
                                     
Figure 1-7 Change in distribution sites with age 
This figure compares the change with age in  total body water, extracellular water 
and body fat as a percentage of body weight [78].  
 
1.1.5.2.1 Lipophilic and Hydrophilic Drugs 
Antimicrobial agents may either be primarily hydrophilic or lipophilic according to their 
solubility. Ciprofloxacin is lipophilic resulting in a large volume of distribution with lower 
plasma concentrations whereas hydrophilic drugs remain in the extracellular space 
and are at greater risk of inter- and intra-individual variability [88]. Lipophilic drugs are 
primarily distributed in tissue therefore the influence of age on the apparent volume 
of distribution may not be as readily apparent compared with hydrophilic drugs that 
are influenced by changes in fluid [78, 102].  Membranes primarily composed of lipid 
can be classified in two groups: polar (phospholipids and glycolipids) and neutral 
(sterols and mono-, di- and triglycerides) [75]. The drug passes through a lipid barrier 
and enters the central compartment from which the drug again passes through 
another lipid barrier and enters the liver, kidney, tissue or plasma. It may then pass 
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via biliary excretion into the gut or undergo urinary excretion [75]. 
 
Figure 1-8 Classification of antimicrobials according to solubility  
Reproduced from Pea et al Springer Publications  [102]  
 
As infants have a higher proportion of body fat than adults, they may have a larger 
weight adjusted volume of distribution for lipophilic drugs. Over the period of sepsis 
changes in volume of distribution and clearance may affect the antibacterial 
concentration at the target site. Pea et al. suggested that increased doses may be 
required for hydrophilic drugs in sepsis [88]. However, lipophilic drug concentrations 
are less likely to be influenced by variations in extracellular fluid during sepsis [103]. 
PK variations for gentamicin were studied in critically ill medical adult patients (n=40), 
suffering Gram-negative sepsis. The apparent volume of distribution (Vd) on the 
second day was 0.43+ 0.12L/kg while on the seventh day of treatment it was 0.29+-
0.17 L/Kg [104].  Roberts et al. reported increased volume of distribution consistent 
with changes in extracellular water with a decreased Cmax during sepsis for most 
antimicrobials including aminoglycosides, B Lactams, carbapenems and vancomycin. 
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In contrast, the volume of distribution for fluoroquinolones was unrelated to changes 
in extracellular fluid [86]. Lipman et al. found that the fluid shifts in adults with intra-
abdominal sepsis and ascites did not alter the distribution of ciprofloxacin [105]. 
Ciprofloxacin is lipophilic, therefore has a greater affinity for intracellular distribution, 
and is less likely to be affected by changes in volume of distribution associated with 
fluid shifts [88, 89]. 
1.1.5.2.2 Protein Binding  
Drug distribution is affected by alterations in the protein binding. Albumin is the serum 
protein responsible for the majority of drug binding and may be altered in critical 
illness. Drug concentrations are affected by fluctuations in protein during the sepsis 
episode [93, 106]. Decreased binding may result from the co-administration of other 
drugs that compete for binding sites or hypoalbuminaemia [89]. Most drugs are 
partially bound to protein in the bloodstream; the unbound fraction exhibits the 
pharmacological effect that can then be metabolized and/or excreted. It is only the 
unbound fraction of a drug that is available for elimination from the vascular 
compartment and distribution into tissues or exerting a pharmacological effect [107-
109]. When the bound fraction is released from the protein the free drug may then be 
eliminated from the plasma [75]. The bound fraction of the drug acts as a reservoir 
increasing the half-life but when it is bound the availability of active drug is lower [89, 
93, 109]. In neonates albumin is lower at birth (35g/L) rising slowly through adult life 
to 45g/L [93, 106]. The reference range at Alder Hey Children’s NHS FT and Liverpool 
Women’s NHS FT for albumin in babies 0 - 2 months age is 30-45g/L and > 2 months 
37-53 g/L but does not include a range for premature babies [93]. However, 
Ciprofloxacin is only moderately bound to protein 20-40% therefore may vary less in 
relation to changes in albumin [53].   
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Neonatal maturation may influence the distribution of the drug into tissues and 
anatomical compartments. Ciprofloxacin has properties that enhance the penetration 
of the blood brain barrier. The entry of drugs, including antibiotics, into the 
cerebrospinal fluid and extracellular space of the brain is governed by the molecular 
size of the compound, protein binding, active transporters and in particular lipophilicity 
(as the whole central nervous system is surrounded by lipid layers) [110].  The ability 
of drugs to penetrate the CNS is clinically important when treating meningitis. 
Transport across the blood brain barrier occurs by both passive diffusion and by active 
transportation [79].  Altered distribution of active substances or metabolites into the 
central nervous system (CNS) may have a potential impact on both clinical efficacy 
and adverse effects. 
Cerebrospinal fluid (CSF) drug concentrations are often higher in infants and the 
elderly than in children and young adults [111]. Depending on the pathogen 
responsible and the severity of disease, CNS infections cause an increase in the 
permeability of the blood-CSF/blood-brain barrier and/or a decrease of the CSF flow. 
This frequently leads to an increase of drug concentrations in the central nervous 
compartments during inflammation [112]. The AUC/CSF v AUC steady state (s) ratio for 
ciprofloxacin has been reported as between 0.24 and 0.43 when the meninges are 
not inflamed increasing to 0.92 when inflamed [111, 113].  
Ciprofloxacin is moderately lipophilic therefore of great value for the treatment of CNS 
infection by Gram-negative aerobic bacteria.  The CSF of neonates contains high 
concentrations of proteins transferred from blood across the epithelial cells of the 
immature choroid plexus, and permeability to small lipid-insoluble molecules is 
greater in the developing than in the mature brain [114]. The penetration into the CSF 
in the absence of meningeal inflammation is much higher than that of β-lactam 
antibiotics based on the AUCCSF/AUCS ratio.  However, because of the relatively high 
CNS toxicity of fluoroquinolones it is not feasible to increase the systemic dose as 
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with β-lactam antibiotics [110]. Any medicinal product interacting with glutamic acid 
and other neurotransmitters may have an effect on neonatal brain development [79]. 
This is unknown for ciprofloxacin but there has been a report of fitting associated with 
higher Cmax[115].  The neonatal blood brain barrier is not fully mature so medicinal 
products and endogenous substances such as bilirubin may gain access to the CNS 
with resultant toxicity [80]. Neonates also have increased concentrations of fatty acids 
and bilirubin that competitively bind to albumin [93].  
 Metabolism 
Drug metabolism or biotransformation refers to the process of modifying or altering 
the chemical composition of the drug. The majority of the metabolites are 
pharmacologically inactive. Most metabolites have increased water solubility 
compared with the parent, which facilitates excretion [116]. Hepatic clearance 
depends upon hepatic blood flow, plasma protein binding, cellular uptake, hepatic 
metabolism and biliary excretion [79, 117]. The determinants of hepatic clearance of 
drugs may be influenced by sepsis and septic shock [118].  
Children may have an enhanced capacity to metabolise drugs due to proportionally 
larger livers and kidneys than their adult counterparts [74]. They have higher weight 
adjusted clearance. Until about six months age the liver is immature and may lead to 
high plasma concentrations of drugs metabolised by the liver [93].  The metabolic 
processes that promote drug excretion from the body are classified as Phase 1 or 
Phase 2 reactions Figure 1-9. 
Phase 1: oxidation, reduction, and hydrolysis reactions are when cytochrome P450 
‘CYP’ enzymes alter the molecule to form a more polar metabolite. Cytochrome P450 
enzymes are essential for the metabolism of many medications and detoxification of 
chemicals: this class has more than 50 enzymes, six of which (CYP1A2, CYP2C9, 
CYP2C19, CYP2D6, CYP3A4, and CYP3A5) metabolize 90 percent of drugs [119]. 
They can be inhibited or induced by drugs, resulting in clinically significant drug-drug 
 
29 
Introduction  
interactions that can cause unanticipated adverse reactions or therapeutic failures. 
Knowledge of the most important drugs metabolized by cytochrome P450 enzymes, 
as well as the most potent inhibiting and inducing drugs, can help minimize the 
possibility of adverse drug reactions and interactions.  
Phase 2: glucuronidation, sulfation, acetylation, and methylation which conjugate the 
metabolite with another, often more water soluble hydrophilic molecule, allows renal 
excretion of phase 1 metabolites that are not sufficiently polar and less lipid soluble 
than the original drug [93].  
 
 
Figure 1-9 Change in metabolic capacity with age 
In this figure the  CYP enzymes are Phase 1 and the UGT287 is Phase II [78] 
 
Ciprofloxacin inhibits CYP1A2, therefore concomitant administration of drugs 
metabolised by this enzyme may result in increased serum concentrations of the 
concomitant medicine resulting in adverse reactions [53, 102]. Drugs relevant to 
ciprofloxacin that are commonly prescribed to neonates include caffeine, theophylline, 
ondansetron and propranolol [53].Figure 1-9 illustrates that CYPIA2 is significantly 
reduced in children <28 days and remains low until one year of age. The EMA advise 
that if the drug investigated is likely to be eliminated mainly via hepatic metabolism, 
%
 o
f 
a
t 
a
c
d
u
lt
iv
it
y
  
Age  
 
30 
Introduction  
markers of hepatic function should be included as covariates in the analysis and 
safety assessment [79].   (see section 1.3.1 specific to  ciprofloxacin) 
 Elimination 
Elimination of renally cleared drugs is dramatically reduced in the newborn compared 
with older infants and children because of reduced glomerular filtration and tubular 
secretion [83]. Variability in elimination may lead to either the risk of over-exposure 
increasing toxicity or under-exposure leading to therapeutic failure [75, 88]. The 
pharmacokinetics of antibiotics that are primarily eliminated renally will vary 
considerably in neonates due to their immature renal excretory function [93].  
Elimination and distribution to target sites might be influenced by active drug 
transporters. Ciprofloxacin is transported by organic anion transporter 3 (OAT3) and 
by the breast cancer resistance protein (BCRP) transporter, both transporters being 
genetically polymorphic. Thus, individual differences in efficacy and in elimination 
might partly depend on genetic polymorphisms of active drug transporters [57, 120, 
121].   
Nephrogenesis is essentially complete at approximately 34 weeks of gestation. 
Glomerular Filtration Rate (GFR) increases rapidly after birth from 10 mL/min/1.73 m2  
to 20-30 mL/min/1.73 m2 in the first two weeks of life then rises steadily until adult 
values are reached between 8 and 18 months of age [78, 79, 122] Figure 1-12. Renal 
function is limited by poor peritubular blood flow, reduced urine concentrating ability 
and lower urinary pH values [79]. Post-natal changes occur in renal blood flow which 
increases from 12 mL/min at birth to 140mL/min by two years of age [123]. Unbound 
drugs can enter the glomerular filtrate where they may be excreted into the proximal 
tubule and reabsorbed by a passive process that is largely governed by the 
physiochemical characteristics of the drug (e.g. lipid solubility, ionization) [93]. When 
medicinal products such as ciprofloxacin are excreted via active tubular secretion 
premature neonates are at a higher risk of toxicity therefore require special attention.  
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The primary covariates for clearance often include weight or surface area. Weight can 
under-predict clearance and the surface area model over-predicts clearance in 
children [124, 125]. Pea et al. suggest that creatinine clearance is the best surrogate 
of glomerular filtration rate to monitor renal function and adjust dosage [102]. 
However, there are limitations as creatinine may be elevated during the first week of 
life due to the persistence of maternal creatinine [79, 83, 95]. Therapeutic drug 
concentration monitoring may be required due to toxicity as a result of reduced 
clearance in neonates as shown with gentamicin [126]. In very low birth weight 
(VLBW) babies this elevated serum creatinine may continue for the first few weeks of 
life [75]. Lower post menstrual age (PMA = age calculated from 1st day of last 
menstrual period) at birth usually results in a higher serum creatinine [123]. GFR 
correlates better with post menstrual age than post-natal age (PNA = calculated from 
the first day of birth) [79]. This may also depend on how GFR is calculated, if corrected 
for body surface area then GFR increases more slowly to reach adult concentrations 
between one and two years of age [79].  
Vieux et al compared Glomerular Filtration Rates for neonates born prematurely 
between 27 and 31 weeks gestational age (GA) for the first four weeks of life. They 
found that a neonate born at 27 weeks had a GFR of 18 mL/min/1.73m2 at 31 weeks 
corrected age whereas the GFR for a neonate born at 31 weeks was considerably 
higher 25 mL/min/1.73m225 [127].  This suggests further delays in nephrogenesis for 
premature babies during the post natal period therefore dose regimen may need to 
be adjusted for prematurity rather than the corrected post natal age. 
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Figure 1-10  Glomerular Ffiltration Rate (GFR) for premature neonates at birth 
(Gestational age) compared to post natal age over the first four weeks of life [128] 
  
 
                                                          Age  
Figure 1-11 Renal Function and Glomerular Filtration Rate with age [78]  
 
Para-aminohippuric acid is used for the measurement of renal plasma flow because 
it is secreted primarily by the renal tubules; only 20-30% is filtered by the glomerulus 
[101]. 
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Figure 1-12 Maturation of GFR with post-natal age (PNA) compared to adults  
Reproduced from Rhodin et al 2009 Springer Publications [122] 
 
Factors associated with sepsis may either increase or decrease clearance. Clearance 
may increase due to hypermetabolic conditions or with administration of inotropes as 
the cardiac output increases enhancing renal blood flow [88]. Pea et al. found 
vancomycin concentrations decreased during co-treatment with inotropes and 
attributed this to the increased cardiac output and renal blood flow [129]. In severe 
sepsis clearance of ceftriaxone almost doubled compared with healthy adult 
volunteers but was only attributed to inotropes for 3/10 patients [91]. Lipman observed 
high ciprofloxacin clearance in one patient and suggested this may have been related 
to the hyper-dynamic condition during sepsis [105]. Hypoxia (at birth or later), 
congenital cardiac defects, septic shock and concomitant drugs (for example anti-
inflammatories) may influence both renal excretion and or hepatic failure in neonates 
[79]. The cytochrome P450 enzyme system is an important clearance mechanism for 
many drugs (section 1.2.2.2), and has been shown to be markedly affected in septic 
conditions, resulting in decreased clearance [118]. 
In summary, PK-PD studies of neonates with critical illness and suspected sepsis are 
particularly challenging. Factors influencing the pharmacology of ciprofloxacin result 
in both inter and intra individual changes that are dynamic throughout their 
development and the disease process (Figure 1-13).  
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Figure 1-13 Developmental and pathophysiological factors influencing PK parameters 
of critically ill neonates  
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1.1.6 Population Pharmacokinetics (PopPK) 
Population pharmacokinetics is the study of the variability in PK parameters between 
individuals. This approach quantifies variability in terms of patient characteristics such 
as age, renal function, sex, weight or disease state as well as residual and 
unexplained variability [130]. In traditional PK inter-individual variability is often 
deliberately minimised through restrictive inclusion/exclusion criteria but in population 
PK the extent of interindividual variability is of primary interest [131]. Sparse or rich 
data can be used [130].  The population PK approach differs to the traditional 
pharmacokinetic evaluation as it includes the following features [132]:   
 PK parameters in patients representative of the population to be treated with 
the drug (using sparse or rich data) 
 Quantifies population mean parameter values and the variability across a 
population of patients.  
 Explanation of the variability by identifying factors including demographic, 
pathophysiological, environmental or concomitant drug-related origin  
 Quantitative estimation of the unexplained (random) variability in the 
population  
 inter-individual variability distribution (between subject variation)  
 
The parameters required to predict concentration (C) at any time (t) may include the 
volume of distribution (V) clearance (CL), inter-compartmental clearance (Q) and an 
absorption rate constant (ka) (or absorption half-life) depending on the context [74]. 
PopPK was originally intended for monitoring drug concentration in clinical practice 
but are  now used almost exclusively for phase II and III studies [133]. EMA Guidelines 
for PK in the paediatric population state that population PK analysis, using non-linear 
mixed effects models, is an appropriate methodology from a practical and ethical point 
of view [73]. 
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 PopPK Sampling Strategy in Neonates 
Sparse sampling requires fewer samples instead of conventionally designed PK 
studies that requires between six to ten samples (per patient per dosing interval 
following the first or a steady-state dose). Fewer samples may still enable the fitting 
of unbiased models particularly if collected at maximally informative times. Even a 
single sample in a population design may provide reliable data. Forrest et al reported 
that as few as three to five samples can provide precise AUC and plasma clearance 
data [134]. Long et al collected 5 - 8 PK samples for netilmicin and ceftazidime and 
analysed the data for comparison with two, three or four time points. They concluded 
that three time points were sufficiently accurate for practical purposes in neonates 
[135]. 
 
Figure 1-14  Typical drug concentration–time curve.  
 
Construction of a drug concentration–time curve from a traditional, intensive sampling 
strategy (e.g. n = 12 samples, A) compared with an identical drug concentration–time 
curve constructed with sparse sampling (n = 6 samples) using optimal sampling 
strategy. Reproduced from Reed et al 1999 American Academy of Pediatrics [83] 
 
The frequent blood sampling associated with traditional rich PK data is difficult in 
critical illness due to restrictions on the volume of blood taken from neonates for 
research purposes to minimise the risk of anaemia, pain, distress and disrupted sleep 
[136-139]. The EMA guideline recommends no more than 3% of total blood volume is 
collected during a four week period and no more than 1% at any single time [79]. 
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Neonatal total blood volume is approximately 80-90 mL/kg. Very premature babies 
weighing <500g, may be restricted to as little as 1.5 mL sampling volume during a 
four week period [140].  
Parameter estimates obtained at optimal sampling times have significantly less 
variability than those generated using the conventional sampling procedures therefore 
fewer samples are needed [141]. The optimal sampling time (OST) has traditionally 
been informed by a priori data from rich sampling data to indicate the information rich 
areas of the drug concentration time curve [142].This strategy is recommended by the 
EMA and American Food and Drug Administration (FDA) for neonatal PK data due to 
the severe limitations on samples [80, 131].  
 
 
Figure 1-15 Concentration versus time curve for informative data  
 
Hypothetical concentration versus time curve describing ‘A’ informative data with full 
sampling ‘B’ informative data with limited sampling, ‘C’ non informative data. The 
observed data are represented by the diamonds, the simulated model curve is 
represented by the solid line and the Bayesian fit curve with appropriate priors is 
represented by a dashed line and with inappropriate priors is the dotted line [143]. 
 
An OST strategy is dependent on the availability of a priori data from previous subjects 
including specific PopPK parameter estimates (e.g. AUC, V, CL, Q) [83, 141]. 
Preliminary a priori data are not usually available for neonates. To some extent the 
sampling strategy can be informed by the drug’s behavior to identify which portions of 
the plasma concentration time curve provides the greatest information. This may 
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include the estimated time between administration, elimination and half-life but is less 
informative than a priori data Figure 1 14. Another option used in this trial is to collect 
sparse samples from two groups at alternating time points to produce a complete 
profile similar to rich PK data but with samples from the population. 
 
In critical illness frequent blood samples are required for clinical care, often includes 
daily haematology and biochemistry in addition to four–six hourly blood gas analysis. 
These samples may be scavenged for further PK analysis if the precise time of 
sampling and drug administration are reliably recorded. One limitation is the need for 
all members of the clinical team to provide precise data on the drug administration 
and timing of samples. More than 200 clinical staff work in each intensive care unit at 
Liverpool Women’s NHS FT and Alder Hey Children’s NHS FT. The time the drug 
reaches the vein may be complicated by the small drug volumes, internal dead space 
of central lines or syphoning of drugs between connected lines. Often the time the 
drug is prescribed is simply signed rather than recording the actual time the drug was 
administered. Similarly, the time the blood sample is collection for clinical purposes is 
not routinely recorded with the precision required for PK analysis. To scavenge 
samples reliably requires the support of the wider clinical team.  
The number of neonates recruited to a PK clinical trial aims to represent each month 
of development as the data will ultimately contribute towards licensing the drug for 
each sub-age group [79]. The appropriate number of patients will also depend on the 
number of subject specific characteristics that need to be evaluated [144]. Tam et al. 
found reasonably robust PK predictions required a population size of ≥ 50 [145]. Most 
neonatal studies have reported <20 patients, they are limited by their capacity to 
identify the predictors of altered PK parameters.  
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 PopPK Modelling 
PK-PD modelling seeks to quantify variability in the data, and then simulate the 
predicted behaviour of the drug in the system [146].  PK model building is the 
application of statistical techniques to mathematically describe the patient outcome 
as a function of measures of drug exposure and other patient covariates [147]. The 
strengths and weaknesses of different methods are summarised in Table 1-5. A 
mathematical model is constructed to describe the data and the parameters that 
influence the model including absorption, distribution, metabolism and excretion. A 
PopPK data analysis can be performed using a number of packages such as 
NONMEM which was developed by Shreiner and Beal et al. [148, 149].   
 
PopPK models determine the variability in drug response among the population 
representative of those for whom the drug will be used clinically. Estimating individual 
parameters for each subject is replaced by estimating a single mode then factoring in 
an inter-individual variability estimate for each parameter. This population information 
may then be used to improve the estimates of individuals with missing data, for 
example neonates who have only one PK sample. In addition the model allows data 
from several studies to be pooled to provide a single robust analysis [150].This is 
particularly valuable for neonatal studies as large sample sizes are rarely achieved.  
NONMEM – Non-linear Mixed Effects Modelling is a software programme that 
determines the clinical variables that have a significant effect on the drug 
concentration for inclusion in the final model  [149]. NONMEM assesses the effect of 
covariates then provides an estimate of the inter-individual variability by minimising 
the difference between the observed and predicted parameters [149]. Because the 
distribution of PK variables is random a nonlinear regression estimation method is 
required. A mixed effect model assesses the effect of random and fixed effects (age, 
weight, creatinine clearance). The influence of between subject variability (BSV) and 
within subject variability (WSV) on the observations i.e., plasma concentrations are 
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simultaneously quantified. The inter-subject variance model describes the between 
subject variability (BSV) on parameters that can be estimated from the standard 
deviation of the individual estimates. The criteria for selecting covariates for inclusion 
in the model is pre-specified and may use a step wise procedure forward inclusion 
5% significance, and backward deletion 1% significance. To determine whether the 
inclusion of a covariate improves the significance of the model the objective function 
value (OFV) determines the probability of seeing the observed data. The smaller the 
objective functional value (OFV) number the less variability in the model, an OFV of 
>3.84 equates to a significance value of P=<0.05 and OFV of >6.635 to P=<0.01 
based on chi square distribution [151]. 
The fixed effects and random effects represent the between subject variability and 
both values are assumed to be represented by parametric distribution. Exploratory 
analysis examines distributions and correlations among covariates and this may 
include a scatter graph or histogram to examine the normal distribution for errors. 
Skewed data may indicate, for example, the under prediction of concentrations. 
Estimates from preliminary analysis can be graphed against likely covariates (age, 
weight, renal function, disease states) in search for trends that can be incorporated in 
the covariate model. 
There are five steps to model building: 
o Structural model  
o Fixed Effects - Covariates Analysis  
o Random effects  
o Residual unexplained variability 
o Internal model validation  
o Simulation to predict the effect in the individual by Bayesian methods 
and in the population with Monte Carlo Simulation  
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Concept Strength Limitations 
Naïve Pooled Data  
Time concentration data are pooled 
as for a single subject (scatter graph) 
Provides mean concentration for a group of patients   
 
Simple methodology  
Provides no information on:  
       Influential factors (age, weight etc.)     
       Individual profiles   
       Subject variability  
       Causes of variability/ standard deviation /IQR 
Imbalanced data per individual could lead to biased estimates. 
Standard Two Stage Approach 
Stage 1 PK parameters for each 
subject ‘individual plots’ 
 
Stage II Summary statistics  
Determines individual patient parameters (e.g. V , CL)   
Between subject variability can be estimated from  the 
standard deviation (e.g. SD and IQR) and dispersion of central 
tendency from individual estimates  (but only if there are 
sufficient rich samples) 
The compartmental model provides more detailed parameter 
estimates   
Requires rich data and precise time points  
Between subject variability may be overestimated (no measure of 
error). Assumes individuals contribute equally.  
Limited ability to accurately determine covariates this is dependent on 
rich samples (parameter estimates)  
Summary data is influenced by outliers 
Missing data could lead to biased parameter estimates. 
Population PK  
Models the variability in drug 
parameters among individuals and 
collectively  
Fixed effects describe the 
predictable between subject 
variability (BSV) 
Random effects describe the 
between occasion variability (BOV) 
Explanatory covariates explain the 
predictable part of the between 
subject variability  
Represents the population treated clinically  
Provides a population average and individual parameters can 
be obtained using empirical Bayes estimates.  
Dense or sparse data even a single sample can be used 
Explores covariates  
Imbalance in data per individual can be handled. 
Data can be pooled across studies  
The compartmental model provides more detailed parameter 
estimates  
De-emphasises outliers - the mean and median are  
representative of actual values in the population  
Sample timing can be flexible in line with standard care.   
Quantifies the unexplained variability in the population 
Parametric therefore assumes the normal distribution whereas the 
extremes in some populations may mean that parameters are not 
normally distributed  
Covariates can exhibit co-linearity (e.g. age and weight) 
 
Complexity of modelling requires specialised training and software 
Table 1-5 Pharmacokinetic Methods for Data Analysis  
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Step 1- Structural Compartment Model  
Compartmental modelling defines drug disposition with greater specificity than is 
possible with a non-compartmental approach this includes clearance and the volume 
of distribution in each compartment. That is, it can describe the rate and extent of drug 
distribution and elimination from the blood, central and peripheral compartments by 
parameters that include central (V1) and peripheral (V2) and the inter-compartmental 
difference (Q). The first step of compartmental modelling is to determine the structural 
model, the number of compartments (usually one, two or three compartment) 
depending on the available data: 
 One compartment – circulatory 
 Two compartment – circulatory and tissue 
 Three compartment – circulatory, tissue and deep tissue. 
In an open one compartment model the drug is assumed to distribute instantly 
between the blood and other body fluids or tissues. A two compartment model is when 
the drug is not instantly distributed. The concentrations in each compartment can be 
predicted even though the actual compartment may not be accessible for sampling. 
The structural model is partly influenced by the availability of samples therefore 
sparse data may not be sufficient for a two compartment model. Figure 1-16 illustrates 
the data required for one or two compartment models  
One Compartment Model Data Two Compartment Model Data 
Intravenous Drug Administration          Intravenous Drug Administration  
   
   
 
 
 
 
 
Figure 1-16 One and two compartment models  
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To determine which model is selected (one or two compartment) the concentration–
time data is plotted on a semi-log plot to find the terminal slope; this is back 
extrapolated to the axis. If there is no concentration-time data above the line it is one 
compartment, otherwise it suggests a delay between the drug distributing into the 
tissues. The first graph represents a one compartment model with immediate 
distribution Figure 1 16 is compared to Figure 1 17 with a non-linear terminal slope.   
                                       
Figure 1-17   Intravascular Administration - One Compartment Model         
                                             
Figure 1-18  Intravascular Administration - Two Compartment Model    
 
Once an injection has been completed (a), the drug concentration in the central 
compartment is highest. The concentration falls mainly because the drug is 
distributed from the central to the peripheral compartment (distribution phase) and 
partly because some elimination begins. At point (b) drug distribution in the central 
and peripheral compartments are approximately equal this is the steady state. At 
this point the main reason for the drug leaving the central compartment changes to 
the elimination process rather than distribution. At (b) the curve is back extrapolated 
and if there are data above this line then it is a two compartment model.   
The distribution between compartments can occur at different rates but eventually a 
steady state will be reached terminating the distribution phase [75] Figure 1-19. 
  a) 
(b
) 
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Figure 1-19 Concentration in central and peripheral compartments  
 
As the concentration in the central compartment decreases the concentration in the 
peripheral compartment increases until steady state is reached. The distribution 
phase informs the volume of distribution between the V1 central compartment and V2 
peripheral compartment. The elimination phase primarily provides data for 
clearance.   
 
 
Step 2 - Fixed Effects - covariate analysis determines factors that influence the 
difference in parameters. Fixed effects on parameters are predictable known 
observable effects that occur across the population such as age and between 
subject variability (BSV). These define the average value for a parameter in a 
population and/or the average relationship between measurable patient factors 
(creatinine clearance) and PK parameter. The estimated parameters are labelled 
THETAS ᶿ. Explanatory covariates (age size, renal function, sex) can be introduced 
to explain a portion of between subject variability. These include the known changes 
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associated with neonatal development including allometric changes such as weight 
or post menstrual age.  Ciprofloxacin is mainly excreted renally therefore the 
immature renal function for neonates would be a fixed effect covariate. A limitation 
of NONMEM is that covariates can exhibit co-linearity. In paediatrics clearance may 
change as a function of age, weight and/or renal function all related with the 
maturation of the child, these are not mutually exclusive and may show a high 
degree of correlation. Bonate et al. recommended that when correlation is >0.5 not 
all covariates are important for inclusion in a model [133]. 
Step 3 - Random Effects define both the error and residual unexplained 
variability (RUV).  
The error model estimates the difference between observed and predicted values. 
These are the population parameters (THETA ᶿ) that are unknown when the model is 
being built or unpredictable variability including:  
o Between Subject Variability (BSV) and inter-individual variability that 
naturally occurs between people (OMEGA Ω).  
o Residual unexplained variability (RUV) including within subject variability 
(WSV) or intra- individual variability (SIGMA  Σ) 
o Between occasion variability (BOV) is a measure of unexplained random 
differences in an individual between different occasions.  
Residual unexplained variability (RUV) represents the uncertainty in the relationship 
between the plasma concentrations predicted by the model and the observed 
concentration. This is the difference between the parameters predicted by the model 
for the individual and the actual measurements observed. This may include model 
misspecification. This is intraindividual or within the individual subject variability. 
Random effects may be accounted for by assay errors (either a consistent error 
throughout the assay range or may increase proportionally), drug dose, or the time of 
measurement. Assay errors may be a consistent error throughout the assay range 
(additive) or as substrate increases (proportional). Residual error is reported as a 
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mean of 0 and the distribution, as positive errors cancel negative errors. When 
variation in the population is high this is recorded as Residual standard error RSE%.  
Step 4 - Internal model validation  
Model validation requires an assessment of covariates that are clinically relevant. A 
posterior predictive test simulates the data that contributed to the model. This includes 
PRED a prediction within the population and iPRED a posterior predictive check for 
the individual. These visual predictive checks provide reassurance that the model is 
capable of recreating the data from which the model was built. Basic internal 
evaluation of a model consists mainly of Goodness-of-fit (GOF) plots, which detect 
potential bias or problems in the structural model and/or the random effects models. 
GOF plots include population predictions (PRED) overlaid on observations (OBS) 
versus time. Simulated data from the final PK model are compared to the original 
data, 90% of predictions should encompass 90% of the observations [152].   
Bootstrapping tests the reliability of the model by randomly simulating patients then 
recalculates the parameters including volume of distribution, clearance and inter-
compartment clearance (V1 and V2). Data for patients are randomly sampled and 
modelled to see if the estimates are consistent. As many as a thousand iterations may 
be required to estimate 95% confidence intervals. If the bootstrap model matches, the 
model is robust. Reliability of the results of the analysis can also be determined by 
evaluating the precision of parameter estimates from standard errors (SE) or 
confidence intervals (CI). 
Step 5 Simulation  
Bayesian statistics is a method of updating uncertainty in the light of evidence when 
the initial beliefs about some unknown quantity are represented by a prior distribution. 
The population PK parameters produced by NONMEM may be explored using 
Bayesian prediction methods. The parameters for an individual with sparse data even 
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as little as one sample can be modelled to predict the individual dose regimens 
informed by prior distributions.   
Monte Carlo Simulation is where a data set is simulated based on the known 
distribution of PK parameter estimates and subject variability. This mathematical 
model may be used to predict optimal dosing associated with the probability of a 
successful outcome in the treatment of an infection. The values from a limited number 
of patients can mathematically create an AUC of an antibiotic’s distribution for many 
subjects. A pharmacodynamic model may then incorporate the AUC for a specific 
dose with the susceptibility of the pathogen to predict the probability of target 
attainment thereby informing clinical breakpoints.  If the therapeutic target for the 
organisms is known the data can be used to determine the proportion of patients that 
will reach the target or predict a dose with a higher probability of attaining the target. 
Each pathogen or location in the tissue may have a different range of optimal 
AUC/MIC ratio.    
1.1.7 Pharmacodynamics  
Pharmacodynamics (PD) is assessing the outcome of a drug. Antimicrobial 
pharmacokinetics and pharmacodynamics (PK-PD) integrate both microbiology and 
pharmacology. This can either be the clinical outcome following systemic exposure 
and response to the drug, or the outcome of the organism either in the laboratory or 
the patient [76]. Rowland and Tozer [76] state this can be assessed as: 
 a clinical response – ‘subjective’ e.g. patient’s personal assessment or 
‘objective’ e.g. mortality  
 a surrogate endpoint  
 a biomarker (a laboratory diagnostic or prognostic test).  
The aim is to link a measure of drug exposure, relative to the susceptibility of the 
pathogen, to the microbiological or clinical effect achieved. This relationship allows 
the drug dose to be chosen in a rational manner so that the desired effect, for example 
maximum bactericidal effect, can be achieved in a large proportion of the intended 
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patient population [147]. Three main PK/PD predictors of efficacy have been 
established that depend on the antibiotic group [153]  
Figure 1-20:  
 Time above the MIC (T>MIC) expressed as a percentage of the dosing  
interval  
 Ratio of the area under the curve over 24 hours to the MIC 
(AUC24/MIC)   
 Peak concentration after each dose to  MIC ratio (Cmax / MIC) 
 
PD studies of ciprofloxacin have established that the area under the curve AUC24/MIC 
ratio is the optimal predictor of clinical outcome in adults and animal models [154, 
155].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-20 PK/PD parameters on a concentration versus time curve  
 
The PK-PD parameters for antimicrobials AUC = area under the serum concentration 
time curve; Cmax = peak serum drug concentration; Cmin = minimum serum drug 
concentration; MIC= minimum inhibitory concentration; T>MIC = time for which the 
serum area under the inhibitory curve (AUIC) is when the actual inhibitory titres (blood 
concentration and MIC) have been measured simultaneously for a specific patient 
and used in the calculation [154]. 
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Thomas et al. found antimicrobial resistance appeared to be strongly associated with 
suboptimal antimicrobial exposure and defined suboptimal as an AUC24/MIC ratio of 
less than 100 [87]. Their study included ciprofloxacin and reported 82% bacteria with 
an AUC24/MIC ratio <100 developed resistance compared to 9% above 100. Also, 
rapid resistance occurred below this ratio when 25% became resistant within 6 days. 
The authors claimed a Cmax/MIC ratio of approximately 5:1 corresponded to an 
AUC24/MIC ratio of 100 for ciprofloxacin. 
 Clinical Breakpoints  
Clinical breakpoint standards aim to predict which organisms will respond effectively 
to the antibiotic. They are set by the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST). In clinical laboratory routine practice the organism 
is cultured then tested against several antibiotics to determine whether it is 
susceptible or resistant using a rapid disc test. The Minimum Inhibitory Concentration 
(MIC) to inhibit growth of the organism may be quantified in the laboratory using the 
E Test. A microorganism is defined as susceptible ‘S’ when the MIC is low enough to 
be associated with a high likelihood of therapeutic success or as resistant ‘R’ when 
the MIC is raised and associated with a high likelihood of therapeutic failure. 
Intermediate ‘I’ implies some uncertainly, the antibacterial may be susceptible if 
concentrated at the site of infection (e.g. in urine) or susceptible if a high dosage of 
the drug is administered [153, 155, 156].  
In the US the Clinical Laboratories Standards Institute  expand these definitions by 
saying susceptible means the growth of the bacterial strain is inhibited by the usually 
achievable concentrations of antimicrobial agent when the recommended dosage 
regimens is used for that site of infection and antibacterial concentration in the range 
found for wild type strains [157]. The Etest is an in vitro measurement of the laboratory 
concentration of the drug required to inhibit bacterial growth. There is no definitive 
relationship between clinical breakpoints and the laboratory MIC (ECOFF) measured 
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by an Etest [153, 158]. The true value of the MIC is as a measuring tool that generates 
values to which PD endpoints and clinical outcomes can be reliably compared [153].  
EUCAST publish clinical breakpoint tables that predict the probability of target 
attainment (PTA) for therapeutic success when treating organisms based on the 
known wild type MIC for the organism. At present clinical breakpoints are based on 
adult outcomes for adult dose regimens [159]. They are not informed by the usually 
achievable concentrations or outcomes of neonates or children. EUCAST’s process 
of setting clinical breakpoints is illustrated in Figure 1-21. [156] 
There are four main variables that inform the probability of target attainment (PTA) for 
therapeutic success: 
i) Dose regimens  
ii) PK parameters  
iii) Minimum inhibitory concentration (MIC) of antibiotic  
iv) PD parameters of the clinical outcome [155, 156, 160, 161].  
 
Treatment success relates to the dose regimens, the site of infection, the species and 
clinical outcome response to infection specific to the population. Clinical breakpoints 
are determined by collecting clinical outcome data for patients then comparing the 
dose they were administered with the MIC of the organism. 
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Figure 1-21 EUCAST’s process of setting PK/PD breakpoints 
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Three definitions of cut off are defined by Turnidge et al. to clarify the difference 
between laboratory and clinical breakpoints [153]:   
Epidemiological Cut off ‘microbiological breakpoints - defines the range 
for the wild type (WT) populations of bacteria as the upper limit of the MIC 
separating those with acquired, mutational  or selected resistance 
mechanisms (based on large numbers of in vitro tests). 
Clinical breakpoints ‘Clinical cut off ‘’ – the MIC that separates strains that 
have a high likelihood of treatment success from those that are more likely to 
fail (based on a specific dose regimen).  
PK/PD Cut off –antibacterial concentrations derived from knowledge of a PD 
parameter and the dimension generated in an animal model then extrapolated 
to humans with a statistical model.  
EUCAST define ciprofloxacin non-species specific clinical breakpoints as susceptible 
when ≤0.5mg/L and resistant ≥ 1mg/L these will render wild type susceptible including 
Enterobacteriaceae, Pseudomonas spp., Acinetobacter spp., Staphylococcus spp., 
Haemophilus influenzae, Moraxella catarrhalis and Neisseria spp. Different species 
are known to have different MIC and are provided in these tables however, in clinical 
practice non-species specific breakpoints or disc tests are used as the organism is 
not usually known at the start of treatment.  
A clinical breakpoint of <0.5 mg/L allows Enterobacteriaceae to be categorised as 
susceptible to ciprofloxacin relating to an oral dose of 500 mg x bi-daily (BD) (or as 
low as 250 mg x 2 BD for uncomplicated urinary tract infections) to 750 mg x 2 BD 
and an intravenous dose of 400 mg x 2 BD to 400 mg x 3 TDS.  The ECOFF for 
Acinetobacter is 1.0 mg/L is one of the less susceptible bacteria it has a higher clinical 
breakpoint of 1 mg/L to avoid dividing wild type MIC distributions therefore 
susceptibility for adults relates to the higher dosages of ciprofloxacin 400mg x 3 TDS 
[56]. For more severe infections EUCAST occasionally recommend either i) a lower 
clinical breakpoint ‘MIC’  ii) a higher dose (if tolerated). They are not related to 
neonatal or paediatric regimen or PK PD data.  
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Table 1-6 Epidemiological cut off (ECOFF) for ciprofloxacin and common Gram-
negative species  
 
Gram-negative species ECOFF ‘wild type’ 
MIC mg/L 
In vitro 
Clinical Breakpoint  
MIC mg/L 
In vivo 
Acinetobacter  spp*. 1.0 <0.5 
Citrobacter spp. 0.12 <0.5 
Enterobacter spp. 0.12 <0.5 
Escherichia Coli 0.03 <0.5 
Klebsiella  spp. 0.06 <0.5 
Pseudomonas aeruginosa 0.5 <0.5 
 
Serratia  spp. 
 
Insufficient evidence 
Source EUCAST [159]  
*Susceptible only for a higher dose regimen  
 
 
The clinical breakpoint relate to a specific dose regimen they indicate the likelihood of 
treatment success when the organism’s growth is inhibited by a specific concentration 
using the laboratory MIC. The breakpoint can be higher, lower or the same as the MIC 
(ECOFF) Figure 1-23, Figure 1-24. If the regimen achieves low serum concentrations 
or low concentration at the site of infection it may only be effective for organisms with 
lower MIC. In this case the optimal MIC for cure would be lower than the ECOFF.  In 
contrast a higher dose may achieve a concentration in the patient higher than the 
laboratory Etest when the breakpoint may be higher than the ECOFF. The important 
distinction is that there is no definitive relationship between clinical breakpoint MIC 
(concentration in the patient) and the laboratory ECOFF ‘MIC’ (concentration in the 
laboratory test) Figure 1-23and Figure 1-24. Organisms with MICs at the marginal 
point of susceptibility may subsequently develop resistance [162].  Falagas et al’s 
reviewed the outcome with the MIC of the Gram-negative organism. Even when the 
MIC was within the susceptible range patients infected with strains with high MIC (RR 
2.03 95% CI 1.05 to 3.92) particularly P aeruginosa and fluoroquinolones had higher 
all-cause mortality [163]. For non-fermentative Gram-negative bacilli mortality was 
higher  with high MIC’s was higher (RR 2.39; 95% CI 1.19 to 4.81) [163].    
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 Mutant Protection Concentration 
The optimal regimen may prevent the emergence of resistance if sufficient drug 
exposure adequately kills susceptible organisms however the efficacy of the 
concentration depends on whether it is tolerated by the patient. The mutant protective 
concentration (MPC) is defined as the drug concentration required to prevent all single 
step mutations in a population of at least 1010 bacterial cells in a population using wild 
type not resistant bacteria [48, 164].  The range between the MIC and the MPC is 
called the mutant selection window (MSW) Figure 1-22. Below the MIC there is no 
selective pressure as mutants are not selected therefore do not grow; above the MPC 
no mutants will be selected because it is thought that a double mutation for growth is 
necessary [48]. Above the MPC no mutants will be selected Increasing antibiotic 
exposure reduce the antibiotic colonies.  
 
 
 
 
 
 
 
 
                                       Concentration mg//L 
Figure 1-22 Mutant Selection Window and Mutant Prevention Concentration 
 
Bacterial colonies reduce (cfu/ml) with increasing exposure to antibiotics. Above the 
MIC bacteria require a mutation to survive. An additional mutation is requierd to 
survive the second step. Selective antibiotic growth may occur when concentrations 
are inbetween these stages known as the mutant selection window. The mutant 
prevention concentration (MPC) requires at least a second step for bacteria to be 
resistant above this.    (Adapted from Dong Y et al by Roberts et al [48, 165] 
For colonies to survive the first step at the bacteria’s MIC a second step mutation is 
required. Selective antibiotic pressures may occur when antibiotic concentrations are 
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in the mutant selection window. The optimal MPC requires a least a concentration 
above the second mutation for bacteria to survive [48]. For Ciprofloxacin Drusano et 
al. compared two drug doses producing AUC/MIC ratios 52 and 157 respectively; the 
suboptimal dose amplified the resistant subpopulation by 1.5 log10 (cfu/g) [147].  
Roberts et al recommend a paradigm change to antibiotic selection and dosing 
strategies designed to consider limiting antimicrobial resistance by administering the 
highest tolerated dose of antibiotic. Olofsson et al found that neither T>MPC nor Cmax 
correlated to preventing resistance to E coli for ciprofloxacin, the AUC24/mutant 
prevention concentration (MPC) was the optimal PD parameter to reduce resistance 
estimated as >22 [166]. For neonates the optimal regimen is unknown as further 
safety data is required [48]. 
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Figure 1-23 Ciprofloxacin and E.coli - ECOFF and Clinical Breakpoint  
 
The ECOFF for E. coli is lower than the clinical susceptibility breakpoint based on the 
MIC distribution for 16702 observations reported in 2015 by EUCAST.  
 
 
             
Figure 1-24 Ciprofloxacin and Acinetobacter spp. ECOFF and Clinical Breakpoint 
 
The ECOFF is higher than the non-species specific clinical breakpoint for 
Acinetobacter MIC >1mg/L therefore it is only susceptible on a higher dose 
regimens of 400 mg x 3 daily in adults.  
Both adapted with permission EUCAST [158]. 
http://mic.eucast.org/Eucast2/SearchController/search.jsp?action=performSearch&B
eginIndex=0&Micdif=mic&NumberIndex=50&Antib=-1&Specium=227 
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1.2 Neonatal Antimicrobial Therapy   
Prescribing practices may influence both the efficacy of the treatment and resistance 
development. Empiric antibiotic treatment is often initiated rapidly for suspected late 
onset sepsis due to the high risk of mortality and long term neurodevelopmental 
sequelae [11]. The frequent prescribing of broad spectrum antibiotics in past decades 
is now associated with the increase in multidrug-resistant Gram-negative bacilli (MDR 
GNB) [167]. Fernando et al. found that most NNUs (89%) used an empirical first-line 
antibiotic regimen for late onset sepsis (180). A quarter (28%) of units prescribed a 
broad spectrum antibiotic (e.g. third generation cephalosporin). Frequent use of third 
generation cephalosporins has been shown to increase resistance on neonatal units 
and outbreaks of extended spectrum β-lactamase producing bacteria [168, 169]. It is 
estimated that these resistant Gram-negative bacteria account for approximately 20% 
of bacteraemia cases and are associated with a 2.8-fold increase in neonatal mortality 
rate compared with non-MDR strains [167]. The use of third-generation 
cephalosporins is also associated with invasive fungal infections from which mortality 
is high [8]. The neonatal unit at Liverpool Women’s Liverpool Women’s NHS FT 
changed from the empiric use of cephalosporins over 25 years ago due to concerns 
for resistance to prescribing ciprofloxacin. 
There is a lack of evidence to guide treatment of late onset sepsis reported by a 
Cochrane review [38]. In contrast, guidance for early onset sepsis is well established 
including National Institute for Health and Care Excellence (NICE) guidance 
(https://www.nice.org. uk/guidance/cg149 accessed January 2015). NICE are 
engaging with clinicians to develop evidence-based guidance for late onset sepsis 
http://www.nice.org.uk/guidance/qs75 /chapter/quality-statement-6-placeholder-
antibiotic-treatment-for-lateonset-neonatal-infection (accessed January 2015). A 
review of antibiotic policies in British and Irish neonatal units found a consistent 
approach to prescribing for early onset sepsis but widespread random use of other 
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antimicrobial regimens for late onset sepsis Table 1-7 (unpublished with permission).  
Regimens frequently prescribed included co-administration of benzylpenicillin and 
gentamicin (35%), flucloxacillin and gentamicin (21%), ampicillin/amoxicillin and 
gentamicin (3%) [12]. Muller-Pebody et al. [71] reviewed 3,482 reports of bacteraemia 
and found that more than 95% of organisms (late-onset) were susceptible to 
gentamicin with either flucloxacillin or amoxicillin and amoxicillin with cefotaxime, but 
only 79% were susceptible to cefotaxime monotherapy. Monotherapy was used in 
only 8% of units [12]. Empirical second-line antibiotics for treating late onset sepsis, 
varied widely across the 46% units (93) that had second line policies, the most 
common regimens (cefotaxime and vancomycin) account for only 8% and other 
recommendations including meropenem, teicoplanin, piperacillin/tazobactam and 
aztreonam.  Over one-third of the NNU policies (37%; 74 units) specified alternative 
antibiotics first-line for septic episodes where central venous catheters were in situ, 
most commonly vancomycin (21%) or teicoplanin (12%) [12]. Table 1-8 summarises 
antibiotics commonly prescribed for late onset sepsis [11, 12, 18, 38] .  
Despite the challenges and lack of research in this population the EMA guidance for 
antimicrobial clinical trials is limited to the general population for drug development 
and has a brief paragraph in relation to paediatrics and neonates (discussed further 
in section 1.5.1) [79, 80].  
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Table 1-7 UK Neonatal Units Antibiotic Survey: Late Onset Sepsis ( n=202) 
 
Ist Line Antibiotics (n=180/202) 
N= % 
Benzylpenicilln and Gentamicin 70 35 
Flucloxacillin and Gentamicin     43 21 
Ampicillin/Amoxicillin and Gentamicin 6 3 
Co-amoxiclav and Gentamicin 2 1 
Benzylpenicillin monotherapy 2 1 
Amoxicillin, Flucloxacillin and Gentamicin 1 <1 
Cefotaxime monotherapy 2 6 
Cefotaxime and Amoxicillin/Ampicillin 11 5 
Cefotaxime and Benzylpenicillin 8 4 
Cefotaxime and Vancomycin 6 3 
Cefotaxime and Flucloxacillin 5 2 
Teicoplanin and Cefotaxime 4 2 
Vancomycin and Gentamicin 3 1 
Ceftazidime and Vancomycin 3 1 
Piptazobactam and Vancomycin 1 <1 
Cefotaxime and Gentamicin 1 <1 
Amikacin and Flucloxacillin 1 <1 
Cefuroxime monotherapy 1 <1 
 
2nd Line Antibiotics NNU (n=93/202) 
  
Cefotaxime and Vancomycin 16 17 
Flucloxacillin and Gentamicin 12 13 
Cefotaxime and Gentamicin 8 8.7 
Teicoplanin and Cefotaxime 6 6.5 
Vancomycin monotherapy 6 6.5 
Teicoplanin monotherapy 5 5.3 
Piptazobactam and Vancomycin 5 5.3 
Cefotaxime and Flucloxacillin 5 5.3 
Teicoplanin and Gentamicin 5 5.3 
Benzylpenicillin and Gentamicin 4 4.3 
Ceftazidime and Vancomycin 4 4.3 
Vancomycin in Gentamicin 3 3.2 
Meropenem monotherapy 3 3.2 
Cefotaxime monotherapy  2 2.1 
Ceftazidime and Teicoplanin 2 21 
Amikacin and Flucloxacillin 1 1 
Ceftazidime and Gentamicin 1 1 
Vancomycin and Azetreonam 1 1 
Teicoplanin and Vancomycin 1 1 
Teicoplanin and Meropenem 1 1 
Co-amoxiclav and Gentamicin 1 1 
Piptazobactam monotherapy  1 1 
Personal communication and permission from Dr P Heath  [12]
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Table 1-8 Properties of antibiotics commonly prescribed for late onset sepsis  
Antibiotic Class Antibiotic  Spectrum Susceptible Organisms Pharmacodynamics (in vivo) Main 
Excretion 
Protein 
binding 
%  
Gram-negative (GN) Gram-
positive 
Inhibition 
dependent  
Parameter for 
clinical efficacy           
Aminoglycosides* Gentamicin  Broad  
 
+ (mainly GN 
excludes anaerobic  
+ Excludes 
streptococci 
Concentration  Cmax : MIC Renal  70-85 
Fluoroquinolones Ciprofloxacin  Broad ** if 
3rd 
generation 
+  + Time  AUC 0-24 /MIC  Renal 20-30 
Glycopeptides Vancomycin Narrow No + inc. MRSA Time  AUC 0-24 /MIC Renal  55 
Teicoplanin No  +  Renal  90 
B-Lactams          
 
Carbapenems 
 
Meropenem 
 
Very Broad 
 
+ 
 
+ 
 
Time  
 
%T>MIC 
] 
Renal 
 
2 
 
Cephalosporins  
3rd generation 
 
Cefotaxime 
 
Broad  
 
+ excludes  
pseudomonas 
+  
Time  
 
%T>MIC 
 
Renal 
 
40 
 
Penicillins 
Ampicillin Broad + + includes 
streptococcal 
Time  %T>MIC Renal 15-25 
Benzylpenicillin Narrow No useful activity against 
Pseudomonas spp., 
Acinetobacter  spp. or 
Enterobacteriaceae 
+ Time  %T>MIC Renal 60 
Amoxicillin **** 
Amoxicillin/Clavulanate  
Broad + + Time  %T>MIC Renal 17-20 
Flucloxacillin  Narrow  + excludes 
Enterococcus 
faecalis 
 %T>MIC Renal 95 
Piptazobactam  Broad + + Time  %T>MIC Renal 30 
* TDM as toxic to kidneys and 8th cranial nerve (penicillin co-administered to increase bacterial permeability) 
** 3rd generation fluoroquinolones are broad spectrum but other fluoroquinolones are narrow    
*** Inactivated by penicillinases produced by Staph aureus and Escherichia coli  
**** Co-amoxiclav is a derivative of ampicillin  
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1.2.1 Ciprofloxacin antimicrobial (fluoroquinolone)   
Ciprofloxacin is a synthetic antimicrobial agent with broad spectrum activity against 
primarily Gram-negative but some Gram-positive organisms [53, 56]. Its mechanism 
of action is by the inhibition of two enzymes, type II topoisomerase (DNA-gyrase) and 
topoisomerase IV essential for bacterial DNA replication, transcription, repair and 
recombination [53, 170]. It is a second generation quinolone; the first generation is 
nalidixic acid. It was synthesised by adding a fluorine at C-6 and a cyclic diamine 
piperazine at C-7 to add antimicrobial activity against Gram-positive and improved activity 
against Gram-negative but not against anaerobic bacteria [159, 171]. 
Ciprofloxacin is a lipophilic antimicrobial active against intracellular pathogens, this 
intracellular penetration results in extensive distribution through anatomical barriers 
including the blood brain barrier [172]. It has significant activity against Pseudomonas 
aeruginosa due to excellent bioavailability with good tissue penetration. Due to its 
lipophilic nature a high proportion is distributed  intracellularly throughout body tissues 
and is present in plasma largely in a non-ionised form [53]. It reaches high 
concentrations in the lung, sinuses, inflamed lesions and urogenital tract where 
concentrations even exceed those of plasma.   
Intravenous guidelines recommend infusing ciprofloxacin over 60 minutes [173]. 
Following intravenous infusion to adults the maximum serum concentrations were 
achieved at the end of the infusion and the PK parameters were linear [53]. Protein 
binding of ciprofloxacin is low (20-40%) [53]. Ciprofloxacin is largely excreted 
unchanged, primarily in the urine and faeces approximately 12.1% is excreted in the 
form of metabolites [53] (Table 1-9). After a single intravenous doses of ciprofloxacin 
75% is eliminated by the kidney and 14 % in faeces compared to 55% renally and 
39% in faeces for an oral dose [53]. 
Since ciprofloxacin is not extensively metabolized by enzymes a genetic 
polymorphism is not likely to significantly influence the overall efficacy or toxicity. 
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Elimination and target distribution might be influenced by active drug transporters as 
ciprofloxacin is transported by organic anion transporter 3 (OAT3) [121].  
Table 1-9 Metabolites of Ciprofloxacin:  
 % of the IV dose excreted in: 
Urine: Faeces:     Biliary   
                  Route                                
Ciprofloxacin (within 5 days) 75% 15%           1%       
 
Metabolites – low concentrations: 
  
   M1   -  desethyleneciprofloxacin  
   M2  -  sulphociprofloxacin 
   M3  -  oxociprofloxacin 
   M4  -  formylciprofloxacin 
 
9.5 
 
2.6 
 
Metabolites and the percentage of the intravenous (IV) dose known to be found in urine and 
faeces  [53]. 
 
Only 10-20% of a single oral or intravenous dose is eliminated as metabolites (which 
exhibit lower activity than the parent drug). Four different antimicrobially active 
metabolites have been reported, Desethyleneciprofloxacin (M1), sulphociprofloxacin 
(M2), oxaciprofloxacin (M3) andformylciprofloxacin (M4). M2 and M3 account for 
one third each of metabolised substance and M1 is found in small amounts (1.3-
2.6% of the dose). M4 has been found in very small quantities (<0.1% of the dose) 
[53]. .  
 
Ciprofloxacin undergoes both glomerular filtration and tubular secretion; renal 
elimination takes place mainly during the first 12 hours after dosing. In adults renal 
clearance is between 180 - 300 mL/kg/h and the total body clearance is between 480 
- 600 mL/kg/h [53]. The half-life of ciprofloxacin is 3-4 hours [53]. Severely impaired 
renal function in adults increases the half-life up to 12 hours. When serum creatinine 
is >124 µmol/L the dose is reduced to half and administered 12 hourly. When above 
168 µmol/L it is administered 24 hourly [53]. Based on population PK analysis of 
paediatric patients with various infections, the predicted mean half-life in children is 
approx. 4-5 hours [53, 174]. Ciprofloxacin dosing in children with impaired renal and 
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or hepatic function has not been studied [53]. Non-renal clearance of ciprofloxacin is 
mainly due to active trans-intestinal secretion and metabolism. Ciprofloxacin is 
present in the bile in high concentrations <1% of the dose is excreted via the biliary 
route [53, 174]. When drugs are primarily eliminated by the kidney clinicians must 
individualise treatment regimens in an age appropriate fashion that reflects both 
maturation and treatment-associated changes in kidney function [78].  A lower dose 
of ciprofloxacin 5mg/kg /day is prescribed in this neonatal unit when renal function is 
impaired [134, 162]  (Neonatal Late onset Sepsis Protocol – Liverpool Women’s NHS 
FT).  
 Ciprofloxacin Pharmacodynamics   
Pharmacodynamic (PD) studies of ciprofloxacin are limited to adult data as there are 
no paediatric studies. The efficacy depends on the ratio of the total antibiotic exposure 
AUC/MIC (area under the concentration time curve at steady state over 24 
hours/minimum inhibitory concentration representing the susceptibility of the 
organism. Ciprofloxacin is effective for Gram-negative and Gram-positive bacteria. 
Pre-clinical studies suggests a higher AUC24h/MIC >125 is required to treat Gram-
negative bacteria effectively than Gram-positive bacteria AUC24/MIC >40 [162].  
To optimise clinical and microbiological outcomes in adults targets of ≥125 are widely 
accepted mainly based on a study by Forrest et al. in 1993 [162, 175, 176]. Clinical 
cure was 80% when above an AUIC ratio of 125 compared to 42% when below 
(P<0.005) and microbiological cure 82% compared to 26% (P< 0.001) respectively 
[162]. The median time to bacterial eradication from respiratory secretions reduced to 
1.9 days with an AUC24/MIC ≥250 compared with 6.6 days when 125 - 250 and 32 
days if <125 [162]. More recently, Zelenitsky et al found higher cure rates (91.4%) 
were attained with an AUC24/MIC ratio >250 when compared to 28.6% when <250 
[176].  
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Figure 1-25 Ciprofloxacin a AUC 24 / MIC (mg/h/L) for adults  
Figure reproduced from Zelenitsky et al. with permission from Oxford Journals  [176]  
 Ciprofloxacin Pharmacokinetics (PK) 
Pharmacokinetic studies in children and neonates are summarised in Table 1-13  
Lipman et al. [115] evaluated the PK of ciprofloxacin 20mg/kg per day administered 
12 hourly for children comparing two age groups >3 months to 1 year (Group A) and 
>1year to 5 years of age (Group B) with severe sepsis (n=20). PK parameters were 
evaluated using non-compartmental methods. Areas under the curve (AUC, 12 h) 
were Group A: 15.6±1.3, 19.2±1.63 and 14.1±1.4 mg/h per L, and Group B 15.9±1.3, 
18.0±1.7 and 13.2±1.26 mg/L. In infants the AUC ranged between 11.8 and 32.0 
mg/h/L (mean 17.4mg*h/L) and children 11.0–23.8 mg/h/L (mean 16.5mg/h/L). The 
authors concluded that AUC were lower than achieved in their adult PK study. The 
paediatric PK data produced a lower AUC insufficient to achieve the minimum AUC 
ratio of >125 – 250 for an optimal outcome. The AUC24 for Groups A and B would only 
be sufficient to treat organisms with an MIC of <0.3 mg/L and achieve a relatively low 
AUC24/MIC ratio of 100 [115]. This is considerably lower than the EUCAST 
susceptibility clinical breakpoint of 0.5mg/L. This suggests 10mg/kg/12 hourly was a 
suboptimal dose and the authors recommended 10mg 8 hourly, particularly for more 
resistant ICU organisms in patients with normal renal function [115].  
A
U
C
 2
4
/M
IC
 
 
65 
Introduction  
Szalek et al. found vast interindividual variability when ciprofloxacin was administered 
to critically ill patients. The standard adult dose of 400mg provided a lower AUC24/MIC 
ratio than 125 for 70%, CV>30%; the Vd (l) increased, elimination rate constant was 
higher 0.21h-1, clearance higher 39.7 l/h [177]. Drusano et al. demonstrated that 
increasing the MIC and dose of ciprofloxacin were proportionate, as both AUC/MIC 
ratios had identical survival curves in rats. Isolates with an MIC of 1mg/L treated with 
20mg/kg/day resulted in the same AUC24/MIC ratio compared to when the MIC was 
4mg/L and treated with 80mg/kg/day [178].  Different dose regimens produce 
variations in the probability of target attainment as demonstrated in Figure 1-24. 
Zelenitsky et al. found the significant factors for treatment failure were low 
ciprofloxacin AUC24/MIC (p<0.0001), high MIC (p=0.0001), male sex (p=0.002) and 
low AUC24 (p=0.01) [176]. 
 
Figure 1-26 Ciprofloxacin MIC and probability of target attainment (PTA)  
 
Probability of attaining an AUC24/MIC ≥250 in Monte Carlo simulations of 5000 
study subjects with Enterobacteriaceae BSI stratified according to MIC. Zelenitsky et 
al. [176]. Reproduced with permission from © Oxford University Press  
 
To optimise clinical cure and prevent spreading resistance a Cmax of 8 – 12 times the 
MIC (Cmax/MIC) has been recommended for ciprofloxacin [179-181]. For critically ill 
septic paediatric patients the Cmax for children aged 3 months to 1 year was 6.1 ± 1.2 
mg/l, mean clearance 3.7l/h (0.58 l/h/kg). A higher Cmax was achieved in children 1 – 
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5 years (7.4 +- 1.3), clearance 7.3 l/h (0.56 l/h/kg). Also, the Cmin was not maintained 
above the MIC for many organisms for much of the dosing period [115].    Forrest et 
al. compared Individual PK parameters values to the MIC to determine the peak 
ciprofloxacin concentration to MIC ratio, a ratio below four was associated with poorer 
clinical and microbiological outcomes. Their data suggest a peak-MIC ratio of eight 
and trough-MIC ratio above one were required to optimise outcome [162]. A Cmax/MIC 
ratio of approximately 5:1 has been reported to correspond to an AUC 0–24/MIC ratio 
of 100 for ciprofloxacin [87].  
CSF penetration of ciprofloxacin has been shown to vary but was approximately 22% 
of the serum concentration in an infant [182].  A case study of a neonate found CSF 
concentrations of 0.88–1.44 mg/L following a dose of 10mg/kg/day approximately 
60% of the plasma peak [183]. Differences may be due to the presence or absence 
of inflammation.  
1.2.2 Neonatal dose regimens  
As ciprofloxacin is prescribed off label this has resulted in a wide range of dose 
regimen. A systematic review of ciprofloxacin in neonates reported the daily dose 
varied between 5 and 60 mg/kg/day and duration of treatment ranged from 5 to 75 
days [184]. Ciprofloxacin regimens in Europe are summarised in Table 1-10.  Existing 
PK data for this population is limited and summarised in Table 1-13. This variation in 
practice reinforces the need for PK data.  
Table 1-10 TINN survey of dose regimens in European neonatal units 
 
Total dose mg/kg/day Units 
 
% (n=51) 
 
≤ 10 12 (22) 
    11-20 20 (40) 
    21-30   9 (18) 
>30   1 (2) 
Missing   9 (18) 
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Paediatric PK data for ciprofloxacin recently led to a recommendation to increase the 
dose from 10mg/kg/day to 20 or 30 mg/kg/day for more resistant organisms [115]. In 
line with this, the neonatal ‘off label’ dose regimens was increased from 10mg/kg daily 
to 10 mg/kg either 8 or 12 hourly in the BNFC [173] Table 1-11. However, this increase 
was not founded on neonatal PKPD data. At present there are neonatal peak and 
trough data whereas the evidence suggests that AUC/MIC ratios are the best 
predictors of cure [115, 185].  To provide neonatal data with AUC additional sampling 
time points to peak and trough are required. Aggarwal et al. [185] compared the peak 
and trough ciprofloxacin concentrations in 24 neonates administered 20mg/kg/day on 
days 1, 3 and 7, the mean peak ranged from 2.3 to 3.0 µg/mL and trough 0.7 to 1.0 
µg/mL. They found no difference in concentrations for VLBW and non VLBW babies. 
Premature babies may have higher or lower drug concentration or AUC as has been 
shown with gentamicin [126]. 
In both recruiting sites ciprofloxacin is part of the standard clinical protocol for neonatal 
sepsis (Table 1-12). Liverpool Women’s NHS Foundation Trust Neonatal Unit admits 
over 1000 newborn babies a year of whom approximately 100 are prescribed 
ciprofloxacin as a second line treatment for suspected sepsis. Approximately 300-400 
babies a year are treated for suspected late onset sepsis. Ciprofloxacin was 
introduced in this neonatal unit to minimise pressures towards cephalosporin 
resistance 20 years ago [183]. Alder Hey NHS Foundation Trust is a lead centre with 
over 20 paediatric wards including a Neonatal Surgical Unit and Paediatric Intensive 
Care Unit (PICU). The PICU has 23 beds and admits over 1000 children a year of 
which 48.1% are aged less than one year and of these 58.4% less than three months 
of age [186].  
 
 
 
68 
Introduction  
Table 1-11 British National Formulary for Children (BNF C) Ciprofloxacin Regimens  
 
Table 1-12 Recruiting Sites Intravenous Antibiotic Guidelines   
 
 Indication Antibiotic 
 
Dose 
(mg/kg) 
Frequency 
(hours)  
Liverpool 
Women’s 
NHS FT  
 
First Line:  
 Early Onset (<5 days birth) 
Benzylpenicillin  
Gentamicin         
25    
4.5   
12 
36 
 Late Onset (>5 days birth) 
Co-amoxiclav  
Gentamicin       
30     
4.5  
 8 
36 
Second line 
  Renal impairment  
  Lack of clinical response  
  Sensitivities of organism 
 
Ciprofloxacin  
(add or replaces 
Gentamicin) 
 
10  *  
(increased 
from 5 in 
2011) 
8 or 12  
  Meningitis Cefotaxime  50    8 
 CoNS Teicoplanin  Load:16  
then  8  
 
24 
Alder Hey 
Children’s 
NHS FT  
(No standard 
protocol) 
Severe Infection 
  Hospital acquired  
  Central line 
Ciprofloxacin 10  
 
12 (Neonate) 
  8 (Term) 
     
 Indication Intravenous dose (mg/kg) 
Neonate Infant >1 month  
Complicated urinary tract infection   6 (12 hourly)    6  (8 hourly) 
Severe respiratory tract infections (RTI)  10 (12 hourly) 10  (8 hourly) 
Pseudomonal lower RTI  10  (8 hourly) 
Anthrax  10  (12 hourly) 
Table 1-13 Ciprofloxacin PK studies in children and neonates 
Author Year Age 
Group 
N= Dose 
mg/kg/
day 
AUC (SD) MIC range 
mg/L 
 
Serum  
C max mg/L 
(SD) 
 
Serum 
C min 
mg/L 
V 
l/kg 
(SD) 
Cl  
L/h/kg 
(SD) 
t ½ 
 
(SD) 
CSF mg/l 
Isaacs et 
al. [182] 
1986 Preterm  
26 weeks 
PMA 
1 
(CSF 1) 
4 - 6 N/A 0.25 – 1   
 
0.98  to 1.3  
 
0.11 - 0.29    0.10 – 0.37 
(11- 28%  
of serum peak) 
Bannon 
et al. 
[183] 
1989 Preterm  
24 -29 
weeks 
PMA  
6 
 
(CSF 1) 
10  - 0.03 – 0.06  1.45 – 5.7  
 
3rd dose: 
0.04-2.6  
   0.88 - 1.45 
64% of serum 
peak (mean) 
Lipman et 
al.  [115] 
2002 
 
Infants 
3-12 
months  
10 20 32.60 0-24 
 
(2.88)  
N/A  6.97 (1.48)  
 
0.19 (2.34) 1.87 
(1.39) 
 
0.58 
(1.46) 
3.74 (1.58)  
Children 
1-5 years  
10 20 31.4 0-24 
(2.84) 
N/A 7.18 (1.42)
  
0.15 (2.17) 1.54 
(1.20) 
 
0.56 
(1.33) 
2.93 (1.26)  
Peltola 
[187] 
1992 Term  
5 – 14 
weeks 
7 Oral  
15 
mg/kg  
 16.1 0-∞ 
(7.4)  
 
N/A 3.3    (1.3) 
 
 N/A  2.73 (0.28)  
Children 
1-5 years  
9 5.3 0-∞ 
(3.3)  
 2.1 (1.7)    1.28 (0.52)  
Aggarwal 
et al.  
[185] 
2004 Preterm 
32 weeks 
PMA 
24 20 N/A N/A 2.6 (0.4) 0.83 (0.16)     
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 Pharmacovigilance  
Too little exposure to an antimicrobial leads to an ineffective drug regimens, and too 
much creates the potential for adverse effects [72]. Critically ill babies have complex 
clinical conditions; adverse events may be confounded by events not related to 
microbiology or antimicrobial therapy but associated with the underlying clinical 
condition including congenital abnormalities, other interventions or concomitant 
medication.   
In a critically ill population the choice of drug therapy balances the risk of adverse 
reactions with the high risk of morbidity and mortality from Gram-negative 
septicaemia. Mortality in neonates increases from 18% to 36% when Gram-negative 
organisms are confirmed in blood cultures [18]. The potential risk of an adverse event 
(such as arthralgia that is likely to resolve) needs to be proportionate to the risk of the 
outcome of Gram-negative sepsis which has high mortality. The observed effect of 
the drug may have a similar effect to the clinical condition on organ function [188]. It 
is difficult to infer causality in this population without a blinded randomised controlled 
trial.  A large prospective observational cohort study of adverse drug reactions in 
children (n= 6,601) admitted to hospital deliberately excluded PICU patients because 
the causality assessment was more difficult and requires different methodologies for 
detection [189]. A reaction may manifest weeks or more after therapy such as 
ototoxicity [63]. Neonates are more susceptible to drug related developmental 
disorders and adverse drug reactions that can sometimes only be detected later in life 
[79].  
Previously reported adverse reactions for ciprofloxacin are summarised in the MHRA 
Public Assessment Report [53] Table 1-14. A systematic review of ciprofloxacin in 
paediatrics reported 105 articles that met the inclusion criteria involving 16,184 
patients.  A total of 1,065 adverse events were reported  (risk 7%, 95% CI 3.2% to 
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14.0%) of which the most frequent were musculoskeletal, abnormal liver function 
tests, nausea, changes in white blood cell counts and vomiting   [190]. This review did 
not include reports of seizures but Lipman et al. [115] found seizures with higher 
Cmax. This review did not provide a separate analysis of blinded randomised 
controlled trials and many of the reported adverse events are commonly reported 
clinical symptoms in sepsis.   
Table 1-14 Expected Adverse Reactions for Ciprofloxacin  
  
Body System Adverse reaction/Hazard Likelihood 
Rare, Low, 
Medium or High  
Joints  Arthropathy/ tendonopathy M 
Vein  Phlebitis L 
Liver Function  Failure /Pancreatitis L  
Renal Function Failure /Crystalluria L  
Blood cells  Deranged L 
Gastro-intestinal  Colitis if severe and  persistent 
Clostridium Difficile 
M 
Anaphylaxis /Allergy Shock  R 
Neurological Convulsions M 
Cardiac Ventricular arrhythmias 
/Prolonged QT interval  
 
Skin Rash/ Photosensitivity  M 
Syndromes Stevens Johnson /Lyell R 
 
Reproduced from  the Summary of Product Characteristics and MHR Public Assessment 
Report  [53]    
 
The potential risk of arthropathy has deterred clinicians from prescribing ciprofloxacin 
to children. An early report of arthropathy for a child led to further safety studies in 
juvenile laboratory animals exposed to quinolones (nalidixic, oxolinic and pipemidic 
acids) [191, 192]. Studies with mature animals (rats and dogs) revealed no evidence 
of cartilage lesions whereas in young beagle dogs (4-12 months of age) severe 
articular changes were observed at therapeutic doses following two weeks of 
treatment and after a period of five months [53, 191]. The long term effects on growth 
were studied in a retrospective cohort of 205 premature babies (61 cases and 144 
controls) and found no evidence of change to their linear growth at 12 months 
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corrected age [193]. The systematic review of adverse events described above found 
258 musculoskeletal events occurred in 232 paediatric patients (risk 1.6%, 95% CI 
0.9% to 2.6%) [190]. Pooled safety data of controlled trials in this review estimated 
the risk of arthropathy as 1.57 (OR 95% CI 1.26 to 1.97).  The majority of 
musculoskeletal events (86%) were classified as possibly related to ciprofloxacin and 
a re-challenge was only done in eight patients of which only one was positive [194]. 
The review concluded that musculoskeletal adverse events are reversible following 
withdrawal of the ciprofloxacin with further symptomatic management [190]. The 
WHO Subcommittee on Essential Medicines for Children found arthropathy was not 
convincingly correlated with the use of fluoroquinolones in children [195].  
Many of the adverse events that have been reported are common in sepsis. Joint pain 
is a common presentation in children and has been associated with as many as 100 
different diagnoses besides traumatic aetiology [196]. The hips of newborn babies 
may be affected by a number of other conditions including developmental dysplasia 
or infection. McCarthy et al. categorised the cause of joint complaints in 250 children, 
19.6% related to bacterial infection, 18% orthopaedic, 17.6% autoimmune disorders, 
44% miscellaneous. Autoimmune or infectious disorders were eight times more likely 
to present with joint pain if the temperature was > 38°C or elevated erythrocyte 
sedimentation rate ≥ 30mm/h [197].  
The clinical assessment of hips in neonates is challenging as they are not weight 
bearing and non-verbal. There are difficulties in assessing whether there is a painful 
response to handling or startle reflex. Due to the limitations of diagnosis in non-weight 
bearing children there were no reports of arthropathy in children under six months 
included in the review, the youngest in the review was seven months [198]. MRI 
provides a useful tool to assess the hips in adults [199]. Pradhan et al. (1995) 
assessed the MRI scans of children following ciprofloxacin between day 10 and 15 of 
therapy and found no significant cartilage damage [200]. The normal MRI 
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appearances of the neonatal hip have been described in detail for neonates [201]. 
MRI assessment of arthralgia requires the development of a method to define and 
validate biomarkers relating to joint spaces and cartilage thickness.  The Liverpool 
Archive of MRI in Babies (LAMB study) is a registry of MRI that commenced in 2011 
to compare the liver, hip and brain of healthy babies with clinically indicated scans. 
Few are treated with ciprofloxacin therefore conclusive results will take several years.  
Altered hepatic or biliary function is common in sepsis. Sepsis associated cholestasis 
induced by inflammation is a common complication in patients with extra-hepatic 
infection or inflammatory processes [202].  This may be associated with the functional 
immaturity of immune system and bile formation especially in the first weeks of life. 
Endotoxins from Gram-negative bacteria can inhibit the function of the membrane 
transporter in hepatocyte cells, thus leading to cholestasis [203]. Oswari et al. [202] 
found elevations of serum AST were a marker of multi-organ dysfunction that reflects 
the severity of sepsis. Victor et al. found extremely premature infants had high plasma 
enzyme activities when compared to babies at a later corrected gestational age that 
may be due to more severe illness immediately after birth [204].   
Ciprofloxacin has been associated with seizures in adults and children with a higher 
Cmax [53, 115]. Ciprofloxacin is active in the central nervous system, and sometimes 
causes psychotic symptoms as side effects, known to be partly mediated by inhibition 
of the GABA A receptor [198]. Adverse reactions of the central nervous system are 
well-known complications of quinolone therapy but the mechanism is unknown [205]. 
Pre-clinical studies suggest the effects are less in ciprofloxacin than other quinolones 
and may be linked to magnesium levels [206].  
Neonatal venous access is limited and cannulation is more difficult than in adults due 
to the small size of veins. Therefore it is particularly important to protect against 
phlebitis when administering a drug. The pH of ciprofloxacin is 3.4-4.5.  The drug is 
administered slowly over 60 minutes. An injection site reaction is described as an 
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uncommon reaction in the SmPC (ranges between >1 in 1,000 and <1 in 100 patients) 
[53]. The Visual Infusion Phlebitis Scale [207] is a method for monitoring infusion sites 
recommended by the Infusions Standards Groups within the Royal College of Nursing 
(UK) [208] (validation is unpublished but cited by Gallant [209]).  
The TINN Consortium (Work Package 2) undertook preclinical studies in mice to 
determine neuro-developmental and physiological parameters including vital signs, 
blood gases. Arthrotoxicity was not identified (unpublished TINN Interim Report June 
2011).  Preclinical safety data for adults revealed no special hazards for humans 
based on conventional studies of single dose toxicity, repeated dose toxicity, 
carcinogenic potential or toxicity to reproduction [53]. A review of safety in relation to 
quinolones recognised the limitations of adverse event reporting and the risk of 
reporting non drug related events. The most reliable comparative data regarding 
tolerability is from double blind randomised controlled trials [205].  In a double blind 
trial Pichler et al. compared adults administered ciprofloxacin and a placebo and found 
the same rate of adverse events [210]. This illustrates the need for a blinded RCT 
when evaluating adverse events and adverse reactions in relation to drug 
administration particularly in critical illness.  
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1.3 Pharmacogenomics  
The host response to infection is at least in part influenced by genetics as 
susceptibility to sepsis and the clinical course of patients is highly heterogeneous 
[211]. Individual differences in efficacy and in elimination might partly depend on 
genetic polymorphisms are changes in DNA sequence of active drug transporters [57, 
121]. These polymorphisms might affect the likelihood of individual adverse reactions, 
toxicity and efficacy of drugs. Since ciprofloxacin is not extensively metabolized by 
enzymes a genetic polymorphism of the metabolising enzymes are less likely to have 
any influence. Drug metabolizing enzymes and transporters that contribute to the 
individual and age dependent capacity to metabolize and eliminate drugs are 
genetically determined and some individuals show an exaggerated response to the 
drug [119]. The main genetic influence may be associated with elimination and 
distribution associated with active drug transporters as ciprofloxacin is transported by 
organic anion transporter 3 (OAT3) [121]. 
To date there have not been any prospective clinical trials to evaluate whether  a 
patient’s genotypic profile improved efficacy, reduced adverse reactions, or lowered 
the overall costs of therapy  [72, 212]. Vast population studies are required to evaluate 
the influence of specific polymorphisms. An understanding of how genetic patterns 
vary according to outcome will allow investigators to stratify biomarkers and develop 
novel pathways for therapeutic targeting [213]. DNA samples collected during the PK 
study may in future contribute to individualised antimicrobial therapy.  
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1.3.1  DNA sampling in neonates 
In this neonatal unit DNA samples are obtained from buccal cells to minimise 
avoidable blood loss. This method may not provide sufficient quantity and quality of 
DNA for pharmacogenomic analysis and blood scavenged from clinical samples that 
would otherwise be discarded could supplement the quantity of DNA required. There 
is a theoretical risk that blood from recently transfused babies may be contaminated 
by the donor’s DNA either in white cells or free circulating DNA.  
Transfusion Associated Microchimerism (TA-MC) describes the presence of 
leucocytes in a recipient from the donor following a transfusion [214, 215]. Critically ill 
neonates may be at increased risk of TA-MC as frequent clinical sampling can result 
in multiple transfusions. Immediately following transfusion  the concentration of donor 
leukocytes has been reported to increase transiently for 3-5 days [216]. As a 
precaution some clinical laboratories recommend delaying sampling for one week 
following transfusion [217].  Other studies suggest TA-MC can persist for years and 
be as much as 5% of circulating leucocytes [214, 215].  
The risk of microchimerism may have reduced since 1996 as blood products are 
leukocyte depleted to <1 x 106 per unit based on the  NHS Blood and Transplant 
Service standards Regulation SI 2005 No 50  [218]. In theory, this may reduce the 
risk of TA-MC allowing DNA to be scavenged from discarded clinical samples. Further 
reduction of white cells in blood products may be achieved by gamma irradiation or 
methylene blue however free circulating DNA may still be present.   
 
When DNA has been extracted and amplified by Multiplex Polymerse Chain Reaction 
(PCR) (sensitivities to concentrations <0.5 ng of DNA) the DNA ‘fingerprint’ is 
illustrated on an electropherogram to compare the  buccal cell DNA with the blood 
derived DNA from the same patient  A DNA profile usually has two alleles (one from 
each parent) but when more are present this suggests either i) contamination of non-
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self cells or ii) artefacts and stutters that are commonly observed in the 
electropherograms. The Genemapper analysis software provides an 
electropherogram to illustrate the allelic ladder with sixteen highly variable loci (alleles) 
known to have a high degree of inter individual variation. In terms of powerplex a 
homozygote is when both alleles are the same and heterozygote is when alleles differ 
and can be resolved from one another. Artefacts may appear as one or two repeat 
units after the true allele peak whereas a stutter is more likely to appear before the true 
peak [219]. This provides a rapid, non-radioactive method designed to obtain a DNA 
type, or genetic fingerprint suitable for very small amounts of DNA.   
Contamination by a blood donor would result in many different peaks particularly as 
the 16 alleles selected for comparison have a high degree of individual variability. In 
contrast,  for example  foetal  DNA can be  contaminated by the mother’s  after birth, 
in this situation a comparison is required for the true peaks in each allele as the mother 
and foetus may have the same alleles genetically [220, 221]. The mother’s genotype 
is presented on an electropherogram then the mother’s alleles are identified on the 
fetal sample. The foetal alleles are tallest as this relates to the amount of material 
present, contaminating maternal alleles are much smaller and where the mother and 
foetus share alleles a larger than normal peak is obtained. 
Figure 1-27 shows a typical electropherogram obtained from the DNA ‘fingerprinting’ 
from a fetal sample with maternal contamination (for example from chorionic villus 
sampling).  To allow the maternal contaminating genotype to be identified with 
certainty from the electropherograms a separate DNA sample from the parents is 
mapped.  The labels in blue boxes ‘M’ show the maternal alleles, the labels in red 
boxes ‘F’ show the foetal alleles, and the green labels show shared maternal and 
foetal alleles. http://www.softgenetics.com/chimerMarker_9.htmL (accessed 19-3-
2013).  
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Table 1-15 Leukocyte depletion of blood products  
 
Blood Product Leukocyte depletion  
Mean 106/Unit*  (SD)  
UK Standard  
SI 2005 No 50 
 
Red Packed Blood Cells SAGM 0.30 0.29 <1 x 106 / unit 
Platelets  
     Apheresis 
     Pooled 
 
0.84 
0.33 
 
19.32 
0.28 
 
<1 x 106 / unit 
 
The NHS Blood and Transplant Service standards for leukocyte depletion are set by 
the Blood Safety and Quality Regulations [222] . The UK standard and the level of 
leukocyte depletion achieved are from personal communication NHS Blood 
Transfusion Service email date 3/2013. 
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Figure 1-27 Foetal DNA with maternal contamination  
This electropherogram was representative of when both the mother and the foetus’ 
alleles are known. 
 
F 
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1.4 Rationale for evaluating the PK PD of Ciprofloxacin  
Successful drug therapy is directly dependent on the administration of the optimal 
dose at the ideal dosing interval and therefore requires PK / PD and safety data 
specific to the population [223, 224]. In addition the increasing burden of resistance 
and lack of new antibiotics for Gram-negative bacteria leads support the need to 
optimize existing antimicrobials [6].  
At present ciprofloxacin is frequently administered throughout Europe but not 
authorised for use in neonates or infants below three months age. The TINN 
Consortium conducted a survey of the prescribing practices in Europe for 
ciprofloxacin in neonatal units (n=193). Ciprofloxacin was prescribed at 25% of these 
units (n=50) [184] Table 1-10. In the USA annual ciprofloxacin prescriptions for 
patients younger than 18 years is estimated as 150 000, 20% <1 year age [225]. Off 
label prescribing has resulted in wide variation in regimen internationally the optimal 
regimen is unknown yet it is commonly prescribed to neonates  [173].  
Table 1-16 European survey of Neonatal Units Indication for Ciprofloxacin (n=50)  
 
Indication Units  
N=50 
%  
First line therapy  
Neonatal Sepsis 
 
1 
 
(2) 
     Severe sepsis 3 (6) 
     CNS documented infection: 
   (meningitis, meningoencephalitis, ventriculitis,  cerebral abscess)   
13 (26) 
     Suspected multi-drug resistant strain infection 15 (30) 
Second Line Therapy 
Sepsis resistant to first line empirical therapy (other than ciprofloxacin) 
 
7 
 
(14) 
Severe sepsis resistant to first line empirical antibiotic therapy  17 (34) 
Culture-proven sepsis due to multi-drug resistant organisms but sensitive to 
ciprofloxacin 
41 (82) 
 
Ciprofloxacin is the only fluoroquinolone on the WHO Essential Medicines for Children 
list. The WHO Expert Subcommittee concluded that sufficient evidence is available to 
support the use of ciprofloxacin as a second-line treatment for specific, severe 
infections in paediatric patients [226].  
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The TINN consortium elected to conduct were funded by the EU Framework 7 Grant 
to develop a Paediatric Investigational Plan [73] in order to improve prescribing 
information about ciprofloxacin.  
1.5 Neonatal Drug Development  
1.5.1 European Medicines Agency Regulations and Guidance  
EMA require a Paediatric Investigation Plan (PIP) describing the strategy for 
developing the medicinal product [80]. To fulfil the requirements of a PIP the European 
TINN Consortium prepared the following work packages: 
 Pre-clinical in silico experiments   
 European survey of prescribing ciprofloxacin for neonates. 
 Systematic review of adverse events  
 Established an Ethics and Safety Advisory Board (EAB) 
 Pharmacogenomics   
 Pharmacokinetics and short term safety reporting of ciprofloxacin  
 
The EU Paediatric Regulation aims to improve medicines for children by licensing 
medicines specific to each age group [73].The EMA provide specific guidance for 
clinical trials involving pre-term and term newborn infants relevant to drug 
development [79]. Covariates for premature babies should include post-natal age, 
postmenstrual age and gestational age. Over this dynamic period of development 
rapid changes can occur in body weight, surface area and body composition and 
additional categories may be required for babies ‘small for gestational age’, and ‘low 
birth weight’. Post-natal weight loss may be 10% of birth weight and body weight in 
preterm neonates may increase three fold during post-natal medical care requiring 
doses to be recalculated. Recruitment should represent nephrogenesis before and 
after 34 weeks of PMA then stratify to further sub-ages for those  <26 weeks, 26-29 
weeks, 30-33 weeks, 34-36 weeks, 37-40 weeks and > 40 weeks gestational age.   
Known complications including respiratory distress syndrome, patent ductus 
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arteriosus, pulmonary hypertension, intra-ventricular haemorrhage, necrotising 
enterocolitis, retinopathy of prematurity and bronchopulmonary dysplasia should be 
evaluated as secondary endpoints. Other important factors include renal and hepatic 
clearance, concomitant medications, serum-bilirubin, feeding patterns, protein 
binding, displacement issues, especially bilirubin, and penetration of medicinal 
products into the central nervous system [79]. 
The EMA drug development guidelines for antimicrobials require efficacy studies in 
relation to different pathogens including multi-drug resistant, even if underpowered 
[63]. A non-clinical assessment of anti-bacterial activity should document in vitro 
bactericidal activity of the test antibacterial against recent clinical isolates for a period 
of five years according to EUCAST. Ideally several hundred isolates should be tested 
from different countries relevant to the clinical indication with a minimum of ten 
isolates for rare organisms. [227]. Selecting a drug regimen should be informed by 
PK/PD data from the population treated rather than healthy subjects. The PK-PD 
analysis should include the highest MIC distribution for wild type populations of 
pathogens (non-resistant) treatable with well tolerated dose regimens [63].  
The EMA guidance in relation to antimicrobials for paediatrics and neonates are 
limited as the guidance is general to drug development [79, 80]. The EMA provide a 
guideline on the evaluation of medicinal products indicated for treatment of bacterial 
infections which includes a brief paragraph on children [63]. There are specific 
challenges that need to be addressed regarding antibiotic trials in neonates and 
children. When the TINN consortium submitted a PIP application, the EMA requested 
a randomised controlled trial to be carried out to determine safety and efficacy. To 
power a paediatric sepsis trial using a baseline mortality of 10% as a primary end 
point would require 4000 babies to detect a significant relative reduction in the risk of 
mortality [29].  Due to the very small number of neonates with confirmed Gram-
negative sepsis that are eligible for such a trial, it was estimated this could take a 
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decade. Accordingly, the requirements of the EMA Paediatric Committee were not 
practicable in this patient population. Similarly, it was agreed in the protocol that safety 
data would be tabulated to provide a description of adverse events during treatment 
with ciprofloxacin. In terms of safety the confounding variables associated with 
prematurity and critical illness would require a randomised controlled trial for a 
definitive evaluation of safety outcomes [228]. Further analysis was not planned in 
this trial due to the complexity of determining causality of adverse reactions in critical 
illness  [228]. Similarly, other studies of adverse drug reactions have excluded critical 
illness for this reason [229, 230].  
 Clinical Outcome Measures for Neonatal Suspected Sepsis    
To evaluate safety or effectiveness requires a definition of the optimal outcome. At 
present there are no core outcome sets specific to neonatal sepsis [29, 220, 221]. 
There are limitations to using mortality as an endpoint due to the high number of 
neonates required when the incidence of both death and Gram-negative blood 
cultures are generally very low in children [29].  Composite outcomes such as organ 
failure–free days or ventilator free days are an alternative in critical illness [29, 220, 
221]. The advantage of selecting a short term outcome may determine a temporal 
association between the antibiotic and the outcome. Composite measures such as 30 
day mortality or ventilator free days are confounded by death and morbidity from other 
causes in critically ill infants [231]. Therefore biomarkers such as C-reactive protein 
or safety parameters such as liver and renal function tests are used in clinical practice 
[221]. 
1.5.2 Regulatory barriers to neonatal clinical trials  
To protect vulnerable groups including children the EU Clinical Trial Directive 
2001/20/EC (2001) includes additional regulatory and ethical principles [73, 232, 233].  
PK Clinical Trials are classed as Clinical Trials of Investigational Medicinal Products 
(CTIMPS) and regulated by the MHRA [234]. The ethical concern for including 
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children in research is balanced against the risk of administering medicinal products 
to a population in which they have not been appropriately tested to ensure safe and 
effective drug administration  [73, 235]. Inadequate dosage information has led to 
increased risks of adverse reactions including death and ineffective treatment through 
under dosing and toxicity with overdosing [236]. The EU Paediatric Regulations were 
introduced to provide incentives for medicines research for this population [73]. More 
recently, the Academy of Medical Science Report 2012 claimed the clinical trial 
regulations were a barrier to research and the Department of Health (DOH) directed 
the MHRA to establish a more proportionate approach based on the risk of the 
investigational medicinal product (IMP) [232]. A joint project in the UK by the MRC, 
DOH, MHRA and in Europe led by the MHRA aimed to develop a risk adapted 
approach that classify the risk of a trial as Type A, B or C relative to the  drugs 
marketing authorisation or use in standard care [232, 237]. Within this proposal the 
MHRA recognised that paediatric medicines are often prescribed off label even 
though they are prescribed in standard care [232]. To determine whether the risks 
could be mitigated the DOH directed the MHRA to publish a model and requested a 
model for the neonatal PK clinical trial for an off label medicine.  
The ethical challenges of paediatric research were extensively considered by the 
European Union ad Hoc group who provided guidance in respect of blood volume, 
parental consent, distress, confidentiality, trial design and data reliability [238]. 
Methods to minimise the volume of blood the distress of sampling procedures and 
development of assays using small volumes are essential particularly when the drug 
level provides no direct benefit to the patient [135]. To protect neonates the EMA 
guidelines specify the volume of blood that can be collected for the purpose of 
research [79]. The Royal College of Paediatrics report categorised blood sampling as 
a low risk relative to other interventions [238].   
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Ciprofloxacin is prescribed for standard care rather than for the purpose of research 
the risk to the patient is mainly due to the additional blood sampling. Parental consent 
is required at a stressful time. To ensure the rights, safety and wellbeing of trial 
subjects and be legally ‘valid’ consent for research must be provided ‘voluntarily’ by a 
person who has been fully ‘informed’ who has the ‘capacity’ at the time it is requested 
to make the decision [233, 239]. Parents may not be available when ciprofloxacin is 
prescribed at any time of the day or night and samples are required within minutes of 
the first dose. Emergency deferred consent was introduced in 2006 for children in 
specific situations when treatment is required urgently to be recruited if approved by 
an Ethics Committee [240]. This allows consent to be deferred to a more appropriate 
time for the families. This research has an ethical duty to ensure that the data 
generated are reliable. The precision of sampling and drug administration are crucial 
to PK analysis.   
1.5.3 Summary  
Antibiotics are central to the management of neonatal infection. The principles of 
antibiotic development are well understood but have not been applied to neonates or 
young infants, as a result there are no antimicrobials authorised by EMA specifically 
for sepsis in children [27]. There is an unmet therapeutic need for the paediatric 
population. Children have specific PK characteristics which have prompted European 
legislation [73]. As a consequence of this legislation the TINN consortium was funded 
to study ciprofloxacin. This thesis aims to support prescribing decisions relating to 
ciprofloxacin in neonates and young infants. 
Following discussions with EMA a PK clinical trial was designed. As paediatric PopPK 
trials are conducted in patients with the disease the data better reflects clinical use 
[80].  A prospective PK clinical trial provides data on PK parameters and the variability 
between each gestational sub-age group for premature and term infants representing 
every four weeks. Short term safety data was monitored systematically consistent with 
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Regulatory requirements. This is the first detailed PK model with AUC data of 
ciprofloxacin in neonates. PK clinical trials in neonates are complicated by rapid 
physiological changes during sepsis, disease influence on organs and technology 
used for organ support and therefore need to consider many covariates [78, 83, 241]. 
The maturity of renal function and metabolic pathways can have profound implications 
on drug disposition in infants [32, 242]. Sufficient eligible babies are required to 
represent each of the six sub age groups of neonates [79, 80]. There is a lack of A 
priori data to inform the sampling schedule as this cannot be reliably extrapolated 
from adult, adolescent or even older children for this population. Changes in total body 
water including dehydration or fluid resuscitation and interventions such as ventilation, 
concomitant medications, haemodynamic effects of congenital cardiac defects or 
inotropes and infection may influence PK/PD [79, 96, 223]. Data reliability is a 
considerable challenge due to the precision required when administering minute drug 
volumes, complex infusions and limitations to blood sampling in a clinical trial. Data 
reliability is essential as PK studies are rare in neonates and these data may inform 
prescribing globally. Parental consent is required at a stressful time when families are 
dealing with the birth of a premature baby diagnosed with suspected sepsis.  
In critical illness the reporting of clinical outcomes and safety are influenced by 
complex covariates. There are few high quality studies due to the small number of 
sepsis patients and difficulties in assessing outcomes [80]. To address this, a 
retrospective study reflects on the microbiological and clinical outcome of neonates 
with Gram-negative sepsis treated with ciprofloxacin over a six year period. Gram-
negative organisms were re-cultured to assess MIC creep and determine the MIC of 
ciprofloxacin for comparison with the neonate’s clinical outcome. Clinical breakpoints 
used to predict therapeutic success of antimicrobial therapy are currently informed by 
adult dose regimens and outcome data.   
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The challenges of neonatal clinical trials associated with the regulatory framework 
have been recognised by the DOH following the Academy of Medical Science Report 
[232, 235]. In response the MHRA were required to develop a risk proportionate model 
for PK clinical trials in neonates. As part of this thesis a model for neonatal 
pharmacokinetic clinical trials was developed and published by the MHRA 
demonstrating methods to mitigate risks within a proportionate regulatory framework.    
1.5.4 Primary Aim and Objectives  
Primary Aim: 
To evaluate the pharmacokinetics, microbiological and clinical outcome of 
neonates and infants with late onset Gram-negative sepsis treated with 
ciprofloxacin. 
Primary Objectives: 
 Describe the population PK of ciprofloxacin in neonates and young infants  
 To optimize the method of collecting DNA samples whilst minimising blood loss 
from neonates for future pharmacogenomic analysis. 
 To describe the microbiological and clinical aspects of the use of ciprofloxacin on 
a Neonatal Intensive Care Unit through a retrospective cohort study. 
 To develop a proportionate regulatory model for neonatal pharmacokinetic trials 
that reduces regulatory barriers whilst mitigating potential risks to the safety of 
neonates and the reliability of trial data for the MHRA.  
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Chapter 2 Pharmacokinetic Clinical Trial  
2.1 Overview  
This Chapter describes a population pharmacokinetic clinical trial of ciprofloxacin 
administered to preterm/term neonates and young infants up to 3 months of age with 
suspected Gram-negative sepsis.  
This clinical trial was developed and conducted at a neonatal lead centre and 
paediatric lead centre in the UK over an 18 month period between 2011 and 2012. 
The protocol was developed consistent with the UK Regulatory and Ethical approvals. 
A clinical trial culture for PK design was developed to ensure data reliability and 
optimise recruitment.  Trial methods including standard operating procedures and trial 
tools were developed consistent with the local practice at sites. The challenges of PK 
trials in critically ill children including clinical, ethical and regulatory were explored and 
solutions developed. The clinical interpretation of the data was explored to ensure 
data captured included the developmental, interventional and pathophysiological 
factors that influence the parameters for each sub-age group between 24 and 48 
weeks PMA. The clinical trial protocol, case report form, standard operating 
procedures were developed then the trial was conducted by the research fellow as 
part of this thesis.    
 The PK model building using NONMEM was completed by the PK analyst appointed 
to the consortium. This includes Figures 2.18 to 2.21 and Tables 2.14, 2.15 and 2.18. 
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2.1.1 Aims and Objectives: 
Aim: Describe the population PK of ciprofloxacin in neonates and young infants 
Primary Objective:  
 To evaluate the multiple-dose PK of ciprofloxacin in neonates and young infants 
(24–52 weeks postmenstrual age) with suspected or proven Gram-negative 
infection. 
Secondary Objectives:  
• Covariate analysis including postmenstrual age, gestational age, postnatal age, 
weight and serum creatinine.  
•     PK parameters including apparent volume of distribution and half-life.    
 Describe the demographics of the population and outcome of treatment episodes 
 Determine the extent to which ciprofloxacin penetrates the cerebrospinal fluid in 
neonates.  
 Describe the short-term safety profile of ciprofloxacin 
 Evaluate the tolerability of ciprofloxacin. 
 Describe the short term clinical outcomes C-reactive protein and mortality. 
Primary Outcome Measures 
 Ciprofloxacin plasma concentration and population PK parameters  
[maximum concentration, clearance, area under the curve (0-tau)], their 
relationship with covariates and inter-individual variability (CV%).  
 PK variables include apparent volume of distribution and half-life. 
Secondary outcome measures:  
 CSF concentration relative to the time of the dose  
 Adverse events (AEs) and serious adverse events (SAEs). 
 To evaluate the tolerability indicated by withdrawal of ciprofloxacin.  
 Clinical outcome of treatment (C–reactive protein and mortality). 
 Pre and post treatment MIC and PCR of organisms in faeces to assess 
rapid resistance 
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2.2 Methods 
2.2.1 Study design:  
This was a prospective, open label, population PK clinical trial of ciprofloxacin with 
sparse sampling at informative time points with additional scavenged samples. 
Ciprofloxacin was administered as part of standard care for suspected or confirmed 
sepsis. The clinical trial protocol and standard operating procedures defined the 
methods and tasks including: 
 Recruitment and screening 
 Drug prescribing and intravenous administration 
 PK samples at informative time points and scavenged blood sampling  
 Laboratory processing  
 Sample collection, shipping and storage 
 Safety monitoring and risk assessment 
 Data management 
 Recruiting sites: 
There were two recruiting sites: Liverpool Women’s NHS Foundation Trust (Neonatal) 
and Alder Hey Children’s NHS Foundation Trust (Paediatric). Both are lead tertiary 
centres with facilities for critical care. The Neonatal Unit has 1,200 admissions per 
annum and the Paediatric Intensive Care Unit 1,100 per annum. In addition there are 
23 wards at the children’s hospital. Non–recruiting sites were set up at 40 hospitals to 
collect follow up data on adverse events and post treatment faeces samples. This 
required R&D approvals, a Principal Investigator with GCP and trial training for 
pharmacovigilance reporting. 
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 Patient population – Inclusion and Exclusion 
Inclusion criteria  
 A clinical decision to prescribe ciprofloxacin according to the unit’s clinical 
protocol for managing late onset sepsis.  
 24 – 52 weeks post menstrual age (calculated from the first day of the last 
menstrual period)  
 A parent or person with parental responsibility gave consent.  
 Ciprofloxacin commenced within <48 hours of the first PK sample 
Exclusion criteria 
 Ciprofloxacin commenced before the fifth day of life  
 Unlikely to survive more than 48 hours as judged by the attending clinician.  
 Active cooling, haemofiltration, extra-corporal membrane oxygenation or 
peritoneal dialysis.  
 Recruited to other trials if the Investigators deemed that one trial would 
interfere with the validity of the other or if additional blood samples would 
exceed the recommended blood volume guidelines in the protocol.  
Pre-trial feasibility data was based on pharmacy records for the centralised sterile 
supplies unit and the neonatal BADGER patient data system. This indicated the 
majority of babies administered ciprofloxacin were located in the PICU or NICU and 
high dependency wards when diagnosed with suspected Gram-negative infection. 
 Sample size  
The target recruitment was 50 babies stratified to represent every four week 
development between 24 weeks and 52 weeks PMA (Table 2-1) consistent with the 
EMA guidelines [79, 80].  The target recruitment was five to eight patients per four 
week period.  
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Table 2-1 Target recruitment stratified for seven sub-age groups  
 
Sub-age groups - Post Menstrual Age (weeks)  
 
Pre–term 
 
Term Infants  
24-27 40-43 
28-31 44-47 
32-35 48-52 
36-39  
 Sparse blood sampling schedule and scavenged samples  
Three blood samples per day were collected at the start of treatment on the first or 
second day, then a further three at the end of treatment on day five, six or seven.  In 
preterm neonates weighing <1000g the sample volume was reduced from three to 
two samples per day to remain within the recommended volume limit.  Depending on 
whether the dose regimens was prescribed either eight or twelve hourly they were 
allocated to one of four sampling schedules Group A, B, C or D Table 2-2. The peak 
drug concentration was collected within three minutes of the end of the drug infusion 
T1. All other concentrations were taken within ten minutes of set time points ranging 
from T2, T3, T4, T6, T8 and T12 calculated as hours after the infusion started. These 
time points were not informed by prior data as this is not available but were distributed 
over twelve hours with more frequent samples in the early period. The researcher 
selected the sampling group in discussion with the clinical team to coincide when 
possible with clinical samples.  
A minimum of 0.2 mL blood was required for analysis to provide between 30 µL and 
150 µL of plasma for PK analysis. The total volume from each patient was limited to 
3% of the total blood volume during a period of four weeks and did not exceed 1% at 
any single time (based on a total blood volume of 80 – 90 mL/kg body weight (3% = 
2.4mL per kg each month) [80, 140]. Blood samples were collected from either a 
capillary heel prick or an arterial line. Central venous lines or long lines were not used 
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for samples due to the risk of contamination from a previous ciprofloxacin infusion.  
Additional samples were scavenged from blood collected for clinical care. The clinical 
teams were trained to record the exact time of the infusion and sampling to the minute.   
Table 2-2 Timed PK blood sampling schedule    
 
  
 Dose regimens 
A commercial, generic preparation of ciprofloxacin solution 2 mg/mL either as 50 mL, 
100 mL or 200mL bottles produced by Claris and supplied by Peckforton 
Pharmaceuticals (Cheshire UK) was dispensed as standard hospital stock. The NHS 
hospital pharmacy dispensed the IMP as standard stock therefore the MHRA 
confirmed there were no further requirements for drug accountability additional to 
NHS standards                             
Intravenous ciprofloxacin was administered as part of standard care in accordance 
with the local protocol for infection, usually as a second line rescue therapy for 
suspected Gram-negative infection. It was also given as the renal sparing drug of 
choice when there were early signs of renal failure due to nephrotoxicity associated 
Sampling 
schedule group 
 
Sample time (T) after the infusion* 
 
Blood 
volume mL  
Total 
(over 7 days) weight 
>1000g    
 weight 
<1000g   
T1 -   3 mins after the end of the infusion 
T2 – 12 = hours after the start of the infusion 
 
 
A 
   
T1 
  
T3 
   
T8 
  
1.2 
 Ai  T1  T3     0.8 
0.8 
0.8 
 Aii  T1     T8  
 Aiii    T3   T8  
 
B 
    
T2 
   
T6 
  
T12 
 
1.2 
 Bi   T2   T6   0.8 
 Bii   T2     T12 0.8 
 Biii      T6  T12 0.8 
 
C 
   
T1 
  
T3 
  
T6 
   
1.2 
 
D 
 
D 
   
T2 
  
T4 
  
T8 
  
1.2 
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with the first line antibiotic gentamicin. The dose regimens was based on British 
National Formulary for Children prescribing guideline [173]: 
   Neonate <1 month 10mg/kg 12 hourly                    
  Neonate >1 month 10mg/kg either 8 or 12 hourly  
           Renal compromise (creatinine >100 µmol/L) 5mg/kg 12 hourly 
The decision to administer a higher or lower dose was at clinician’s discretion. A lower 
dose of 5mg/kg/12 hourly was prescribed when there were signs of renal failure 
indicated by a creatinine >100 µmol/L. A higher dose 10mg/kg 8 hourly was 
prescribed for neonates >36 weeks PMA if indicated by the severity of illness.  
To determine whether this dose needed adjustment an interim analysis was 
performed for the first ten babies. An increased dose was envisaged if the AUC/MIC 
ratio was below the expected target of 125. If more than 25% of patients exhibited an 
AUC/MIC <80, the dose would have been increased by 20% or if the AUC/MIC<50 
the dose would have been doubled. A dose decrease would only have been supported 
if acute side effects were reported as monitored by the safety data monitoring board. 
PK analysis was carried out using the nonlinear mixed effects modelling program 
NONMEM VI (V2.0; GloboMax LLC, USA).  
 Drug Administration  
The intravenous infusion was prepared and administered according to routine clinical 
practice by central or peripheral intravenous line. The total drug volume and flush 
were administered over 30 minutes in the neonatal unit or 60 minutes in the paediatric 
intensive care unit. The exact time the infusion commenced and completed was 
recorded.  
Standard operating procedures were developed specific to the drug administration 
method at each site. In the paediatric hospital the infusion line may be primed with 
either the drug or saline. When saline was used the time between the drug reaching 
the vein depended on whether the rate was set to include the drug and flush volume 
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(total mL/hour) or the rate (mL/hour) and drug volume. Adjustments were made 
according to the following formula to estimate the time the drug takes to reach the 
vein:  
a) Infusion line primed with ciprofloxacin  
The drug was drawn into the syringe then purged to prime the infusion line and the 
actual volume to be administered remained in the syringe. The line was then 
connected to the cannula. The pump was set to deliver the required volume of drug 
in the syringe (not the drug in the line). On completion the line primed with 
ciprofloxacin was disconnected from the cannula. A saline flush was connected 
directly into the cannula.  
b) Infusion line primed with a saline (flush included in the total volume infused) 
Dead space volume (mL) = 
   
infusion line                                                              + the filter         + cannula  
 
Figure 2-1 Dead space between the infusion pump and the vein  
 
The syringe with the exact volume of drug was connected to the line primed with 
saline. The rate of infusion was set to include the volume of drug to be administered 
and the flush volume (estimated as 2mL). A syringe with a 2mL saline flush was 
connected as soon as the pump detected the volume had been infused. The flush 
was then infused at the same rate to ensure the remaining drug in the dead space of 
the infusion line was delivered within the same period (30 or 60 minutes). The delay 
in the drug reaching the vein was calculated as in Table 2-3.  
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c) Infusion line primed with a saline (flush excluded from the total volume infused)  
The syringe with the exact volume of drug to be administered was connected to a line 
primed with saline. The rate of infusion was set to exclude the flush volume (estimated 
as 2mL). A syringe with a 2mL saline flush was connected at the end of the infusion 
and administered at the same rate therefore the drug did not reach the vein until the 
initial flush has been infused. This delay was calculated as Table 2-4: 
Infusion time (mins) / rate set on infusion pump x 2 (flush volume) = 
= time before the drug reaches the vein. 
 
Table 2-3  Time for the drug to reach the vein (includes the flush volume) 
 
The line is primed with saline then infused over 60 minutes and includes the flush 
volume of 2mL 
 
Infusion time (mins) / rate set on infusion pump x 2 (flush volume) = 
= time before the drug reaches the vein. 
 
Table 2-4  Time for the drug to reach the vein (excludes the flush)  
The rate excludes the flush volume of 2mL and the line is primed with saline then 
infused over 60 minutes 
Neonate’s 
weight 
(kg) 
Drug 
volume 
(mL) 
Rate 
(mL/hour) 
Delay 
before the 
infusion 
reaches the 
vein (mins) 
Total time to 
administer 
(mins) 
1 5 7 17 77 
2 10 12 10 70 
3 15 17 7 67 
4 20 22 5.4 65 
5 25 27 4.4 64 
Neonate’s 
weight 
(kg) 
Drug 
volume 
(mL) 
Rate 
(mL/hour) 
Delay before 
the infusion 
reaches the 
vein (mins) 
Total time 
to administer 
(mins) 
1 5 5 24 84 
2 10 10 12 72 
3 15 15 8 68 
4 20 20 6 66 
5 25 25 4.8 
 
65 
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 Laboratory analysis   
Serum creatinine concentrations were measured at Alder Hey Children’s NHS FT with 
an adapted Jaffé method and Architect C system (Abbott diagnostics, Illinois, US). 
The PK blood sample was allowed to clot for a period of 30 minutes or more then 
centrifuged at 4,000 rpm for 10 minutes at room temperature or 4°C within 24 hours 
of collection. The serum was transferred to a clean polypropylene tube/plain tube and 
stored at −20°C until shipped in batches to the PK laboratory.   
A method suitable for assaying small plasma volumes was developed and 
implemented by the pharmacology laboratory University Hospital of Tours, France 
[243]. Ciprofloxacin concentrations were determined using high-performance liquid 
chromatography (HPLC) and quantification with mass spectrometry (LC-MS). D4–
ciprofloxacin was the internal standard.  The calibration curve ranged from 25 to 3000 
ng/mL. The inter- and intra-day coefficients of variation (CVs) of controls were 4.1% 
and 2.4%, respectively. The lower limit of quantification was 25ng/mL.   
 Screening and Recruitment   
Daily screening of all admissions in the neonatal and paediatric intensive care units 
identified neonates who met the eligibility criteria.  A log was kept detailing which 
parents/babies were approached, recruited or declined and the reason. As this was a 
population PK clinical trial the population included those treated with ciprofloxacin for 
suspected sepsis as part of their standard care rather than administering the drug for 
the purpose of research. Parental consent was requested primarily to collect PK blood 
samples and optional requests for sub-studies: 
i) Collection of DNA samples   
ii)  CSF sample when a lumbar puncture was required for clinical care.  
Consent for those prescribed ciprofloxacin and prospective consent for those 
identified as more likely to be prescribed ciprofloxacin at a later date. Administration 
of ciprofloxacin was not delayed by the consent process. To allow the first PK sample 
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to be taken within three minutes of the end of the first infusion of ciprofloxacin, the 
following approaches to consent were approved by National Research Ethics Service 
and European Ethics TINN:  
Prospective consent - those more likely to commence ciprofloxacin were identified 
and routinely consented using the following criteria: 
a) Screened for sepsis due to presenting clinical signs.   
b) Extreme prematurity - born <28 weeks post menstrual age. 
c) First line antibiotics for suspected Gram-negative infection.  
Telephone Consent – when the information sheet had been provided to families, the 
investigator telephoned the family to request consent within a set process approved 
by NRES and witnessed by a member of the clinical team. 
Deferred Emergency Consent - Amendment 2008 for Children in Emergency - UK 
SI 941 [240, 244] allowed the initial blood sample to be collected then request consent 
to use the data retrospectively. Data were only included in the analysis if the parent(s) 
subsequently gave informed consent. Every effort was made to request parental 
consent first. Last day samples, DNA samples, or CSF samples were not collected 
unless consent was subsequently obtained.  
These consent processes are consistent with the Medicines for Human Use Clinical 
Trial Regulations (2004) and International Conference on Harmonisation Good 
Clinical Practice (ICH GCP)(1996) [239, 245] and UK law.  Consent was obtained 
from a person with parental responsibility defined by the Children’s Act 1989 and the 
Children and Adoption Act 2002 [246, 247]. The parent information sheet was 
designed with input from parents and approved by REC and included the twenty 
elements of consent [232]. Parent(s) were approached initially by the clinical team. 
Parents were given repeated opportunities to ask questions, clarify any issues about 
the study and confirm or withdraw consent. The informed consent process was 
delivered by health care professionals experienced in PICU/NICU, trained in ICH 
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GCP, consent law and the trial procedures then delegated by the Principal 
Investigator. A medically qualified doctor assessed the eligibility prior to any study 
procedure (required by the regulatory body MHRA).   
 Cerebro-spinal fluid (CSF) sampling 
To determine the CSF penetration of ciprofloxacin samples were collected if/ when a 
lumbar puncture was performed for clinical care following the administration of 
ciprofloxacin. Between 150 µL and 0.5 mL of CSF was collected in a sterile 
polypropylene ‘plain’ tube. Labels and CSF sample bottles were prepared and added 
to cots to ensure the clinical team were reminded at the time of sampling. The exact 
time of sampling was recorded by the clinical team and the CSF was stored 
immediately at -20°C. 
2.2.2 Population PK modelling of ciprofloxacin 
PK analysis was carried out by the Department of Clinical Pharmacology Robert 
Debre Hospital using the nonlinear mixed effects modelling program NONMEM V 7.2 
(Icon Development Solutions, USA). First order conditional estimation (FOCE) 
method with interaction was used to estimate PK parameters and their variability.  
Inter-individual variability of the PK parameters was estimated using an exponential 
model and was expressed as follows: 
Θi= θ mean*eηi where θ i represents the parameter value of the ith subject, θmean the 
typical value of the parameter in the population and ηi the variability between subjects 
which is assumed to follow a normal distribution with a mean of zero and variance ω2.  
The model was parameterised in terms of: 
 V1 central volume of distribution  
 V2 peripheral volume of distribution 
 Q inter-compartmental clearance  
 CL clearance 
Inter–individual variability was described by an exponential model and was estimated 
for V1, V2 and CL. Inter occasion variability on CL was coupled to inter-individual 
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variability by an additive model.  A proportional model best described residual 
variability.   
 Covariate analysis  
Covariate analysis followed a forward and backward selection process. The likelihood 
ratio test was used to test the effect of each variable on model parameters including:  
 current weight  
 birth weight 
 gestational age 
 postnatal age (when administered ciprofloxacin)  
 postmenstrual age (at birth) 
 serum creatinine concentration (within ≤48 hours of  PK sampling)  
Pre-specified co-medication included: inotropes, ibuprofen, diuretics, caffeine, 
teicoplanin, amoxicillin-clavulanic acid, nystatin and selective decontamination of the 
digestive tract (coliston, amphotericin, tobramycin) 
 
During the first step of covariate model building, a covariate was included if there was 
a significant (p<0.05, 2 distribution with one degree of freedom). This was indicated 
by a reduction of >3.84 in the objective function value (OFV) from the basic model. All 
the significant covariates were then added simultaneously to construct a ‘full’ model. 
Subsequently, each covariate was independently removed from the full model. If the 
increase in the OFV was >6.635 (p<0.01, 2 distribution), the covariate was 
considered to be statistically significant therefore retained in the final model. 
An allometric scaling function was used a priori to describe the effect of weight on 
clearance and volume average (allometric coefficients of 0.75 for CL and Q, for V1 
and V2) (0.75 based on the average adult weight).    
Model validation was based on graphical and statistical criteria. Goodness-of-fit plots, 
including observed (DV) versus population prediction (PRED); DV versus individual 
prediction (IPRED); conditional weighted residuals (CWRES) versus time and 
CWRES versus PRED were initially used for diagnostic purposes [248]. The stability 
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and performance of the final model was also assessed by means of a nonparametric 
bootstrap with re-sampling and replacement. Re-sampling was repeated 500 times 
and the values of estimated parameters from the bootstrap procedure were compared 
with those estimated from the original data set. The entire procedure was performed 
in an automated fashion, using PsN software (v2.30) [249].  
 Model evaluation:  
Model validation was based normalized prediction distribution errors (NPDE) [250]. 
Goodness-of-fit plots, including observed (DV) versus population prediction (PRED); 
DV versus individual prediction (IPRED); conditional weighted residuals (CWRES) 
versus time and CWRES versus PRED were initially used for diagnostic purposes. 
The stability and performance of the final model was also assessed by means of a 
nonparametric bootstrap with re-sampling and replacement. Re-sampling was 
repeated 500 times and the values of estimated parameters from the bootstrap 
procedure were compared with those estimated from the original data set. The entire 
procedure was performed in an automated fashion, using PsN (v2.30). One thousand 
datasets were simulated using the final population model parameters. NPDE results 
were summarised graphically by default as provided by the NPDE R package (v1.2) 
[251]: (i) QQ-plot of the NPDE; (ii) histogram of the NPDE. The NPDE is expected to 
follow the N (0, 1) distribution to show there is no bias in the model. 
 Ciprofloxacin penetration into the cerebrospinal fluid 
Assessment of the ciprofloxacin penetration into the cerebrospinal fluid (CSF) was 
evaluated by the CSF/serum ciprofloxacin concentration ratio. Because serum 
ciprofloxacin concentrations were not obtained concurrently with CSF sample 
collection, serum concentrations at the time of CSF sample collection were calculated 
from the Bayesian estimates for the concentration obtained from each individual 
patient. 
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 Simulation of Dose Regimens  
Monte Carlo simulations were performed using the parameter estimates obtained 
from the final model in order to define optimal dosing regimens able to attain the target 
AUC/MIC of 125 in about 80% of patients. To ensure comparable safety profiles, the 
percentage of patients below the reported maximum AUC was also considered. The 
paediatric dose of ciprofloxacin was simulated on a mg/kg basis according to different 
age groups. Thus, various mg/kg dosing regimens (5, 7.5, 10, 12.5, 15 mg/kg twice 
daily) were simulated in each neonatal group. One thousand simulations were 
performed and AUC0-24 at steady state was calculated for each simulated patient. The 
target attainment rate was then calculated for each dosing regimens to define the 
optimal dose regimens in each neonatal group. Two graphs illustrated the simulated 
dose regime for neonates above and below PMA 34 weeks then PMA 36 weeks as 
estimates of the changes due to nephrogenesis.  
2.2.3 Pharmacovigilance  
A risk assessment of the investigational medicinal product included a summary of the 
adverse reactions reported in the SmPC and MHRA Public Assessment Report, back 
ground papers, British National Formulary for Children [53, 173] inclusive of the wider 
group of fluoroquinolones Table 2-5.   
Clinical data were collected regarding adverse events to evaluate the study outcome 
and to comply with pharmacovigilance reporting of Clinical Trial Investigating a 
Medicinal Product (CTIMP) [245] . The non-serious events in the protocol that 
required reporting were approved by the Sponsor. Pharmacovigilance reporting 
continued until week six following administration of ciprofloxacin. All events were 
followed up until satisfactory clinical resolution. Each patient was reviewed daily until 
three days following the last dose. This included reviewing a patient data system that 
collects data from routine blood values, vital signs, microbiology results and possible 
adverse events during this period. Confounding variables associated with treatment, 
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other medications and known adverse events were systematically collected in the 
case report form based on a risk assessment of the IMP. As most patients were 
critically ill they were intensively monitored with continuous monitoring of vital signs 
as part of standard care. Biochemistry/haematology and frequent blood gas analyses 
were carried out for routine care and assessed against validated laboratory normal 
values with specific monitoring of renal and hepatic parameters (set by the paediatric 
laboratory).  The development of a framework for more proportionate 
pharmacovigilance reporting in critical illness was developed and is described in more 
detail in Chapter 7. 
Table 2-5 Known Adverse Reactions for Ciprofloxacin Injection  
 
Body System Hazard Likelihood 
Rare        (R)  
Low          (L) 
Medium  (M)  
High        (H) 
Joints Arthropathy/ Tendinopathy M 
Vein Phlebitis L 
Liver Function Failure /pancreatitis L  
Renal Function Failure 
Crystalluria 
L  
Blood cells Deranged L 
Gastrointestinal Colitis if severe and  persistent 
consider Clostridium Difficile 
M 
Anaphylaxis /Allergy  R 
Skin Rash/photosensitivity M 
Cardiac ventricular arrhythmia, 
QT interval prolongation 
R 
Neurological Convulsions M 
Syndromes Stevens Johnson /Lyell R 
 Serious Adverse Events  
The Principal Investigators were required to report Serious Adverse Events (SAE) or 
Suspected Unexpected Serious Adverse Reactions (SUSARs) to the Sponsor within 
24 hours. These are defined by the Medicines for Human Use Clinical Trial 
Regulations (2004) 1031[240] as: 
 resulting in death 
 life-threatening 
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 requiring hospitalisation or prolongation of existing hospitalisation 
 resulting in persistent or significant disability or incapacity.  
SAEs anticipated due to critical illness (including death) were exempt from the time 
frame associated with expedited reporting to the MHRA and NRES. Anticipated SAE 
were listed in the protocol based on the incidence at Liverpool Women’s NHS FT 
between 1980 and 2004 Table 2-6. The Sponsor (Trust) monitored the incidence of 
anticipated SAE, an increase would require expedited reporting as a Suspected 
Unexpected Serious Adverse Reaction (SUSAR) due to a novel causal relationship 
not stated in the Summary of Product Characteristics [53]. The Principal Investigator 
was required to report all other SAE and SUSARs to the Sponsor within 24 hours. 
The Sponsor then determined whether the event required expedited reporting to the 
MHRA and REC within 7 or 15 days in accordance with regulation 33 [245] . Annual 
safety reports were submitted to the MHRA and NRES and SAE were reviewed by 
the Data Monitoring Committee (DMC) at regular intervals throughout the trial. 
Table 2-6 Anticipated Serious Adverse Events for Neonates 
Adverse event Incidence  
Weeks PMA: 
< 28   >28 -34 
Death  20 8 
Necrotising enterocolitis or intestinal perforation  15 3 
Intracranial abnormality  15 6 
Patent ductus arteriosus  25 8 
Retinal surgery for retinopathy of prematurity 5    0.14 
Pulmonary haemorrhage 5 0.5 
 Arthralgia/Arthropathy  
Parents and the clinical team who frequently handle the babies were asked to report 
any signs of joint inflammation or pain during handling until discharge or up to a period 
of six weeks. These terms describe musculoskeletal adverse events including the 
commonest symptom arthralgia ‘pain’ (50%), tendon or joints disorders (19%) and 
reduced movement (15%) [190]. This pragmatic approach reflects clinical practice as 
it is vital to minimise disturbing neonates and there is no validated method for 
assessing arthralgia in non-weight bearing neonates.      
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 Tolerability - Peripheral Infusion Site 
Tolerance at the site of peripheral infusion was monitored immediately before and 
after the infusion using the validated Visual Infusion Phlebitis Scale [207, 208] cited 
by Gallant and Schultz [209] Table 2-7. Phlebitis was assessed by monitoring pain, 
erythema (redness or rash), induration (hardened skin), swelling and palpable venous 
cord on a scale of 0-5 at three time points immediately before and on completion of 
the 30 - 60 minute infusion then six hours later. This group were administered other 
drugs and fluids through the same intravenous site. 
Table 2-7  Phlebitis Scale 1- 5          
Assessment  Score Action  
IV Site appears healthy 0 No sign of phlebitis observe cannula  
Slight pain or redness near IV site   1 Possibly first sign of phlebitis observe cannula 
2 of the following: 
Pain at IV site when touched 
Erythema  
Swelling 
2 Early stage of phlebitis  
Re-site cannula 
All 3 signs are evident & extensive 
Pain along path of cannula  
Erythema   
Induration  
3 Medium stage of phlebitis re-site cannula and 
consider treatment 
All 4 signs are evident & extensive 
Pain along path of cannula  
Erythema   
Induration  
Palpable venous cord 
4 Advanced stage of phlebitis or start of 
thrombophlebitis 
Re-site cannula  
Consider treatment 
All 5 signs are evident & extensive 
Pain along path of cannula  
Erythema   
Induration  
Palpable venous cord 
Pyrexia 
5 Advanced stage of Thrombophlebitis  
Initiate treatment  
Re-site cannula 
2.2.4 Research Culture  
This was the first population PK clinical trial at either of the recruiting sites. To ensure 
parents were not overburdened by research a co-ordinated approach to participation 
in research was developed within the neonatal unit. Parents were informed of all 
studies that they may be approached for at the outset and a research poster board 
included a lay summary of each trial in the parent’s rest room. Over this period four 
other clinical trials were conducted involving this population.  
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To establish a PK culture the clinical teams including over 200 staff in each intensive 
care unit were trained to adhere to the precise sampling and drug administration 
methods and provide support to families. This included pharmacists, phlebotomists, 
nurses and medical staff providing care 24/7 care. Laboratory technicians were 
GCP/GLP trained and trained in study specific standard operating procedures by the 
research fellow. At the 40 non-recruiting sites the PI’s and research nurses were GCP 
trained and provided with simplified SOPs specific to the activities at the follow up 
sites. Further guidance was provided at the time of transfer. 
2.2.5 Regulations and Governance  
A Clinical Trial Authorisation (CTA) was approved in accordance with the Medicines 
for Human Use Clinical Trial Regulations (2004) as the aim is to verify/compare the 
effect of the drug on the body including absorption, distribution, metabolism and 
excretion PK clinical trials are classed as CTIMP [240, 245]. The UK National 
Research Ethics Service approved the trial and subsequent amendments. The trial 
was registered with the European Clinical Trials Database Registry (EudraCT:2010-
019955-23). The TINN Consortium European Ethics Advisory Board approved the 
study. A generic site specific information form was approved by the Comprehensive 
Research Network Service for Central NHS Permissions for forty continuing care sites 
with a statement of responsibilities specific to follow up. A Material Transfer 
Agreement covered the transfer of samples to Robert Debre Hospital, Paris for PK 
analysis and the DNA samples to University Ulm, Germany.  
The storage and management of data was compliant with GCP, Data Protection Act  
and the National Information Governance Board [252].  The trial master file included 
version controlled essential documents [233]. Source data was obtained from 
BADGER and Meditech electronic patient data management systems and medical 
notes. Anonymised data was entered into a GCP compliant electronic case report 
form (Clininfo SA France).  A unique study number was assigned to link to clinical 
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source documents with patient identifiable data. Medical notes and the tables linking 
unique study numbers to patients will be archived for 15 years using the NHS hospital 
appointed archiving services. GCP required that data was not extracted from Clin-info 
for reporting until data has been examined and locked by the Sponsor. 
2.2.6 Oversight and monitoring 
An independent Data Monitoring Committee (DMC) was established and the charter 
followed the DAMOCLES statement and safety reports sent every six months on 
safety [253]. The Sponsor (Trust R&D Department) monitored the study including 
compliance with GCP, Research Governance, source data checks, the laboratory 
handling of samples and data reliability. The case report forms were checked with 
multiple sources to verify sample times/infusions/or protocol deviations including the 
blood gas analyser (Rapid Lab Co-oximeter 1265 -Bayer UK), laboratory and clinical 
records. Serious breaches were minimised by preparing detailed standard operating 
procedures, trial tools and staff training provided by the research fellow. Breaches 
that affected the safety of the subject or the scientific integrity of the trial were required 
to be reported to the Sponsor (Trust R&D Policy) as per Regulation 29A [240]. A 
serious breach identified by the Sponsor (Trust) required reporting to the MHRA within 
seven days.  
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2.3  Pharmacokinetic Clinical Trial Results     
Recruitment commenced February 2011 and the target of 50 was exceeded. In total 
63 neonates and young infants up to 48 weeks PMA were recruited by October 2012. 
Recruitment continued above the initial target as requested by the TINN Consortium 
partly to gain more last day samples. The target for neonates (n=30) at Liverpool 
Women’s NHS FT was exceeded as 63% of those eligible were recruited mainly in 
the premature age group (n=37). The target at Royal Liverpool Children’s NHS FT 
was 20,   43% of those eligible were recruited mainly term babies (n=25). Each of the 
seven PMA sub-age groups represented by seven to thirteen babies but excluded 
those 49-52 weeks PMA (as ciprofloxacin was not prescribed to this age group).  One 
patient withdrew from the study and one was excluded as peritoneal dialysis 
commenced and one had previous administration of ciprofloxacin within 24 hours. 
Over 2539 babies were screened on each day of their admission. The mean (SD) for 
postmenstrual age (PMA) when commencing PK sampling was 35.7 (6.5) (range 
24.9–47.9) weeks and weight 2060 (1020) (range 700–4200) grams (n=60). PMA and 
current weight were all normally distributed (p=0.4 and p=0.2, respectively).  
2.3.1 Interim analysis  
As part of an interim analysis the proposed neonatal regimen of 10mg/kg 12 hourly 
was assessed for the first ten neonates recruited from Liverpool Women’s NHS FT. 
The aim was to evaluate whether the minimum AUC24/MIC ratio 1:125 required to 
optimise the probability of target attainment for therapeutic success informed by adult 
PD data was achieved by this dose.  The mean (SD) postmenstrual age (PMA) was 
31.74 (4.7) weeks (range 24.86 – 38.9 weeks), postnatal age (PNA) 34 (28) (range 8 
-91) and mean weight (SD) was 1398 (601) g (range 720 -2630 g) Table 2-8.  
Ciprofloxacin serum and plasma concentrations from 44 PK samples and 35 
scavenged samples were measured (n=79) Table 2-9 . Concentrations ranged from 
830–9,630 ng/mL for PK samples and 58.4–8,850 ng/mL for scavenged samples.  
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Four babies did not have last day (day 5-7) samples due to death or ciprofloxacin 
being stopped earlier. The subject LW8 had a higher concentration at T3 than T1 
following intravenous administration. The AUC24h/MIC ratio was higher than the 
minimum recommended ratio 1:125 [134, 176], for a dosing regimens of 10mg/kg 
twice daily. Simulated AUC24h was calculated as ratio of daily dose/CL. AUIC was 
estimated as the ratio of simulated AUC24h/MIC. 
Based on these results the Trial Management Group and TINN Consortium decided 
to continue with the planned regimens for the main clinical trial of 10 mg/kg 8 or 12 
hourly except when signs of renal impairment were present (creatinine >100 µmol/L) 
then 5 mg/kg 12 hourly was prescribed.  
 
Table 2-8 Characteristics of neonates in the Interim Analysis  (n=10) 
ID PMA 
(weeks) 
PNA 
(days) 
Weight 
(g) 
Serum creatinine 
(µmol/L) 
1 30 42 1040 151 
2 36.4 73 1960 43 
3 32.1 26 1390 39 
4 28.6 15 1025 54 
5 29.6 28 1150 35 
6 30.7 22 1260 40 
7 27.8 20 850 24 
8 38.8 8 2630 41 
9 38.4 91 1950 25 
10 24.8 11 720 53 
Median 30.36 24 1205 41 
Min 24.86 8 720 24 
Max 38.86 91 2630 151 
Mean 31.74 34 1398 51 
SD 4.70 28 601 37 
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Table 2-9  Individual Bayesian estimated PK parameters –Interim Analysis 
 
ID 
CL 
(L/h) 
V1 
(L) 
V2 
(L) 
Q  
(L/h) 
Dose 
(mg) 
Dose 
(mg/L) 
AUC24 
(mg*h/L) 
AUC24/ 
MIC 
1 0.146 0.608 3.235 5.733   8.4   8.1 114.9 229.8 
2 0.292 2.387 2.997 0.821 18   9.2 123.4 246.8 
3 0.182 1.647 1.173 0.509 14 10.1 153.5 307 
4 0.105 1.012 0.765 0.337   9.5   9.3 181.3 362.6 
5 0.203 1.676 1.126 0.049 11.5 10 113.3 226.6 
6 0.260 1.581 1.133 0.359 12.6 10 97.0 194 
7 0.160 0.705 1.029 0.442   8.15   9.6 101.9 203.8 
8 0.401 5.779 0.451 0.240 23   8.7 114.8 229.6 
9 0.504 4.569 3.886 0.267 18   9.2 71.4 142.8 
10 0.120 0.599 0.680 0.424   5.6   7.8 93.5 187 
median 0.193 1.614 1.129 0.391     
min 0.105 0.599 0.451 0.049     
max 0.504 5.779 3.886 5.733     
*MIC based on EUCAST’s clinical breakpoint 0.5mg/L 
 
 
Table 2-10 PK parameters, simulated regimens and infusion time Interim Analysis 
 
 Percentiles 
10 mg/kg  
12 hourly  
(30 min infusion) 
10 mg/kg  
12 hourly  
(60 min infusion) 
5 mg/kg  
12 hourly 
(30 min infusion) 
AUC24h 
(mg*h/L) 
5% 80 80 40 
Median 123 123 61 
95% 189 189 94 
Cmax 
(ng/mL) 
5% 3420 1710 1710 
Median 7077 3540 3540 
95% 13552 6804 6804 
Cmin 
(ng/mL) 
5% 751 773 375 
Median 1516 1547 758 
95% 2499 2539 1250 
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2.3.2 Main Pharmacokinetic Clinical Trial Results 
Sixty three babies were recruited, one was subsequently withdrawn by parents and 
two found to be ineligible. A further thirty were consented prospectively were not 
recruited either because they were not prescribed ciprofloxacin or their target age 
group was completed when they became eligible. 
A high ratio between screened and eligible patients resulted from the systematic 
screening of all neonates <52 weeks of age (each day during their admission). The 
optimal time for recruitment was before the first dose therefore screening aimed to 
identify participants who were at greater risk of Gram-negative sepsis classed as 
those more likely to commence ciprofloxacin to allow prospective consent as follows: 
 Screened for sepsis due to presenting clinical signs.   
 Extreme prematurity - born <28 weeks post menstrual age. 
 First line antibiotics for suspected Gram-negative infection.  
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Figure 2-2 Consort flow diagram Pharmacokinetic Clinical Trial 
This figure depicts the passage of all recruited and eligible participants through the 
clinical trial that contributed to a population PK analysis.    
 
Ineligible: (Total n=2428) 
  Not prescribed ciprofloxacin (n=2401) 
  Prescribed before day 5 of birth (n=18) 
  Ciprofloxacin commenced >48 hours (n=1) 
  ECMO/haemofiltration/peritoneal dialysis (n=8)  
Loss to follow up  
Ciprofloxacin stopped before last day (n=21) 
Death before last day samples (n=4)  
 
Assessed for eligibility daily during admission  
(< 52 weeks PMA (n=2539) 
Eligible (n=111) 
Recruited with parental consent (n=64) 
Not recruited (Total n=48): 
  Declined (n=27) 
  Staff/parents not available (n=21) 
Samples included in PK analysis (Blood n=430) (CSF n=6) 
Excluded (Total n=3): 
  Commenced peritoneal dialysis (n=1) 
  Ciprofloxacin administration <24 hours (n=1) 
  Parent withdrew (n=2) 
PK bloods 
scavenged from 
clinical samples 
(n=165) 
CSF 
Recruits 
(n=6) 
Neonates with paired PK bloods on the 
first and last day of treatment (n=35) 
PK blood samples 
on day 1 or 2   
(n=171) 
PK blood samples 
on last day of 
treatment (n=94) 
Included in analysis (n=60) 
PMA weeks 24-27 28-31 32-35 36-39 40-43 44-48 49-52 
N= 9 11 8 13 12 7 0 
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Figure 2-3 Neonatal Accrual Liverpool Women’s NHS FT (n=37) 
 
 
Figure 2-4 Paediatric Accrual Alder Hey Children’s NHS FT (n=26) 
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Table 2-11 Demographic and Baseline Characteristics  
Recruits N  (%) Mean (SD) Median (Range) 
 
Total recruited 64      
   withdrawn 4      
   Proportion of those eligible:   
       Neonatal hospital  
       Paediatric hospital  
  
(63) 
(43) 
    
Gender: male 39  (62)     
Race:       
   Asian 5  (8)     
   Caucasian 53  (88)     
   Unknown 2      
 
Age and weight: 
      
Post Menstrual Age: at birth (weeks)   30.4  (5.8) 27.9  (23.3-42) 
Post-Natal Age: when recruited (days)   38  (30) 27  (5-121) 
Post Menstrual Age: recruited (weeks)   35.7  (6.5) 36.5  (24.9-47.8) 
IUGR 3      
Birth Weight (g)   1518  (884) 1115  (540-3850) 
Weight (g) when recruited   2060  (1020) 1955  (700-4200) 
Neonates weight <1000g 9  (14.5)     
 
Mortality: 
      
Born < 28 weeks PMA 7  (11)     
Born > 28 weeks PMA  1  (1.6)     
 
Ciprofloxacin Administration:  
      
Duration (days)    5  (4) 5  (1-17) 
Dose (mg/dose)   18.9  (10.1) 18.7  (4.5- 40.0) 
Dose (mg/kg/dose)   9.1 (1.6) 9.7  (4.4-11.0) 
Broviac line in situe  16      
 
Other: 
      
Admitted to Intensive care  
Ventilated during PK sampling 
58  
50   
(94) 
(83) 
    
Serum Creatinine (µmol/L)   52  (32) 41  (22 -164) 
 
Pre-defined in the protocol  
co-medication*  
      
   Inotropic agents 22      
   Teicoplanin  41      
   Diuretics 30      
   Ibuprofen 2      
   Caffeine 15      
   Amoxicillin-Clavulanic acid   12      
   Nystatin 12      
   Colistin/Tobramycin/Amphotericin   10      
* patients were administered other medication but these were specified in the protocol 
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 Age and Weight  
 
 
Figure 2-5 Weight (grams) range for each PMA Group 
 
The weight range for the recruited babies was 700g – 4200g (median 1955g). The 
weight range at birth was 540 -3850g (median 1115g). The mean (SD) post 
menstrual age was 35.7 (6.5) range 24.9-47.9 weeks when recruited. PMA and 
current weight were distributed normally (p=0.4) and (p=0.2) respectively 
(Kolmogorov-Smirnov test). A weight increase >20% was evident for six neonates 
(20%) over the pre and post sepsis period. Figure 2-6  illustrates two examples of 
pre and post sepsis weight where weight increased by between 20% and 38% more 
than the neonates expected weight (expected weight gain of premature neonates is 
estimated as 15g/kg/day).   
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Figure 2-6 Variation in individual weight pre and post sepsis  
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 Ciprofloxacin Administration  
Ciprofloxacin was administered either over 30 minutes at Liverpool Women’s 
(Neonatal) NHS FT or 60 minutes at Alder Hey (Paediatric) NHS FT. The regimens 
were determined by clinicians as per the sites policy, in most cases 20mg/kg/day 
(76%) Table 2-12. A renal sparing dose was prescribed 10mg/kg/day for six neonates 
and eight term babies received the higher regimen of 30mg/kg/day.   
 
Table 2-12 Dose regimens administered mg/kg/day (n=60)  
 
 
 
 
 
 
 
 
 
  Co-administration of Inotropes  
 
Figure 2-7 Type of Inotropes administered  
 
Inotropes were administered to 22/60 (37%) neonates. Each neonate was 
administered up to three types of inotrope concomitantly. Post-operative cardiac 
patients were administered Milrinone. 
6
12
17
7
1
0 5 10 15 20
Adrenaline
Dobutamine
Dopamine
Milrinone
Noradrenaline
Total Inotropes (n=43) administered to 25/60 patients 
In
o
tr
o
p
e
PMA 
(weeks) 
Dose Regimens (mg/kg/day) (%) 
10 20 30 
24-27 1 8  
28-31 2 9  
32-35 2 6  
36-39 1 12  
40-43  9 2 
44-48  2 6 
Total 6 (10) 46 (76) 8 (14) 
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 Blood sample collection 
A total of 60 neonates had PK samples collected at the pre-specified protocol times 
on the 1st or 2nd day and last day (n=268). Most samples (80% were collected on the 
first day either within three minutes or two hours of the first infusion depending on the 
group allocated.  Fewer neonates 35 (58%) had samples on the last day of treatment. 
This loss was due to mortality or early discontinuation of treatment when the clinical 
signs of sepsis had resolved or when antimicrobial therapy was changed following 
laboratory confirmation of the organism.  A further 168 samples were scavenged from 
clinical blood samples with precise infusion and collection times for up to a ten day 
period following the commencement of ciprofloxacin. In total 436 samples were 
collected, an average of 7.3 samples per neonate including 4.5 timed PK samples 
plus 2.8 scavenged from clinical bloods.    
 
Figure 2-8  Neonates /Infants Sampled and Post Menstrual Age 
 
Includes three patient who were subsequently withdrawn (n=63) 
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Figure 2-9  Blood samples representing each PMA Group  
 
 
Figure 2-10  Distribution of population PK samples over time  
The number of samples collected were distributed over informative time points on 
the 1st or 2nd day (n= 171) and on the last day (n=97).  T1 was collected within 3 
minutes of the first infusion and all other planned times were within 10 minutes of 
the protocol time. (T4 replaces T6 when prescribed 8 hourly rather than 12 hourly).  
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2.3.3 Pharmacokinetic Parameters  
 Ciprofloxacin concentrations  
 
 
 
Figure 2-11 PK timed and Scavenged Samples concentrations 
 
PK samples collected at set protocol time points (n=265) and scavenged samples 
(n= 165) v time. Total (n=430).  
 
PK timed sample concentrations range 450–15976 ng/mL (median 3505 25th – 75th 
2191 -5428). Mean 4120 (SD 2660)  
 
Scavenged samples concentrations range 52–10961 ng/mL (median 4066; 25th – 
75th 2212 – 5748). Mean 4257 (SD 2517)  
 
(1 mg/L = 1000 ng/ml) 
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
0 4 8 12 16 20 24
C
ip
ro
fl
o
x
a
c
in
 c
o
n
c
e
n
tr
a
ti
o
n
 (
n
g
/m
L
 
Time since last dose (h)
Scavenged PK Timed
 
122 
Pharmacokinetic Clinical Trial  
 
Figure 2-12 Clearance L/h/kg and PMA Group (weeks) 
 
Clearance ranged from a minimum of 0.04 L/h/kg to max 0.81 L/h/kg  
(each group’s median and range is based on the median weight (n=60) 
 
 
Figure 2-13 Creatinine µmol/L when commencing ciprofloxacin 
 
Median and range for each PMA Groups when commencing ciprofloxacin (n=60) 
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Figure 2-14 Half- Life Beta (h) and PMA Group 
(N=60) 
 
 
Figure 2-15 Volume of distribution (L/kg at steady state) and PMA Group 
Median and range 2.20 (0.4 - 3.55) for PMA sub-age groups (n=60) 
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Figure 2-16 Area under the curve 0-24 and PMA Groups  
 
The AUC0-24 at steady state for each PMA groups (median and range) for the 
evaluated dose regimens ranged from 35 to 291 mg*h/L. (n=60) 
 
Table 2-13 Co-efficient of variation (CV) % for PK Parameters  
   
 
PMA 
 
 
Clearance  
(CL) % 
 
Area under the curve  
(AUC) % 
 
Half-life 
% 
24-27 60          44 58 
28-31 35 46 48 
32-35 66 33 37 
36-39 44 34 40 
40-43 38 53 41 
44-48 65 50 31 
Range 35-66 33-53 31-58 
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Figure 2-17 Area under the curve0-24 and the Clinical Breakpoint  
 
This figure illustrates the AUC at steady state/MIC 0.5 mg/L (median and range) 
representing each PMA Group based on EUCAST clinical breakpoint. The AUC 
ranged from 35 to 291 0-24 mg*h/L. The optimal pharmacodynamic predictor of 
clinical outcome is a minimum AUC/MIC ratio of 125 ranging to recommendations 
for target of 250.    
 
 
A two compartment model with first order elimination showed the best fit with the data. 
The objective functional value (OFV) and residual variability of the two-compartment 
model were lower than a one compartment model. The model was parameterized in 
terms of central volume of distribution (V1), peripheral volume of distribution (V2), 
inter-compartment clearance (Q) and clearance (CL) of ciprofloxacin. Inter-individual 
variability was best described by an exponential model and was then estimated for 
V1, V2 and CL. Inter-occasion variability on CL was coupled to inter-individual 
variability by an additive model, respectively. A proportional model best described 
residual variability. 
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 Covariate analysis  
Covariate analysis found that gestational age, postnatal age, current weight, serum 
creatinine and inotrope administration had a significant impact on ciprofloxacin PK 
parameters. The parameter estimates of the final PK model include the median 
(range) of estimated weight-normalized CL 0.20 (0.04-0.81) L/h/kg and volume 
distribution at steady-state (sum of V1 and V2) 2.02 (0.40-3.55) L/kg. The AUC0-24 at 
steady-state for the evaluated dose regimens ranged from 35 to 291 mg*h/L. 
Ciprofloxacin CL increased allometrically with current weight, decreases with 
increasing creatinine concentration and showed a 29% decrease with co-
administration of inotropic agents Table 2-14.  
The allometric size approach was used by incorporating a priori the current weight 
into the basic model (allometric coefficients of 0.75 for CL and Q, 1 for V1 and V2), 
caused a significant drop in the OFV of 113.9 points from the structural model. 
Postmenstrual age was identified as the most important covariate on CL, associated 
with a drop in the OFV of 56.0 units. However, gestational and postnatal age together 
proved to be superior (ΔOFV 66.7 units) to postmenstrual age alone.  A further 
decrease in the OFV of 25.8 units was achieved by implementing serum creatinine 
concentration on clearance. The model was further improved by introducing co-
administration of inotropic agents (ΔOFV 7.5 units) as a third covariate on clearance. 
For the central volume of distribution V1, only the co-administration of inotropic agents 
caused a significant drop in the OFV of 3.9 points in the forward selection process. 
However, it was not retained into the model after the backward selection process. The 
covariates were tested for significance using the OFV and included in the model when 
significant p=<0.05 = >3.84 (p= <0.01 = OFV >6.6). An allometric model was used 
therefore the difference between OFV and each covariate was tested against current 
body weight. Ciprofloxacin clearance variability was explained by size 31.2%, renal 
maturation 25.6%, renal function 5.7% and co-administration of inotropic agents 
2.4%.  
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 Model evaluation 
The mean parameter estimates resulting from the bootstrap procedure closely agreed 
with the respective values from the final population model, indicating that the final 
model is stable and can re-determine the estimates of population PK parameters 
Figure 2-18Figure 2-19. Model diagnostics showed acceptable goodness-of-fit for the 
final model of ciprofloxacin. Predictions are unbiased. 
 
Figure 2-18 Predicted and actual concentrations of ciprofloxacin  
(direct variable ng/mL) 
 
Figure 2-19 Individual predicted and actual concentrations ciprofloxacin  
(direct variable ng/mL)  
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Table 2-14 PK covariate analysis and Objective Function Value (OFV)  
 
PK 
parameter 
OFV 
P= 0.05 
if OFV 
>3.84 Structural Model   6569 
Allometric model  CL, V1, V2, Q  
    
Current body weight  6455.1 113.9 
Impact of age V1   
  GA  6454.9 0.2 
  PNA  6451.9 3.2 
  PMA  6453.2 1.9 
Impact of age V2   
  GA  6455.1 0 
  PNA  6452.3 2.8 
  PMA  6453.7 1.4 
Impact of renal maturation CL   
  Birth weight  6442.0 13.1 
  GA  6438.7 16.4 
  PNA  6425.2 29.9 
  PMA  6399.5 55.6 
  Birth weight and PNA  6396.2 58.9 
  GA and PNA  6388.4 66.7 
Impact of renal function CL   
  Serum creatinine  6429.3 25.8 
Impact of renal maturation and renal function CL   
    GA, PNA and serum creatinine  6371.3 83.8 
 
Impact of renal maturation, function and co-
medication 
CL   
  GA, PNA, serum creatinine and diuretics  6371.4 83.7 
  GA, PNA, serum creatinine and caffeine  6369.2 85.9 
  GA, PNA, serum creatinine and teicoplanin  6371.0 84.1 
  GA, PNA, serum creatinine and 
                   amoxicillin-  clavulanic acid 
 6366.8 88.3 
  GA, PNA, serum creatinine and nystatin  6370.9 84.2 
  GA, PNA,  serum creatinine and inotropic 
agents 
 6363.8 91.3 
 
GA: gestational age; PNA: postnatal age. PMA: postmenstrual age. 
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Table 2-15 Population PK parameters of ciprofloxacin and bootstrap 
 
 
V1: central volume of distribution; V2: peripheral volume of distribution; Q: inter-
compartment clearance; CL: clearance; RF: renal function; CW: current weight in 
gram; Finotrope: scaling factor applied for patients co-administrated with inotropic 
agents; CREA: serum creatinine concentration in μmol/L; GA: gestational age in 
weeks; PNA: postnatal age in days.  
 
 
 
 
 
 
 
Parameters 
Full dataset Bootstrap 
Final  
estimate 
RSE 
(%) 
Median 5th – 95th 
V1 (L)     
V1=θ1× (CW/1955)     
   θ1 1.97 17.7 1.82 0.78 – 2.59 
V2 (L)     
  V2=θ2× (CW/1955)     
   θ2 1.93 21.9 1.97 1.38 – 3.02 
Q (L/h)     
  Q=θ3× (CW/1955)0.75     
  θ3 2.5 32.6 2.62 1.02 – 5.41 
CL( L/h )     
CL=θ4×(CW/1955)0.75×Fage×RF×Finotrope     
  θ4 0.366 6.0 0.365 0.323 – 0.407 
Fage= (GA/27.9)θ5×(PNA/27)θ6     
  θ5 2.11 11.9 2.09 1.60 – 2.57 
  θ6 0.494 10.8 0.492 0.386 – 0.606 
  RF= EXP((CREA-42)× θ7)     
  θ7 -0.00335 46.0 -0.00331 -0.00753 – 0.00063 
Finotrope     
  θ8 0.708 10.9 0.719 0.572 – 0.869 
Between Subject Variability (BSV) 
Inter-individual variability (%)  
    
  V1 48.1 63.6 49.6 26.2 – 77.2 
  V2 49.3 68.3 51.2 15.8 – 76.9 
  CL 33.2 19.9 31.3 25.3 – 37.4 
Between Occasion Variability (BOV) 
Inter-occasion variability (%) 
    
  CL 16.4 55.6 16.6 9.2 – 26.2 
Residual unexplained variability 
(RUV) (%) 
19.3 28.2 18.7 14.8 – 23.1 
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Table 2-16  Creatinine (µmol/L) levels and inotrope administration  
 
 Inotropes 
administered 
(n=20)* 
No Inotropes  
Administered  
(n=36) 
Difference 95% CI 
Mean (St Dev) 81.80 (42.58) 40  (14.75)  
Median (IQR) 74.50  
(46.50 - 114.50) 
37.5  
(30- 44.5) 
36.5  
(18.0, 58.00) p=0.0001  
 
Neonates (n= 56) were evaluated to compare creatinine levels at baseline for those 
administered inotropes.  Those administered inotropes had significantly higher 
creatinine levels prior to the initial PK levels blood samples were collected. (n=56) 
 
2.3.4 Cerebrospinal fluid concentrations   
Concentrations in CSF samples (n=6)  with exact collection times were obtained post 
administration of ciprofloxacin ranged from 187 to 1650 ng/mL, respectively Table 
2-17. The median value of CSF/serum ratio was 0.32 (range 0.08 -0.58).  A trend for 
correlation between CSF collection time and CSF/serum concentration ratios suggests 
less elimination from (or diffusion in) the CSF than the systemic circulation.   
Assessment of the ciprofloxacin penetration into the cerebrospinal fluid (CSF) was 
evaluated by the CSF/serum ciprofloxacin concentration ratio. Because serum 
ciprofloxacin concentrations were not obtained concurrently with CSF sample 
collection, serum concentrations at the time of CSF sample collection were estimated 
via Bayesian estimation by the developed model.  
Table 2-17 CSF concentrations and predicted serum concentration  
 
Patient 
ID 
PMA 
(weeks) 
Predicted serum 
concentrations 
(ng/mL) 
CSF 
concentrations 
(ng/mL) 
CSF/serum 
concentrations 
ratio 
LW07 28.2 2830 1650 0.58 
LW20 30 2001 701 0.35 
LW21 36.7 2347 680 0.29 
LW35 27.2 4508 351 0.08 
AH24 41.5 471 187 0.40 
AH36 38.8 2403 686 0.29 
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Figure 2-20 Ciprofloxacin CSF/serum concentrations ratio versus time (n=7) 
 
2.3.5 Dose optimisation 
The target attainment rates as a function of dose and age groups were estimated for 
an AUC/MIC target of 125 using the EUCAST susceptibility clinical breakpoint of 
0.5mg/L. Two visual cut-off points of age PMA 34 weeks and 36 weeks to represent 
nephrogenesis were evaluated as shown in Figure 2-21. Monte Carlo Simulation 
demonstrated that 90% of hypothetical new borns with PMA <34 weeks treated with 
7.5 mg/kg twice daily and 84% of new borns with PMA ≥34 weeks and young infants 
receiving 12.5 mg/kg twice daily would reach the AUC/MIC target of 125 using the 
EUCAST susceptibility of 0.5mg/L.  
The paediatric dose of ciprofloxacin was simulated on a mg/kg basis according to 
different age group for various mg/kg dosing regimens (5, 7.5, 10, 12.5, 15 mg/kg 
twice daily) Table 2-18. One thousand simulations were performed using the original 
dataset, and the AUC0-24 at steady state was calculated for each simulated patient. 
The target attainment rate was then calculated for each dosing regimens to define the 
optimal dose regimens in each neonatal group. 
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a) 
 
b) 
 
                          Ciprofloxacin dose mg/kg/bi-daily 
Figure 2-21 Dose v Target Attainment of the AUC/MIC 125 with age  
For PMA 34 weeks and B) for PMA 36 weeks  
 
 
 
 
 
 
 
 
133 
Pharmacokinetic Clinical Trial  
Table 2-18 The percentage of neonates that achieve an AUC/MIC 125 ratio simulated 
for dose regimen (mg/kg) administered 12 hourly   
This illustrates the dose of ciprofloxacin required to achieve the AUC/MIC target of 125 
based on EUCASTs non-species specific clinical breakpoint (0.5mg/L). Two cut off points for 
PMA s were selected to allow a comparison of the age range between which  
nephrogenesis is estimated to occur a)  PMA above and below 34 weeks  b) PMA above and 
below 36 weeks.  
 
(a) Comparing neonates pre and post  completion of nephrogenesis when 
estimated as 34 weeks PMA  
PMA 
(weeks) 
Dose (mg/kg) BID 
5 7.5 10 12.5 15 
<34 0.69 0.90 0.97 0.99 1.00 
≥34 0.15 0.39 0.66 0.84 0.92 
      
(b) Comparing neonates pre and post  completion of nephrogenesis when 
estimated as 36 weeks PMA 
PMA 
(weeks) 
Dose (mg/kg) BID 
5 7.5 10 12.5 15 
<36 0.65 0.87 0.96 0.99 1.00 
≥36   0.14   0.40   0.65   0.82   0.91 
 
2.3.6 Clinical outcome and Pharmacovigilance  
The clinical test-of-cure cure defined cure as survival and CRP <10mg/L three days 
after the cessation of ciprofloxacin compared to treatment failure. This definition of 
cure was based on the fact that there are no standard clinical outcome measures for 
neonatal sepsis (see section 1.5.1.1). This approach is pragmatic reflecting clinical 
decision making the availability of CRP from clinically required blood tests.  CRP data 
were available on day 10 for 39 neonates; 28/39 (71%) had CRP value <10 mg/L. The 
survival status or CRP data (3 days after the cessation of ciprofloxacin) were available 
for 61 participants: one participant was transferred to another hospital and lost to 
follow-up. Overall 47/60 (78%) were cured. Of those classed as cured, 28% did not 
have a CRP >10mg/L during the course of ciprofloxacin. Among the 48 with a CRP 
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>10mg/L during the course of ciprofloxacin 34 (71%) were cured. The four participants 
with proven Gram-negative infections were cured. 
Table 2-19 Indication for ciprofloxacin treatment for suspected Gram-negative Sepsis 
(n=64) 
Ciprofloxacin was prescribed for suspected Gram-negative sepsis and selected as 
opposed to other antimicrobials when indicated:  
 
 
 
 
 
 
 
 
 
 
2.3.7 Serious Adverse Events  
As part of pharmacovigilance data safety monitoring reports as required by Ethics and 
the MHRA there were 24 Serious Adverse Events (SAE) reported to the Sponsor. 
Throughout the study there were no Suspected Unexpected Serious Adverse 
Reactions (SUSAR). In this critically ill population SAE were anticipated as 
complications associated with extreme prematurity and suspected Gram-negative 
sepsis Table 2-20. The independent causality assessments for each case were 
deemed to be unlikely in relation to ciprofloxacin administration. Eight deaths were 
reported during the six week pharmacovigilance period, a mortality rate of 13%. Four 
occurred within ten days of treatment with ciprofloxacin. 82% of these deaths were 
babies born very premature <26 weeks PMA.  A further three babies died prior to 
discharge after the 42 day period for regulatory pharmacovigilance reporting, in total 
eleven (18%) (Table 2-21). The base-line mortality in this neonatal unit is 20% for 
those born <28 weeks PMA and 8% for those 28-34 weeks PMA. 
Indication  % N= 
   
Second line following gentamicin     
Renal sparing 
80 
12.5 
51 
8 
Suspected meningitis 1.5 1 
Proven meningitis  1.5 1 
 
Proven blood culture 
            Enterobacter cloacae 
            Haemophilus influenza 
            Serratia  marcescens              
            Pseudomonas aeruginosa    
 
 
1.5 
1.5 
1.5 
1.5 
 
 
1 
1 
1 
1 
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Table 2-20 Potential Serious Adverse Events reported to the Sponsor (n=24) 
 
Potential SAE/SAR  N= Causality 
No SAE reports 
Potential SAE reports 
SUSAR 
 41 
24 
0 
 
Death 
 
<28 weeks PMA (birth) 
>28 weeks PMA (birth) 
7 
1 
Probably not related 
Definitely not related 
Cardiac     Cardiac arrest 2 Probably not related 
Hepatic Deranged liver function 1 Possible 
Multi system organ 
failure 
 1 
1 
Probably not related 
Definitely not related 
Neurology Hydrocephalus 
Fitting 
1 
1 
Definitely not related 
Probably not related 
Renal  Decreased renal function 
Bilateral renal calculi 
Haematuria  
Echo genesis of medulla  
1 
2 
1 
1 
 
 
Probably not related 
 
Respiratory  Desaturation and bradycardia 
Polyps (surgery) 
 Probably not related 
Definitely not related 
 
 
Table 2-21 Mortality and PMA at birth 
 
 
 
 
 
 Haematology and Biochemistry Values 
Of those recruited 10% had a creatinine >100 μmol/L prior to commencing treatment 
classed as a surrogate for renal failure within the unit. 23% had a creatinine >58 
(upper limit of the reference range).  Creatinine was high in 2/61 (3.2%) with a median 
increase across the whole study population of 1micromol/L on therapy and a median 
reduction from baseline of 4 micro mol/L three days after the end of treatment. 
Bilirubin on-therapy was high in 19/55 (35%). On-therapy AST was high in 5/56 (8.9%) 
and ALT was high in 7/56 (12%) but both parameters were a median of 16 IU/L below 
the baseline value at 3 days after treatment was stopped.  
Renal dysfunction was classed as an adverse event (possible nephrotoxicity) when 
‘serum creatinine doubled or increased >44 µmol/L over baseline for blood samples 
Time to death after starting 
ciprofloxacin (days)  
PMA at birth (weeks) 
<26 27-31 >32 
< 10    4 0 0 
   10 - 42   3 1 0 
> 42  2 1 0 
 
Total 9 2 0 
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taken prior to commencing ciprofloxacin ’. This was based on consensus of opinion 
of the TINN Consortium. The laboratory reference range was 30-58 µmol/L.  Three 
recruits were assessed as possible nephrotoxicity but subsequently the blood were 
found to be taken earlier in the day prior to ciprofloxacin being commenced. Each had 
increased creatinine on the first day of ciprofloxacin Figure 2-22. LW1 and LW16 
creatinine subsequently decreased during ciprofloxacin treatment and LW28 
increased.  
Table 2-22 Haematology and Biochemistry Values during Ciprofloxacin Therapy 
 
Table 2-23 Creatinine values µmol/L 
Blood value Reference 
range  
(>14 days of 
birth) 
Baseline  
median (IQR) n= 
Range n = 
 
%  
<normal  
>normal  
  n=58 Minimum on therapy n=61 
Haemoglobin  g/L 13  - 21 11 (10-14) 11 (9-12)  
 
< 52  
Platelets  150 - 400 
  
198 (110-310) 
 
147(64-294)  
 
< 51  
Haematocrit  42  - 66 35 (30-40)  
 
30 (29-40) 
 
< 61 
White cell count  5 -18.4 14 (10-18.5) 
 
12 (10-18) 
 
< 6.6 
Albumin g/L 30  - 45  
 
27 (25-30) 25 (20-28) 
 
< 87 
   Maximum on therapy 
Creatinine μmol/L 30 - 58  43.5 (34-64) n=50 46 (36-68) n=61 
 
 
Lactate mmol/L 0.7 – 2.1 1.3 (1.1-2.1) n=48 
 
1.8 (1.3-2.8) n=58 
 
 
Magnesium mmol/L 0.78 – 1.02 0.85 (0.75 -0.92) n=52 
 
0.7 (0.67-0.81) n=62 
 
 
Total Bilirubin μmol/L <340  82 (25-245) n=46 
 
57  (23-163) n=55 
 
>35 
AST IU/L 23 – 73  37 (26-83) n=41 
 
44 (28-85) n=56 
 
>8.9 
ALT IU/L 9  -  44     27 (12-78) n=39 
 
29 (17-65) n=56 
 
>12 
Alk phosphate IU/L <1600  590 (341-1230) n=40 687 (469-956) n=56   
Serum creatinine 
concentration 
(µmol/L) 
Pre-treatment 
baseline 
Day 1 
Pre or post 
dose 
Last day of 
ciprofloxacin 
N 57 61 40 
Median 
Range  
42 
(26-188) 
42 
(22-232) 
40 
(24-271) 
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a)  
 
 
b)  
 
c) 
Figure 2-22 Increased creatinine (µmol/L) at baseline   
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Figure 2-23 Creatinine and Ciprofloxacin Administration LW17  
LW17 Creatinine concentrations were 139 on day 11 before commencing 
ciprofloxacin. On day 22 ciprofloxacin was recommenced but the creatinine was 232 
before starting. On day 34 the creatinine was elevated prior to ciprofloxacin.  
 
Two cases of renal calculi (renal stones) and nephrocalcinosis (calcification in the 
renal parenchyma) were classed as non-serious adverse events with possible 
causality. LW02: male born at 26 weeks PMA weighing 780g. Clinical history: 
Trisomy 21 with duodenal atresia and severe broncho pulmonary dysplasia. An 
episode of oliguria was associated with staphylococcal infection. A renal ultrasound 
showed several renal calculi bilaterally, the calculi were not present early in the 
admission and resolved at a later stage. Several courses of ciprofloxacin were given 
one before the normal scan, two between normal and abnormal scan and two 
between abnormal scan and recovering scan. LW03: male born at 28 weeks PMA 
weighing 1.17 kg. Clinical history: Anal stenosis then Meckel’s diverticulum requiring 
an ileostomy. Haematuria noted on day 35. A renal ultrasound on day 39 showed both 
kidneys were normal in size but small calculi were evident bilaterally, more prominent 
on the right side (>4mm). There was no evidence of hydronephrosis or ureteric 
dilatation.  
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 Hepatotoxicity  
Hepatotoxicity was defined as:  
 Aspartate aminotransferase (AST) increased 10-fold over baseline 
 Alanine aminotransferase (ALT) increased 10-fold over baseline  
 Conjugated bilirubin>85.5 µmol/L  
 Unconjugated bilirubin>256.5 µmol/L if <36 weeks PMA  
 Unconjugated bilirubin > 342 µmol/L if ≥36 weeks PMA 
 
Table 2-24 Laboratory Neonatal reference range for AST and ALT   
 
AST/ALT   Post Menstrual Age 
<26 >26 
AST (units) n=171 n=2434 
10th centile 24 19 
50th centile 64 33 
90th centile 674 115 
ALT (units) n=247 n=4004 
10th centile 2 6.6 
50th centile 11 11 
90th centile 129 47 
 
Table 2-25 Liver Function Test Results Day 1 - 7 
 
 
 
Liver Function Base-line Day 
1 2 3 4 5 6 7 
Bilirubin 
Conjugated (n) 
15 13 10 6 8 8 6 4 
Median  
range (µmol/L) 
13 
(4-128) 
11 
(5-152) 
15 
(2-152) 
12 
(6-133) 
41 
(7-160) 
93 
(9-199) 
72 
(4-139) 
18 
(6-230) 
Unconjugated 
(n) 
15 11 10 5 7 7 5 4 
Median 
range (µmol/L) 
69 
(6-268) 
69 
(7-245) 
46 
(2-232) 
65 
(4-157) 
45 
(5-192) 
78 
(4-137) 
36 
(4-96) 
19 
(5-83) 
AST (n) 41 31 29 26 20 19 12 12 
Median 
range (IU/L) 
37 
(13-1023) 
41 
(11-1734) 
35 
(19-1041) 
34 
(16-418) 
41 
(18-169) 
40 
(16-120) 
34 
(19-98) 
33 
(15-120) 
ALT (n) 
Median 
range (IU/L) 
39 
27 
(6-514) 
31 
31 
(10-463) 
29 
29 
(10-356) 
26 
26 
(7-322) 
20 
20 
(9-308) 
19 
27 
(11-227) 
12 
34 
(9-176) 
12 
25 
(11-81) 
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Table 2-26 Highest values of conjugated bilirubin during ciprofloxacin treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Seven patients had elevated conjugated bilirubin (reference range >85.5 µmol/L). 
The highest values of conjugated bilirubin for each of these patients during the 
ciprofloxacin treatment are shown in Table 2-26 
 
Prior to starting ciprofloxacin LW18 had an elevated unconjugated bilirubin 268 
µmol/L (reference range >256.5 µmol/L if <36 weeks PMA). 
 
 
Figure 2-24 Hepatotoxicity AH28  
 
AH28: Male 44 weeks PMA  
Clinical History – cardiac surgery one day post bypass. ALT increased >10 fold.  
Changes in liver function were consistent with bypass.    
 
 Neurology  
Seizures were reported in five participants prior to commencing ciprofloxacin. Clinical 
staff did not report seizures in participants after recruitment. Abnormal cranial 
Patient ID 
LW 
conjugated bilirubin (µmol/L) 
  1 112 
  2 143 
  7 160 
11 119 
12 133 
18   96 
26 114 
1st dose of ciprofloxacin  
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ultrasound findings were present at recruitment in 16 participants. One developed 
periventricular leucomalacia on cranial ultrasound after recruitment but this was not 
confirmed on magnetic resonance imaging.   
 Arthropathy    
There were no reports of arthralgia or arthropathy (altered mobility, pain and/or 
redness) in the follow up period up to six weeks.   
  Tolerability of Ciprofloxacin  
The reasons for discontinuing ciprofloxacin are shown in Table 2-27. The phlebitis 
score summarises the highest daily score  
Table 2-28. The scale of 0- 5 assesses phlebitis by monitoring pain, redness, swelling 
and palpable venous cord. In total 259 daily assessments were made of infusions 
administered via peripheral lines (53%). Over 259 days only ten assessments (4%) 
reported either a ‘possible’ or ‘early stage’ phlebitis. 7.2% of the infusion sites scored 
1-2 indicating possible early stage of phlebitis over this period. None of the 
participants had thrombophlebitis and seven required a line to be re-sited during 
treatment.  One peripheral line was re-sited during an infusion  
Table 2-27 Reasons for Discontinuing Ciprofloxacin Administration  
  
Reason for discontinuing ciprofloxacin  N 
 
5 day treatment schedule complete 
 
43 
Death during treatment   3 
Resistant Organism    0 
Symptoms resolved CRP<10   9 
Antimicrobial changed due to confirmed culture    5 
Not tolerated   0 
Total  60 
 
Table 2-28 Phlebitis Scores - tolerability of the intravenous infusion 
Assessments 
Days 1- 5  
1 2 3 4 5 
Total 
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 Neonates administered Ciprofloxacin 62 62 51 44 40 259  
Central lines excluded 27 28 24 23 19 121 
Peripheral lines  35  34 27 21 21 138 
Infusions administered over 30 mins  29 27 23 19 19 117 
Phlebitis Score 1-5             
1. Possible early stage  1 1 1 1 0 4 
2. Early Stage phlebitis   0 1 2 1 1 5 
3. Medium  0 0 0 0 0 0 
4. Advanced  0 0 0 0 0 0 
5. Thrombophlebitis  0 0 0 0 0 0 
 Total  1 2 3 2 1 9 
Infusions administered over 60 mins 6 7 4 2 2 21 
Phlebitis Score 1-5       
1. Possible early stage  0 0 0 0 0 0 
2. Early Stage phlebitis  0 1 0 0 0 1 
3. Medium  0 0 0 0 0 0 
4. Advanced  0 0 0 0 0 0 
5. Thrombophlebitis  0 0 0 0 0 0 
Total  0 1 0 0 0 1 
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2.4 Discussion  
The strength of the population PK clinical trial is that critically ill neonates and young 
infants for each sub-age group were recruited. These data represent the variability of 
the target population treated with ciprofloxacin that influences parameters which is 
essential as these data and analyses will ultimately contribute to licensing 
ciprofloxacin for neonates and young infants. Each stage of development is 
represented including those born extremely premature as early as 23.3 weeks PMA 
at birth and young infants (median 30.4 range 23.3 – 42 weeks). In total 64 babies 
were recruited, with between seven and thirteen participants for each sub-age group 
representative of every four weeks of development. Extreme variation in 
concentrations is evident between subjects even within each individual sub-age 
group. For neonates 28-31 weeks PMA the AUC 0-24 (SD) ranged between 65 – 291 
mg*h/L (60). The majority were recruited in intensive care with complex comorbidities 
and clinical interventions associated with critical illness and suspected sepsis. Most 
babies (91%) were ventilated and 37% received inotropes.   
Although this was a pilot PK trial this study has produced relatively rich data for each 
participant. Despite the limitations in blood sampling, on average 7.3 samples per 
neonate were collected of which 38% were scavenged from clinical samples without 
any additional burden to the baby. Despite this relatively large recruitment target these 
data are insufficient for more detailed sub-group analyses as they are stratified into 
seven age groups. The time frame for this sampling strategy was challenging because 
PK blood samples were collected within three or ten minutes of pre-defined time 
points yet this was achieved even though the drug was prescribed at any time day or 
night. The population design schedules produced data at six time points with between 
25 -35 samples on day one for each time (T4 combined with T6) distributed up to 
twelve hours following the infusion providing AUC data to predict the probability of 
clinical cure. Other trials of this vulnerable population recruited far fewer participants 
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(<24) and limited to peak and trough data [182, 183, 185, 187].  The main findings of 
these data were:   
 Clearance increased with age. The combined effect of gestational age and 
post menstrual age had a greater effect on clearance. Creatinine was inversely 
associated with clearance and decreased with age.  
  Inotrope administration was associated with reduced clearance associated 
with underlying renal compromise at baseline.  
 The conventional PD target from adult data AUC/MIC ratio >125 was 
achieved by the median of each sub—age group for the regimens 
administered.  
  Ciprofloxacin penetrated the CSF and achieved a ratio of 0.33 of the serum 
plasma concentrations.   
2.4.1 Multiple dose PK parameters and covariate analysis  
Post menstrual age (PMA) was the most important single covariate on clearance, but 
the combined effect of gestational age (on administration) and PMA (at birth) had a 
greater effect. Ciprofloxacin is mainly excreted renally therefore this higher clearance 
with maturation is consistent with completion of nephrogenesis estimated as occurring 
between 34-36 weeks PMA [123]. The model suggests the main change in clearance 
within the sub-age groups is on completion of nephrogenesis. Less variation was 
evident within the sub-age groups above or below this cut off. The mean clearance 
increased considerably above 35 weeks PMA from 0.09 to 0.13 l/h/kg to 0.20 to 0.33 
l/h/kg. Similarly, Lipman et al. found minimal variation in clearance when comparing  
infants (aged 3 and 12 months) 0.56 L/h/kg (SD 1.40) with young children (1 – 5 years 
age)  0.53 L/h/kg (SD 1.22) [115]. Similarly, this trial suggests a dosing interval of 12 
hours before 34 weeks PMA and 8 hourly following this period. Regimens specific to 
each sub-age groups may be required consistent with neonatal PK studies of 
gentamicin found that those <29 weeks PMA required a lower dose regimens [126].   
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The combined effect of PMA and PNA together had more effect on clearance (OFV 
66.7 for PMA and PNA v PMA alone OFV 56.0). Although this trial recruited a 
relatively large number of patients (n=64) these data were divided into six sub-age 
groups. As few as nine babies represented those very premature <28 weeks PMA 
therefore further data is required. This suggests the renal maturation for those born 
very premature is delayed post-natally more so than would have been in utero. 
Estimating the optimal dose may therefore have to factor in prematurity at birth as 
well as corrected gestational age when being prescribed the drug. Very premature 
neonates tend to be hospitalised for long periods and factors associated with 
immaturity or other morbidity. Adjustment of doses for prematurity will be relevant to 
many treated for late on set sepsis.   
As this clinical trial was a population PK design there is wide variability in 
developmental changes pre and post nephrogenesis and in respect of critical illness. 
For example 12.5 % were prescribed ciprofloxacin due to renal compromise (Table 
2-19) and renal function has considerable effect on concentrations. As a result the C 
max ranged considerably from 0.45 -15.9 mg/L. However, the median 3.5 (IQR 2.1 – 
5.4) Figure 2-11 was below Lipman et al [115] reported 6.97 (SD 1.48) for infants 3 
months age and above that found by Aggarwal et al [185] for pre-term neonates for  
2.6 (SD 0.4) mg/L. The wide range illustrates the need for caution regarding toxicity 
and the importance of covariates such as renal function when determining population 
regimen. This highlights the need to individualise regimen during critical illness and 
developmental changes.    
Renal function indicated by serum creatinine concentrations was significantly and 
independently correlated with ciprofloxacin clearance.  Many risk factors for renal 
impairment co-exist in this population and renal failure is frequently (26%) reported in 
sepsis [254]. A high proportion had renal compromise prior to being recruited as 13% 
had creatinine >100 µmol/L.  Ciprofloxacin is often the drug of choice when there are 
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early signs of renal failure as gentamicin is known to be nephrotoxic.  Also, 
ciprofloxacin is generally a second line rescue therapy administered at a later stage 
when multi-system organ failure may be increasingly evident. These factors account 
for high creatinine levels reported on day one. It is important to consider the time of 
the routine clinical bloods on day one as these were usually collected prior to the 
decision to commence ciprofloxacin as PK studies are comparing the effect of the 
body on the drug. A high creatinine on day one therefore was not adverse drug 
reactions. Creatinine concentrations correlated with clearance, suggesting it may be 
a useful biomarker when selecting the optimal regimens. This is practical as 
biochemistry values are readily available in critical illness. However, there are 
limitations, creatinine concentrations may be falsely low masking renal failure due to 
an increased volume of distribution following fluid resuscitation [254]. Creatinine may 
be less reliable as a marker for babies <5 days of birth due to the effect of maternal 
creatinine. Further data are required as these babies were excluded from this trial. 
Inotrope administration resulted in decreased clearance by 29%.This is clinically 
relevant as 37% of this population were administered inotropes. In contrast clearance 
in adults increased when co-administered inotropes with antibiotics attributed to the 
increasing cardiac output and renal blood flow or a hyper-metabolic response to 
sepsis [105, 129]. Ceftriaxone clearance almost doubled in 30% of adults [91].  
Similarly, vancomycin clearance increased in adults [129]; whereas a neonatal trial of 
the same drug found the opposite as clearance decreased by 28% with concurrent 
use of dopamine [255].  Further analysis of the ciprofloxacin PK data found the sub-
group administered inotropes had increased median creatinine (difference 36.5 95% 
CI 18.0, 58.00 p=0.0001) prior to commencing ciprofloxacin  
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Table 2-16. Therefore inotrope administration is a marker of underlying renal failure. 
The different response between adults and neonates may be due to inadequate PK-
PD data of inotropes in neonates compared to a more established evidence base for 
critically ill adults. The optimal dose of inotropes and optimal blood pressure for 
neonates particularly for each sub-age group is unknown. The limited PK/PD data that 
exists for inotropes in neonates has wide variation in plasma concentrations and poor 
correlation with blood pressure response [256-261]. The most common inotropes 
administered in this trial included dopamine (27%) and dobutamine (19%), there is 
uncertainty regarding the optimal regimens for different ages. A Cochrane review 
found dopamine achieved haemodynamic targets more than dobutamine (RR 0.41, 
95% CI 0.25 to 0.65; RD -0.23, 95% CI -0.34 to -0.13; NNT = 4.3, 95% CI 2.9 to 7.7) 
[262]. Studies of dopamine in infants and older children suggested higher doses (>7.5 
micrograms/kg/min) may be necessary to treat hypotension [263]. In contrast other 
uncontrolled studies in preterm infants found lower dose therapy (2 to 8 
micrograms/kg/minute) may be more effective [264]. Equally, there is uncertainty 
amongst neonatologists about the acceptable lower limit for systemic arterial blood 
pressure [262]. This is compounded by limitations to monitoring blood pressure during 
late onset sepsis as umbilical arterial catheters tend to be removed early to reduce 
the risk of infection. Radial or femoral arterial lines are rarely used due to the risk of 
occluding blood supply to limbs resulting in amputation in rare cases. In summary, 
suboptimal renal perfusion appears to account for the reduced clearance when 
neonates were co-administered inotropes.   
The main predictor of treatment success for ciprofloxacin is the AUC24/MIC ratio. The 
median AUC24/MIC for each sub-age group achieved the minimum conventional 
target 125. As many as 14% of subjects were below this target, they may have been 
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undertreated which is of great concern considering the increased morbidity and 
mortality associated with Gram-negative bacteraemia. Predicting the optimal dose is 
challenging as the AUC varies considerably ranging between 34 and 291mg/h/L at 
steady state Figure 2-16. Those above this optimal target may be exposed to adverse 
reactions. The PK Modelling simulated the optimal regimens to achieve the 
conventional AUC24/MIC ratio of 125 for two age groups above and below:  i) 34 weeks 
then ii) 36 weeks PMA. Neonates below 34 weeks PMA administered 20mg/kg/day 
were more likely to achieve the AUC24/MIC ratio 125 (97%) compared to only 66% 
above this age. The proportions were similar when comparing those <36 weeks PMA 
as 96% achieve this target compared to only 65% of those >36 weeks PMA Table 
2-18.  
This clinical trial protocol aimed to evaluate AUC24/MIC ratio 125 as this is the 
conventional target widely applied for adults over many years and as this study was 
cautious as the safety data for higher dose regime to target an AUC 250 for 
neonates was unknown.  However, a higher regimen for neonatal bacteraemia is 
worthy of consideration due to the high mortality. However, there is compelling 
evidence from both paediatric and adult data to support a higher AUC24/MIC ratio of 
250 to improve outcome and reduce resistance [48, 115, 162, 176]. PD studies have 
shown that organisms are eradicated at an earlier stage when the AUC/MIC ratios 
are higher than 125 [162, 176].  Forrest et al. found bacteria were eradicated within 
1.9 days when the ratio was 250 compared to 32 days below 125 (p<.005) [162, 
265]. Zelenetski et al. found the risk of treatment failure was 27.8 times greater   
below an AUC24/MIC 250 (P=0.011) [176]. Only 38% of the neonates in this trial 
achieved the higher AUC24/MIC target of 250. The model did not predict the dose 
required to achieve an AUC24/MIC >250. Further analysis of these data is planned to 
simulate the optimal dose to achieve the higher ratio. However, these data illustrate 
that the median of each sub-age group below 36 weeks PMA achieve a higher ratio 
than 250 ranging up to 578. Further safety data is required stratified to each sub age 
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group as the toxicity is unknown. Regimen may need to be adjusted for those born 
prematurely due to delayed renal maturation despite corrected gestational ages as 
illustrated by Vieux et al [127]. The TINN Consortium completed a safety study in 
new born mice and found no adverse effect of Ciprofloxacin at 10 and 30 mg/kg/day. 
However, a considerably higher dose than used in clinical practice of 100 mg/kg/day 
resulted delayed weight gain, impaired cardiorespiratory and psychomotor 
development and caused inflammatory infiltrates in the connective tissues 
surrounding the knee joint  [266]. Toxicity is expected with antimicrobials when high 
dose regimen are administered therefore the optimal dose for the MPC and efficacy 
requires safety data.           
The optimal interval between doses in the BNF C recommends either 12 hourly for 
neonates and 8 hourly for term babies this interval is supported by this trial’s data. 
The median half-life was considerably longer ranging between for each sub-age group 
below 35 weeks PMA ranging between 9.10 -12.65 hours (max 33.8) compared with 
>35 weeks 4.9 – 7.10 (max 14). This is consistent with gentamicin, as the half-life 
averages approximately eight hours at a gestational age of 26 to 34 weeks compared 
with about 6.7 hours when 35 to 37 weeks gestation [173]. In adults the half-life 
increases in renal impairment and doses are adjusted based on renal function tests 
[267]. A systematic review of gentamicin for neonatal sepsis recommended that a 
once a day regimens may be superior in treating neonatal sepsis in neonates more 
than 32 weeks gestation [268]. In these ciprofloxacin data the half-life was 
considerably long in very premature neonates up to 33.8 hours. Caution is required if 
administering 8 or 12 hourly regimen that may result in toxicity. Further safety data is 
required to determine the optimal regimens. An extended dosing regimen of once in 
36 to 48 hours may be more suitable for very preterm infants born less than 32 weeks 
gestation [269-271].  
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Of the 64 neonates recruited eight died within the six week pharmacovigilance 
reporting period and a further three prior to discharge (n=11).  The majority of deaths 
80% (n=9) were in those born <26 weeks PMA at birth. This mortality rate is lower 
than neonates with confirmed Gram-negative bacteraemia in this unit as only 6.3% of 
the trial participants had Gram-negative bacteria in blood cultures. Most were 
prescribed ciprofloxacin for suspected sepsis. Optimising the regimens for confirmed 
bacteraemia is particularly important as mortality in this unit is 20% if < 28 weeks PMA 
and 8% between 28-34 weeks but increases to 44% when Gram-negative bacteria 
are confirmed. Similarly, other neonatal studies reported mortality increased from 18 
% to 36% with confirmed Gram-negative late onset sepsis [18]. A review of the long 
term consequence of prolonged sepsis found considerable effect on the long term 
quality of life as only 28% of neonates were alive and considered normal at 18 months 
follow up [30]. Early eradication of bacteria may be more important than the risk of 
some adverse reactions such as arthralgia that is known to resolve. Equally, adverse 
reactions must be considered relative to the risk associated with alternative 
antimicrobials such as gentamicin. Balancing the risk of higher doses with adverse 
reactions may depend on whether sepsis is suspected or confirmed as the risk of 
Gram-negative bacteraemia is greater. Rapid methods of identifying organisms would 
allow higher doses to be prescribed earlier.      
The physiological changes associated with maturation and critical illness influence 
drug disposition associated with fluid shifts and hypoalbuminaemia [88, 89, 105, 162, 
177, 272-274]. Wide variations in PK parameters were evident in this population. This 
was not reflected by changes in the volume of distribution. Gous et al. found the 
volume of distribution of vancomycin almost doubled early in sepsis on day two 
associated with aggressive fluid therapy in infants compared to day eight [275]. The 
volume of distribution for gentamicin on the second day of treatment was reported as 
0.43+ 0.12L/kg then decreased on the seventh day of treatment 0.29+-0.17 L/kg [104]. 
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Such changes are less likely with drugs such as ciprofloxacin that are lipophilic as 
they have greater affinity for intracellular distribution. Roberts et al. found 
fluoroquinolones responded less to extracellular fluid changes than hydrophilic drugs 
(aminoglycosides, B Lactams, carbapenems and vancomycin) [86]. Equally, the 
change in volume of distribution of ciprofloxacin in adults with severe abdominal 
sepsis was not significant [105].  
In critical illness PK parameters vary within a short time frame.  Lipman et al found 
the Cmax was higher on day two than day one indicating the need for a loading dose 
[115]. This may be because the dose was insufficient to saturate the tissues during 
the initial distribution phase or that renal function deteriorated by the second day.  
When comparing the median of each sub-age group the volume of distribution was 
relatively constant. Loading doses are not commonly required for lipophilic drugs [88, 
103].  Tayman et al. found the volume of distribution decreased during neonatal 
development for hydrophilic drugs but increased for fat soluble drugs [97]. Decreasing 
extracellular fluid and increasing body fat associated with maturation can influence 
concentrations. Further analysis of this trial’s PK data to evaluate the changes in 
parameters between the early samples on days one or two and late samples between 
days five and seven would provide valuable insight to the variability pre and post 
suspected sepsis.   
Changes in albumin levels are common in sepsis associated with capillary leak, poor 
nutrition and reduced production of albumin concentrations [86, 102]. As ciprofloxacin 
is moderately bound to protein 20-40% [53] hypoalbuminaemia may have a moderate 
effect on concentrations.  Albumin was lower at baseline than the laboratory reference 
range (median 27 range 30-45g/L) Table 2-22. As many as 40% of septic patients are 
reported to have low albumin levels ≤25 g/dL (reference range 42g/L +-10%) [90]. 
Trans-capillary escape of albumin from the intravascular to extravascular space can 
increase considerably by 200% during the first two days of critical illness [90]. This 
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partly explains the vast increase seen in weight for septic neonates. The effect on PK 
parameters can be considerable; in relation to amikacin hypoalbuminaemia was 
associated with requiring a 1.6 fold higher loading dose [92]. Ceftazidime volume of 
distribution increased fourfold due to the increased extracellular volume associated 
with capillary leak [276]. Fluctuations in PK parameters are evident during the 
distribution and elimination phase may have been associated with 
hypoalbuminaemia. When the albumin is low a higher proportion of the drug is 
unbound within the extravascular compartment resulting in a high drug concentration 
[88, 89]. However, the unbound drug is then free to be eliminated resulting in a lower 
concentration [7, 84, 88]. As a result of critical illness PK concentrations fluctuate. 
There is little published data relating to the later stage of sepsis when capillary leak 
resolves. In theory the drug distributed into the peripheral compartment during 
inflammation may return to the central compartment increasing drug concentration. 
This may result in an increase in the half life as the drug is redistributed from the 
tissues back into the central compartment [89]. Changes are evident clinically as 
capillary leak resolves and the weight decreases there is a vast increase in urine 
output in ml/kg. Fewer samples were available for the last day of treatment (58%) due 
to mortality or discontinuation of treatment. Further analysis of paired early and late 
sample data would provide useful information about the variability in concentrations 
over the different stages of sepsis. Less variability is expected with ciprofloxacin as it 
is lipophilic which this analysis may illustrate.  
Extreme changes in weight are evident in this population over the sepsis period 
increasing up to 38% Figure 2 6. In paediatrics drug regimens are based on weight 
(mg/kg). To avoid over dosing the pre-sepsis weight is often used but may result in 
under treatment if the concentration of the drug is lower. This may be dependent on 
whether the drug is hydrophilic or lipophilic. These data may contribute to deciding 
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whether drugs should be prescribed on the pre-septic weight or adjusted daily based 
on the actual weight. The correct dose may change daily pre and post sepsis. 
Therapeutic drug monitoring (TDM) may optimise therapy by responding to each 
phase of infection. However there are practical and ethical limitations to sampling and 
concentrations may change before laboratory results are available. A pragmatic 
approach is to estimate the optimal regimens initially using the significant co-variates 
(creatinine, post menstrual age at birth and post- natal age) found in these PK data. 
However, the wide range of PK parameters during critical illness per subject and per 
sampling occasion even within age sub-groups emphasise the need for an 
individualised therapy.  
The risk of error with sampling and drug administration may have contributed to the 
variability in parameters. This risk is greater in neonates and young infants than 
adults due to the minute drug volumes, minute blood volumes and complex infusion 
lines. To ensure the reliability of data an extensive training programme for over 400 
staff was implemented and the research fellow was on call seven days a week for 
the year. The interim analysis report included a higher concentration three hours after 
the drug was administered than three minutes after the infusion. Possible causes 
explored included: 
i) delayed distribution between central and peripheral compartments  
ii) delay in the drug entering the vein due to infusion line dead space 
iii) inadequate flush volumes (particularly via central lines) 
iv) syphoning of drugs from one line to another via a Y connection 
v) poor peripheral perfusion at the capillary sample site  
vi) contamination if sampling from the line in error where the drug had    
been infused (contrary to the standard operating procedure)  
vii) laboratory measurement error  
Different drug infusion practices existed at each hospital.  Each site administered the 
infusion over a different time either 30 or 60 minutes, in the neonatal hospital this was 
30 minutes therefore less risk to the data. Also, the paediatric hospital primed the 
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infusion line with saline first which resulted in up to 24 minutes delay between the 
drug leaving the pump and reaching the vein. By accurately recording the 
administration data this allowed adjustments for the delay to be estimated. The 
duration of an infusion is known to alter peak concentrations therefore may have 
affected values particularly the Cmax  [277]. The flush may not have been adequate 
particularly for internal long lines such as Broviac lines as it is difficult to estimate the 
dead space. Flush volumes are kept to the absolute minimal.  Post-operative cardiac 
infants are fluid restricted to as little as 1mL/kg/hour in total for all drugs and nutrition 
and are often administered as many as twenty drugs per day. Although, early PK 
values are valuable in an informative sampling schedule, a recommendation of the 
study is to delay the first blood sample time to ten minutes when drugs are 
administered via central lines. During critical illness infusions are administered 
simultaneously with multiple lines connected via a Y connector or traffic light. As fluids 
follow the route of least resistance the drug may enter another infusion line with less 
resistance then enter the vein at a later stage when the second infusion starts.  
Variation in PK concentrations may have been influenced by different sampling 
practices. Most of these PK blood samples were collected from capillary heel pricks. 
Venous cannula samples were not collected due to the risk of contamination from the 
drug administered via the same line. Studies comparing blood gas results taken from 
capillary, venous and arterial sites found wide limits of agreement [278-280]. Poor 
perfusion is known to effect absorption of intramuscular or trans-dermal 
administration and is equally likely to affect sample concentrations [118].  
The frequency of clinical sampling during critical illness provided a practical and 
ethical opportunity to scavenge blood that would otherwise be discarded. The PK 
sampling schedule was selected to be in line with the time clinical bloods were 
required for standard care. On average 2.8 additional samples were scavenged 
without additional burden to the baby. This opportunistic method of scavenging 
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samples was dependent on the precision of data provided by training staff providing 
24/7 care. The scavenged samples gave similar PK models to the samples obtained 
at informative time points [273]. The data was reliable as the range of PK timed 
samples concentrations 52 to 10,961 (median 4066; 25th-75th: 2212-5748) ng/mL 
and scavenged samples 450 to 15,976 (median 3505; 25th-75th: 2191-5428). The 
limitation of this methods is that the scavenged bloods were clustered at the start of 
the day taken during a phlebotomist ward round therefore underrepresents the range 
of times required for AUC data. Also, the number of samples per patient included in 
the model varied >10 and is biased to more severely ill who require more clinical 
bloods.  
There are considerable risks to data reliability when dealing with minute volumes of 
drugs and blood samples. Standards for conducting PK trials in neonates are required 
to minimise the risk to data reliability as the large neonatal PK studies are rarely 
repeated and can influence prescribing practice internationally.   A recommendation 
of this study would be to develop international standards for neonatal PK with a view 
to accredited PK ready clinical wards and laboratories. This would be supported by 
training the clinical teams and implementing systems to achieve the precision 
required.  Implementing changes to standard practice such as drug prescription charts 
that include the time the drug was given rather than a signature against the time 
prescribed would improve precision.  Standardised case report forms with minimum 
data sets would ensure covariates are systematically collected such as fluid therapy, 
poly pharmacy and organ support that influence PK parameters. Data should be 
explored by clinicians before data lock due to the complexity of the population.   
2.4.2 Ciprofloxacin penetration in cerebrospinal fluid (CSF) 
Ciprofloxacin has good tissue penetration therefore maybe useful for treating 
meningitis. Obtaining CSF samples was particularly challenging as samples were only 
collected if a lumbar puncture was required for clinical care which had generally been 
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completed prior to ciprofloxacin administration as it is second line therapy). Despite 
these challenges samples were collected and immediately frozen for 10% of recruits. 
CSF drug concentrations in infants are often higher than children and young adults 
associated with changes in the blood brain barrier [111]. Correlation between the CSF 
collection time and CSF/serum concentration ratios suggests slower elimination from 
or diffusion into the CSF compared to the systemic circulation and the median value 
of CSF/serum ratio was 0.32 (range 0.08 -0.58). This is consistent with adult studies 
AUC/CSF v AUC/serum steady state ratio was reported as 0.24 – 0.43 which increase 
to 0.92 when meninges were inflamed [111, 113]. Whether levels are higher when 
meninges are inflamed is not evident from these data as only one patient had 
confirmed meningitis. Meningitis may be underdiagnosed as lumbar punctures are 
not always obtained prior to commencing antimicrobial therapy. Six patients had 
seizures prior to ciprofloxacin administration but there were no reports following 
treatment. There is a higher risk of toxicity and seizures have been reported with 
higher Cmax in children [115]. The recent systematic review on safety of ciprofloxacin 
excluded reports of seizures [190].  
2.4.3 Characteristics of the population and short term outcome  
This population had complex comorbidity and a high risk of mortality associated with 
extreme prematurity and critical illness confounding the outcome assessment in 
relation to ciprofloxacin. This is evident as most were recruited in intensive care, 91% 
were ventilated and 40% were co-administered inotropes during their admission. CRP 
data were available on day ten for 39 neonates; 28/39 (71%) had CRP value <10 
mg/L classed as cure. Few participants (6.3%) were subsequently diagnosed with 
confirmed Gram-negative bacteraemia limiting the clinical outcome assessment. 
Suspected sepsis was more commonly diagnosed in males (62%) Table 2-11, this 
gender bias is consistent with other reports of infection but there is no consensus as 
to the cause to date. Also, ciprofloxacin is generally prescribed late in the course of 
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illness as a second line rescue therapy therefore this group are often deteriorating 
with unknown aetiology. These data are limited as the response to treatment may 
have been influenced by earlier antimicrobial therapy or co-administration of co-
amoxiclav. This PK trial design aims to detect the effect of the body on a drug 
concentration therefore it was not designed or powered to evaluate safety or the 
clinical outcome of late on set sepsis.  
 Short term safety and tolerability  
There were no SUSAR reported during this period, due to the nature of this population 
24 SAE were reported to the Sponsor and found to be unrelated to ciprofloxacin.  
 Mortality 
Eight babies died during the six week post dose pharmacovigilance reporting period 
and a further 3 prior to discharge (n=11). The majority of deaths were associated with 
extreme prematurity as 67% occurred in those aged <28 weeks PMA. The overall 
mortality was slightly lower than this unit’s mortality rate of 20% for this age group <28 
weeks PMA which decreases to 8% between 28-34 PMA weeks (LWH BADGER 
patient data system). Mortality generally increases with severe infection but the 
majority of babies in this trial were diagnosed with suspected rather than confirmed 
Gram-negative sepsis. The DMC were satisfied that the mortality rate was no higher 
than anticipated in this patient population.  
 Arthropathy  
Visual signs such as redness or swelling of joints were not reported. Arthropathy or 
arthralgia may have been underreported as there is no definitive method for 
diagnosing this in neonates. This population are not weight bearing and their response 
to handling may be a simple startle reflex rather than pain. This clinical limitation is 
evident in the systematic review of safety in  children that did not include any reporting 
for infants less than six  months age [190]. Even before the introduction of 
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fluoroquinolones there were reports of arthralgia during sepsis. Children often present 
with joint complaints including 18% orthopaedic disorders, 17.6 % autoimmune 
disorders, 19.6% joint complaints related to bacterial infection and  44% unknown 
[197].  Also, children with cystic fibrosis occasionally present with articular damage 
unrelated to quinolones [281, 282]. The WHO Selection and Use of Essential 
Medicines Report stated that arthropathy was found to be reversible, without long 
term sequelae and not convincingly correlated with the use of fluoroquinolones in 
children [226].  
Ciprofloxacin is reported as being the least arthrotoxic of the quinolones. Chalmeau 
et al. found musculoskeletal events tended to be more frequent with Pefloxacin 18.2% 
versus 3.3%; for ciprofloxacin (P <0.06) [283].The mechanism of arthropathy is 
unknown, but may be associated with magnesium deficiency. Magnesium 
supplementation in immature rats reduced ciprofloxacin-induced chondrotoxicity 
[284]. The range of magnesium concentrations for this population reduced over time 
but was not considerably lower than the reference range Table 2-22. Caution is 
required when intravenous supplementation is administered as Stahlmann et al. found 
that co-administration with ciprofloxacin considerably reduce the AUC from 8.2 to 0.7 
[205]. A review of arthralgia specific to blinded randomised controlled trials would be 
valuable. The systematic review of safety included 15/105 RCT but did not publish 
this data separately [190].  
 Renal and Hepatic Function  
Renal and hepatic function varied over the course of sepsis but no causality was 
associated with ciprofloxacin. In general creatinine median concentrations decreased 
over the period of administration. Three patients creatinine levels met the criteria for 
safety reporting (serum creatinine doubled or increased > 44 µmol/L over baseline). 
In each case the clinical biochemistry samples were collected prior to commencing 
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ciprofloxacin. The elevated creatinine led to ciprofloxacin being prescribed due to 
concerns for nephrotoxicity associated gentamicin. Figure 2-22 
One case of renal calculi (renal stones) and one of nephrocalcinosis (calcification in 
in the in the renal parenchyma) were found on clinical abdominal scans. Crystalurea 
has been reported in pre-clinical studies [53] therefore the IDSMC were informed for 
further investigation of causality . Other factors known to be associated with renal 
calculi are common in this population.  Short et al. found, 21 (27%) neonates had 
some form of renal calcification and four (5.1%) had renal calculi and the risk 
increased by 62% with oxygen therapy [285]. Renal calcification is a known 
complication of long term furosemide therapy, Toffolo et al. [286] reported 12 (63%) 
premature neonates with bronchopulmonary dysplasia had some sort of renal 
calcification including three (16%) with renal calculi that did not receive furosemide. 
Nephrocalcinosis was not subsequently associated with long term renal dysfunction 
at four to five years old [287]. A safety review of ciprofloxacin did not report 
nephrotoxicity or crystalluria during phase II and II trials [190]. Abdominal scans 
required for clinical care were reviewed retrospectively and the incidence was no 
higher than in the literature. The DMC were satisfied that there were no concerns 
regarding ciprofloxacin but recommended routinely scanning neonates in future 
studies. 
Liver function tests were high in some babies but there was no change in median 
values following the start of ciprofloxacin and values were lower than baseline three 
days after the end of therapy. Hepatotoxicity was reported for a patient following 
emergency cardiac surgery. Ciprofloxacin was started the day after the initial rise and 
settled after a few days in keeping with post bypass alteration in LFTs. The start of 
ciprofloxacin treatment was associated with a statistically significant fall in the platelet 
count. Again, this could also be part of the natural history of infection. These data 
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suggests there was no temporal association between ciprofloxacin and altered liver 
function but are not conclusive. 
 
 Phlebitis  
Neonatal veins were assessed following the administration of ciprofloxacin for a total 
of 259 patient days and only 4% reported as ‘possible’ or ‘early stage’ phlebitis. This 
incidence is low and several drugs were often administered to the same vein in most 
cases. The BNF C recommends administration over 60 minutes as this injectable 
solution is acidotic (pH 3.5 – 4.6). This is longer than most antibiotic infusions in 
clinical practice and can be difficult as there are a limited number of lines when other 
drugs or total parenteral nutrition need to be administered. It was not possible to 
compare the effect of the short versus long infusion as most of the term babies had 
central lines. Ciprofloxacin was administered over 30 minutes to neonates suggesting 
the shorter infusion was tolerated even in the very premature.  
In general ciprofloxacin was tolerated by this population. There was no clear, novel 
safety signal or evidence of unanticipated clinical events, acute articular problems, 
excess phlebitis or clinically significant derangements in laboratory parameters that 
could be attributed to ciprofloxacin. The reasons for stopping ciprofloxacin included 
death (unrelated), discontinuation of antimicrobial therapy or confirmed microbiology. 
As, three different regimens were administered to this population ranging between 10 
– 30 mg/kg/day the outcome assessment is limited. PK data generated within a critical 
care population may not be generalizable to the wider paediatric population as other 
interventions may mask adverse events. These safety data included follow up data 
limited to six weeks. Neonates are more susceptible to drug related developmental 
disorders and adverse drug reactions can sometimes be detected later in life [79]. 
Further safety follow up date is required.  
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2.4.4 Recruitment, Ethical and Governance Challenges 
The key to the success of the trial was developing a research culture with the wider 
clinical team and families. Ciprofloxacin was infrequently prescribed as it is a second 
line therapy. To avoid missing eligible participants over 2500 babies were screened 
daily each day of their admission. The screening log was cross checked against 
pharmacy records to confirm that no eligible babies were missed during this period. A 
high recruitment rate of 63% was achieved at the neonatal hospital and 43% at the 
children’s hospital. By training the wider clinical team meant they were informed and 
could respond to questions from parents. This transparency reassured families who 
viewed the trial as being led by the clinical team.  
The time frame for consent was challenging as the decision to prescribe ciprofloxacin 
could be anytime day or night. Administration had to commence within 30 minutes of 
the decision to prescribe the drug due to the risk of severe sepsis. Most babies were 
extremely ill; despite being in a stressful situation the parents accepted the importance 
of the research and had an altruistic approach to protect future babies. Prospective 
consent allowed families more time to consider participation and to be approached at 
a less stressful time before signs of sepsis. The population PK models allows some 
flexibility in sampling times, parents were reassured when the researcher selected  a 
sampling schedule most in line with the blood gas or daily biochemistry bloods to 
minimise additional distress to their baby. Only one parent withdrew.  
Neonates often move from a lead centre to a local neonatal unit during their care. 
There were only two recruiting sites but forty hospitals were set up with a Principal 
Investigator and R&D approvals at all units within 100 miles to provide follow on data. 
Only three babies were subsequently transferred and there were no safety issues 
reported. A recommendation of this trial is to promote a more proportionate approach 
to the governance requirements in Chapter 5.   
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2.4.5 Conclusion  
Pharmacodynamic data and safety data specific to neonates and young infants is 
essential to apply PK parameters to determine the optimal regimen. This study has 
demonstrated that the regimens 10 mg/kg 12 hourly achieved the minimum 
acceptable PD target 125 (AUC24/MIC ratio). Due to the severity of illness in Gram-
negative sepsis a higher ratio may optimise outcome.  It is evident from these PK data 
that the time interval between doses needs to adjust for completion of nephrogenesis. 
This is consistent with current recommendations for 12 hourly for preterm babies 
increasing to 8 hourly for those > either 34 or 36 weeks PMA [173]. Further individual 
dose adjustments are required for those born very premature as their renal function 
may mature at a slower rate post-natally. Also, for those with signs of renal failure are 
present indicated by raised creatinine and inotrope administration. In the absence of 
neonatal PD data the optimal dose remains unknown. 
It is evident from the wide range in PK parameters that the clinical condition, clinical 
interventions and co-administration of other medication all influence PK parameters 
in addition to the dynamic changes within days or weeks in development. This 
strengthens the argument for individualised regimens in this population including 
timely adjustment of antibacterial dosing with real time application of therapeutic drug 
monitoring. Even with sub-age groups wide variability is evident to the extent there is 
a considerable risk of undertreating or overdosing. The optimal dose may change at 
each dosing interval pre and post sepsis due to the inter occasion variability. There 
are limitations to individualised dosing in neonates particularly due to restrictions on 
blood sampling yet this study provides data regarding the optimal parameters 
including PMA, PNA and creatinine to individualise regimens. This may improve both 
the clinical outcome and minimise antibacterial resistance. Equally, the interpretation 
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of data from PK studies in critical illness may not be generalizable to other populations 
due to these complex variables. 
High mortality, morbidity and alterations in vital signs or clinical parameters outside 
the normal range are anticipated in this population, causality was not associated with 
the administration of ciprofloxacin. There was no evidence of arthralgia although the 
assessment is limited by a non-verbal and non-weight bearing population. To 
minimise the effects of confounding factors a blinded randomised controlled trial 
would be required for definitive safety or outcome analysis. 
Despite the ethical, regulatory and logistical challenges of PK trials in neonates this 
study succeeded to recruit 63 neonates and develop methods to minimise the burden 
to babies or their families. Also, methods to achieve the precision are essential for 
reliable data in large clinical teams. In addition Chapter 3 describes methods for 
scavenging DNA for pharmacogenomic analysis and Chapter 5 a more proportionate 
regulatory model for pharmacokinetic clinical trials in this population.    
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Chapter 3 Neonatal DNA Sampling  
3.1 Overview  
This sub-study aimed to evaluate whether donor blood transfusions interferes with 
genotyping in the short term. The DNA from the scavenged blood and the buccal 
samples were extracted for comparison of the genotype. Pharmacogenomic analysis 
for ciprofloxacin is not part of this study but will be undertaken the by the 
Pharmacogenomics Laboratory University Ulm, Germany 
3.1.1 Aim and Objectives 
Aim:  
 To optimize the method of collecting DNA samples from neonates for future 
pharmacogenomic analysis.  
Objectives:  
 To compare the quantity and quality of DNA extracted from neonatal DNA in 
blood and buccal samples 
 To determine whether DNA scavenged from clinically required full blood 
counts is contaminated by donor blood following allogenic transfusions.   
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3.2 Methods  
DNA samples from a sub-group of neonates from the PK clinical trial were collected 
The DNA scavenged from a clinically required blood sample was compared with the 
buccal sample as the control.   A sub-group of neonates were transfused at least one 
blood product including packed red cells (SAGM), platelets or fresh frozen plasma 
within a week of DNA sampling. Their transfusion history was recorded including the 
number, date and type of allogeneic blood products transfused. The time period 
between transfusion and DNA sampling was recorded. In addition, it was noted 
whether the blood product was irradiated or treated with methylene blue as this 
diminishes the white cells [288].  A minimum volume of 5µg DNA was required 
by the pharmacogenomic team. In neonates the yield from buccal cells was likely to 
be much lower (estimated as ~ 2 µg).To increase the yield further DNA was obtained 
from pooled scavenged full blood count samples taken for clinical care.  
3.2.1 Inclusion criteria for the quality and quantity of DNA:  
 Parental consent for neonatal DNA samples 
 Recruited to the PK clinical trial   
 Inclusion for comparing contamination by a donor 
 Neonates transfused packed red cells (SAGM), platelets or fresh frozen 
plasma within a week of a clinical blood sample.   
3.2.2  DNA Sample Collection:  
 Buccal Samples   
Cells were collected by gently scraping the inner cheek using an Isohelix SK-2 
buccal swab kit (Kent UK). The product information states this will yield 1 to 10µg in 
adults http://www.isohelix.com/PDF/isohelix swab_brochure.pdf#page=2  (accessed 
March 2013).  
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 Scavenged Blood Samples  
All blood samples collected for clinically required full blood count analysis were 
scavenged from the haematology laboratory in EDTA bottles over a period of 3 – 5 
days. The samples were centrifuged at 4000 rpm for 10 min at 4°C to separate plasma 
components; the remaining cells and buffy coat were retained and stored cool.     
3.2.3  DNA Extraction 
DNA was extracted from buccal and blood samples by the Regional Molecular 
Genetics Laboratory at Liverpool Women’s NHS FT.    The method of extraction 
depended on the quantity of blood, when <700 µl was available a Qiagen kit EZ1 
(Qiagen Inc, Manchester, UK) was used but for larger volumes >700µl Chemagen 
(Perkin-Elmer Beaconsfield, UK) extraction was performed according to the 
manufacturer’s instructions. The extracted DNA was then stored at -400C until 
analysis. 
 DNA samples were anonymised and couriered on cool packs to the 
Pharmacogenomics Laboratory University of Ulm (Germany).  The quantity sent was 
calculated using the formula:  volume of DNA (µl) = 5000/DNA concentration (ng/µl) 
to ensure a minimum of 5 µg. Where insufficient DNA was available the whole sample 
was sent.  
3.2.4  Quality of DNA Samples  
To measure DNA purity and yield, each sample was analysed using a Nanodrop ND-
1000 Spectrophotometer (version 3.3 Nanodrop Technologies Inc. Wilmington USA). 
DNA concentration is measured by absorbance at 260nm adjusted for turbidity 
measured by absorbance at 320nm http://www.promega.con/pubhub (May 2014).  
DNA purity absorbance was measured from a spectrum of readings between 230 – 
320nm that detects the range of possible contaminants. DNA may be contaminated 
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by other molecules; RNA also absorbs at 260nm, Aromatic Amino Acids at 280nm 
and presence of guanidine increases A260, when present these may overestimate 
the DNA quantity.  
Turbidity is indicated by high absorbance at 320nm. A strong absorbance at 230nm 
can indicate organic compounds or chaotropic salts are present in the purified DNA 
carried over from the DNA extraction procedure. This salt carryover can be evaluated 
by the ratio of A260nm to A230nm, the lower the ratio the greater the amount of salt 
present. The A260 /A230 ratio is best if greater than 1.5. The most common purity 
calculation is the ratio of absorbance at 260nm divided by 280 nm. Good quality DNA 
will have an A260/A280 ratio 1.7 – 2.0. 
Table 3-1 DNA Concentration, yield and purity values 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DNA Measure  Range  
Concentration µg/mL (A260 reading – A230 reading) x dilution factor x 50 µg/mL  
A260 of 1.0 = 50 µg/mL pure DNA 
Yield  µg Concentration x total sample volume (mL) 
Purity (A260 / A280) (A260 reading – A320 reading) / (A280 reading – A320 reading) 
Salt carry over: A260nm:A230nm  
Good quality purity ratio  1.7 – 2.0 
Optimal >1.5 a lower ratio suggests contamination or salt carry over 
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3.2.5  DNA Analysis by PCR Typing 
DNA PCR Typing was undertaken by the Regional Molecular Genetics Laboratory at 
Liverpool Women’s NHS FT. The PowerPlex 16 HS System (Promega Madison USA) 
and GeneMapper Software (3.7) established the genotype. A comparison of the 
genetic profiles from both buccal and blood samples was made to determine the 
presence of peaks and the area under the peak (GeneMapper software version 3.7).  
This determines whether there was a match between buccal and blood cells or 
contamination. PCR allows for the simultaneous single-tube amplification and two-
colour detection of eight polymorphic STR loci. CSF1PO, TPOX, TH01 and vWA 
primers are labelled with tetramethylrhodamine; D16S539, D7S820, D13S317 and 
D5S818 primers are labelled with fluorescein. Loci are named by two conventions. 
Some are named for nearby genes – such as THO1 (HUMTHO1, human tyrosine 
hydroxylase gene), while others, such as D7S820, are named for their chromosomal 
positioning. All of the loci included in this set are true tetranucleotide repeats. The 
quality control method was consistent with Promagen Standards that control changes 
in buffers, ionic strength and primer concentrations.  
Analysis for reporting: 
The percentage of contamination, where present, was quantified as:  
                Area of contaminating peak / Area of true peak x 100 
The Genemapper software allocates allele designators (shaded blocks on 
electropherograms) that indicate where each allele should be compared to peaks on 
the electropherogram. The software size marker gives the size of the allele and 
calculates the peak area of the allele identified.  The percentage contamination can 
be assessed by comparing the peak area of a contaminating peak to the peak area 
of a non-shared allele.   
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3.3 Results 
DNA samples were extracted for 58 participants of the PK clinical trial with parental 
consent. Paired buccal and blood samples were obtained for 45 babies to compare 
the quality and quantity.  Eleven neonates were included in the sub-study to determine 
whether DNA was contaminated by the donor’s DNA following transfusion. This 
subgroup had been transfused allogenic blood product (s) within a week prior to DNA 
sampling.  
3.3.1 DNA Quantity and Quality 
A total of 51 DNA samples were obtained from scavenged blood and 30 from buccal 
cells to compare the yield and quality of DNA. The mean amount of DNA obtained 
from buccal cells was 3.4 µg compared with 42.95 µg from scavenged blood 
(P<0.0001). The purity of DNA ratios A260:A280 were satisfactory for all DNA, but 
were significantly higher in buccal cell derived DNA (2.10 cf 1.88, P<0.0001). Low 
values could indicate protein contamination. A260:A280 and A260:A230 are 
indicators of DNA purity with expected values in the range of 1.8 – 2.2. However, the 
A260:A230 was significantly lower in buccal cell derived DNA (0.23 cf 1.88, P<0.0001) 
which may indicate salt carry over from the DNA extraction procedure. Figure 3-1 
shows the spread of results. This may affect the efficiency of future the PCR reactions. 
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Figure 3-1 DNA Quantity and Quality of DNA from Buccal or Blood samples 
 
Blood scavenged from clinical samples compared to a buccal scrape (n=45) 
 
3.3.2 Contamination by donor blood following allogenic transfusion 
The shortest time between the DNA sample being taken and the most recent 
administration of an allogenic blood transfusion was no greater than a maximum of 
four days.  This sub-group were inpatients for between 11 to 132 days (median 55) 
and during this period they were administered up to 38 transfusions (median n= 18).   
The transfusion service issue gamma irradiated products when neonates are 
diagnosed with suspected Di George syndrome or if administered an inter-uterine 
blood transfusion. Occasionally an irradiated product will be administered because it 
is readily available or when it is about to expire. Fresh frozen plasma and 
cryoprecipitate are routinely treated with methylene blue. In this group LW35 received 
2 irradiated products on 19th and 25th January 2012 but this was after the DNA sample 
was collected.  None of these products were treated with methylene blue.  
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Table 3-2 Blood products administered during the admission 
ID Transfusions  
Total  
Days  
of  
Admission  
Prior to DNA Sample During the admission 
Packed 
Red 
Cells or 
SAGM 
Platelets Total 
blood 
products 
 
Days 
before 
DNA 
Total  Irradiated 
Products 
LW01 
 
11 
 
2 
 
13 
 
1 
 
31 
 
No 
 
102 
LW02 5 4 9 1 20 No 85 
LW11 3 0 3 1 9 No 11 
LW12 1 0 1 1 4 No 26 
LW14 5 4 9 4 18 No 26 
LW16 3 0 3 1 14 No 132 
LW17 4 0 4 1 20 No 44 
LW20 6 0 6 1 6 No 115 
LW22 4 0 4 2 8 No 38 
LW33 1 1 2 1 38 No 55 
LW35 4 0 4 3 13 Yes** 85 
 
Mean  
 
4.3 
 
1 
 
5.2 
 
1.5 
 
16.4 
  
65.4 
Median  4 0 4 1 18  55 
Q1-Q3 (3-5) (0-2) (3-9) (1-2) (8-20)  (26-102) 
SD 2.72 1.6 3.64 1.03 10.55  40.5 
*FFP was not administered to the sub-group ** (2 units after DNA sample) 
3.3.3 Genotyping 
Representative electropherograms from Powerplex analysis are shown in Figure  3-2 
and 3.3. On detailed inspection of the electropherograms there were very low 
concentrations of alleles that could have arisen from donor contamination. Figure 3-3 
illustrates a Y peak observed in female sample.  The contaminating Y peak area = 
223, non-shared allele peak area = 32133, estimated contamination = 223/32133 x 
100 = 0.69%. Estimated contamination was less than 1% for all alleles observed.  
Sample LW14 showed the most potential contamination of all the samples, with 
additional peaks observed in the blood derived DNA for at least 4 of the 16 loci tested.  
It is possible that additional peaks were present but undetectable in other loci due to 
being “lost” in baseline noise. In this female patient a ‘Y’ allele was present therefore 
suggesting contamination from a male donor but the donor details are not available 
to confirm this.  
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 Figure  3-2 Electropherogram of a Buccal and Blood Samples  (LW14) 
Different coloured traces represent different fluorescent labels.  Peaks are labelled 
according to molecular size, allele assigned to each locus and peak area. The 
genotyping of the buccal and blood derived DNA samples matched when using the 
standard analysis used in clinical practice. 
 
 
 
Figure 3-3 Blood Derived DNA Electropherogram (LW14) 
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3.4 Discussion 
A substantially larger quantity and higher quality of DNA was obtained for 
pharmacogenomic analysis than was available from a buccal scrape. This study 
suggests that despite these babies being transfused frequently and immediately prior 
to DNA sampling, the genotyping of allelic polymorphisms in transfused babies did 
not affect genotyping data.  
Scavenging blood from clinical samples that would otherwise be discarded is 
beneficial.  As these babies were critically ill they require frequent clinical sampling, 
often leading to multiple blood transfusions due to their small circulating volume [79]. 
This sub-study therefore represents a particularly high risk group; these babies were 
frequently transfused with as many as thirteen blood transfusions prior to DNA 
sampling and up to 38 transfusions during their admission, (median n=18). Many 
babies (70%) had been transfused within 24 hours prior to DNA sampling for this 
comparison.  Some studies suggest this can persist for years and be as much as 5% 
of circulating leucocytes [214, 215]. Prior to leukocyte depletion in 1998 
Vervoordeldonk reported microchimerism persisted for several weeks in post 
transfusion patients [289]. More recently, Gong et al. [290] found similar results to 
these neonatal data; they reported no major effects on the genotype of common 
polymorphisms when DNA was collected within a day after transfusion. 
The risk of donor contamination is reduced since leukocyte depletion of blood 
products however, the white cells are not totally eradicated and there is an argument 
that circulating leukocytes increase after 2-3 days [290, 291]. In theory this may result 
in a higher risk of DNA contamination after 2-3 days. This was not evident in this 
neonatal population. The median time between transfusion and DNA sampling was 
1.5 days, however, 90% of these babies had additional transfusions prior to this 
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(median 4). Therefore the increase in leucocytes over time as a result of prior 
transfusions does not appear to have resulted in DNA contamination.  
Even in this high risk group with recent multiple transfusions these data suggest that 
DNA testing following transfusion does not need to be delayed due to microchimerism.  
The frequency of clinical sampling provides an opportunity to scavenge discarded 
blood for DNA avoiding further blood loss and distress to babies when required for 
research. Genotyping of the DNA identified some additional peaks after zooming in 
but concentration of contamination was negligible these peaks were not frequent 
enough within the 16 allelic groups to suggest donor contamination. Donor 
contamination may have been present in a few samples but at such a low 
concentration that it would not have affected genotyping. The peaks were not big 
enough to constitute a high enough proportion of the source DNA to change 
genotyping results or other results from pharmacogenomic studies. These rare peaks 
may have been artifacts or stutters and would have required comparison with the 
donor’s DNA to confirm this. These data have shown that irrespective of whether a 
low concentration of donor cells may be present this has not interfered with the 
genotype. A limitation of the study is that samples were assessed retrospectively 
therefore the donor’s blood was not available for comparison.  A prospective study 
would be required to validate this by comparing the true peaks of the donor blood 
against possible artefacts and relate to data such as gender of the donor.  
In conclusion, DNA extracted from clinically required samples in critically ill neonates 
has provided a greater quantity and quality of DNA than buccal cells. Genotyping has 
shown that the DNA is unlikely to have been significantly contaminated by donor cells 
despite being transfused less than a week before DNA sampling.    
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Regulatory Model  
Chapter 4 Microbiological and Clinical Outcome 
4.1 Overview  
This Chapter describes a retrospective study of neonates with confirmed Gram-negative 
septicaemia over a six year period. Organisms were cultured and the MIC determined 
using an E Test. For a sub-group administered ciprofloxacin (5mg/kg 12 hourly) each 
neonate’s clinical outcome was compared to the minimum inhibitory concentration (MIC) 
of ciprofloxacin required to inhibit growth of the Gram-negative isolate identified in their 
blood culture. The change in illness severity score before and after confirmation of Gram-
negative bacteria in blood cultures was assessed.  
The annual changes in MIC of Gram-negative organisms over this period were compared 
to assess MIC creep defined as a change in Ciprofloxacin MIC distributions over time so 
that strains with higher MICs become more common [292]. Due to concerns regarding 
resistance, data from surveillance surface swabs over a thirteen year period was 
summarised. This allowed a comparison of the incidence of bacteria resistant to 
gentamicin (the first line antibiotic) with ciprofloxacin.  
The laboratory assessments of MIC and cultures, retrospective review of the clinical 
outcome and statistical analysis were completed by the research fellow.  
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4.1.1 Primary Aim and Objectives  
Aim: 
To describe the microbiological and clinical aspects of the use of ciprofloxacin on a 
Neonatal Intensive Care Unit using a retrospective cohort study. 
Objectives: 
 Distribution of MIC: To examine the distribution of the MIC of ciprofloxacin among 
Gram-negative organisms isolated in blood cultures from in-patients on a neonatal 
intensive care inpatients 
 Clinical Outcome: to determine the clinical outcome for Gram-negative 
septicaemia in neonates treated with ciprofloxacin  5mg/kg 12 hourly according to 
the organism and the MIC  
 Illness Severity: To assess the change in the severity of illness (NTISS score) 
when Gram-negative organisms in blood cultures are confirmed. 
 Sub-clinical resistance: to assess whether frequent use of ciprofloxacin in 
Liverpool Women’s NHS FT Neonatal Unit had an effect on MIC over time by 
comparing annual changes in MIC. 
 Surveillance: To compare the incidence of organisms resistant to ciprofloxacin 
and gentamicin reported on surveillance swabs including throat and rectal.  
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4.2 Methods  
The study was approved by the Trust and University Research and Development 
Departments and the National Research Ethics Service (10/H1002/79). Consent from 
families was not required for the retrospective analysis of data as samples were collected 
as part of routine clinical practice. 
4.2.1 Distribution of the Minimum Inhibitory Concentration (MIC)  
The MIC for ciprofloxacin of isolates retrieved from blood cultures were assessed using 
the EUCAST methodology [155]. The MIC was defined as the lowest concentration (mg/L) 
of antimicrobial that under defined in vitro conditions prevented the growth of bacteria 
within a set period of time [155]. Based on the clinical breakpoint set by EUCAST non-
species specific isolates treated with ciprofloxacin were classed as susceptible ≤0.5mg/L, 
intermediate >0.5 to 1mg/L and resistant to ≥1mg/L [159].   
 
Table 4-1 EUCAST non-species specific clinical breakpoints 
S= Susceptible and R = Resistant  
 
 
 
 
Standard E Test Disc Test 
MIC breakpoint (mg/L) 
 
Disc  
content  
(µg) 
Zone 
diameter 
(mm) 
Zone 
diameter 
(mm) 
EUCAST S ≤ R >  S ≤ R > 
Ciprofloxacin 0.5 1 5  22 19 
Control   
E Coli ATCC 
25922  
0.008 0.004-0.015  5 35 30-40 
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Gram-negative organisms isolated from blood cultures were routinely stored on beads in 
the clinical diagnostic laboratory at -80oC between 2004 and 2010. For the purpose of this 
evaluation they were transferred temporarily to the study -80C freezer in the clinical 
diagnostic laboratory (without defrosting in transit). As part of the clinical diagnosis Gram-
negative organisms had been classified to both genus and species level using API strips: 
using biochemical and enzymatic reactions (http://www.biomerieux-diagnostics.com/apir-
id-strip-range accessed August 2015). These data were retrieved from the patient data 
system 
A total of 112 isolates from 103 patients were retrieved from storage and were cultured. 
Colombia agar plates were incubated for 18 to 20 hours in air at 37oC. A suspension was 
prepared using colonies that formed after overnight growth by removing a single colony 
with a loop and emulsifying in 2 mL of sterile water. The EUCAST standard method 
requires the inoculum turbidity to be equivalent to 0.5 McFarlane standard solution and 
this was confirmed using a photometric turbidometer (Optek Germany).  Further colonies 
or water were added to the inoculum to achieve the exact turbidity. Two Muller Hinton agar 
plates were then inoculated within 15 minutes of preparing the inoculums. A swab was 
used to inoculate the plates and achieve an even growth.  
A ciprofloxacin E Test strip (AB bioMerieux Sweden) was applied to one plate using flamed 
forceps. The antimicrobial disc test (Oxoid Hampshire England) for both ciprofloxacin and 
nalidixic acid were added to the second plate. 112 plates had the E Test ciprofloxacin 
applied. The plates were then incubated within 15 minutes for 18-20 hours and inverted to 
prevent humidity contaminating the plate. The plates were assessed to ensure an 
acceptable inoculum density produced by a confluent lawn of growth such as that shown 
on the 3rd plate.  
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Figure 4-1 E Test confluent lawn of growth  
 
A ciprofloxacin E Test strip (AB bioMerieux Sweden) was applied to one plate using flamed 
forceps. The antimicrobial disc test (Oxoid Hampshire England) for both ciprofloxacin and 
nalidixic acid were added to the second plate. 112 plates had the E Test ciprofloxacin 
applied.  
Nalidixic acid is an early synthetic fluoroquinolone that has less activity than ciprofloxacin 
therefore is more sensitive to identifying resistant strains. For comparison 25 plates were 
inoculated and had a nalidixic acid E Test applied. In addition a further 112 plates had both 
a nalidixic acid and ciprofloxacin disc test to compare the ability of nalidixic acid to more 
readily detect resistance for ciprofloxacin. 
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Figure 4-2 E Test for ciprofloxacin  
 
The EUCAST MIC breakpoints for susceptibility and resistance are indicated by arrows 
on the E Test strip. This figure illustrates a susceptible strain of Pseudomonas 
aeruginosa with arrows indicating the clinical breakpoint. 
 
For quality control, an E. coli inoculum was used with a known MIC. After incubation the 
zone edge was read at the point of complete inhibition as judged by the naked eye with 
the plate held about 30 cm from the eye.  Discrete colonies growing within zones were 
sub-cultured to identify contamination with other organisms and then repeated if required. 
The MIC of each individual organism was categorised as susceptible, intermediate or 
resistant based on EUCAST breakpoints.  The data was coded using a laboratory number, 
but not the patient’s details, to ensure the investigator was blinded to the results. 
 
 
 
Resistant   
Susceptible  
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4.2.2 Clinical Outcome Cohort 
Clinical outcomes were assessed retrospectively. The isolates were retrieved and re-
cultured for comparison with the MIC. Retrospective data for the short-term clinical 
outcome of neonates with Gram-negative infection was determined from the patient data 
system (BADGER) and the case notes. 
 Inclusion criteria:  
 A Gram-negative organism isolated from blood cultures whilst an in-patient on the 
Neonatal Unit at Liverpool Women’s NHS FT between 2004 and 2010. 
 Administration of ciprofloxacin 5mg/kg 12 hourly within 48 hours of a confirmed 
blood culture and continued for a minimum of five days.  
 The isolate could be retrieved and re-cultured from storage at the Microbiology 
Laboratory for Liverpool Women’s NHS FT.  
The primary outcome of ‘cure’ was defined as survival and a C-reactive protein <10mg/L 
on the 10th day after confirmed Gram-negative infection. Neonates who had an elevated 
C-reactive protein or died within the 10th day following a confirmed Gram-negative blood 
culture were classed as treatment failure. Due to the high incidence of co-morbidity in this 
population if an elevated CRP or mortality occurred after the 10 day period this was not 
viewed as a direct temporal relationship with confirmed Gram-negative bacteraemia. 
There are limitations to outcome measures in neonates or critical illness (see section 
1.5.1.1).  This short term outcome was chosen as it is believed to be more sensitive to a 
direct link between the intervention and the outcome following administration of this 
antibiotic. Similarly,  C-reactive protein (CRP) may have a temporal association with the 
intervention [293]. CRP was routinely monitored as a component of clinical practice and 
these concentrations were also available for retrospective analysis. Blood cultures were 
taken as part of the standard screening protocol for suspected sepsis. Isolates are 
routinely stored by the microbiology laboratory.  
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Retrospective data for the short-term clinical outcome of neonates with Gram-negative 
septicaemia was determined from the patient data system (BADGER) and case notes. 
Further demographic data including gender, postmenstrual age at birth, post menstrual 
age at the time of Gram-negative infection, and illness severity were recorded. 
 
4.2.3 Severity of Illness Score 
A retrospective analysis of the severity of illness of all babies with confirmed Gram-
negative organisms in blood cultures was undertaken. In total 103 medical records were 
reviewed to evaluate the impact of the severity of illness on clinical outcome. Each baby 
was scored two days prior to confirmed Gram-negative septicaemia and on the day of 
confirmed septicaemia using the validated Neonatal Therapeutic Intervention Scoring 
System (NTISS) [294]. This is a detailed score of 8 organ systems or therapies and a total 
of 66 values per baby that may be scored between 1- 4 depending on the severity of illness 
including seven domains: 
 Respiratory 
 Cardiovascular 
 Drug Therapy 
 Monitoring  
 Metabolic/Nutrition 
 Transfusion 
 Procedural Vascular access  
 
This validated score was selected as it provides continuous values relating to the clinical 
management of the patient rather than  binary outcome data. Source data was collected 
from the medical notes, patient data system, drug prescriptions, blood prescriptions and 
administration records.   
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4.2.4 Change in MIC over time –Sub-clinical resistance   
The Minimum Inhibitory Concentration (MIC) of Gram-negative organisms from blood 
cultures was measured to determine the annual changes in MIC over time over a period 
of six years.   
4.2.5 Surveillance: relative resistance of gentamicin v ciprofloxacin  
A retrospective study of blood cultures, surveillance throat and rectal (surface) swabs was 
performed to quantify the number of organisms resistant to ciprofloxacin compared to 
gentamicin over a 13-year period.  
 Inclusion criteria:  
 Neonates admitted to the Neonatal Unit 1997 - 2010 
The microbiology database for a tertiary neonatal unit was searched for Gram-negative 
isolates from surface throat and rectal swabs between 1997 and 2010. All Gram-
negative organisms from surface swabs were routinely tested for gentamicin and 
ciprofloxacin sensitivity.  Clinically and epidemiologically relevant organisms were 
reported throughout this period this included Gram-negative bacilli (Enterobacteriaceae 
& Pseudomonas aeruginosa) and Gram-positive cocci (Staphylococcus aureus, Group B 
& Group A streptococci, Enterococci, MRSA). 
4.2.6 Statistical Analysis  
All statistical procedures were performed in SPSS software (version 18 SPSS Inc. Chicago 
IL USA) and Minitab statistical software (version 16 Inc. Coventry UK).  
The distribution of MIC to ciprofloxacin among different groups of Gram-negative 
organisms the median and IQR ciprofloxacin MIC were calculated and plotted.  Clinical 
Outcome (clinical cure or treatment failure) and its relationship to MIC included a 
comparison of babies who did and did not meet the primary outcome of clinical cure. These 
were presented as medians and interquartile ranges or percentage frequencies. Univariate 
statistical analyses were performed using the Mann-Whitney U test for continuous data 
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except for categorical frequency data, which were analysed using a chi-squared test or 
Fisher’s exact test. (Insufficient events were available for explanatory variables for linear 
regression). The optimal MIC values to predict cure were computed to produce an area 
under the Receiver Operating Characteristic (ROC) curve including sensitivity and 
specificity values (null hypothesis AUC 0.5). The optimal MIC value from the ROC analysis 
was used to define low and high MIC groups within the susceptible range for comparison 
with short-term outcome. Where appropriate differences were considered significant at the 
p<0.05 concentration, and results are presented with 95% confidence intervals.  Positive 
predictive value was determined by a two by two table using vassarstats.net/clin2.html. 
The NTISS score on the day of confirmed septicaemia and two days earlier were 
compared using median and IQR to determine the change in illness severity following 
confirmed Gram-negative infection. NTISS was correlated for comparison with gestational 
age at birth and at Gram-negative blood culture. The change in NTISS over the two days 
was compared. Clinical outcome of babies with Gram-negative infection was then 
compared using regression analysis to determine whether the outcome was associated 
with the severity of illness prior to Gram-negative infection. 
The combined MIC for all organisms collected during each year of the study were 
compared and presented as the median and 95% CI to determine whether there was a 
visual increase in MIC over time. The percentage of isolates resistant to ciprofloxacin was 
compared to those resistant to gentamicin.  Non-duplicate surveillance results were 
tabulated.  
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4.3 Results   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3 MIC Ciprofloxacin Distribution and Clinical Outcome of Gram–negative 
bacteraemia  
The MIC ciprofloxacin distribution and Clinical outcome of neonates administered 
ciprofloxacin with confirmed Gram–negative bacteraemia between 2004 and 2010 
(n=103) 
 
 
MIC Distribution (n=88) 
 
Gram-negative organisms 
  E.Coli   (29.5%) 
  Pseudomonas spp. (21.6%) 
  Klebsiella spp. (19.3%) 
  Enterobacter spp. (18.2%) 
  Serratia spp. (6.8%) 
  Other (4.5%) 
10% not susceptible to 
ciprofloxacin 
Clinical cure 
n=18 
Clinical Outcome Study 
Included 
n=33 /69 
 
n=15  
Failed to be re-cultured 
Not retrieved 
Neonates with confirmed 
Gram-negative organisms  
in blood cultures 
n= 103 (1.3%) 
(Gender: 64% male) 
Neonates admitted 2004-2010  
n =7913 
 
Clinical Outcome  
n=69 /88 
 Administered ciprofloxacin 
5mg/kg 12 hourly 
Clinical Outcome Study 
Excluded 
36 /69 
Administered ciprofloxacin <5 days  
or 
>48 hours after confirmed blood 
culture 
  
Treatment failure 
n=15 
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4.3.1 MIC Ciprofloxacin Distribution: Gram-negative Blood Cultures   
The incidence of Gram-negative organisms in blood cultures between 2004 -2010 was 
1.3%. Eighty-eight of 103 original blood culture isolates were successfully re-cultured to 
assess the organism’s MIC to ciprofloxacin (15 either failed to be re-cultured or retrieved). 
The most common organisms associated included Escherechia, Pseudomonas spp., 
Klebsiella spp. and Enterobacter spp. Table 4-2. The median and inter-quartile range 
(IQR) ciprofloxacin MIC for each of the main organism groups were below the susceptibility 
breakpoint 0.5 mg/L Figure 4-4. Amongst all organisms, Pseudomonas spp. and Serratia 
spp. had a higher median MIC. The main types of organisms (n=88) are shown in Table 
4-2. Nine (10%) organisms were classed as not susceptible to ciprofloxacin >0.5mg/l; 6 
(6.8%) of these isolates were classed as frankly resistant MIC ≥1mg/l and 3 (3.4%) 
organisms were classed ‘I’ intermediate >0.5 <1mg/L. 
 
Table 4-2  Gram-negative organisms in blood cultures 2004 – 2010  
 
Organisms  (n=88) MIC  
non-susceptible 
≥0.5mg/L 
 N = (%) N = (%) 
E.coli 26  (29.5) 2 (2.2) 
Pseudomonas spp. 19  (21.6) 2  (2.2) 
Klebsiella  spp.  17  (19.3) 2  (2.2) 
Enterobacter spp.  16  (18.2) 0  (0) 
Serratia  spp. 6    (6.8) 2  (2.2) 
Other 4    (4.5) 1  (1.1) 
Total 88  (100) 9 * (9.9)* 
*6 intermediate 0.5 – 1mg/l and 3 resistant ≥ 1mg/l 
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Figure 4-4 Ciprofloxacin MIC (mg/L) for Gram-negative organisms in blood cultures  
Blood cultures were collected from neonates during 2004 -2010 (n=84) these data 
exclude isolated incidence of 4 organisms (Acinetobacter , Citrobacter, Morganella and 
Raoultella).  
 
 Clinical Outcome of Gram-negative Bacteraemia v MIC Ciprofloxacin  
A sub-group of neonates were treated with ciprofloxacin 5mg/kg 12 hourly. The clinical 
outcome was compared and the optimal sensitivity and specificity for cure assessed by 
the ROC analysis that defined a low and high MIC group.  Figure 4-5 and Figure 4-6. This 
was further assessed by the positive predictive value. 
 
 
Resistant 
Intermediate 
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Table 4-3 Clinical Outcome: Gram-negative Bacteraemia v MIC Ciprofloxacin 
 (n=33) 
        *The MIC of one organism was 0.75 and had not been classed as resistant by the disc test.   
Variable  N= Clinical 
Cure  
(n=18) 
Treatment 
Failure 
(n=15)  
Difference 
(95% CI) 
p 
Ciprofloxacin MIC             
  Median 
  IQR 
  Range 
33  
0.012 
0.008- 
0.023 
0.006- 
0.190 
 
0.047 
0.012 - 0.094 
0.0060 - 0.75* 
 
-0.009     
(-0.078,0.0019) 
 
 
0.17 
 
High and Low MIC groups 
(indicated by ROC analysis)       
Total susceptible MIC Low 
MIC   ≤0.035            
High MIC  >0.035–0.5    
 
 
33 
22 
11 
 
 
18 (56%) 
15 (68%) 
  3 (27%)          
                    
 
 
15 (47%) 
7 (32%)                  
8 (73%)  
 
 
 
  
0.061 
Positive Predictive  Value  
Area under the curve  
   0.68 
0.612  
(0.407, 0.817)  
 
GNO (n=33)                             
       E. Coli                          
       Pseudomonas spp.    
       Klebsiella spp.           
       Enterobacter spp.  
       Serratia spp.               
Total 
  9 
  6 
  7 
  9 
  2 
 
4   (44%) 
2   (33%) 
3   (43%) 
8   (89%) 
1   (50%) 
18 (55%) 
 
5   (56%)   
4   (67%) 
4   (57%) 
1   (11%) 
1   (50%) 
15 (45%) 
  
PMA Week (w) day(d)  
PMA at birth (Median)    
PMA at GN Sepsis 
(Median) 
  
25 w 
28 w 4 d 
 
25 w 5 d 
29 w  4 d 
   
 4  (-5,12)  d   
10  (-7,39) d 
 
0.33 
0.26 
Gender 
       Male  
       Female 
  
13 
  7 
 
9 
4 
 
- 4% (-36.9%, 
4.8%) 
 
 
0.8 
Illness Severity NTISS 
(Median  IQR) 
 12.5 (8-
17) 
16 (14-21) - 4 (08.9,-0.002) 0.04  
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Area Under the Curve 
Test Result Variable(s):   Minimum Inhibitory Concentration of Ciprofloxacin mg/L   
Area Std. Error a Asymptotic Sig.b 
Asymptotic 95% Confidence Interval 
Lower Bound Upper Bound 
.612 .105 .285 .407 .817 
The test result variable(s): has at least one tie between the positive actual state group and the 
negative actual state group. Statistics may be biased.  
a. Under the nonparametric assumption b. Null hypothesis: true area = 0.5 
 
Figure 4-5    Receiver Operator Curve - optimal MIC mg/L for cure (n=33)  
 
 
Positive if > or 
equal toa 
Sensitivity 1- Specificity 
.000000 1.000 1.000 
.007000 .933 .833 
.010000 .800 .722 
.014000 .600 .444 
.019500 .600 .333 
.035000 .533 .167 
.055500 .467 .167 
.079000 .400 .167 
.157500 .067 .056 
.470000 .067 .000 
1.000000 .000 .000 
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Figure 4-6 Clinical Outcome of neonates treated with Ciprofloxacin v MIC  
(Mg/L) 
The clinical outcome of neonates treated with ciprofloxacin for Gram-negative 
bacteraemia v MIC Ciprofloxacin (n=33) Ciprofloxacin MIC median for cure was 0.012 
(IQR 0.008 -0.023) compared to treatment failure 0.047 (IQR 0.012 to 0.094).              
 
Table 4-4 Mortality and morbidity for neonates with Gram-negative organisms (GNO) in 
blood cultures   2004 – 2010 (n=103) 
 
 
 
 
 
 
 
 
 
 
 
Mortality and Co-morbidity N= % 
 
Mortality  
   within 10 days of  GNO    
   within 28 days of  GNO  
   after 28 days  
 
45 
27  
36 
  9 
 
(44) 
(26) 
(35) 
  (9) 
 
GNO associated with mortality <10 days  
     E.coli 
     Pseudomonas spp. 
     Klebsiella   spp. 
     Enterobacter spp. 
     Other 
 
 
 
9 
7 
5 
3 
3 
 
 
 
(33) 
(25) 
(18) 
(12) 
(12) 
Co-morbidity (main)   
 Necrotising enterocolitis 28 (28) 
 Intraventricular haemorrhage 51 (51) 
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Mortality for neonates with confirmed Gram-negative septicaemia was 44% prior to 
discharge or 26% within 10 days of confirmed Gram-negative septicaemia. The main 
organisms associated with mortality within 10 days included E.coli, Pseudomonas spp., 
Klebsiella spp. and Enterobacter spp. MIC over time – Sub-clinical Creep Resistance  
MIC data was plotted to evaluate whether there was an annual increase in MIC within the 
susceptible range over time.  There were 9/88 resistant organisms. Among the 79 
susceptible isolates with MIC <0.5 mg/L (susceptible to ciprofloxacin) a change in MIC was 
not visibly associated with the year of isolation (Figure 4-7).   
Table 4-5 Ciprofloxacin Resistant Organisms in Blood Cultures  
 
Year  Intermediate Resistant Total 
n=9 
2004   0 
2005  Acinetobacter spp. 1 
2006   0 
2007 Klebsiella spp. (x2) Pseudomonas spp. 3 
2008  Pseudomonas spp. 1 
2009  E.Coli 1 
2010 Serratia E.Coli (x2) 3 
 
This table includes resistant and Intermediate susceptible Organisms from blood cultures 
per year 2004 - 2010 (n=9 /88) 
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Figure 4-7  MIC mg/L (log 10) of ciprofloxacin for susceptible organisms (median and IQR) 
from blood cultures in neonates (n=79) 
 
4.3.2 Surveillance: relative resistance to ciprofloxacin and gentamicin  
 Surveillance surface swabs (throat and rectal) 
Epidemiologically significant organisms on surface surveillance swabs (throat and rectal) 
were reported during 1997 – 2010) (Table 4-6). This resulted in 42,507 reports from 
routinely collected throat and rectal surface swab monitored on admission then weekly for 
15,951 neonates. Therefore, these data provide the proportion of resistant Gram-negative 
organisms per annum for both gentamicin and ciprofloxacin. Gentamicin is the first line 
treatment for suspected Gram-negative sepsis whereas ciprofloxacin is generally the 
second line treatment. 209 babies (1.31%) of all admissions had one or more surveillance 
swabs with a Gram-negative organism not susceptible to gentamicin and 151 (0.95%) to 
 Regulatory Model 
194  
ciprofloxacin; these included 69 (0.43%) isolates that were not susceptible to both 
gentamicin and ciprofloxacin.  
The most common resistant organisms included E.coli, Acinetobacter spp. and 
Pseudomonas spp. These data exclude S. maltophilia from further analysis as it is less 
susceptible to both gentamicin and ciprofloxacin therefore would not have been selected 
in clinical practice.  
Table 4-6  Surveillance of surface swabs for neonates 1997 to 2010 
 N=        %   
 
Neonatal admissions 
Average per annum 
 
15 951 
  1 227 
 
 
Surveillance with clinically relevant growth:  
    Swabs  
    Neonates  (% of admissions) 
    Average swabs screened per neonate 
Blood culture organisms identified on surface swabs 
 
42 507 
  6 114  
      6.9 
 
 
(38) 
 
(40) 
 
Neonates Gram-negative organisms*    
    Surface swabs  
Epidemiologically relevant swabs**  
     Proportion of admissions 
Sensitivity tested for gentamicin 
Sensitivity tested for ciprofloxacin  
 
 
5 059  
 
 
5 059   
3 944   
 
 
 
  (82 
  (31) 
(100) 
  (78) 
 
Neonates with non-duplicate resistant  
Gram-negative organisms                                           
 
Gentamicin         Resistant  
           Intermediate resistant 
Total                               
 
Ciprofloxacin*      Resistant organism  
                             Intermediate resistant 
Total  
 
Both gentamicin and ciprofloxacin (included in above) 
           Resistant  
           Intermediate 
           Total  
 
 
 
 
195    
  14    
209    
 
  123   
28    
151 
 
 
54     
15  
69  
 
% of 
admissions  
 
(1.22) 
(0.09) 
(1.31) 
 
(0.81) 
(0.18) 
(0.99) 
 
 
(0.34) 
(0.09) 
(0.43) 
 
* Non-duplicate **Epidemiologically relevant included Gram-negative bacilli 
(Enterobacteriaceae & Pseudomonas aeruginosa) and Gram-positive cocci 
(Staphylococcus aureus, Group B & Group A streptococci, Enterococci, MRSA). 
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Figure 4-8 Gram-negative organisms on surface swabs  
Gram-negative organisms (non-duplicate) epidemiologically relevant and identified on 
routine surveillance surface swabs between 1997 – 2010 (n=10,007)  
 
Figure 4-9 Non-susceptible Gram-negative Organisms  
Illustrates the Gram–negative organisms (non-duplicate) not susceptible to ciprofloxacin 
(n=151) and gentamicin (n=209) between 1997 – 2010  
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4.3.3   Severity of Illness Score pre and post Gram-negative Bacteraemia 
The Neonatal Therapeutic Intervention Scoring System (NTISS) illness severity score 
monitored the change in illness severity with confirmed Gram-negative organism. This was 
available for 79 neonates with Gram-negative isolates from blood cultures between 2004 
and 2010 (E. coli 24, Pseudomonas spp. 16, Enterobacter spp.16, Klebsiella spp. 13, 
others 10).  Two days prior to the isolation of Gram-negative bacteria NTISS had median 
14, IQR 11 - 18, max 28  on the day a Gram-negative isolate was identified median 20, 
IQR 14 - 25, max 34.1 (n=70). NTISS was negatively correlated to gestational age at birth 
(rs = -0.344, p< 0.005) but was not associated with postnatal / postmenstrual age at 
culture, sex or the nature of the bacteria. 
The NTISS changed over the two days by a median 5 (IQR 1 – 8) max 23 and was  
inversely correlated to NTISS 2 days before isolation of Gram-negative bacteria (-0.365, 
p<0.01). The higher the NTISS was two days before the isolation of GN bacteria the lower 
was the change in NTISS when infection started. Five neonates had lower NTISS scores 
when positive blood cultures were recognised compared to two days before. Each of these 
improvements was less than four NTISS units. Figure 4.10  
 
Figure 4-10 Illness severity score pre and post Gram-negative blood cultures 
The Illness severity score NTISS was determined two days prior to and on the day of 
confirmed Gram-negative blood culture to assess the of the score to identify Gram –
negative bacteraemia and the change in illness severity    
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4.4 Discussion 
This chapter examined the clinical features and outcomes of neonates with Gram-negative 
bacteria in their blood cultures relative to the MIC ciprofloxacin and the incidence of Gram-
negative organisms identified in surveillance data. This population were born extremely 
premature (96%) <31 weeks PMA and a high proportion (75%) were ≤31 when Gram-
negative bacteraemia was confirmed. Mortality increased considerably to 44% when 
Gram-negative infection was confirmed in blood cultures compared with mortality rates in 
this unit for babies <28 weeks gestation at 20% and between 28-34 weeks gestation is 
8%. Similar increases in mortality have been reported for late onset sepsis, Stoll et al. 
found mortality of VLBW neonates increased from 7% to 18% but when associated with 
Gram-negative organisms this increased considerably to 36% [18]. The extreme 
prematurity and complex co-morbidity confound the clinical outcome assessment of 
bacteraemia in this population. Many were severely ill as they presented with grade III and 
IV intra-ventricular haemorrhage (51%) and/or necrotising enterocolitis (28%) (Table 4-4).  
4.4.1 MIC Ciprofloxacin Distribution: Gram-negative Bacteraemia 
Gram-negative isolates in blood cultures are relatively uncommon. This neonatal unit has 
approximately >1200 admissions per annum, yet over a six year period 103 cases (1.3%) 
were reported (Figure 4-3).  Most isolates were retrieved and successfully re-cultured 
(89%). The majority of organisms (90%) were classed as susceptible by EUCAST Figure 
4-4. The least susceptible species were Pseudomonas spp. and Serratia spp. Figure 4-4. 
Enterobacter spp. had the lowest MIC and no resistant organisms were identified.  The 
most common organisms were E.Coli (29.5%) followed by Pseudomonas spp. (21.6%) 
then Klebsiella spp. (19.3%) consistent with other studies [11, 18, 25, 26, 39, 40] (Figure 
1-3).  A UK survey found the most common bacteria causing late-onset sepsis were Gram-
positive CoNS (45%), followed by Staphylococcus aureus (13%), then Gram-negative 
bacteria including Enterobacteriaceae (9%), E. coli (7%) and Group B Streptococcal (7%) 
[71].  
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Over a seven year period 10% of Gram-negative bacteraemia were resistant Table 4-5. 
MIC creep or sub-clinical resistance would illustrate a trend for increasing MIC within the 
susceptible range. This maybe present but was not evident from these data due to the low 
number of confirmed isolates in blood cultures over the time period of seven year period 
(n=79) Figure 4-7. There were less than 12 susceptible organisms per annum and there 
were different species within this small number that naturally have variation in MIC. As a 
result the median MIC fluctuated over this period but a visible trend was not evident Figure 
4-7. Another limitation for assessing MIC creep is the possibility that there is cross infection 
within a neonatal unit that may result in a bias towards that organism’s MIC which has 
greater influence on data when the numbers are so small. To observe organism specific 
MIC creep would be optimal but more challenging as even less isolates are available from 
bacteraemia. An option may be to a prospective study to determine MIC creep from 
surveillance isolates.          
4.4.2 Clinical outcome v MIC: Gram-negative Bacteraemia  
A subgroup of neonates were administered ciprofloxacin 69 (78%), of whom 33 (56%) met 
the eligibility criteria for assessment of their clinical outcome (Table 4-3). The MIC of the 
organism found in the neonate’s blood culture was compared to the same neonate’s 
clinical outcome. Relatively higher MICs were associated with a greater risk of treatment 
failure even when within EUCAST’s susceptible range but was not statistically significant 
(p= 0.17) (Figure 4-6). ROC analysis Figure 4-5 indicated the optimal specificity and 
sensitivity was ≤0.035 mg/L (AUC 0.641 CI 0.445 – 0.836). Although this was non–
predictive the optimal point defined two groups to compare the outcome; a low MIC group 
as ≤0.035 mg/L and high group >0.035mg/L. In the low MIC group ≤0.035, 68% neonates 
were cured compared to only 27% in the high MIC group >0.035 to 0.5mg/L (p=0.61). The 
risk of treatment failure for the high MIC group was much higher (RR 2.5 95% CI 0.9139 - 
6.8391 p=0.074) with a positive predictive value of 79%. Falagas et al. found increased 
mortality when the Gram-negative organism had a higher MICs within the susceptible 
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range (RR, 2.39; 95% CI, 1.19 to 4.8). The authors  concluded that there is a need to 
reconsider the treatment of organisms with relatively high MICs even when in the 
susceptible clinical breakpoint range [163].  In respect of fluoroquinolones, Labreche et al. 
reported several studies with declining susceptibility and the need to review of clinical 
breakpoints for Gram-negative infection in particular for blood stream infections [67].  
This is clinically significant as the microbiology laboratory classed the majority of blood 
cultures (90%) as susceptible to ciprofloxacin over this six year period Figure 4-4.  A 
considerable proportion 43% of these bacteraemia had an MIC higher than 0.035mg/L. 
Ciprofloxacin was a treatment option based on EUCAST’s clinical breakpoints and these 
neonates may have been under treated increasing the risk of treatment failure by 2.5 (95% 
CI 0.9139 - 6.8391 p=0.074). Fortunately not all of the babies with confirmed Gram-
negative sepsis were treated with ciprofloxacin (n=33/103) as at the time of this 
retrospective study the dose was lower (10mg/kg/day) than the current recommended 
dose 20mg/kg/day). At present the optimal ciprofloxacin regimens for neonates and each 
sub-age group remains unknown. These outcome data are limited but support the view  
that there is a need to review clinical breakpoints within the susceptible range. Also, to   
extend breakpoints specific to the regimen and outcomes for sub-age groups of children.  
These retrospective data suggest a higher daily dose was required than the 10mg/kg/day 
administered during this period or a lower breakpoint. This is consistent with the higher 
daily dose was proposed as a result of PK data in children > 3months age by Lipman et 
al.  They found that a paediatric dose of 20mg/kg/day produced a lower AUC24 of 30-40 
than their study of adult [115].  This AUC would only achieve the minimum AUC24/MIC 
ratio of >125 for organisms with MIC >0.24mg/L (AUC24/MIC 30/0.24 =125) and led to a 
recommendation to increase the regimen to 30 mg/kg/day for more severe infections [115]. 
Based on this single paediatric PK study  (n=20) the BNFC increased their dose 
recommendations to 10mg/kg either 8 or 12 hourly for infants >1 month age in 2011 [173]. 
This 
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higher dose has not yet been validated with subsequent PK, PD or safety data for infants 
or neonates. This emphasises the need for neonatal and infant PK data presented in 
Chapter 2.  
To optimise treatment of more serious infections a higher AUC24/MIC target of ≥250 is 
strongly supported by adult PD data. Historically the optimal predictor of efficacy targets  
a minimum AUC24/MIC ratio >125 and this has informed clinical breakpoints [134, 162, 
176, 178]. Forrest et al. found the median time to bacterial eradication significantly reduced 
to 1.9 days with an AUC24/MIC ≥250 compared with 6.6 days when 125 - 250 and 32 days 
if <125 [162]. More recently in 2010, Zelenitsky et al. found higher cure rates (91.4%) were 
attained with a higher doses of 400mg 12 hourly resulting in an AUC24/MIC ratio >250 
when compared to 28.6% when <250 [176]. Lipman [115] recommended higher doses for 
more severe infection or pathogenic organisms in critical illness. The risk of adverse 
reactions from higher doses is relative to the risk associated with the severity of illness. 
Mortality in neonates with Gram-negative bacteraemia increased in this unit to 44% which 
indicates the need to target the higher ratio >250. Shortening the duration of bacteraemia 
is essential as prolonged hospitalisation is associated with increased morbidity and 
mortality [18]. The median (IQR) for days treatment with ciprofloxacin was 6 (2-10) range 
1 – 37 days. Prolonged treatment may be due to under-dosing or, less susceptible 
organisms within the clinical breakpoint. These preliminary data are not conclusive but  
illustrate the need for ongoing evaluation of both PK and PD data specific to neonates.   
The clinical outcome also depended on the type of organism. Neonates with bacteraemia 
caused by Enterobacter spp. were more likely to be cured (89%) compared to 44% with 
E.Coli even when the median and IQR of the MIC were similar Table 4-3. In contrast the 
MIC for Pseudomonas spp. was considerably higher than E.coli but the clinical outcome 
of the neonates was similar (Table 4-3). This suggests E.coli may be more pathogenic 
even when the MIC is lower. Fulminant late onset sepsis has previously been associated 
with 
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Pseudomonas spp. (42%) and E.coli spp. (10%) (lethal within 48 hours) [36]. In this cohort 
study E.coli spp., Pseudomonas spp. and Klebsiella spp. were the most common 
organisms associated with mortality in within ten days of confirmed Gram-negative 
septicaemia. Mortality from Gram-negative bacteria is mainly associated with antibiotic 
resistant bacteria (73%) [6]. Dose regimen may be based on the susceptibility when the 
organism is known. EUCAST’s rationale document includes species specific breakpoints 
for adults and in some cases a higher dose or lower breakpoint is included for more serious 
infections [135]. Acinetobacter species is less susceptible than other Gram-negative 
bacteria yet the ECOFF (1mg/L) is higher than the non-species specific clinical breakpoint 
(0.5mg/L) therefore it is only classed as susceptible in adults when a higher dose is 
administered [138]. This confirms that breakpoints are specific to estimating the optimal 
outcome for a dose. These data suggest that the clinical outcome is determined by 
pathogenicity of the organism, the dose,  the MIC and host response as is evident from 
other studies [36, 163, 295]. 
These critically ill patients were not a homogenous group. Surprisingly, the extremely 
premature babies with bacteraemia tended to have less treatment failure including the 
lowest PMA at birth (p=0.33) and lowest PMA at the time diagnosed (p=0.26) (Table 4-3). 
This may be associated with their immature renal function as the reduced excretion may 
have resulted in higher drug concentrations achieving a more optimal AUC24/MIC ratio. 
This is plausible as ciprofloxacin is mainly excreted renally (70%) [296].  As with other 
antibiotics sub-age groups below 34 weeks PMA are reported to have slower excretion, 
including gentamicin and teicoplanin [126, 297, 298]. Teicoplanin concentrations were 
higher in neonates AUC 392 μg/h/mL than older children 221 μg/h/mL when administered 
the same dose per kilo [297, 298]. When a different regimen was administered to adults 
(400mg 12 hourly) this  produced a higher AUC 550 mg/h/L [299]. This illustrates there is 
variability in AUC between neonates, children and adults yet the same breakpoint is 
applied even though different AUC in adults will result in different clinical breakpoints. 
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These data are consistent with the higher AUC found in more premature neonates in 
Chapter 2 (Figure 2.16). An alternative interpretation is that the more mature babies may 
have been exposed to a longer hospital stay with an increased risk of exposure to infection 
over time or other morbidity associated with a protracted illness resulting in a poor 
outcome. Again this illustrates that many factors not related to microbiology confound the 
clinical outcome in critical illness and rapid changes during neonatal development 
including co-administration of other antimicrobials, co-morbidity and effect of clinical 
interventions. 
Outcome may be influenced by the host including the maturation of the immune system 
[36, 163, 295]. A higher proportion of male babies (64%) presented with Gram-negative 
sepsis but there was no significant difference in their clinical outcome Table 4-3. A gender 
bias is consistent with poorer outcomes as mortality is higher for male neonates globally 
58%, yet the reason for this is unknown [300]. Equally, the clinical outcome may have been 
influenced by first line treatment with gentamicin or concomitant administration of co-
amoxiclav. Pseudomonas spp. is dependent on susceptibility to either ciprofloxacin or 
gentamicin whereas Enterobacter are susceptible to co-amoxiclav [155].  Although these 
data are not statistically significant they are worthy of consideration to further understand 
the complexity of individual neonate’s response to infection. This highlights the need for 
rapid identification of organisms and their susceptibility to antibiotics to individualise 
regimen. 
Further safety data for different regimens is required to ensure there are no long term 
adverse reactions. The risk of an adverse reaction to a drug must be balanced against the 
severity of the outcome. As high mortality is associated with confirmed Gram-negative 
sepsis it may be more appropriate to increase the dose only when confirmed by a blood 
culture rather than suspected. Alternatively, the NTISS Score may be applied to classify a 
higher risk group. Individualised therapy may require titrating doses to the type of organism 
as some 
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bacteria are more pathogenic or for higher MIC. Safety data for dose regimen specific to 
each sub-age groups is required. Historically the main barrier to prescribing ciprofloxacin 
has been the potential risk of arthralgia/tendonitis [191]. A recent systematic review 
reported that musculoskeletal adverse events in children were reversible following 
withdrawal of the drug [190]. A brief episode of joint pain that subsequently resolves must 
be balanced against the risk of the outcome if 44% mortality Table 4-4.  
4.4.3 Resistance  
 Sub-clinical resistance - changes in MIC over time  
Over a thirteen year period the annual incidence of bacteraemia was too low to  determine 
whether sub-clinical resistance is emerging,  a maximum of 15 isolates were available per 
annum (Figure 4-7). Few Gram-negative organisms in blood cultures were resistant (10%) 
(Table 4-2). The clinical outcome data found treatment failure was associated with higher 
MIC supporting the view by  Falagas et al. and Labreche et al. that organisms classed as 
susceptible may need to be reviewed [67]  
 Surveillance: relative resistance to ciprofloxacin and gentamicin  
This Neonatal Unit’s has an extensive surveillance programme to monitor throat and rectal 
surface swabs to identify epidemiologically significant organisms. Blood cultures are 
frequently collected (average 1000+- per annum) and routine surface swabs (average 6.9 
per neonate).  The incidence of ciprofloxacin resistance for each admission on surface 
swabs (0.99%) was no higher than gentamicin (1.31%) for non-duplicate resistant 
organisms (Table 4-6). The incidence of non-susceptible organisms on surveillance swabs 
was higher for Acinetobacter spp and Pseudomonas spp. yet  less than 8 % for any 
species Figure 4-9. 
There are limitations to using routine surveillance culture data to guide empiric therapy as 
neonates are colonised with many bacteria [42-44]. The aim is not to treat the patient for 
any bacteria identified in surveillance unless there are signs of suspected sepsis as this 
 Regulatory Model 
204  
would result in the over use of antibiotics and increase resistance. The main purpose is to 
identify resistant Gram-negative bacteria so that when a patient has signs of sepsis the 
early empiric therapy avoids antimicrobials that their surveillance swabs show resistance 
to in case the bacteria translocate . This rigorous surveillance is beneficial as a 
considerable proportion of Gram-negative isolates subsequently found in blood cultures 
(40%) were identified earlier on surveillance surface swabs Table 4 6. Early identification 
is valuable as these outcome data included four neonatal deaths subsequently found to 
have intermediate or resistant organisms in blood cultures. Clinicians may use surveillance 
data to predict the likely causative organisms prior to selecting antimicrobials and attempt 
to avoid those that likely bacteria are resistant to.   
 Antimicrobial resistance in adult intensive care patients are considerably higher. 
Neuhauser et al. evaluated 35,790 non-duplicate Gram-negative isolates in the US 1994 
-2000 and found resistant P.aeruginosa 23%, Enterobacter spp. 14%, Klebsiella 
Pneumoniae 14% E. coli 11%. The authors related the decreased susceptibility of 10% 
over a six year period to increasing fluoroquinolone use [301]. The Meropenem Yearly 
Susceptibility Test Information Collection (MYSTIC) programme demonstrated a decrease 
in susceptibility of fluoroquinolones over a ten year period. E. coli resistance rose rapidly 
from 4.1% to 31.8%, Klebsiella Pneumoniae  from 4.2 % to 16.5% and Enterobacteriaceae 
3.7 to 17.8% [302]. Frequent treatment with antibiotics may increase resistance particularly 
when administering broad spectrum antimicrobials [43, 46].  Suspected sepsis requires 
rapid treatment therefore many more neonates were treated than subsequently confirmed. 
Stoll et al. reported half of their cohort received antibiotics but only 21% subsequently had 
a blood culture proven infection [18]. In this unit approximately 30% of neonates are 
prescribed gentamicin (Badger patient data system) fewer are prescribed ciprofloxacin as 
this is often introduced as rescue therapy, yet the incidence of resistance for gentamicin 
and ciprofloxacin were similar. The over-use of antibiotics and in particular broad spectrum 
antibiotics causes an imbalance in gut flora that may subsequently lead to late onset sepsis 
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[43]. A higher proportion of resistant organisms were found in blood cultures (10%) than 
surveillance swabs (1.37%) (Table 4-2 and Table 4-6). This may be due to the fact that 
more resistant organisms have an increased risk of translocation from the gut flora as they 
are less effectively treated by early empiric therapy [43, 46, 47].  
A review of antibiotic resistance concluded the highest tolerated dosing regimen must 
target the most resistant populations in an effort to prevent the emergence of resistant 
organisms due to selection pressures [48].  Achieving the mutant preventive concentration 
inhibits the least susceptible mutant within the wild type but this range is not usually 
targeted in clinical practice  due to the lack of toxicity data [48, 164, 166, 303]. Higher 
doses may be required to prevent resistance.  There may be an increased risk of 
resistance in paediatrics as antimicrobials are commonly prescribed unauthorised or off 
label. Inevitably the regimen is based on clinician preference rather than informed by 
reliable PK PD data. This is evident at there are wide variations in ciprofloxacin regimens 
internationally between 5 and 60 mg/kg/day [184]. Resistance may be fuelled by the 
resulting suboptimal regimen thereby allowing mutants to thrive. 
The broadened anti-anaerobic spectrum of newer fluoroquinolones is thought to 
predispose patients to develop C. difficile [60]. McCusker et al. found an increased risk of 
C. difficile associated diarrhoea with ciprofloxacin 13.5 (3.1-58.8 p<0.01 compared to other 
antibiotics (1.6 0.7 -4.1 p<0.28) [304]. Rashid et al. monitored surface and faecal samples 
following a ten day course of ciprofloxacin to health volunteers and found no evidence of 
C.difficile [305]. Although infants have very high carriage rates of C.difficile in the gut it 
does not seem to cause disease in those < 2 years of age. This may be due to a lack of 
development of toxin binding receptor on the colonocytes of newborn infants [306]. 
Therefore C.difficile is not routinely monitored in neonatal surveillance. 
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4.4.4 Severity of illness score pre and post Gram-negative bacteraemia. 
The change in illness severity when Gram-negative organisms were confirmed in blood 
cultures was quantified using the NTISS score. As anticipated those with more severe 
underlying illness at baseline were found to have a worse outcome (Table 4 3). These data 
illustrate a correlation between NTISS scores increasing on the day of isolation of Gram-
negative organism compared to a baseline score two days previously. Equally, the 
neonate may have improved by the time septicaemia is recognised or responded to earlier 
treatment with antibiotics. An elevated NTISS score occasionally occurred two days before 
Gram-negative isolates were confirmed. This may be due to underlying illness, 
complications of prematurity, or delay between symptoms and the Gram-negative bacteria 
being isolated.  
Illness severity scores are widely used in neonatal care. The NTISS Score was chosen for 
this study as it provides a more extensive detailed assessment of patients than other 
scores. It is unusual as it is mainly based on treatments administered rather than 
pathophysiological changes and treatment protocols may vary between hospitals [307]. 
The main limitation of this score in clinical practice is the extensive number of variables  
(n= 66)  as compared to other scores such as CRIB (n=6)  or SNAP (n=28) [307]. Even 
during a research study this is time consuming when case notes are extensive in critical 
illness. Bastos et al compared the four scores retrospectively and found comparable area 
under the ROC curve (for predicting in-hospital mortality) in each score was: CR18 0.90; 
SNAP 0.88; SNAP-PE 0.88; NTISS 0.85 [308]. However, there is no comparison yet of the 
ability of these scores in relation to detecting early signs of sepsis and the simpler scores 
may not have sufficiently variables to be sensitive.     
The strength of the score is that in this retrospective study the illness severity score 
correlates to an objective laboratory measurement of confirmed organism in blood 
cultures. The value of these data is that they suggest the NTISS score may be a useful 
tool to 
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contribute to the clinical diagnosis of sepsis prior to the availability of confirmed cultures. 
The score may also be useful for randomised controlled trials either to assist in defining 
sepsis prior to laboratory confirmation or to stratify participants based on illness severity. 
Further assessment of the score including neonates with suspected versus clinically 
diagnosed sepsis would be valuable.    
4.4.5 Clinical Implications and limitations 
The strength of this study is that these data are clinically important. They provide insight 
to the clinical outcome and the susceptibility of Gram-negative organisms for a particularly 
vulnerable population with high mortality and morbidity associated with Gram-negative 
bacteraemia. Most isolates over a six year period were retained by the clinical laboratory 
and successfully re-cultured yet due to the low incidence of eligible neonates these data 
are neither statistically significant nor conclusive. However, there is a consistent trend 
suggesting the regimen was inadequate to optimise therapeutic success for severe sepsis 
as follows:   
 A lower MIC within the susceptible range improved clinical outcome 
 The MIC group >0.035 mg/L had a greater risk of treatment failure (RR 2.5)  
 The pathogenicity of species influenced the clinical outcome  
 Very premature neonates improved outcome may be associated with a higher AUC 
due to immature renal function or disease progression.  
This retrospective outcome study provided an early indication of the need for a higher drug 
regimen in the absence of PK data specific to the population. The regimens at the time of 
this study (10mg/kg/day) may have been suboptimal to treat organisms with higher MIC. 
More recently this has been increased to 20 – 30 mg/kg/day based on infant and paediatric  
PK data supporting the findings from this clinical outcome study  [115]. This crude model 
for comparing isolates from cultures with the MIC and the neonate’s outcome may provide 
a framework for monitoring the effectiveness of regimen in the absence of conventional 
PK/PD data.   
This study illustrates the limitations of assessing clinical outcome in neonatal sepsis. Even 
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in this large neonatal unit with >1200 admissions per annum the incidence of confirmed 
Gram-negative infection in blood cultures was relatively low 1.3%. The true number of 
neonates with bacteraemia may be higher. Frequent blood cultures are restricted due to 
the risk of anaemia, to protect veins and minimise distress. Equally, there is a risk of false 
negative results as small volumes of blood <0.5 mL are used which may be inadequate 
for sensitive and timely detection of bacteraemia. Schelonka et al. suggested 1-2 mL is 
required to recover microorganisms for low-colony-count sepsis [21]. Fewer than eighteen 
babies per annum were eligible for analysis and only a third were treated with ciprofloxacin 
for at least five days to meet the inclusion criteria (n=33) over a six year period. To achieve 
statistically significant data multi centre studies with international collaboration are required 
to represent each sub-age groups for both gestational and post natal ages and covariates 
associated with critical illness.  
 
The challenges highlighted by this study partly explain why neonatal drugs are commonly  
unauthorised therefore prescribed off label more so than to any other patient population 
[309]. In vitro susceptibility testing of new antimicrobials usually requires several hundred 
isolates and at least ten organisms of each species to be tested [6]. To determine clinical 
breakpoints ideally requires several trials, and data sets with thousands of MIC. These 
neonatal data are limited to 33 patients with less than nine MIC values for each genus to 
compare with clinical outcome in this single centre. The outcome is confounded by the 
complexity of critical illness and clinical interventions therefore a randomised controlled 
trial would be required to evaluate safety and clinical outcome in this population. Yet this 
is difficult to achieve as to power a paediatric sepsis trial to detect a significant relative 
reduction in the risk of mortality using a baseline mortality of 10% as a primary end point 
would require 4000 babies [29]. There were insufficient patients at this single centre to 
compare the complex variables and host response for conclusive analysis. 
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The cure endpoint in this study may not be optimal, cure was defined simply as survival 
and CRP <10mg/L at day ten. This was chosen arbitrarily to reflect decision making in 
clinical practice. The advantage of selecting a short term outcome was in an attempt to 
determine a temporal association between the antibiotic and the outcome. Composite 
measures such as 30 day mortality or ventilator free days are confounded by death and 
morbidity from other causes in critically ill infants [231]. The time frame chosen for mortality 
resulted in different outcomes, short term mortality (within 10 days of confirmed Gram-
negative organism) was lower (15%) when compared to mortality prior to discharge (44%). 
This illustrates the difficulty of selecting an outcome representing different stages of the 
admission. There is a need to standardise outcome of sepsis in neonate to allow evidence 
synthesis and meta-analysis. At present there is no consensus on standardised outcome 
measures specific to neonatal sepsis or published standards within the Core Outcome 
Measures for Clinical Trials initiative (COMET) [29, 231, 310]. 
Individualised therapy may improve the outcome of critically ill neonates by applying 
personalised antimicrobial strategies. Higher doses may be prescribed for organisms 
found to be more resistant even within the susceptible range, those that cause severe 
infections including E.coli, Pseudomonas spp. and Klebsiella spp. or high risk sites such 
as bacteraemia or meningitis. This is dependent on the knowledge of the exact organism 
and MIC when antimicrobial therapy is commenced. In clinical laboratory practice the E 
Test is not routinely used as it is expensive and results are not available for a minimum of 
24 hours incubation period. Newer rapid methods for identifying the organism at species 
level include MALDI-TOF-MS a mass spectrometer and real time PCR assays may resolve 
this [311]. Resistance may vary locally depending on antibiotic usage and infection control 
practice therefore monitoring MIC’s at each site is recommended. Further safety and PK 
data is required to determine the standard and maximum effective dose that can be 
tolerated without significant adverse effects [79].   
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Clinical laboratories throughout Europe determine the susceptibility of organisms by 
estimating which MIC is most effectively treated by an adult regimen and outcome data. 
At present there are no clinical breakpoints specific to neonatal or paediatric PK-PD data.  
EUCAST’s breakpoints are mainly informed by three variables i) drug regimens ii) clinical 
outcome (specific to the adult population) iii) MIC of the organism (Figure 1-21). Any 
change to a variable other than the MIC in particular the dose, site of infection or population 
will alter the predictability of the MIC to achieve therapeutic success. In contrast to the 
ECOFF which is the concentration required to inhibit bacterial growth in a laboratory. 
Ciprofloxacin clinical breakpoint predicts the MIC most likely to be effectively treated by a 
regimen 500mg 12 hourly (oral) or 400mg x 12 hourly (intravenous) [159]. As the neonatal 
drug regimen varies not only from adults but between neonatal units internationally, 
therefore the application of the same breakpoint is unlikely to predict success. The 
AUC/MIC ratio is the optimal predictor of cure for Ciprofloxacin and different antimicrobial 
regimen result in different AUC as shown when comparing Teicoplanin PK data for an 
adult compared to either a child or neonate [155, 297, 298]. There is an established 
evidence base that drug regimens for adults cannot be extrapolated to children [79, 80] 
similarly the outcome of an adult drug regimen cannot be extrapolated. Whilst these 
neonatal data are insufficient to inform a clinical breakpoint but indicate that a dose of 
10mg/kg/day was only sufficient for organisms with a MIC of 0.035mg/L. To some extent 
the interpretation of these data are supported by   the fact that the dose was subsequently 
increased based on PK data for older infants. This retrospective non-invasive method for 
monitoring neonatal outcomes compared to the MIC of the causative organism may 
provide a framework for identifying sub-optimal treatment regimen.  
 
Further data are required. These data are insufficient to determine the optimal clinical 
breakpoint but illustrate that the optimal MIC treated by a neonatal regimen is unknown. 
This study led to the hypothesis that neonatal and paediatric microbiological breakpoints 
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informed by PK, safety and PD data for each sub-age group are required to optimise 
outcome. Different breakpoints may be required for sub-age groups as antimicrobial 
regimen are prescribed on weight (mg/kg) and maturation may influence the individual’s 
response. This issue has not been published previously. Historically, the lack of PK /PD 
data for children has prevented the licensing of medicines but since the EU Paediatric 
Regulations 2006 [73] the increase in paediatric research may now provide the evidence 
base for a paediatric breakpoint model.  To obtain sufficient data collaboration of neonatal 
units throughout Europe is required such as the consortium funding this ciprofloxacin study 
(Treat Infection in Neonates www.tinn-project.org).  
 
 
4.4.6 Conclusion 
In conclusion, there was a low incidence of confirmed Gram-negative organisms in 
neonatal blood cultures but when present this was associated with considerably higher 
mortality. A lower ciprofloxacin MIC was associated with likelihood of cure among Gram-
negative strains in blood cultures that were nominally susceptible to ciprofloxacin. 
Infections with susceptible strains that have relatively high MIC values or those known to 
be more pathogenic may need dosage optimisation. Despite long term use of ciprofloxacin 
in this unit there is no evidence of rapid resistance developing. Individualising drug 
regimens based on the MIC, pathogenicity and anticipated host response of the organism 
may optimise therapy.  In the absence of classic PD data this non-invasive retrospective 
PD model developed in this research has value in identifying suboptimal treatment 
regimens. An evaluation of neonatal and paediatric clinical breakpoints informed by PK, 
safety, microbiological and clinical outcome data is required to guide clinical practice.  
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Chapter 5 Regulatory Model: Neonatal PK Clinical Trials    
5.1 Overview 
Neonatal clinical trials are possibly the most stringently regulated  research as there is 
additional provision in the regulations to protect this vulnerable group [233]. The regulatory 
requirements are more rigorous for PK clinical trials as they are commonly for unlicensed 
or off label drugs. Neonatal PK data are scarce therefore data reliability is essential as the 
results have considerable influence on prescribing globally. The Clinical Trials Directive 
applies to all clinical trials of medicinal products in Europe, from “first in man” trials to 
pragmatic comparisons of commonly used treatments yet made no distinction between 
them with regard to the GCP requirements [232]. The Academy of Medical Science Report 
regarding the regulation and governance of health research stated the regulatory 
framework is a barrier to trials [235]. In response to this the MHRA, DOH and MRC 
prepared a consultation paper to develop a more proportionate approach. This Chapter 
describes a model for PK trials in neonates following a direct request by the MHRA.  
The request was to develop a risk assessment tool with guidance principles on how to 
manage and conduct CTIMP in a risk proportionate way. The research fellow developed 
a bespoke model with methods to mitigate risk to the safety of participants and reliability 
of data. The model was validated by the national steering group appointed by the DOH led 
by the MHRA including national stakeholders for the National Research Ethics Service, 
GCP Inspectorate, Pharmaceutical Industry, MHRA Medical Assessors and Academics 
and NHS Research Governance Leads. To engage with international Competent 
Authorities the research fellow presented the model at an international meeting with the 
EMA and FDA drug development leads. The model is published on the MHRA web site. 
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5.1.1 Aim and Objectives:  
To develop a regulatory model for neonatal PK clinical trials within the MHRA Consultation 
process more proportionate to the Investigational Medicinal Product.  
Objectives: 
To reduce regulatory requirements and barriers whilst mitigating potential risks to the 
safety of participants and reliability of trial data  
To risk assess the investigational medicinal product (IMP) relative to ciprofloxacin’s  
marketing authorisation relative to use in standard medical care for neonates and infants.  
To summarise EU and UK Regulatory requirements relevant to clinical trials then identify 
adaptations proportionate to the risk of the IMP. 
To design a bespoke trial model for a PK clinical trial with methods to mitigate potential 
risks related to the design and methods of the trial.  
To validate the model within a national consultation process with experts within the 
national steering group chaired by the MHRA.  
To assess the impact of reduced regulatory requirements for a PK clinical trial in neonatal 
and paediatric intensive care.  
To illustrate:  
 The incidence of adverse events in critical illness  
 The complexity of determining causality  
To develop a safety reporting framework proportionate to the complexity of causality 
in critical care. 
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5.2 Methods 
The MHRA Consultation process for a risk proportionate approach to clinical trials was 
the outcome of a risk-stratification project initiated by the Department of Health, MHRA 
and Medical Research Council to address key issues for clinical trials in the UK [232].  . 
The current regulatory framework in the UK/EU allows for a range of risk-adapted 
approaches largely related to how much is known about the investigational medicinal 
product (IMP). A simple risk categorisation based on the marketing status of the IMP and 
standard medical care determined the lower risk trials, where simplification of regulations 
results in a more risk proportionate approach. Three risk categories were proposed in the 
MHRA Consultation Document: 
Type A – comparable to or no higher than authorised use or use in established 
standard care,  
Type B – somewhat higher than licensed use for example a new indication or dose 
modification   
Type C – Markedly higher than the risk of standard medical care   
5.2.1 Risk assessment of ciprofloxacin specific to neonates and infants 
A risk assessment process is proposed to identify potential vulnerabilities in trial design 
and methodology, and to prepare a trial management and monitoring plan to minimise the 
risks. Risk was defined as the likelihood of a potential hazard occurring and resulting in 
harm to the participant and/or an organisation, or to the reliability of the results [232]. A 
risk assessment was undertaken for the IMP ciprofloxacin administered to neonate and 
young infants relative to the marketing authorisation. Ciprofloxacin is unauthorised 
therefore prescribed off label to neonates in the MHRA public safety assessment report 
[53, 173].  The MHRA Medical Assessor then evaluated the risk of the IMP relative to use 
in standard care. This was a summary of published evidence reporting the administration 
of the ciprofloxacin to neonates in standard care including neonatal and infant prescribing 
guidelines in the BNF for Children and publications including systematic reviews and 
surveys. 
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The risk assessment evaluated ‘the likelihood of a potential hazard occurring and resulting 
in harm to the participant, the sponsoring organisation or reliability of the results’ [232]. 
The safety profile of known adverse reactions was summarised from the Summary of 
Product Characteristics (Bayer PLC www.medicines.org.uk/emc/history/22508 accessed 
2015.  
5.2.2 Regulatory requirements proportionate to the risk of the IMP  
The EU and UK Directives and Regulations relevant to CTIMP in paediatrics were 
summarized. Potential adjustments proportionate to the risk category Type A, B or C of 
the Investigational Medicinal Product were determined for the following activities:  
Table 5-1 Adaptations based on the Risk 
 Increasing Risk  
Risk Adaptations Possible Type A Type B  Type C 
Reduced role of competent authority approval for clinical 
trial authorisation and the content 
Content of Application 
Investigational Medicinal Product management  
              Labelling 
              Storage  
              Drug accountability 
Safety Surveillance 
Documentation  
GCP Inspections 
Yes 
 
Yes 
Yes 
 
 
 
Yes 
Yes 
Yes 
No 
 
(Yes)* 
(Yes)* 
 
 
 
(Yes)* 
(Yes)* 
(Yes)* 
No 
 
No 
(Yes)* 
 
 
 
No 
No 
(Yes)* 
*On a case by case basis 
5.2.3 Design a bespoke clinical trial model with methods to mitigate risks. 
A bespoke clinical trial model was developed with a risk assessment of: 
 Sponsorship and governance 
 Investigational Medicinal Product  
 Patient consent rights and confidentiality 
 Reliability of Trial Results  
 Facilities, equipment and resources 
 Documentation, Governance and GCP Compliance 
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Strategies to mitigate each risk incorporated local or national standards for neonatal and 
paediatric clinical practice. Methods to mitigate risks were integrated in the protocol and 
standard operating procedures.  
5.2.4 Validation of the model  
The model was submitted to the MHRA National Consultation Group for publication on the 
MHRA web site. During face to face discussions at the MHRA Head Quarters each 
regulation and methods to mitigate risks were examined by the steering group including: 
 MHRA Good Clinical Practice (GCP) Inspectors  
 MHRA Medical Assessor 
 National leads for the pharmaceutical industry  
 Academic researchers 
 National Research Ethics Service 
 NHS Research Governance Managers  
  
5.2.5  Framework for safety reporting proportionate to critical care   
To extend the model a pharmacovigilance framework was designed proportionate to the 
high incidence of adverse events and complexity of determining causality in critical illness.  
The aim was to minimise reporting events that could not be directly associated with 
causality without a RCT thereby avoid nuisance reporting. The nature of intensive care 
means that events are frequently but associated with critical illness. Adverse events were 
defined as ‘any untoward medical occurrence in a subject to whom a medicinal product 
has been administered including occurrences which are not necessarily caused by or 
related to that product’ [245].   
To illustrate incidence of adverse events in a critical care setting events reported in the 
discharge letters were summarised to illustrate the frequency of events in critical illness. 
Serious and non-serious adverse events that the clinician considered to be clinically 
important were summarised for 20 neonates recruited to the PK clinical trial. To illustrate 
the complexity of causality assessments an observational case study of a critically ill infant 
admitted to paediatric intensive care included a level IV patient representing the most 
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severe illness based on the Paediatric Intensive Care Society definition [312]. The 
research fellow trained in paediatric intensive care and a trial pharmacist observed the 
patient over a seven hour period. Potential triggers for each adverse event were identified 
that may have contributed to the event including: 
i) clinical interventions  
ii) clinical condition   
iii) concomitant medications   
Baseline values for vital signs and ventilator observations were agreed for the patient’s 
stage of development with an Intensivist and two senior PICU nursing staff. Baseline 
laboratory reference ranges were consistent with the PK clinical trial protocol. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1 Framework for assessing Adverse Events in Critical Care 
 
This figure illustrates the method for assessing potential adverse reactions masked by the 
clinical interventions or concomitant medication 
  
Patient’s Expected Individualised range 
 
Identify clinical interventions or 
medication that may have masked 
changes or treated expected adverse 
reaction  
(For example: anticonvulsants and 
seizures) 
 
Acceptable range 
 
Change outside range  
classed as serious or non- serious 
 
Identify potential triggers for the event 
 
Clinical 
Intervention 
Clinical 
Condition 
Concomitant 
Medication 
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5.3 Results  
This Risk Proportionate Approach to the regulations for PK clinical trials was implemented 
by the MHRA in 2013 [232].  This model for neonatal and paediatric clinical trials met the 
Department of Health deadline and was published as a guide to investigators on the 
regulatory web site http:// forums.mhra.gov.uk/forumdisplay.php?22-Risk-adaptive 
approach.  The full model is included in appendix V.  
5.3.1 Risk Assessment of Ciprofloxacin specific to neonates and infants 
The Marketing Authorisation confirmed that ciprofloxacin is prescribed off label for 
neonates: it is licensed in children >1 year age for infections where the benefit is 
considered to outweigh the potential risks of the drug [53, 173]. The MHRA medical 
assessor initially classed the IMP as Type B as the IMP did not have a marketing 
authorisation when prescribed to neonates. A review of evidence supporting the use of 
ciprofloxacin in standard care was summarised including a systematic review of 
ciprofloxacin in neonates and a European survey funded by the TINN Consortium (Table 
5-2)[73].  MHRA were satisfied with this evidence and revised the risk classification as 
Type A (low risk). The lower risk was supported by the fact that the inclusion criteria 
required ciprofloxacin to be prescribed as standard care therefore the risk of participation 
related to additional monitoring (blood samples) rather than administration of an IMP. 
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Table 5-2 Evidence of Ciprofloxacin prescribed to neonates in standard care 
 
 
 
5.3.2 Regulatory requirements proportionate to the risk of the IMP  
EU and UK Regulatory requirements applicable to a PK clinical trials for neonates were 
reviewed then adjustments proportionate to the Type A risk category were summarised  
 
 
 
 
 
 
 
Clinical Trial 
Protocol 
IMP is prescribed by the clinical team as standard care (not for the purpose of 
research)  
Prescribing 
Guidelines 
SmPC and MHRA Public Safety Report include the indication severe infection [53] 
British National Formulary for Children includes off label prescribing guidelines for 
neonates [173] 
Liverpool Women’s NHS FT Neonatal Sepsis Protocol   
Published evidence  Systematic review of adverse events in children (105 articles and 16 184 patients) 
[190] 
Systematic Review of the use of ciprofloxacin in neonates  (32 cohort studies or 
case reports [184] 
Ciprofloxacin in neonatal Enterobacter spp. cloacae septicaemia confirming use 
since1989 [313] 
Improving antibiotic prescribing in neonatal units – time to act - [183] 
European Survey 26% (50/193) units prescribe ciprofloxacin as first or second line antimicrobial 
therapy     http://www/tinnproject.org 
Off label use Off label use in Europe of established practice for children and neonates – 55% of 
drugs are administered off label to neonates [309]  
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Table 5-3  Regulatory requirements for a Type A trial of ciprofloxacin in neonates  
*  Regulation refers to the Medicines for Human Use Clinical Trials Regulation [245] and 
subsequent amendments 
5.3.3 A bespoke clinical trial model to mitigate risks  
A detailed risk assessment and methods for mitigating the risk were referenced to the 
appropriate regulations Appendix V. The following areas of risk were identified: 
 Sponsorship and Research Governance  
 Investigational Medicinal Product administered to neonates 
 Safety  
 Patient Consent, Rights and Confidentiality 
 Reliability of Trial Results  
 Facilities, Equipment and Resources 
 Documentation, Governance and GCP Compliance 
Regulation* Reduced Regulatory Requirement  for the Neonatal PK Trial  
MHRA 
Authorisation 
Exempt from a Clinical Trial Authorisation ( automatically approval) [232] 
Content of 
Application  
SmPc replaced the IMP dossier and Investigator Brochure [232].  
Substantial Amendments are not required when the protocol change was 
consistent with the SmPC.  
IMP Management  Prescribing standards within the NHS allowed exemption from: 
Drug accountability log (of expiry dates and batch numbers)  
Labelling of dispensed drugs specifically for the trial 
Temperature monitoring of ward stock  
Safety Serious Adverse Events anticipated in critical illness including death were 
exempt from expedited reporting 
Non-serious adverse events /reactions were limited to those identified by the 
Sponsor as critical to the safety of the trial.  
The period of reporting during follow up was limited to 42 days post 
administration of the drug rather than the end of the trial.   
Consent, rights 
and confidentiality 
Consent was delegated to medical staff and registered nurses with relevant 
generic research training and study specific training who appeared on the 
delegation log  [234] (not restricted to medically qualified personnel) 
Emergency deferred consent allowed the blood sample to be collected prior to 
consent  Amendment 2984 [240] 
Monitoring and 
Inspections  
Site monitoring visits were higher based on the risk assessment for data 
reliability  
Frequency of MHRA Inspections was reduced for Type A 
Documentation, 
Governance and 
GCP  
Reduced content of trial master files was allowed at follow up sites using a 
simplified electronic site file specific to the role of the site (limited to the protocol, 
statement of responsibilities and site specific standard operating procedures 
relevant to follow up). 
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The risk assessment categorised the likelihood of each potential hazard as low medium or 
high and the impact (see appendix V). The risk of the IMP to patient safety was assessed 
as low risk as the drug was administered as part of standard care not for research.  
Three high risk categories were identified all associated with precision and data 
reliability:  
 Drug administration  
 Drug accountability 
 Blood Sampling 
  Drug administration Risk of precision – High Risk   
This quality of the data and the validity of the trial were classed as a high risk to achieve 
the level of precision required for a PK trial. Potential sources of variation were determined. 
The risk to precision depended on how the infusion was set up either primed with saline 
first or with the drug. The risk was higher for the low weight babies partly due to the fact 
that the volume of drug was less therefore took longer to reach the vein when administered 
via long infusion lines.  At the paediatric site the drug could be delayed from reaching the 
vein for up to 24 minutes as the dead space between the patient’s vein and the drug could 
be up to 2 mL and the drug was administered over 60 minutes.    
There is a risk that not all the drug enters the circulating blood prior to taking the sample. 
As the internal length of neonatal long lines and Broviac lines could not be reliably 
estimated. This posed a particular risk for the group A sampling schedule as T1 was taken 
within 3 minutes of the end of the infusion. The flush volume was restricted for critically ill 
babies particularly those with cardiac defects to 1mL/kg/hour. In a neonate weighing 1kg 
their total allowance is 1 mL per hour. Small flush volumes can be a considerable 
proportion of their daily intake particularly when administering multiple drugs. These 
patients are often administered >20 drugs per day.  Each mL results in a decrease in the 
baby’s nutritional allowance.    
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 Risk of drug accountability – high risk  
The requirement for trial specific drug stock accountability logs, labelling and temperature 
monitoring was avoided as the drug was prescribed and dispensed within the NHS [232]. 
The drug could be dispensed from ward stock. The impact was considerable during this 
PK trial as over 500 intravenous infusions of ciprofloxacin were administered. The burden 
was reduced for clinical staff as they were not required to collect a trial supply from 
pharmacy. Equally this avoided the risk of delaying administration as the neonatal 
antimicrobial policy states antibiotics should be administered within thirty minutes. 
Potential patients may have presented on any of seventeen paediatric and neonatal wards 
in two lead centres. The proportionate approach reduced the burden of monitoring the 
temperature of drug stock in each area and the cost of purchasing minimum/maximum 
thermometers. To monitor the temperature of the ward stock of trial drugs in each of these 
areas would have taken over two hours a day. Neonatal units are often warmer than the 
recommended temperature for storing this drug.  To mitigate this risk unpublished data 
from the pharmaceutical company was obtained stating that ciprofloxacin is stable up to 
40˚C. 
 Risk and burden of blood sampling – high risk  
The population PK design reduced the risk of frequent sampling as it allows individual 
patients to contribute sparse samples rather than rich sampling from a single patient. The 
HPLC MS laboratory method was developed to measure drug concentrations on small 
plasma volumes 0.2mL. DNA samples were scavenged from blood that was taken for 
clinical care if sufficient remained following the clinical analysis.  A sub-study confirmed 
that DNA could be scavenged post transfusion without donor contamination affecting the 
genotyping as blood products are now leucocyte depleted (Chapter 3). Blood samples 
were obtained  within the guidelines on the total volume of blood collected from a child for 
research [80, 140]. 
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 Methods to Mitigate Risks 
To optimise the precision of drug administration and sampling it was essential to train all 
the clinical staff as data was required at any time day and night. The research fellow 
provided approximately 50 training sessions day and night to >300 clinical staff including 
medical, nurses, pharmacists, laboratory and phlebotomists. Precision of the data 
depended on accurate clinical records being completed by each clinical nurse including 
the method of priming an infusion line, start and end times.  Standard operating procedures 
were prepared based on the risk specific to each recruiting site as different infusion 
practices were in place. Trial tools including recruitment packs were prepared with the 
exact information needed for the bed side nurse.  The research fellow attend the neonatal 
unit each shift that either a sample was due to remind staff of the precision required and 
to provide the patient labelled blood or CSF bottles or swabs etc. To minimise distress 
from sampling each sampling schedule was planned individually to coincide where 
possible with clinical blood gas or laboratory samples.  The frequent clinical sampling 
provided an opportunity to minimise the distress and blood loss for PK analysis.  
On site monitoring of sources verification data was undertaken by the  Sponsor based on 
this risk assessment [245]. Serious Breaches that may have affected the scientific integrity 
of the trial were reported to the Sponsor as per Regulation 29A [233]     
5.3.4  Validation of the model  
The model was validated initially by two Senior GCP Inspectors and the MHRA Medical 
Assessor. They examined the model to ensure the model was consistent with the 
regulations [233, 245, 314]. The final approval was a face meeting with stakeholders 
including the national consultation group members. The model was published on the 
MHRA website in fulfilment of the requirement by the Department of Health. Each clinical 
trial regulation was examined in detail to ensure the adaptations proposed in the risk 
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proportionate approach were consistent with the UK regulatory framework and that 
potential risks were mitigated.   
 Evaluation of a pharmacovigilance framework proportionate to critical care   
A safety reporting framework was developed proportionate to the high incidence of 
adverse events and complexity of determining causality.  SAE anticipated in this 
population were defined in the protocol based on the incidence of conditions in very 
premature babies (Prof Cooke personal communication). Whilst these were reported they 
were exempt from expedited reporting to the Sponsor Regulation 32 (4) [245] . This 
reduced the pressure for a Principal Investigator to report the event to the Sponsor within 
24 hours. The incidence of SAEs is monitored by the Sponsor and Independent Safety 
Data Monitoring Committee (ISDMC). The reporting interval is determined by a risk 
assessment. The incidence was compared to what was anticipated (associated with the 
health condition) or expected (associated with the drug based on the reference safety 
information (RSI)). If this increased the PI must notify the MHRA and National Research 
Ethics Service of a Suspected Unexpected Serious Adverse Event (SUSAR). In this way 
the safety of the patient is protected without the burden of reporting within 24 hours. The 
rational is that a decision to stop or changing the trial protocol would only be made if there 
was an increase in the incidence not an isolated event. During this trial there were 
seventeen serious adverse events. These were subsequently assessed by independent 
clinicians as having no evidence of a causal link and were exempt from expedited 
reporting. 
In critically ill patients non-serious adverse events occur frequently. Regulation 32 (5) 
allows the Sponsor to define the non-serious adverse events or reactions ‘critical to the 
safety’ of the trial or of interest to the outcomes that require reporting in the protocol. A risk 
assessment of the IMP identified adverse reactions previously reported in the SmPC, 
MHRA public assessment report and systematic review on safety in children with an 
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estimate of the likely hood of the event occurring Table 5-4.  These non-serious adverse 
events were collected systematically in the case report form and summarised in safety 
reports for review by the ISDMC and the Sponsor. This reduced the burden for 
investigators completing reports for events that were not required and ensured that any 
event of interest was systematically collected.   
Table 5-4 Expected adverse reactions listed in the ciprofloxacin SmPC   
Body System Adverse reaction/Hazard Likelihood 
Rare, Low, Medium or 
High  
Joints  Arthropathy/ tendonopathy M 
Vein  Phlebitis L 
Liver Function  Failure /Pancreatitis L  
Renal Function Failure /Crystalluria L  
Blood cells  Deranged L 
Gastro-intestinal  Colitis if severe and  persistent 
Clostridium Difficile 
M 
Anaphylaxis /Allergy Shock  R 
Neurological Convulsions M 
Cardiac Ventricular arrhythmias /Prolonged 
QT interval  
 
Skin Rash/ Photosensitivity  M 
Syndromes Stevens Johnson /Lyell R 
 
The period of pharmacovigilance reporting was specified as a set time of six weeks after 
drug administration supported by Regulation 32(5) Section 3 MRC /DOH Clinical Trial Tool 
Kit [245, 315]. Open statements are often used in protocols such as last patient ‘last visit’ 
yet the trial may last several years imposing considerable burden on the researcher. As 
neonates are often readmitted to hospital for other reasons associated with prematurity 
this would require frequent further reports for the duration of the trial of admissions to other 
hospitals not just the recruiting site. Limiting the reporting period in the protocol avoids 
unnecessary reporting and is supported by the Clinical Trial Tool Kit [315]. By defining a 
time in the protocol means the safety reproting peroid is approved by the MHRA and Ethics 
as being a sufficient period to record the safety outcomes.  
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Figure 5-2 Pharmacovigilance reporting framework proportionate to critical care 
 
 
 
 
Serious Adverse Events or Reactions (SAE /SAR) 
Anticipated SAE: Sponsor specifies SAE anticipated in this patient population in the protocol 
Unanticipated SAE: All SAE are reported but are exempt from expedited reporting within 24 hours 
SAE that are not anticipated in the protocol must be reported by the Investigator immediately 
(usually within 24 hours) of their knowledge of the event to the Sponsor Regulation 32 (4) 
 
Monitoring Non-serious Adverse Events and Reactions defined by the Sponsor  
Non-serious adverse events may be systematically recorded in the case report form 
depending on the urgency of reporting based on the Sponsor’s risk assessment.  
 Case report forms must capture clinical interventions, concomitant medications or clinical 
conditions that may confound the assessment of causality  
Suspected Unexpected Serious Adverse Reaction (SUSAR) 
If the incidence of SAE increases above the anticipated rate the Sponsor expedites a SUSAR 
report to the MHRA/NRES/competent authority of other member states involved) 
SUSAR that are fatal or life threatening’ must be reported  within 7 days after being aware of the 
reaction or 15 days if not fatal or life threatening. Regulation (33) 
Non-serious Adverse Events / Reaction Reports 
The Sponsor defines the non-serious AE/AR that are ‘critical to the safety’ of the trial in the 
protocol if they require reporting. This is based on the known reactions for the group of 
drugs in the SmPC Regulation 32 (5)  
Investigators may report any other adverse reactions when causality is suspected 
particularly if  this is not a known adverse reaction.  
 
Limit the period of pharmacovigilance reporting 
Define the period of safety reporting following the administration of the drug to that 
patient rather than an open statement ‘last patient last visit’ Regulation 32 (5)  
 
Annual Safety Report 
The Sponsor provides an Annual Safety Report for the REC and MHRA (competent 
authority of any member state) taking into account all new available safety information 
received during the trial (Regulation 35)  
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 Evaluation of Adverse Events in critical illness  
5.3.4.2.1 Adverse events in neonatal discharge letters 
A retrospective review of discharge letters assessed the number of reports that met the 
regulatory definition of non-serious adverse event or reaction. Among the first twenty 
neonates recruited to the clinical trial an average of 11.3 adverse events were reported 
Table 5-5. Serious Adverse Events that occurred during the six week follow up period 
included eight deaths and six other SAE. Most SAE were exempt from expedited reporting 
to the Sponsor (93%) as they were pre-defined as anticipated in this population due to 
prematurity and the incidence stated in the protocol. One SAE had not been listed as 
anticipated but subsequently classed as no causality). Three non-serious adverse events 
relating to renal calculi had possible causality. The Independent Data Monitoring 
Committee found this was likely to be associated with other factors such as administration 
of diuretics.  Causality for adverse reactions was confounded by the fact that each baby 
was administered an average of 18.8 concomitant medication during their admission.    
Table 5-5 All cause AE /AR reported in Discharge Summaries for Neonates  
(n=20) 
Adverse event /reaction N= % of babies 
Respiratory Distress syndrome  17 85 
Jaundice 16 80 
Anaemia 14 70 
Thrombocytopenia 14 70 
Hyponatraemia 13 65 
Intraventricular haemorrhage  10 50 
Bronchopulmonary Dysplasia  10 50 
Metabolic Bone Disease 9 45 
Necrotising enterocolitis 6 30 
other 126 n/a 
Total 226  
Average 11.3 adverse events or reactions per baby 
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5.3.4.2.2  Adverse Events: Paediatric Intensive Care Infant: observational case-study  
To illustrate the complexity of assessing causality for adverse events an infant diagnosed 
with Meningococcal Septicaemia was observed to represent a most severely ill category 
level IV of Intensive care patients. Adverse events anticipated with the clinical condition 
for meningococcal septicaemia include:  
 Disseminating intravascular coagulopathy (DIC) 
 Systemic Inflammatory Response Syndrome (SIRS) 
 Multi System Organ Failure (MSOF) 
 
Fifteen non-serious adverse events or reactions were identified over a seven hour period 
that met the regulatory definition of ‘any untoward medical occurrences’ (estimated as 360 
reports per week) (Table 5-6 ).  These included changes to vital signs, blood values, 
ventilation parameters and blood gas analysis. This illustrates how these factors are 
equally associated with their clinical condition, clinical interventions and concomitant 
medication confound the assessment of causality. This patient was administered 14 
concomitant medications during the seven hour period including seven continuous 
infusions.  Interventions to treat low blood pressure included inotropes, human albumin 
solution or intravenous fluid would mask hypotension associated with an anaphylaxis to 
the IMP. As the patient was haemofiltered this renal support would mask potential adverse 
reactions.  
Regulatory Model  
Table 5-6  Potential Triggers Confounding Causality of Adverse Events 
Adverse Event 
/Reaction 
Clinical 
Conditio
n 
Clinical Intervention Concomitant Medication 
Vital signs:  
    Tachycardia  
     
    Hypotension 
    Core Temperature ↑↓  
      
 
 
Yes (all)  
 
Physiotherapy /Endotracheal Suction 
Haemofiltration (negative balance) 
Active warming  
Oesophageal temperature probe (risk: detects external 
heat 
Haemofiltration circulating temperature 
 
Inotropes - adrenaline, nor-adrenaline, dopamine and milrinone  
Opiates (Fentanyl)  
Temperature masked by paracetamol   
Blood Values 
     Anaemia  
     Thrombocytopenia 
     AST ↑     ALT ↑  
     Derranged clotting      
    ↓Bilirubin 
     ↑Albumin  
     ↑C-reactive protein  
     Hypoglycaemia  
 
 
 
Yes (all)  
 
 
Blood loss from sampling, central line insertion  
or priming haemofiltration circuit 
 
 
Anticoagulants for haemofiltration 
 
 
Naso-gastric or intravenous nutrition delayed or 
inadequate 
 
Fluid resuscitation  
Human Albumin Solution (over correction)  
 
Heparin in the circuit 
Respiratory compromise 
    ↓ tidal volume 
    ↓ respiratory rate 
    Acidotic        
 
Yes (all) 
  
 
Ventilation rate masks respiratory depression  
Endotracheal tube blocked with secretions  
 
Opiate associate respiratory depression Fentanyl or sedation 
Midazolam  
Fluid Resuscitation 
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5.4 Discussion:  
Despite the fact that this is a vulnerable neonatal population, this model has 
demonstrated that a regulatory risk proportionate approach may be applied to trials 
involving off label medicines to neonates. A bespoke trial management plan including 
methods to mitigate potential risks avoids compromising the safety of children or data 
reliability in intensive care. The MHRA considered the use of off label drugs that are 
commonly prescribed in  standard care as low risk rather than restricting the category 
to the marketing authorisation as it is common in paediatrics for medicines to be 
administered off label [309].  It is evident that the highest risk for this PK trial was data 
reliability which has considerable implications as the data will influence prescribing 
regimens internationally.  
Monitoring the safety for critical care patients has challenges. As this patient 
population are clinically unstable they present with a complex series of adverse events 
anticipated by the nature of their condition. Pharmacovigilance reporting can be a 
burden to busy clinical teams and result in a vast amount of nuisance reporting of 
events that are either not related or possible to know in this design. In the absence of 
an event with a temporal association to the intervention causality could not be reliable 
out with a randomised controlled trial. The burden to busy clinical teams is immense. 
The observational case study suggests as many as 360 non-serious adverse event 
reports would be generated within a seven day period for a critically ill PICU patient. 
The retrospective review of discharge letters found 11.3 adverse events per neonatal 
admission. A proportionate approach to safety reporting provides a pragmatic solution 
for clinical teams that limits pharmacovigilance reporting to SUSAR, SAE and non-
serious AE that the sponsor has identified as being crucial to the participant’s safety.  
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Safety reports risk inferring causality without proven association with the IMP.  
Adverse events commonly associated with infection were reported in the systematic 
review of ciprofloxacin safety in paediatrics [190]. These adverse events are 
commonly anticipated as part of the clinical condition therefore this review may 
mislead clinicians and regulators. The review did not provide a separate analysis of 
adverse events identified in randomised controlled trials therefore it was not possible 
to reliably determine causality in respect of ciprofloxacin administration.    
Determining causality in critical illness is complex as the clinical condition, clinical 
interventions and concomitant medications confound an assessment of the IMP. For 
example in the observational study of meningococcal sepsis deranged clotting is 
anticipated due to the illness and therefore difficult to determine when causality is due 
to the IMP.  In this PK clinical trial neonates were administered on average eighteen 
medicines during their admission. Adverse reactions listed in the SmPC are often 
common to more than one medication. Equally, clinical interventions and medication 
that support organ function may mask adverse reactions such as inotropes masks 
hypotension and ventilation masks respiratory depression. As such safety data from 
intensive care patients may not be generalisable to other patients who may then be 
at risk when organs are not supported. Despite this the intensive care environment 
provides a unique opportunity to observe trends following the administration of a drug 
due to the continuous monitoring and skilled nursing staff. This may allow the 
identification of temporal changes that may not be observed in other populations. 
This study illustrates opportunities specific to critical care that can mitigate risks of 
research and overcome ethical challenges.  The frequent clinical blood sampling 
during critical illness allowed the PK samples to be taken at the time of clinical blood 
samples preventing additional distress to the baby. Scavenging clinical samples from 
clinical blood samples prevents further blood loss for research by reusing blood that 
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would otherwise be discarded. However, this required a rigorous training programme 
inclusive of almost every member of the clinical team to ensure precise timing of 
infusions and sampling during especially as most drugs are given and samples taken 
during routine care.  Scavenging clinical samples has the potential to collect a priori 
data to inform an optimal sampling schedule for future PK models.  
Consent from parents was required to obtain samples.  Prospective consent was used 
to achieve the tight time frame (3 minutes following the first infusion) as the drug was 
prescribed at any time of day or night. Parents often lived at a distance and have other 
siblings to care for so they are not always available. Requesting prospective consent 
allowed parents more time to consider participation. Also, they could be approached 
at a less stressful time. UK legislation allows nurses to be delegated the role of which 
meant information could be given to parents by the wider team at the children’s 
hospital where there were >20 wards. At a later stage Emergency Deferred Consent 
and telephone consent were approved by the National Research Ethics Committee 
for this trial but rarely applied [240]. Legislation allowing emergency deferred consent 
is approved by amendments to the Medicines for Human Use Clinical Trial 
Regulations [240, 244, 245].  
Follow up of neonates is challenging as they tend to move to another hospital nearer 
home across the neonatal referral network often up to 100 miles in case the baby was 
transferred [316]. Safety data was required for a six week follow up period , this 
required R&D approvals at 40 hospitals and a GCP trained Principal Investigator 
[317]. As this population were critically ill only 3/65 babies were transferred during the 
follow up period. It is difficult to predict which hospital babies transfer to therefore 
approval was required. The Centralised Service for NHS Permissions allows the use 
a single research governance application form but individual approval was required 
for each site. The NHS Health Research Authority propose to centralise this approval 
with national single sign off to be implemented in 2016 
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http://www.hra.nhs.uk/documents/2014/01/sponsorship-consultation-paper-final-1-
0.pdf (accessed August 2015).    
The Regulatory standards led to indirect improvements in clinical practice. Training 
clinical teams has increasing awareness of precision required for therapeutic drug 
concentration monitoring. Temperature monitoring of ward stock found that the 
neonatal unit’s temperatures often exceeded recommended temperature resulting in 
the need for improved storage in NICU. Surprisingly, the storage of drugs on wards is 
not governed by the same standards as storage within the pharmacy department 
[318]. Training the clinical teams in sample precision has increased awareness of 
precision required for therapeutic drug level monitoring. 
There are cost implications for mitigating risks effectively. Training 200 staff per site 
for 30 minutes is equivalent to 5.5 weeks full time clinical hours. The NIHR allocate 
service support costs for non-commercial research to NHS Trusts [319] for training 
clinical teams but the time and cost is underestimated. The cost of conducting a 
clinical trial increased following the Directive 2001/20/EC [320]. For example the 
Academy of Medical Science reported a disproportionate amount of time spent by 
staff preparing for inspections [235]. This proportionate model may reduce costs as 
Type A studies are less likely to be selected for inspection by the MHRA (daily rate 
per inspector £2583). The MHRA are moving towards reducing documentation by 
allowing electronic site files [234]. In this trial electronic site files were used for follow 
up sites.   
A limitation of this proportionate approach is that it focuses on the risk of the IMP to 
categorise the study as A, B or C whereas the risk of data reliability in PK trials can 
be greater. Detecting precision errors is even more important for neonatal PK trial due 
to the small scale of drug volumes, blood samples and complex infusion lines so there 
is a risk of error. The consequences of unreliable data are considerable.  Effective 
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monitoring for data reliability requires clinical knowledge to detect errors in sampling 
or drug administration and a detailed examination of source verification data. The 
MHRA risk stratification allows the Sponsor to authorise central monitoring for lower 
risk trials [232, 234, 296]. Unfortunately, central monitoring is often delegated to non-
clinical personnel and focuses on governance checks. Drug administration and 
sampling can be mitigated by providing standard operating procedures specific to the 
clinical practice at the hospital and methods for cross checking data. The optimal 
model would include accredited sites for conducting clinical trial where there are 
standards for each stage of the process. This was the first PK trial at either recruiting 
site and detailed planning was undertaken in each area including the laboratory, 
wards and pharmacy. In addition to a thorough regulatory assessment, these insights 
have been shared with other research teams to prevent risks to neonatal PK trials.       
This risk proportionate approach is an initiative of the MHRA in the UK therefore may 
not be applicable to trials with European partners. At present each EU member state 
has some discretion on how they interpret the EU Directive 2001/20/EC [235, 237]. 
The European Commission has passed a clinical trial Regulation that include some 
elements of proportionate risk management [321].  This will harmonise trial conduct 
and allow a more consistent approach to some of the regulations across Europe by 
binding each state rather than allowing each state to select clinical trial regulations in 
the directive. European collaboration is valuable when recruiting to neonatal trials as 
the sub-age groups result in small numbers of eligible patients especially for rare 
conditions such as GN sepsis. Approximately 24% of all EU clinical trials are 
performed in at least two Member States these larger trials involve approximately 67% 
of all subjects enrolled in a clinical trial [320].  
This PK clinical trial model was published on the MHRA web site 
http://forums.mhra.gov.uk/forumdisplay.php?22-Risk-adaptive-approach then 
presented 
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to the European Medicines Agency towards standardising a risk proportionate 
approach throughout Europe [237]. The MHRA invited the research fellow to present 
this model to the EMA and FDA during the consultation process for the EU Regulation 
[321] to encourage a proportionate approach internationally.  Many drugs are not 
authorised for children and a standardised approach to regulations throughout Europe 
is beneficial to achieve the objectives of the EU Paediatric Regulations to license 
drugs for children by the EMA [73]. This is highlighted by these PK and clinical 
outcome data. 
Clinicians view by the regulatory process as a barrier and the complexity of the 
regulations results in misconceptions. Most of the regulatory adaptations 
implemented in this model were possible prior to the introduction of this risk 
proportionate approach but negotiation with the MHRA was required on a study by 
study basis. This caused delays and uncertainty and the advantage of this initiative is 
that adaptations are more transparent. Unfortunately, the process for applying for 
Type A may deter investigators as the MHRA require a detailed prospective risk 
assessment of the IMP with a plan to mitigate risks reviewed by the Sponsor, funders 
and other investigators [232]. Providing sufficient evidence of use in standard care for 
the population may be a barrier in the absence of a systematic review. A simpler 
approach would be for the MHRA to accept that the BNF C is viewed as sufficient 
evidence of use in standard care [173]. By publishing models for different types of trial 
design on the MRHA web site will provide useful templates and the recently published 
a GCP Guide will simplify the process for investigators [234].  
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5.4.1 Conclusion  
Critically ill patients are a challenging vulnerable patient population and this 
proportionate approach considerably reduced the barriers to conducting a PK clinical 
trial. The model provides methods to mitigate potential risks to the patient and data 
reliability. Determining causality for pharmacovigilance reporting in critical illness can 
generate vast ‘nuisance data’ as causality cannot often be determined for the 
numerous adverse events. In most cases a blinded randomised controlled trial is 
required to determine causality due to the complexity of the illness, interventions and 
concomitant medication. It is evident from these data that a proportionate approach 
to monitoring adverse events is beneficial to reduce the burden to the clinical team. 
Events more likely to be reactions and provide new safety knowledge are not missed 
by the burden of over reporting un-related events.   
Even though this drug is prescribed off label to a vulnerable population the MHRA 
awarded a Clinical Trial Authorisation for a Type A trial as comparable to standard 
care. The need for a more proportionate approach is highlighted by this study of 
neonates as many medicines are prescribed as part of standard care off label in 
paediatrics. PK trials of medicines used in standard care require an adaptation for a 
lower risk model compared to early phase trials of healthy volunteers that have 
informed many of the regulatory standards. The proposed framework provides a more 
transparent and proportionate method appropriate to the complexity of children in 
intensive care. This model provides a more proportionate application of the 
regulations that are specific to the investigational medicinal product and the 
population rather than a ‘one size fits all’ approach at the same time as minimising 
potential risks to the patient or data reliability.  
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Chapter 6 Final Discussion 
6.1 Implications for Clinical Practice 
Ciprofloxacin is an option for the treatment of suspected sepsis in neonates and young 
infants. Optimising existing therapy to treat Gram-negative bacteraemia is essential 
due to the severity of illness, rapidly increasing resistance and lack of new 
antimicrobials in development [6]. The burden of Gram-negative bacteraemia is 
evident in this neonatal unit as when Gram-negative bacteraemia was confirmed 
mortality increased to 44% compared to approximately 20% for those <28 weeks PMA 
or 8% for those 28-34 weeks PMA. Sub-optimal antimicrobial drug exposure also 
increases the generation of resistance [322]. This is evident when medicines are 
administered off label by the wide variation in regimen, which further compounds PK 
variability and increases resistance. Ciprofloxacin regimens internationally range 
between 5 to 60 mg/kg/day [184]. The preliminary PK-PD data in this thesis contribute 
towards optimising the regimens and authorising ciprofloxacin for neonates and 
young infants.  
The strength of this popPK clinical trial is that the data were acquired in a real world 
setting where the effect of critical illness and rapid changes in organ development 
from extreme prematurity to young infants. Of the 64 neonates and young infants 
recruited a minimum of seven babies were stratified to each four-week sub-age group. 
Extreme variation is evident between subjects even within each individual sub-age 
group. For neonates 28-31 weeks PMA the AUC 0-24 (SD) ranged between 65 – 291 
mg*h/L (60). This extensive variability illustrates the limitations imposed by a fixed 
dosing strategy and the potential benefit of individualised therapy. However, there are 
significant practical implications to personalising therapy. Covariate analysis found 
that gestational age, postnatal age, current weight, serum creatinine and inotrope 
administration had a significant impact on ciprofloxacin PK parameters. A pragmatic 
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approach is to adjust ciprofloxacin regimen using these covariates that have an impact 
on clearance associated with either maturation or altered renal function during critical 
illness. As the combined effect of post-natal age and post menstrual age at birth 
affected clearance, different regimens may be required for neonates with the same 
post-natal age depending on how premature they were at birth. More frequent dose 
intervals are indicated for neonates >34 or 36 weeks PMA from 12 to 8 hourly than 
are currently recommended in the BNF C [173]. These PK data found that neonates 
>34 weeks PMA may be undertreated with 20mg/kg/day as only 66% achieved the 
conventional AUC/MIC 125 target estimated by Monte Carlo simulation. Individual 
AUC data was available for each patient and 14% of those treated did not achieve the 
AUC/MIC ratio >125. The optimal dose of ciprofloxacin is dependent on establishing 
the optimal predictors for therapeutic success specific to neonates and infants which 
is currently unknown.  
Pharmacodynamic studies specific to neonates and young infants are uncommon. 
The conventional target of an AUC/MIC 125 for optimising therapeutic success is 
based on adult outcomes and regimen [162]. More recent paediatric and adult data 
supports a higher ratio particularly for severe infection [115, 176].  Zelenetski et al in 
2010 [176] found a ratio of >250 was required to achieve therapeutic success reliably. 
Fewer than half of our trial participants (42%) achieved this target when administered 
20 – 30 mg/kg/day (Chapter 2). Over a six year period the incidence of this condition 
was insufficient to generate statistically significant findings in a study relating 
susceptibility to ciprofloxacin outcomes. Vast numbers of babies would be required to 
power the necessary efficacy and safety studies, which is challenging. In this large 
tertiary neonatal unit the incidence of Gram-negative bacteraemia was only 1.3%. The 
data described in Chapter 4 indicates that the ‘lower’ dose 10mg/kg/day was only 
sufficient for therapeutic success for isolates with an MIC <0.035mg/L, considerably 
lower than the non-species specific clinical breakpoint. Clinically this is significant as 
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44% of isolates had an MIC greater than this yet are currently classified as susceptible 
according to the EUCAST clinical breakpoint. Therefore these neonates may have 
been undertreated for those prescribed ciprofloxacin. Lipman’s PK data for infants >3 
months of age found 20mg/kg/day was only sufficient for organisms with an MIC of 
<0.24 mg/L [115]. This outcome study suggest that in neonates given ciprofloxacin at 
a dose of 5 mg/kg 12hourly for GNS, there is a marked difference in clinical outcome 
depending on the ciprofloxacin MICs, even though this was within the susceptible 
breakpoint range. This was not statistically significant but indicates that either a lower 
clinical breakpoint or higher dose may be required for bacterial inhibition if a higher 
dose can be tolerated without significant adverse reactions.  Further analysis of the 
PK data is planned to estimate the dose and interval to achieve an AUC/MIC >250.  
In addition to the MIC the pathogenicity of the bacteria is likely to determine the 
outcome. The rate of cure for Enterobacter spp. was much higher (89%) than E.coli 
(44%) for a similar MIC. In contrast, the median MIC for Pseudomonas spp. was much 
higher than E.coli with a similar outcome to E.coli. These outcome data indicate that 
the optimal regimens may be dictated by the type of bacteria, the MIC and age. 
Administering higher doses for more pathogenic and less susceptible organisms may 
improve clinical outcome. These data are not definitive but strengthen the need for 
PK-PD data that is specific to each age group and clinical context of severe illness. 
Ideally with AUIC data that compares the outcome with both the MIC and PK data for 
the same patient. 
Variability in PK parameters exists even between age sub-groups. The PK clinical trial 
(Chapter 2) found clearance increased three-fold within these age groups (range 0.11 
to 0.35 L/kg/h). These limited clinical outcome data (Chapter 4) suggests that the 
more premature babies tended to have an improved outcome. This was unexpected 
as mortality is higher with extreme prematurity and whilst recognising these data were 
not statistically significant it is worth consideration. It may be due to a higher AUC 
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possibly due to relatively low clearance associated with their immature renal function. 
Other factors such as disease progression confound this assessment highlighting the 
challenge and complexity of outcome assessments in critical illness. Although the 
higher AUC may be beneficial caution is required as this may result in toxicity. There 
is a wide range in half-life (range 2.8 to 33.8 hours). Gentamicin has extended dose 
intervals up to 36 hours in neonates and regimens are stratified according to sub age 
groups of <29 , 29-35 and >35 weeks PMA. Dosing intervals may need to be specific 
to the individual as targeting the mean or median AUC even for a sub-age group will 
inevitably undertreat those above the targeted range. 
Variability within an individual patient over the period of sepsis and inflammatory 
response requires further analysis as rapid changes in organ function and weight are 
extreme in neonates and infants. As dosages are based on weight in paediatrics the 
pre septic weight is often used for calculations. This method may be appropriate for 
ciprofloxacin as concentrations are considered to be affected less by the fluid shifts 
caused by inflammation and fluid resuscitation than hydrophilic drugs. The effect of 
critical illness on PK parameters has been described in detail but there is little 
published data on the later stage of sepsis as inflammation resolves. Frequent 
adjustment may be required over the sepsis period for example as inflammation 
resolves the drug may re-enter the central compartment resulting in higher 
concentrations. Further individual analysis is planned to estimate the change in 
concentrations for the paired early and last day samples. Some variability in 
concentrations may be due to imprecise measurement.  The risk to precision is 
greater in neonatal PK studies due to the minute drug volumes, minute samples and 
complex administration lines. Close agreement between scavenged and PK timed 
samples was achieved. This suggests data reliability is achievable with rigorous 
planning, training of the vast number of clinical staff, bedside tools and standard 
operating procedures specific to the site.    
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Resistance of Gram-negative bacteria are reported to be increasing rapidly 
throughout Europe and is of increasing concern due to the lack of new antimicrobials 
[6]. Over the six year retrospective study (Chapter 4) the incidence of confirmed 
Gram-negative bacteraemia was too low to determine whether annual changes in 
susceptibility occurred. Surveillance data of surface swabs over a thirteen year period 
found the incidence of ciprofloxacin resistance was no greater than for gentamicin 
although ciprofloxacin is prescribed less frequently. Sub-optimal treatment with 
ciprofloxacin increases the risk of resistance due to selection pressures as some 
antibacterial concentrations allow bacterial mutants to thrive [48]. Roberts et al review 
of antibiotic resistance concluded the highest tolerated dosing regimen must target 
the most resistant populations in an effort to prevent the emergence of resistant 
organisms due to selection pressures [48]. Increasing resistance of Gram-negative 
bacteria may be due to sub-optimal antibiotics regimens rather than related to usage 
over time. The mutant preventive concentration inhibits the least susceptible mutant 
within the wild type [48, 164, 166, 303]. The clinical relevance is unclear as further 
safety data is required for higher doses.  
These neonatal data in Chapter 4 found higher MIC were associated with treatment 
failure (RR 2.5). This is consistent with recent reports of higher MICs in the susceptible 
range resulting in a recommendation to revise clinical breakpoints [67, 163]. These 
data were not statistically significant but indicate that the regimen at the time would 
only have treated bacteria with MIC less than the clinical breakpoint derived from adult 
outcomes. Data from the clinical trial reported in Chapter 2 shows that some neonates 
restarted ciprofloxacin on as many as three occasions during their admission. 
Retreatment may have been due to a new episode of presumed sepsis however this 
is less likely as this reoccurred within short intervals. Children are approximately 20% 
of the population and many antimicrobials are prescribed off label resulting in the risk 
of sub-optimal dosing allowing mutant bacteria to. One hypothesis is that this may be 
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fuelling resistance. Further safety data is required to determine the maximum dose 
tolerated. 
In these critically ill babies adverse events not related to microbiology confounded 
causality assessment. The observational study in PICU and review of neonatal 
discharge letters (Chapter 5) has shown a vast number of adverse events are 
simultaneously associated with the clinical condition, clinical intervention and co-
medication. Adverse clinical events such as abnormal biochemistry values are the 
nature of critical illness. In this trial safety data was purposefully reported rather than 
analysed as definitive causality assessment would require a blinded RCT. In the 
absence of a blinded RCT there is a risk of attributing events associated with critical 
illness to the administration of the investigational medicinal product. There were no 
suspected unexpected serious adverse reactions (SUSAR) and no clear, novel safety 
signal or evidence of unanticipated clinical events, acute articular problems, excess 
phlebitis or clinically significant derangements in laboratory parameters attributed to 
ciprofloxacin.   
The main safety concern historically is the potential risk of arthralgia / tendonitis that 
may be underreported in this trial as there is no validated method for assessment in 
a non-weight bearing non-vocal population. These musculoskeletal events are 
potentially reversible [190]. Arguably the benefits of ciprofloxacin as an effective 
treatment for Gram-negative bacteraemia with high mortality out weights joint 
concerns that resolve with management.  Seizures have been associated with higher 
Cmax in children. In the trial reported in Chapter 2, ciprofloxacin was found to 
penetrate the CSF by 0.33 of the serum concentration which may enhance treatment 
of meningitis but may result in neurotoxicity. Seizures were reported in this population 
even prior to ciprofloxacin administration and no temporal causality was found post 
administration. A pre-clinical study of high dose regimen in mice pleads for careful 
watching of cardiorespiratory and motor development in neonates [266]. The 
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Liverpool Archive of MRI in Babies (LAMB study) is a registry including scans of the 
hip, liver and brain of healthy neonates and patients some of whom were administered 
ciprofloxacin that will provide short term safety outcome data. Further long term safety 
outcomes are required. Potential risks of adverse events must be balanced against 
the benefits of improving the clinical outcome and adverse reactions to alternative 
antimicrobials (such as gentamicin).  Short and long term safety data with a dose 
ranging study and blinded RCT is required to determine the maximum dose tolerated 
without significant effects.     
6.2 Limitations  
There are challenges to obtaining statistically significant PK-PD data especially when 
stratifying to sub-age groups. Vast numbers of babies would be required to power the 
necessary safety or efficacy studies due to the confounding effects of critical illness. 
The incidence of confirmed Gram-negative bacteraemia is rare and despite 
approximately 1200 admissions to the neonatal unit per annum these data are not 
statistically significant. Clinical outcome of Gram-negative bacteraemia for those in 
the trial cannot be determined as most participants were treated for suspected rather 
than confirmed bacteraemia and few had Gram-negative blood cultures.  
Ciprofloxacin is infrequently administered at either of the recruiting sites and no infants 
>48 weeks PMA received ciprofloxacin. Also, these data excluded neonates treated 
within five days of birth. Ciprofloxacin is mainly a second line agent therefore clinical 
outcomes may be influenced by first line therapy or co-administration of other 
antibiotics for example in these centres amoxicillin/ clavulanic acid or illness 
progression. Clinical breakpoints are informed by several studies and ideally 
thousands of MICs collected internationally. These outcome data illustrate the 
challenges of setting paediatric clinical breakpoints due to the limitations of the small 
number of neonates with confirmed bacteraemia treated with Ciprofloxacin. Even over 
a six year period in this tertiary neonatal unit despite retrieving most isolates this 
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resulted in as few as 88 MIC’s. Only 33 of the patients were treated with ciprofloxacin 
therefore these clinical outcome data were insufficient for a conclusive analysis but 
the trend is consistent.  This is insufficient to inform a paediatric clinical breakpoints 
as EUCAST often include PD data several thousand MIC’s and collected 
internationally. A further challenge is that paediatric breakpoints would vary 
depending on each developmental stage and need to be stratified according to each 
sub-age group with PK and PD data specific to each age. There would still be 
variability with these sub-populations due to critical illness. An individualised regimen 
informed by rapid methods of detecting organisms and MIC’s maybe a more 
pragmatic approach.  
Definitive safety and outcome data require an RCT design due to the complexity of 
critical illness. Nevertheless, descriptive data can provide some support to 
prescribers. The definition of cure was pragmatic as at present there is no consensus 
on standardised outcome measures specific to neonatal sepsis [27, 29]. The PopPK 
model combines sample data from both the first and last days of treatment. Therefore 
further analysis is planned to assess the potential impact on PK Parameters over the 
early and late stage of sepsis on PK. This data may inform individualised therapy.    
6.3 Further Recommendations  
This research further supports the need for individualised therapy supported by real 
time therapeutic drug monitoring. This is challenging due to limitations on blood 
sampling and because the organism and the MIC is not usually known at the start of 
treatment. Real time therapeutic drug monitoring would require rapid throughput of 
ciprofloxacin assays and tests that identify bacteria. New methods for rapid 
identification including MALDI-TOF-MS a mass spectrometer and PCR assays with 
real time therapeutic drug monitoring may facilitate this. There are practical limitations 
of PCR due to cost and availability for clinical laboratories, assays are limited at 
present and universal detection systems for clinical diagnostics would be optimal 
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[323]. Banerjee et al RCT found the time from Blood Culture Bottle Gram stain to 
microorganism identification was shorter rapid multiplex PCR (rmPCR)  (1.3 hours) 
vs conventional methods  (22.3 hours) (P < .001). Using a template for antimicrobial 
stewardship they demonstrated reduced treatment of contaminants and use of broad-
spectrum antimicrobials and antimicrobial de-escalation [324]. Whilst this increased 
the cost and complexity of patient care it may be balance against the potential for 
shorter inpatient stay and improved outcome. There is a risk that this method may 
detect low level concentrations of pathogen microbial DNA after successful treatment 
as the assay may detect viable and non-viable organisms [325] [326]. A false positive 
may be detected from exogenous DNA contamination or false negative if the sample 
is too small [327].  Equally, MALDI-TOF-MS is limited to specific species. In addition 
there are newer methods for rapid phenotypic susceptibility testing (sample to MIC). 
There is a need to determine resistant genes rapidly and Accelerate Diagnostics Inc 
www.acceleratediagnostics.com/products/asm2015symposium/ (Arizona, US) 
produce a system that identifies an MIC within 5 hours of a culture and includes the 
main Gram-negative organisms in found in these studies and ciprofloxacin [328].  
There are limitations to the PK data produced in this highly variable population 
influenced by both critical illness and rapid development changes as illustrated by the 
wide range of AUC even within sub-age groups. Drug levels vary between doses. 
There is a need for further neonatal PK studies to guide prescribing of antimicrobials 
in particular the initial dosing for that population however it is evident from these data 
that the wide range of AUC even within a sub-age group  requires real time 
characterisation, MIC and PK based on dose adjustment.      
A unique opportunity exists in this population as the frequent clinical samples for blood 
gas analysis, biochemistry and haematology provide an opportunity to scavenge 
samples for PK analysis including priori data. Data reliability is dependent on precision 
by the wider team when drugs are administered day and night. Clinical teams and 
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parents were engaged by conveying the importance of the research to future 
neonates and developing a research culture sensitive to such a stressful situation. 
Establishing accredited   PK-ready clinical wards and laboratories would enhance 
data reliability with standards for conducting PK trials, training clinical teams and 
recording administration data on drug charts. Neonatal PK studies are rarely 
repeated; these data can influence prescribing practice internationally therefore data 
reliability is ethically essential.  
The utility of interpreting PK data is limited in the absence of PD and safety data 
ideally AUIC comparing the dose and concentration in a patient with their outcome. 
Further population PK/PD studies will support the development of clinical breakpoints 
for children. Knowledge of the drug concentration achieved does not indicate efficacy 
without clinical outcome data specific to the PK for that patient. This clinical outcome 
study has illustrated that without PK data the outcome of the patient and the dose 
administered can equally indicate efficacy without the PK concentration. However, PK 
concentrations are useful to determine covariates allowing an estimate of the optimal 
initial dose and a baseline to monitor safety. Neonatal and paediatric clinical 
breakpoints informed by pharmacokinetic, safety, microbiological and clinical 
outcome data are required. Clinical breakpoints estimate the susceptibility of an 
organism by estimating the MIC that will be treated effectively by a specific dose 
whereas the ECOFF is a laboratory measure of susceptibility. The true value of an 
MIC is as a measuring tool that generates values to which other parameters such as 
PD endpoints and clinical outcomes can be reliably compared [153]. The paediatric 
outcome and drug regimen are vastly different to adults.  At present clinical 
breakpoints are solely derived from adult data as referenced in the rationale 
documents [161]. This study emphasises the need for PK/PD data for antimicrobials 
in children. A modified breakpoint model may be required for each sub-age group of 
children. This is challenging as seen in the PK clinical trial there are as many as seven 
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sub-age groups just for neonates and the EMA recommend a further four for children 
[79, 80]. Clinical Breakpoints even for adults are often informed by relatively few PK 
papers for example the ciprofloxacin rationale document by EUCAST [56] cites only 
seven PK papers all dated before the year 2000 yet influences prescribing practices 
globally. Undoubtedly, there are challenges to obtaining sufficient neonatal PK/PD 
data evident in this study that have resulted in many drugs being prescribed off label. 
However, newer methods such as population PK and the additional incentives 
provided by the Paediatric Regulation may be the foundation for developing a 
framework for future paediatric breakpoints. The need to optimise therapy is not only 
for efficacy but also to reduce resistance. Sub-optimal therapy may be increasing 
resistance correlated to the over use of antimicrobials as opposed to the over use 
itself being the cause. Increasing evidence of the burden of resistance International 
collaboration of neonatal units is required that may be facilitated by recent initiatives 
including the European Union Paediatric Regulations in 2006 and the EU Clinical 
Trials Regulation implemented in 2015 [321] and contribute to an evaluation of a 
paediatric breakpoint model.  
Practical solutions to obtaining reliable neonatal PKPD data were developed during 
the research. This included designing a model to reduce regulatory barriers by the 
Risk Proportionate Approach for PK clinical trials in collaboration with the MHRA. In 
addition to less invasive methods for sampling PK blood concentrations and DNA by 
scavenging from of clinical samples. As this was the first PK clinical trial in either 
recruiting site a PK clinical trial culture was established within the neonatal and 
paediatric intensive care units for future studies. This PD cohort study of clinical 
outcome provides a non-invasive framework for systematic PD surveillance. In the 
absence of PK clinical trial data this model may provide an interim framework to 
monitor the outcome of ore severe infection such as bacteraemia and meningitis 
comparing the MIC and clinical outcome.  
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6.4 Conclusion 
PK-PD for neonates and young infants is challenging. This is evident by the fact that 
so many antimicrobials are unauthorised and prescribed off label, as a result of which 
there is a lack of data available to contribute to clinical breakpoints. Gram-negative 
bacteraemia in this vulnerable population has severe consequences. Despite 
advances in intensive care adverse outcomes of sepsis are likely to increase due to 
the rapid development of resistance to antimicrobials. Optimising therapy aims to 
improve outcome at the same time as minimising resistance. These preliminary data 
contribute to optimising ciprofloxacin therapy for this population. The incidence is 
relatively rare and collaboration of national and international neonatal and paediatric 
units is required to obtain statistically significant data representative of the effects of 
ontogeny on each sub-age group. The popPK model reflects the rapid changes during 
development and impact of illness. A bespoke trial design mitigated the risks to the 
subjects and the data whilst adhering to ethical and regulatory standards. Methods 
developed in this research may contribute to a PK-PD framework for future research. 
Optimising PK-PD data for antimicrobials that target Gram-negative organism is 
essential with the rapidly increasing threat of resistant organisms.        
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Synopsis 
Synopsis: ‘Treat Infection in Neonates’ (TINN) Ciprofloxacin Pharmacokinetic (PK) Study 
Type of study Pilot Population PK study - Clinical Trial  
Study Design Phase I, open-label study to evaluate the pharmacokinetics, tolerability and 
short-term safety of ciprofloxacin in neonates with suspected (or proven) Gram 
Negative infection. 
Type of control Nil 
Location Liverpool Women’s NHS Foundation Trust (Neonates) 
Alder Hey Children's NHS Foundation Trust, Liverpool UK   
Test products Ciprofloxacin 
Dosage regimen 10 mg / kg / dose, 12 hourly (adjusted if indicated by interim analysis) 
Route of 
administration 
Intravenous, 30 - 60 minutes infusion 
Objective(s) of the 
study 
To evaluate the multiple-dose pharmacokinetics of ciprofloxacin in neonates and 
young infants (24 – 52 weeks postmenstrual age) with suspected or proven 
Gram Negative infection. 
To evaluate the tolerability and describe short-term safety of ciprofloxacin in 
neonates and young infants with suspected (or proven) Gram Negative infection. 
To describe the clinical outcomes of neonates treated with ciprofloxacin 
Sample size 50 patients between 24 -52 weeks postmenstrual age 
M/F not predetermined 
Sample Size   
(Pro rata to the ICH 
EMEA age-groups for 
paediatric studies)  
50 neonates stratified according to postmenstrual age (premature or not) to 
represent ages between 24 -52 weeks with 5- 8 patients in eachba 4 /5 week 
period. 
The target recruitment is 5-8 patients to represent each 4/5 week period in the 
range 24-27, 28-31, 32-35, 36-39, 40-43, 44-47 and 48-52 weeks postmenstrual 
age.  
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In order to attain this number of samples on day 5- 7, we will need to recruit more 
participants than this as some participants will die, others will move to other 
centres and some parents will decline repeated sampling. 
Study Interventions Sparse blood samples (n=2 or 3 depending on weight) will be drawn on day 1 and day 
5- 7 (or last day of treatment if the course is completed before day 7). 
Monitoring of adverse events  
DNA for pharmacogenetics (scavenged clinical samples or buccal) 
CSF (if required clinically)  
Faeces   
Duration of 
ciprofloxacin treatment 
At least 5 days 
Duration of follow up 3 days after completion of ciprofloxacin treatment (plus stool sample 4 -6weeks after 
completion of ciprofloxacin) 
Inclusion criteria Receiving ciprofloxacin following clinical decision by attending physician 
Exclusion criteria Likely not to survive 48 hours in the judgement of attending physician 
Endpoints  
Primary Ciprofloxacin plasma concentration and population pharmacokinetic (PK) parameters 
[maximum concentration, clearance, area under the curve (0-tau)], their relationship 
with selected covariates their interindividual variability (CV%). Covariate analysis will 
include postmenstrual age, gestational age, postnatal age, weight, and serum 
creatinine  
Secondary 1. PK variables, including apparent volume of distribution and half life.  
2. Withdrawal due to lack of tolerability 
3. Adverse events (AEs) and serious adverse events (SAEs). 
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4. Outcome of treatment episodes (clinical and microbiological) 
Power calculation This is not a hypothesis-testing study. The pharmacokinetic (PK) data generated from 
this study will assist in dose selection for use in neonates and infants. At this stage there 
is no data for this medicine in this age group. Accordingly, sample size calculations are 
not possible for this pilot study. Sample size and number in each age-range have been 
based on the experience of the PK scientists involved in the study.  
Options  
Recruitment issues If recruitment is poor, other sites will be approached. 
Interim analyses Blood levels will be monitored after every 10 patients recruited and interim 
pharmacokinetic analyses will be conducted, following which adjustments may be 
made to optimise the dose based on PK PD modelling.  
Stopping rules None anticipated 
Statistical methods  
Primary analysis Population pharmacokinetic analyses will be performed and the effect of covariates. 
This preliminary POP-PK model (PK parameters and their variability estimates in the 50 
neonates and infants) will be used for simulations to determine the optimal dosing 
regimen in this population. The optimal dose will be defined based on the 
pharmacokinetic-pharmacodynamic break points extrapolated from adult patients: 
AUC0-24/MIC (AUIC) >100 for gram-negative pathogens. The optimal dose will be 
evaluated in further clinical studies. 
Secondary analyses PK: to investigate the potential effects of other covariates.  
Tolerability: proportion of participants who withdraw due to intolerance of 
ciprofloxacin as judged by attending clinicians 
Safety: descriptive statistics of adverse events 
Outcome of treatment episodes: proportion of participants who have recover within 3 
days of stopping ciprofloxacin. 
 Pharmacogenetic analyses will focus on ciprofloxacin transporters (OAT3, BCRP).  
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Time and Events Schedule 
Action Following 
admission to 
the neonatal 
unit 
At time 
judged 
suitable by 
clinical staff 
Clinicall 
suspicion 
of sepsis 
Clinical 
decision to 
start cipro-
floxacin 
First dose 
of cipro-
floxacin 
Sampling Final 
dose of 
cipro- 
floxacin 
3 days after 
completion 
of cipro- 
floxacin 
4 – 6 weeks 
after 
completion 
of antibiotics 
Day 1 Day 
5-7 
  
Parents or legally appointed 
representative told about study 
X          
Formal discussion with parents or legally 
appointed representative  
 X  X*       
Consent  X  X*       
Blood culture as per clinical practice   X        
Gram Negative (suspected or proven)    X       
Enrolment (when eligible)    X       
Ciprofloxacin administered     X      
Baseline safety blood sample#     X      
Repeat safety blood sample#        X X  
PK blood sample and pharmacogenetics      X X    
CSF sample if required clinically and if 
consented 
   X       
Safety data collection    X X   X   
Safety evaluation        X X  
Faeces sample    X        X 
DNA sample – if consented   X         
DNA sample from blood required for 
clinical care if consent obtained   
   X       
Test-of-cure         X  
* Formal discussion about the study and consent will be undertaken before clinical suspicion of sepsis when possible but in some cases consent will be requested at the time the baby is assessed 
to be septic.   
# Safety blood samples will be clinically indicated sampling episodes that may be slightly before or after the start or finish of ciprofloxaci
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Abbreviations  
AUC    Area Under the Curve 
AUC24h    Area Under the Curve over 24h 
CRP    C Reactive Protein 
CSF    Cerebrospinal fluid 
MHRA    Medicines and Health Care Products Regulatory Agency 
MIC    Minimum Inhibitory Concentration 
PK     Pharmacokinetic  
VLBW    Very Low Birth Weight 
 
Notes: The term 'parent ' includes those with parental responsibility throughout this document.   
The term ‘Sponsor’ refers to which ever co-sponsor has responsibility for the issue under 
discussion, as defined in the written agreement between the co-sponsors. 
Introduction  
We propose to conduct a pharmacokinetic study in preterm and term neonates and infants up 
to 3 months post menstrual age with  suspected (or proven) systemic gram negative infection, 
collecting pharmacokinetic data using sparse sampling techniques. Appropriate 
pharmacokinetic parameters will be assessed (e.g., AUC, but also apparent clearance, T1/2, 
apparent volume of distribution, Cmax and others as appropriate). Pharmacokinetic 
characteristics following repeated dose will be evaluated and compared to those of the first 
dose. 
The EU Paediatric Regulation [1] introduced in 2006 aims to ensure that a medicinal product 
for use in children undergoes extensive studies to ensure that it is safe of high quality and for 
use in the target population. Many products used in the paediatric population have not been 
authorised for such use. In particular, there is often inadequate dosage information which leads 
to increased risks of adverse reactions including death and ineffective treatment through under 
dosing.  
The EU Paediatric Regulation recognised the failure of market forces to provide appropriate 
medicines for children, particularly neonates. In order to address this failure the Regulation 
introduced a Paediatric Use Marketing Authorisation (PUMA). To encourage PUMA applications 
the Commission also established funding for collaborative research projects under Framework 
Programme 7. Projects were expected to address the needs contained with the European 
Medicines Agency (EMA) priority list of off-patent medicines current at the time [2]. One project 
to receive this funding is the Treat Infections in NeoNates (TINN) collaboration led by Prof. E. 
Jacqz-Aigrain in Paris. TINN will assess two antimicrobials, ciprofloxacin and fluconazole. This 
protocol relates to one aspect of the research programme in ciprofloxacin.  
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The WHO Expert Subcommittee considering Essential Medicines for Children concluded that 
“sufficient evidence is available to support the use of ciprofloxacin as a second-line treatment 
for specific, severe infections in paediatric patients. It has been included as the only 
fluoroquinolone on the list of Essential Medicines for Children prepared by WHO [3].  Indications 
include concern about antibiotic resistance in particular settings, or when other classes of 
antimicrobials (e.g. aminogylcosides) are contraindicated due to toxicity.  
Ciprofloxacin is not a common choice of antibiotic in neonates. Nevertheless, it is a useful option 
in some circumstances. We have conducted a systematic review which found reports of 
ciprofloxacin use in several settings in Europe and Asia (Kaguelidou, personal communication). 
The TINN consortium has conducted a web-based survey of practice in Europe. 193 units 
responded including units from 20 countries between Uzbekistan and Portugal. 50 of 193 units 
(26%) use ciprofloxacin at least occasionally (Pandolfini, personal communication).  
Among these units, the indications for using ciprofloxacin were: 
Indication Number of 
units 
Percentage of units using 
this  indication for 
ciprofloxacin 
First line therapy neonatal sepsis 1 2% 
Severe neonatal sepsis 3 6% 
Neonatal sepsis only when CNS 
documented infection (meningitis, 
meningoencephalitis, ventriculitis, cerebral 
abscesses…) 
13 26% 
Neonatal sepsis resulting from a suspected 
multi-drug resistant strain infection 
15 30% 
Neonatal sepsis resistant to first line 
empirical antibiotic therapy (other than 
ciprofloxacin) 
7 14% 
Severe neonatal sepsis resistant to first 
line empirical antibiotic therapy (other than 
ciprofloxacin) 
17 34% 
Culture-proven sepsis due to multi-drug 
resistant organisms but sensitive to 
ciprofloxacin 
41 82% 
NB Units could give more than one indication 
 
Although this survey relied on self-report it does show that some units use ciprofloxacin in 
neonates.   
Pharmacokinetic data of ciprofloxacin in neonates are extremely limited (see below). In the 
TINN survey there was significant variation in dosage regimen.  
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Total dose /kg / day Number of units Percentage of units 
≤ 10 11 (22%) 
   
11-20 20 (40%) 
21-30 9 (18%) 
>30 1 (2%) 
(missing = 9) 
 
This justifies more detailed study of this medication in this population. The literature suggests 
that the efficacy of ciprofloxacin in neonates is at least comparable to other antibiotics used in 
cases of suspected (or proven) Gram Negative neonatal sepsis. The advantages of more 
information about ciprofloxacin include more robust dosage information for those units that 
already use it. This includes many units in resource-constrained settings. Units that do not use 
it due to uncertainty about dosage may find it more useful if dosage information is available. In 
units with resistance to other antibiotics it may be possible to use ciprofloxacin. Disadvantages 
to more widespread use of ciprofloxacin might be increased selective pressure for resistance, 
but this is not unique to ciprofloxacin. There is a risk that ciprofloxacin could cause adverse 
reactions. The potential reaction that might concern clinicians the most is arthropathy or 
tendinopathy. As noted in section 5.3 there is no specific evidence that these problems are 
caused by ciprofloxacin in neonates. The TINN registry will collect data about safety in babies 
exposed to ciprofloxacin, this will then be held in Paris. This data will allow clinicians to weigh 
the potential risks against the potential benefits.  
It is necessary to extend the evidence base used to support prescribing of this medication in 
neonates.  Pharmacokinetic data from adult, adolescent, and older children cannot readily be 
extrapolated to the infant patient population. Varying levels of protein binding, metabolic 
pathway maturity and renal function in infants can have profound implications on drug 
disposition (ICH Topic E11) [4-5]. Extant literature provides PK data for infants aged 3 months 
and older (Lipman et al. [6]). This study will examine ciprofloxacin PK in infants aged less than 
3 months and in neonates of all gestational ages. 
The TINN collaboration has submitted a Paediatric Investigation Plan to EMA. We have 
received comments from the Paediatric Committee (PDCO) at the day 60 stage of the PIP 
process.  The PDCO have agreed in principle that further data is not needed for children aged 
3 months and older so that further work will examine infants aged less than 3 months and 
neonates. The ciprofloxacin PIP will include some preclinical studies and the development of a 
formulation appropriate for neonates. The clinical development programme will describe PK and 
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safety.  Efficacy will not be studied because the efficacy of ciprofloxacin can be assumed in this 
age group based on its effects in older age-groups [7]. 
This study will gather the data required for an initial PK analysis in this age-group. Data from 
this study will be combined with pre-existing data about physiology in this age range to model 
concentrations of ciprofloxacin in neonates, that is, a physiologically based PK (PBPK) model 
will be developed. In turn this will be combined with information about the concentrations of 
ciprofloxacin required to treat Gram Negative infections. This will lead to an optimised dosage 
recommendation in this age group. The PK study will be undertaken in the UK. PDCO 
recommended that recruitment is limited to one neonatal unit and one paediatric unit, but this 
may be reviewed to achieve targeted recruitment. The optimized dosage recommendation will 
be evaluated in further clinical, specifically PK sampling among patients recruited to a European 
Neonatal and young infant ciprofloxacin TINN registry. Therefore the PK study will establish a 
framework for ongoing data collection in the Registry.  
 
The separate TINN Ciprofloxacin European Registry study will assess safety and the 
outcome of treatment episodes involving ciprofloxacin. This PK study will also provide some 
short term safety information. Participants in this PK study will also be eligible for the registry: 
the registry will involve separate consent. The registry will also include further opportunistic 
samples to extend the PK models and will include a pharmacogenetic module. Participants in 
the PK study will be eligible for the pharmacogenetic study.  
Ciprofloxacin has been used as second line treatment for neonatal sepsis on the Neonatal Unit 
at Liverpool Women’s Hospital for twenty years. It is used at Alder Hey Children’s Hospital for 
hospital acquired infections. This setting provides an opportunity to study this agent on a 
population who are receiving it according to physician preference. 
 
 
5.1 Neonatal sepsis 
Definition -Neonatal sepsis is defined as “a clinical syndrome characterized by 
systemic signs of infection and accompanied by bacteremia in the first month of 
life” [8].  
Neonatal sepsis is generally classified as “early onset” and “late onset”. Early onset sepsis is 
likely to reflect infection with organisms acquired before, or during birth. Late onset sepsis 
occurs more than 72 hours after birth and is likely to reflect nosocomial infection. The incidence 
of neonatal sepsis is inversely proportional to gestational age and birth weight. Very low birth-
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weight infants (VLBW < 1500g) represent 5% of all births. Among VLBW infants culture-proven 
early onset sepsis is seen in 2% of infants and late-onset sepsis in 25% of infants [9-10]. All 
cause mortality is approximately 25% in early-onset sepsis and 18% in late-onset sepsis in 
VLBW infants [9, 11].  
Prevalence- Gram-negative neonatal sepsis is a significant problem in neonates, especially 
VLBW infants [12-13]. In developed countries, although there is a wide variation between units 
regarding the type of germs responsible of late infections in VLBW infants, Gram-negative 
bacteria account for approximately half of the early onset and one third of the late onset neonatal 
infections [10-11] whereas in developing countries Gram-negative organisms remain the major 
cause of neonatal sepsis [11] [14]. Currently, the most common Gram-negative organisms 
isolated in cases of neonatal sepsis are E.coli, Klebsiella and Pseudomonas species [11-13]. 
The overall mortality due to Gram-negative sepsis varies from 19 to 52% depending on the 
infecting organism (Pseudomonas aeruginosa infections are generally more lethal) and host 
factors (gestational age and birth weight)[11, 13, 15]. 
Morbidity & Mortality - The overall mortality due to Gram-negative sepsis varies from 19 to 
52% depending on the infecting organism (Pseudomonas aeruginosa infections are generally 
more lethal) and host factors (gestational age and birth weight) [13]. Mortality due to Gram-
negative infections is significantly higher than that of Gram-positive infections at all ages of 
sepsis onset [13, 16-17]. Fulminant late-onset sepsis (i.e. sepsis that is lethal within 48 hours) 
is more likely to be caused by Gram-negative organisms [17]. Hospital acquired infections from 
Gram-negative bacilli may be increasing [17-18].  
Important aspects of brain development are ongoing during the neonatal period, particularly 
among premature and VLBW infants. There is a significant risk of long-term 
neurodevelopmental sequelae among survivors of Gram-negative infections, particularly when 
the disease is complicated by meningitis [15]. Brain development can be disrupted by ill-health 
during the neonatal period. Developmental delay and disability is increased among children who 
were unwell during the neonatal period. It has been suggested that recurrent postnatal 
infections can influence early biomarkers of brain development [14]. 
The antibiotic regimen used to treat neonatal sepsis varies considerably between neonatal units 
and between countries. This variation is due to the pattern of resistance to antibiotics observed 
in different units. In some settings multiply resistant bacteria are found. In these settings it can 
be difficult to select an adequate antibiotic. When faced with difficult choices about antibiotic 
usage, some units have elected to use ciprofloxacin. The literature provides a strong prime facie 
case that ciprofloxacin has efficacy in neonates with suspected (or proven) Gram negative 
infection.   
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Neonatal/Infant Systematic Review - Ciprofloxacin -The published experience of 
ciprofloxacin in other neonatal centers has been summarized by Kaguelidou et al. following a 
systematic review (submitted for publication). They found 5 cohort studies. Measures of 
treatment outcome were available in only 2 cohort studies. The first [19] , reported a clinical 
response rate of 64% among 86 ciprofloxacin-treated neonates compared to 27% among 344 
controls. The second study [20] reported a global survival rate of 91% for the ciprofloxacin group 
(n=116) and 89% for the control group (n=100).   
In case reports, clinical response to ciprofloxacin was observed in 77% (108/141). Evaluation 
of the rate of bacteriological eradication was feasible in only two of these studies. The first one 
reported an eradication rate of 100% in 6 cases of neonatal Enterobacter cloacae septicemia 
(clinical response=50%) [21] and the second one a rate of 93% (27/29) in a multi-resistant 
nosocomial Pseudomonas infection  (clinical response=83%)[22].  
Epidemiology Data Liverpool Neonatal Unit - Ciprofloxacin has been used in neonates since 
the early 1980s motivated by the need to treat suspected (or proven) infection with multi-
resistant bacteria in neonates who are very susceptible to infection or to avoid aminoglycosides 
in patients with compromised renal function while minimizing unit-wide exposure to 
cephalosporins. The use of ciprofloxacin in Liverpool neonatal units was initially reported by 
Bannon et al in 1989. [21]  Since then over 500 neonates have been exposed to ciprofloxacin. 
In that time informal clinical surveillance has not yielded any serious adverse events that have 
been ascribed to ciprofloxacin. 
Data from this unit confirms that the minimum inhibitory concentrations for ciprofloxacin lie within 
the EUCAST breakpoints for sensitivity (≤ 0.5 mg/L) for 91.4% of different isolates of gram 
negative organisms archived in the microbiology lab between 2004 and 2010 (n=93).    
Neonatal Sepsis Protocol - Liverpool Women’s NHS FT (LWFT) Neonatal Unit 
Suspected Infection requires prompt treatment before laboratory confirmation. When clinical 
features of sepsis in neonates are found a sepsis screen is performed. This includes blood 
cultures and a lumbar puncture (LP is not routinely done for preterm babies with suspicion of 
early onset sepsis). Routine blood monitoring includes CRP, differential white cell count and 
platelets. These aspects of patient management are at the discretion of the clinician and are 
not included in this protocol. 
Antibiotic Guidelines at LWFT Neonatal Unit  
 
Timing 1st line treatment 2nd line treatment  
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Early onset 
infection 
1st 5 days of 
life 
Benzylpenicillin 
25mg/kg 12hourly  
Gentamicin 4.5 
mg/kg  
36 hourly 
Ciprofloxacin 10mg/kg 12 hourly 
Is added or replaces gentamicin if there is 
renal impairment or a clinical decision 
based on lack of clinical 
response/sensitivities of organism isolated. 
 
Late onset 
infection 
After 1st 5 
days  of life 
 
 
Co-amoxyclav 
30mg/kg  
8 hourly 
 
Gentamicin 4.5 
mg/kg 
36 hourly 
 
Ciprofloxacin 10mg/kg 12 hourly 
replaces gentamicin if there is renal 
impairment or a clinical decision based on 
lack of clinical response/sensitivities of 
organism isolated. 
Meningitis – add cefotaxime 50mg/kg 8 
hourly 
Coagulase Negative Staphylococci (CoNS) 
– add Teicoplanin 16mg/kg load then 
8mg/kg 24 hourly 
   
    
NB these antibiotics are not specified in this study protocol. All medicines given to the 
participants in this study are entirely at the discretion of the attending physician. In all cases 
ciprofloxacin is co-prescribed with an antimicrobial targeted at Gram positive bacteria likely to 
be encountered in neonatal infection. 
In practice this means that between 40 and 50 babies a year are treated with ciprofloxacin in 
LWFT neonatal unit. 
Ciprofloxacin is prescribed at Alder Hey Children’s NHS FT for hospital acquired infection 
including pneumonia or central line infections and specific guidelines for cystic fibrosis.   
5.2 CIPROFLOXACIN PHARMACOKINETICS AND PHARMACODYNAMICS 
Pharmacokinetics in Adults  
The pharmacokinetics of ciprofloxacin in adults is summarized by Andriole [23] as follows: 
Absorption 
In adults, oral bioavailability is 60 – 70%. Absorption is impaired by simultaneous administration 
of cations which bind to the molecule. Oral absorption is not  relevant to neonatal sepsis in 
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Europe, as parenteral administration is required. We are not aware of any studies of absorption 
of ciprofloxacin in neonates. 
Distribution  
In adults the plasma half-life is 3 – 4h, the volume of distribution is 3 – 4 L/kg and plasma protein 
binding is 20 – 40%. Ciprofloxacin is widely distributed in body water and intracellularly. For 
example, concentrations within phagocytic cells approach that in plasma. In adults, 
concentrations in CSF are about half those in plasma, irrespective of the presence or absence 
of meningitis. 
Gous et al. found that ciprofloxacin PK parameters did not differ between adults on intensive 
care with intra-abdominal sepsis and those with other forms of sepsis. They interpreted this as 
indicating that fluid shifts did not alter the distribution of ciprofloxacin [24].  
Metabolism  
There are four metabolic products of ciprofloxacin. Three of these are microbiologically active 
(sulfociproprofloxacin, oxociprofloxacin and formylciprofloxacin), while one of them 
(desethylciprofloxacin) is not active. Formylciprofloxacin, while formed in very low amounts, 
shows an antibacterial effect equivalent to ciprofloxacin. 
Very low concentrations of ciprofloxacin metabolites have been found in human serum and 
urine. Of an oral dose, 11.3% and 7.5% were excreted as metabolites via the urine and faeces 
respectively and after an intravenous dose, respectively 9.5% and 2.6%. Metabolism is 
quantitatively and qualitatively similar after oral and intravenous administrations. There is no 
information in the literature about the hepatic cytochromes that are implicated in the metabolism 
of drug. 
Excretion 
The liver and kidney are responsible for more than 90% of drug elimination. More than 65 % of 
ciprofloxacin is excreted unaltered by the kidney. Glomerular filtration and tubular secretion are 
the main mechanisms of renal excretion. The renal clearance varies between 3 and 5 ml/h/kg 
and the total clearance between 8 and 10 ml/h/kg 
Renal excretion: Renal clearance mechanisms account for approximately two-third of 
ciprofloxacin elimination.  60% of the unmetabolized ciprofloxacin is eliminated through the 
kidneys. Renal clearance of ciprofloxacin is 2.7-times higher than the creatinine-clearance, 
indicating that the drug is excreted by both glomerular filtration and tubular secretion.  Non renal 
clearance: one-third of ciprofloxacin elimination and comprise a combination of hepatic 
metabolic degradation, biliary excretion, and transluminal secretion across the enteric mucosa. 
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Ciprofloxacin is actively secreted by kidneys and bile. Studies in rodents have shown that the 
renal basolateral transporter OAT3 is involved in ciprofloxacin secretion, and that impaired 
elimination occurs in oat3 null mice [25]. The apical transporter breast cancer related Protein 
(BCRP) encoded by ABCG2 contributes to the biliary secretion of ciprofloxacin [26]. 
Interactions 
The interactions of ciprofloxacin in adults have been summarized by Shakeri-Nejad [27]: 
Binding to divalent and trivalent cations. This leads to marked reductions in bioavailability 
of ciprofloxacin if it is co-administered with substances that contain magnesium or iron (but not 
calcium). This effect is thought to be similar to the binding between magnesium ions and 
ciprofloxacin that is central to the actions of ciprofloxacin in bacteria. This mechanism of this 
interaction effect can be extrapolated across age-groups. However, the significance of this 
interaction in neonates is likely to be low because few neonates are prescribed oral 
ciprofloxacin. The potential for this interaction will be included in the clinical studies. 
Compatibility with parenteral nutrition solutions will be assessed during in vitro testing.  
Inhibition of CYP1A2, but not other CYP 450 isoenzymes. Ciprofloxacin is classed as a 
moderate inhibitor of CYP1A2 by the FDA [http://www.fda.gov/cder/drug/drugInteractions/ 
tableSubstrates.htm last accessed 19th May 2009]. CYP1A2 metabolizes a limited number of 
drugs. Of the drugs metabolized by CYP1A2, only caffeine and theophylline are used in 
neonates. Concomitant therapy with ciprofloxacin and each of these agents is associated with 
significant increases in the circulating concentrations of both of these agents. Both of these 
agents have been used in neonates in the past. Recently, theophylline has been superseded 
by caffeine because caffeine has a much broader safety margin and because of evidence that 
long-term administration of caffeine can reduce the incidence of bronchopulmonary dysplasia. 
The expression and function of CYP450 enzymes during development is an area of active 
research. Caffeine plasma concentration will be assayed during the study when plasma can be 
scavenged from existing samples for babies receiving caffeine. c) Reduction in levels of 
phenytoin. This has been reported in one person. If the opportunity arises to examine the effects 
of ciprofloxacin on phenytoin levels in neonates we will do this. 
Considering the role of transporters in the renal excretion of ciprofloxacin, drugs known to 
interact with SLC or ABC transporters should be studied as potential covariates in the population 
pharmacokinetic model that will be one of the secondary objectives of this study. With this aim, 
the drugs received by the babies (and breast feeding mother) will be exhaustively recorded in 
the patient’s chart. At the time of data analysis, each drug will be classified as “substrate”, 
“inhibitor” or “inducer” of the main human drug transporters (according to FDA classification 
below) and studied as binary covariates (association with an inhibitor : yes/no, with an inducer 
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y/n,…) http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources 
/DrugInteractionsLabeling/ucm093664.htm#classSub) 
Pharmacodynamics  
Reviewed in Andriole and Ven Bambeke [28-29]. Ciprofloxacin is a fluoroquinolone with 
molecular weight 331.4. Fluoroquinolones are bactericidal. They bind to topoisomerases and 
DNA and disrupt DNA. It is thought that this binding exposes free ends of DNA which trigger 
apoptosis. The target enzyme varies from species to species with DNA gyrase being the 
predominant target in Gram negative bacteria and topoisomerase IV being the predominant 
target in Gram positive bacteria.  
Fluoroquinolones display concentration dependent killing and a significant persistent effect / 
postantibiotic effect [30]. In adults the AUC24h/MIC appears to be the best predictor of outcome. 
When targeted to Gram Negative bacteria animal work suggests that the optimal AUC24h/MIC 
is 125 [31]. When targeted to Gram positive bacteria the optimal AUC24h/MIC has been reported 
to be 40. A high Cmax and AUC24h/MIC > 100 may provide some protection against resistance. 
Pharmacokinetics in Children  
Minimal data are available in the literature regarding neonates and only a few studies have been 
conducted that include infants and children (Appendix 1). Drug pharmacokinetics in neonates 
differs from other age groups[5]. Preterm babies who are particularly vulnerable to neonatal 
infections, can present notable differences because of higher extracellular fluid volume, 
immature renal and hepatic functions at birth and post-natal maturation of these organs.   
(Appendix 1 PK data in infants and children). 
Lipman et al. [6] examined ciprofloxacin PK in 20 children (3 months -5 years) on PICU given 
an intravenous dose of 10mg/kg 12 hourly as a one hour infusion. In 10 infants aged between 
3 months and 1 year the peak concentrations (Cmax) on D0 were 6.1±1.2 mg/L, D2 9.0±1.8 mg/L 
and D7 5.8±1.3 mg/L. The AUC12h was estimated to be around 15-20 mg/L.h. This suggests that 
the AUC24h/MIC would only be above 100 for bacteria with an MIC < 0.3mg/L. As MIC for gram 
negative pathogen may be higher (up to 0.8 mg/L for some strains of Ps. Aeruginosa [5, 31-32], 
this dose may be too low. However, the authors did not studied infants < 3 months in whom 
elimination may be impaired, leading to higher exposure. Results were similar in children aged 
1 year to 5 years. 
Bannon et al. treated 6 preterm neonates (24-29 weeks) with E. cloacae septicemia using 
intravenous ciprofloxacin at a dose of 10 mg/kg/day (divided into 2 administration, i.e. 5 mg/kg 
12 hourly) and measured peak (30 min after injection) and trough concentration following the 
third administration [21]. The mean peak concentration was 3.1 μg/mL (range 1.45 to 5.7 μg/mL) 
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after the third dose and mean trough level was 1.25 μg/mL (range 0.04 to 2.6 μg/mL). Aggarwal 
et al. [32] used intravenous ciprofloxacin at a dose of 10mg/kg/dose twice daily (20 mg/kg/day) 
in 24 Indian preterm neonates (28-36 weeks) having severe infections of variable aetiologies. 
[32]. In this study, peak and trough ciprofloxacin levels at 1, 3 and 7 days of treatment were 
comparable and no differences were observed between the <1500g and >1500g of weight and 
the <7 days and >7 days of postnatal age sub-groups, with respect to corresponding peak and 
trough levels on sampling days. Of note, estimated clinical cure rate was 67% and no adverse 
events were observed during the use of ciprofloxacin. At day 3 (as comparison with Bannon’s 
study [21]), peaks ranged 0.1 – 7.3 mg/L and trough ranged 0.0 –  2.1 mg/L. Steady state levels 
were reached from the 1st day, and there was no evidence of accumulation over a week’s 
duration. 
Goepp et al. [33] studied a single infant with ventriculitis, who received 35 mg/kg/day of 
ciprofloxacin. The peak serum level was 11.6 μg/mL after the 6th dose, but the trough level (0.9 
μg/mL) was similar to that in Aggarwal’s study [32].  
Wessalowski, et al.[34] reported serum levels of 0.1 to 2.8 μg/mL in random serum samples 
drawn from one term neonate, who had a brain abscess (dose not reported). 
Van den Oever et al. [35] reviewed the pharmacokinetics of ciprofloxacin in 7 preterm infants, 
less than 30 weeks gestation, reported from various studies. Intravenous doses ranging from 4 
to 40 mg/kg/day yielded adequate serum peak concentrations (0.98 to 5.7 μg/mL), but trough-
to-peak ratio were high (median 32%), suggesting slow elimination in preterm babies. 
These studies concluded that ciprofloxacin was an effective treatment of neonatal sepsis. They 
indicate that higher doses might be required for treating infections with less sensitive strains like 
Pseudomonas aeruginosa (MIC 0.8 mg/L). However, none of these studies provide data on 
individual AUC that could be extrapolated in terms of AUC/MIC. Peak concentrations were 
similar to those found in adults. However, elimination is dependent on renal function and 
elimination is expected to be slower in neonates than older children and adults. In adults, intra-
abdominal sepsis was not associated with altered PK parameters implying that fluid shifts did 
not alter the handling of ciprofloxacin [24], but this issue has not been examined in neonates.  
Some PK studies have been conducted in cystic fibrosis (CF) patients but will not be reported 
here since important PK differences exist as compared to non CF children. 
Pharmacokinetic Models -In pharmacokinetic studies, a sufficient number of samples, taken 
at adequate times are of great importance to provide a reliable estimation of PK parameters. 
Samples obtained in routine clinical practice may be inadequate (e.g. sampling during the 
infusion of the drug), or, more often, not well-balanced across the dosing interval. The non-
optimal sparse sampling schedule can bias the estimates of clearance and volume of 
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distribution. For example, sampling too late after end of infusion can underestimate clearance 
if the first compartment of distribution is missed. A modelling study conducted with theophylline 
concluded that observational study designs with only 20 premature neonates and unbalanced 
sampling was inadequate to allow for precise estimation of theophylline population PK 
parameters. (ref  Y. Zhang et al. : Simulation-Based Sample Size Optimization for Population 
Pharmacokinetic Studies in Premature Neonates 
www.aapsj.org/abstracts/AM_2009/AAPS2009-001792.PDF). 
The ideal option would have been to select an “optimized” sampling schedule, based on D-
optimal strategy. However, this is not applicable because we do not have the preliminary PK 
information in neonate and young infants (typical PK parameters, variability, covariate etc) to 
optimize such a sparse sampling schedule.  
Another option is to select a priori a sampling schedule which will ensure reliable estimation of 
PK parameters and limit the number of samples to a maximum of 3 on the first and last day of 
treatment (section 6.13). 
Pharmacogenetics 
Pharmacogenetic variability together with variable factors` contribute to the variability in 
individual risk/benefit ratios. In neonates, the pharmacogenetic underpinnings together with the 
developing activity of drug metabolizing enzymes and transporters contribute to the individual 
and age dependent capacity to metabolize and eliminate drugs. Ciprofloxacin is eliminated 
more than 65% unchanged by the kidney. Metabolism takes place to 3 active and one inactive 
metabolite but the liver enzymes involved have not yet been identified. Since ciprofloxacin is 
not extensively metabolized, genetic polymorphism in metabolizing enzymes of ciprofloxacin to 
single metabolites are not likely to influence the overall efficacy or toxicity of ciprofloxacin.  
Elimination and target distribution of ciprofloxacion might be influenced by individual activity of 
active drug transporters. Ciprofloxacin is transported by organic anion transporter 3 (OAT3) and 
by the BCRP transporter, both transporters being genetically polymorphic. Thus, individual 
differences in efficacy and in elimination might partly depend on genetic polymorphisms of 
active drug transporters [25-26, 36].  
In addition to pharmacokinetics, pharmacogenetic polymorphisms might affect safety and 
efficacy of drugs. Ciprofloxacin is active in the central nervous system, and sometimes causing 
psychotic symptoms as side effects, known to be partly mediated by inhibition of the GABA A 
receptor [37]. Genetic variants in the GABA A receptor therefore might modulate the 
susceptibility to central nervous side effects of ciprofloxacin.  
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Some pharmacologically relevant gene polymorphisms divide the population into large group 
such as halves or thirds. Pharmacogenetic data will be used to explore whether any such 
prominent differences in genotype are associated with differences in variation in ciprofloxacin 
PK. More definitive evaluation of genotype-phenotype correlations will come from the registry 
study which will have a genetic component. 
In addition to specific drug targets, genetic variability is known to contribute to the individual 
susceptibility to septicaemia. Polymorphisms in genes like Toll-like receptor 4, Il-6, Il-10, CD14, 
as well as hemostasis genes might contribute to the severity and course of sepsis and therefore 
influence the individual benefit of the treatment with ciprofloxacin.  
Justification for the study 
In order to support prescribing decisions relating to ciprofloxacin in neonates, it is necessary to 
gather more information about:  
PK variables 
Dosage regimen 
Short Term Safety 
Licensing  support 
PK Variables: There have been no reports of PK in infants less than 3 months old that include 
an assessment of the key PK/PD parameter, the AUC24h/MIC. CSF penetration of ciprofloxacin 
has not been reported in neonates or young infants. 
Dose Regimen - the daily dose reported in the studies involving neonates included in the 
systematic review by Kaguelidou et al. varied from 5mg/kg to 60mg/kg. The results from Lipman 
et al. [6] suggest that a dose greater than 10mg/kg/12h would be required for optimal 
pharmacokinetics in infants 3 months-1 year of age. However, this dose may be sufficient in 
neonates who have impaired renal function. However, given the PD characteristics of 
ciprofloxacin a detailed description of exposure including AUC24h is required to optimize the 
dosage regimen in neonates and young infants. None of the published studies in neonates < 3 
months have provided such data  
 
Short Term Safety: A number of adverse events have been associated with ciprofloxacin. 
These are summarized in the Summary of Product Characteristics for marketed products. A 
generic ciprofloxacin SPC is included as Appendix II. This study will document adverse Events 
occurring during treatment and during a 3 day washout period will be recorded in this study. 
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Safety issues, including those occurring g after the 3 day washout period, will also be studied 
in the TINN Registry Study. Participants in this study will be eligible for the registry study. 
The most prominent concern in children has been the possibility of arthropathy. The WHO 
Subcommittee on Essential Medicines for Children recommended that more data about safety 
in neonates is needed but noted “a summary of findings in children (31 reports, > 7000 children) 
where arthropathy was found to be reversible, without long-term sequelae, and not convincingly 
correlated with the use of fluoroquinolones in children.” [3].  
Licensing Support To provide data required by the European Medicines Agency for a 
Paediatric Use Marketing Authorisation consistent with the EU Paediatric Regulation 2006 [1] 
to ensure that a medicinal product for use in children undergoes extensive studies to ensure 
that it is safe of high quality and for use in the target population.  
 
Study  Design 
Objectives 
Primary Objective   
To evaluate the multiple-dose pharmacokinetics of ciprofloxacin in neonates and infants 24 up 
to 52 weeks postmenstrual age with suspected (or proven) Gram negative infection  
Secondary Objectives:  
To evaluate the tolerability1 of ciprofloxacin in neonates with suspected (or proven) Gram 
Negative infection. 
To describe short-term safety 
To describe the outcome of treatment episodes 
                                               
 
 
 
1 We use the standard definition of tolerability: “The tolerability of the medical product represents 
the degree to which overt adverse effects can be tolerated by the subject”. This is taken from the 
Glossary of ICH E9 “Statistical Principles for Clinical Trials”  
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC50000
2928.pdf (last accessed 28th August 2010). 
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 Endpoints 
Primary Endpoints: 
 Ciprofloxacin plasma concentration and population pharmacokinetic (PK) parameters 
[maximum concentration, clearance, area under the curve (0-tau)], their relationship with 
selected covariates their interindividual variability (CV%).  
Covariate analysis will include postmenstrual age, gestational age, postnatal age, weight, and 
serum creatinine on the day of the first PK sample of each period (D1 and D5-7). 
 
Secondary Endpoints: 
PK variables, including apparent volume of distribution and half life.  
Withdrawal due to lack of tolerability as judged by attending clinicians. 
Adverse events (AEs) and serious adverse events (SAEs). 
Reasons for stopping ciprofloxacin and changing or changing to other antibiotics with nature of 
other medicines. 
Outcome of treatment episodes (clinical and microbiological) –Test of Cure 
Data will also be collected for covariates that may cause between-subject variability:  
Demographic (postmenstrual age, gestational age, post conception age, birth weight,  
postnatal age, current body weight, gender). 
Clinical (serum creatinine, albumin, total bilirubin, conjugated bibirubin, hemoglobin,         
hematocrit, AST, ALT and marker of severity of illness) 
Co-medication - (including cations and caffeine)  
Treatment  – surgery, ventilation and transfusion  
Necrotising Enterocolitis  
Pharmacogenetics - major transporters implicated in ciprofloxacin disposition and clearance  
Time Frame - recruitment will commence February 2011 until 2013.   
 Assessment of outcomes 
The MIC data for ciprofloxacin in Gram Negative bacteria isolated from participants in our 
studies will be obtained (this will be a small percentage of those recruited). This will allow us to 
estimate AUC24h/MIC for common Gram negative infections and indicate whether achieved 
circulating concentrations are likely to be sufficient.  
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This study is not large enough to enable a definitive assessment of the safety of ciprofloxacin. 
The physiological changes in development stratified from 24 - 52 weeks gestation would require 
large numbers of babies receiving ciprofloxacin. The study will establish initial, short term safety 
data. The TINN ciprofloxacin registry that includes other European Centres will describe safety 
data.  
Study Population 
Recruiting Sites: Participants will be recruited on a neonatal unit, paediatric wards or the 
paediatric intensive care unit at Liverpool Women’s NHS FT and Alder Hey Children’s NHS FT 
that share services for neonates including laboratory services for neonates. Recruited neonates 
who are subsequently transferred to other hospitals having completed ciprofloxacin treatment 
will be followed up by collaborators at approved step down sites across the region.  
Sample Size: Neonates and infants (n=50) will be recruited and stratified between 24 
up to 52 weeks post menstrual age. The target recruitment is 5 - 8 patients per 4/5 week 
period depending on the number of patients available. The minimum acceptable 
recruitment is 10 patients within two adjacent time periods (8 weeks), recruitment will 
ensure there are at least 10 patients under 32 weeks; 20 below or above 36 weeks; and 
10 above 44 weeks.  
 
Recruitment target (n=50) aims to represent each postmenstrual age (PMA) group 
between 24 -52 weeks stratified over  4/5 week periods:                                                 
Pre -term Term newborn 
infants  
Infants > 28 days to 3 
months 
 
24-27 
 
28-31 
 
32-35 
 
36-39 
 
40-43 
 
44-47 
 
48-52 
The target recruitment is 5 - 8 patients per 4 week period but a minimum of 10 patients will 
be accepted within two adjacent time periods (8 weeks).  
 
This is consistent with the EMEA age classification for the clinical investigation of medicinal 
products in the paediatric population (CPMP/ICH/2711/99) preterm newborn infants, term 
newborn infants (0-27 days) infants and toddlers 28 days -23 months [5]. As this study is 
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designed for neonates and young infants the age is limited to a maximum of 3 months corrected 
gestational age.   
 
This is not a hypothesis-testing study. The pharmacokinetic (PK) data generated from this study 
will assist in dose selection for subsequent studies and for labelling purposes. So, no formal 
power calculation has been used to determine the sample size.  
Inclusion Criteria 
Prescribed ciprofloxacin for clinical care based on the unit’s clinical protocol for managing 
sepsis. As decided by the physician caring for the baby. All other medication will be at the 
discretion of the attending physician. 
 
Post menstrual age 24 – 52 weeks  
 
Parental consent to participate. 
Exclusion criteria 
Likely not to survive for more than 48 hours in judgement of attending physician. 
Ciprofloxacin commenced before 5th day of life (excluded due to immature renal function) 
 
Babies may also be recruited to other studies unless this would require additional blood samples 
during the same sampling period above the maximum allowed by the EMEA / MCRN guidance 
for blood sampling for neonates /children in research. 
Subject withdrawal 
Ciprofloxacin stopped due to clinical decision before day 5 of a course of ciprofloxacin 
Transfer to another unit before day 5 of ciprofloxacin (excluding transfer between recruiting 
sites)  
Parental request 
In these cases data obtained up to the point of withdrawal will be used in the analyses. 
 Consent 1  
Consent to this study is to allow detailed monitoring of the babies (receiving ciprofloxacin as 
part of their clinical care) and access to medical notes.   
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Consent for the Pharmacokinetic Study is to allow the research team to commence: 
Detailed monitoring of the baby  
Collection of samples at specific times (blood and faeces)  
Access to the baby’s medical notes or clinical data 
Further, specific consent is also requested for additional samples: 
Cerebrospinal Fluid Sample – an additional sample when required clinically 
DNA sample for pharmacogenetic analysis 
The parent information sheet and researcher will explain that the risks are minimal and specific 
to sample collection and use of data.   
The decision to start ciprofloxacin will be made by the attending physician in accordance with 
standard unit practice as part of clinical care. Consent is specifically for monitoring babies not 
for the treatment with ciprofloxacin. Any side effects of the drug relating to their clinical care 
have therefore not been included in the consent process. As with many drugs in paediatrics 
ciprofloxacin is used off-label in this age-group. The participating institution has considerable 
experience of this medication and does not consider it a novel or experimental treatment. It is 
not routine practice to discuss off-label medication use with patients. 
Stages of Consent Process - to ensure parents have ample time to reflect on the information 
relating to a study before making an informed decision about their baby participating in the 
clinical trial a continuous consent process will include 3 approaches: 
Flyer/Leaflet  
Formal Informed Consent Process 
Continuous Consent Process   
To ensure parents are given ample time and are approached at a time that is less stressful for 
them we aim to approach them prior to the baby becoming eligible and when the neonate / 
infant is judged to be stable enough by the clinical care team.  An important issue is the need 
to seek informed consent within the time available to allow a PK sample to be taken at the end 
of the first infusion of ciprofloxacin.   Parents are not present on the unit in a predictable manner. 
Many neonates are transferred significant distances, parents have to care for other children, 
find visiting distressing and mothers are unwell in the days after birth. By requesting consent 
prior to the baby becoming eligible (prior to ciprofloxacin being prescribed) we will allow families 
ample time to make an informed decision whilst avoiding any delay in commencing the 
monitoring. 
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Flyer/Leaflet  (Appendix III) -The initial approach to parents of any baby under 3 months of age 
will be to routinely advise them about the potential for recruitment to the study by providing a 
flyer as a brief introduction to the study. This will also be displayed in public areas. 
Formal Consent - detailed information as part of the formal consent process will then be 
provided to families of babies who are more likely to be prescribed ciprofloxacin as part of their 
care.  The following groups will be approached for formal consent: 
a)    Neonates / infants screened for sepsis due to presenting clinical signs (these babies  will 
be started on different antibiotics but some of them will be changed to ciprofloxacin because of 
their clinical course (section 5.1). 
b)    Neonates with suspected (or proven) Gram negative bacteria 
 Prescribed the first line antibiotics for Gram negative infections  
 Neonates / infants at high risk of infection – those born before 28 weeks post menstrual 
age. 
Informed consent: a parent information sheet (Appendix IV) will be provided and used to 
structure a discussion with the parent(s). Parent(s) will be allowed ample time to make their 
decision. They will be asked how long they would like to consider the information and what time 
is convenient for them when the researcher may return to answer any questions they may have. 
At the second discussion they will then be asked if they need more time to make a decision or 
if they feel that they are sufficiently informed to make the decision.  Consent will be sought 
before any procedures that are not part of routine clinical care are carried out. 
 
Administration of ciprofloxacin will not be delayed by the consent process. If parents or 
designated legal representative have not been able to make a decision by the time the first 
blood sample is required the child will not be enrolled in the study. 
Continuous Consent - The study team will adopt a process of “ongoing consent” during which 
the progress of participants and the study will be discussed, parents will be given repeated 
opportunities to ask questions, clarify any issues about the study and confirm or withdraw their 
agreement to their child participating the study [38]. The aim of this process is to optimize the 
comfort of parents with the study when the time comes for blood sampling, OR, to give parents 
the opportunity to withdraw consent if they feel that that is appropriate.  
Consent Forms – 3 copies of the signed consent form (attached to the information sheet) 1) 
parent 2) Case Report File 3) Medical notes (Appendix V). 
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Parental Responsibility - Consent will be obtained from a person with parental responsibility 
defined by the Children’s Act 1989 and the Children and Adoption Act 2002.  
Research Team – the informed consent process will be delivered by health care professionals 
with suitable paediatric /neonatal experience and training, including GCP[39], and who are 
delegated this role by the Investigator and listed on the delegation log.  
Other studies – neonates who have been recruited to other trials will be eligible for this trial 
unless the Investigator deems that one trial would interfere with the validity of the other trial. 
Recruitment to this trial will not preclude recruitment to other trials. This is subject to parental 
consent. 
 Recruitment: 
When a clinical decision to start ciprofloxacin has been made AND consent is in place AND 
medical eligibility has been confirmed, a neonate / infant will be recruited to the study and given 
a study number. This is consistent with ICH GCP [39]. 
Determining Eligibility - following consent the medical suitability for recruitment will be 
confirmed by a physician listed on the delegation log and written in the notes to state the patient 
meets the eligibility criteria prior to any study procedure (required by the regulatory body 
MHRA).         
 
Promotion/Transparency – Information sheets, brochure, posters and other material will be 
approved by the Ethics Committee. 
Screening: A log will be kept of all eligible babies detailing which parents/babies are 
approached and which babies are recruited. When babies are not recruited a reason for this will 
be recorded, including the comments of parents if they wish to make a comment.  
Benefits and Risks of the PK Study 
The risk /benefit evaluation of study-specific procedures depends on whether the participant 
could derive any benefit from the study and the extent of risk arising from each element of the 
study. In this study, the participants will not gain any benefit since the assays will be sent to a 
different centre for batch analysis  The results of the assays will not be available to the clinicians 
during the course of ciprofloxacin and so there will be no opportunity for “therapeutic drug 
monitoring” to come from the study. Thus, the only benefits are to other babies. 
The guidance from the UK Royal college of Paediatrics states ‘where children are unable to 
give consent to taking of blood for non-therapeutic purposes by reason on insufficient maturity 
or understanding their parents or guardians may consent to the taking of blood for non-
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therapeutic purposes provided they have been given and understand a full explanation of the 
reasons for blood sampling and have balanced its risk to their child’ [40] Sampling blood for 
non-therapeutic purposes, provided appropriate consent is given on behalf of the participant, is 
also recognized in the USA, see US 21 CFR 50.51 and 50.53 as discussed in [41]. 
“Blood taken by a skilled person poses only a minimal risk of physical harm, except possibly the 
taking of a separate sample of blood from a very immature infant’ (a commentary on the RCP 
guidance) [40] This refers to both the volume of blood and the sampling procedure: 
Blood Sampling Procedure: The aspects of the procedure to be considered are: pain/distress, 
and impact on future procedures due to loss of potential sites for vascular access. To minimize 
the risk of distress and harm we will liaise closely with the clinical team and parents. Septic 
babies require frequent bloods to monitor blood gases or blood glucose therefore the timing of 
sampling will be co-ordinated closely with the clinical requirements and babies cares.  
 
Blood will be taken by those skilled in sampling from neonates. When possible, an arterial or 
intravenous line that is suitable for sampling blood will be used. When there is no suitable 
indwelling line the clinician will make a choice between venepuncture and capillary sampling 
based on the available opportunities for sampling. There are a range of options to minimize pain 
and distress, see “Points to consider when planning the collection of blood samples in clinical 
trials of investigational medicinal products.” 
http://ctuprod.liv.ac.uk/mcrnweb/images/mcrn_guide_for_blood_sampling_v1.0.pdf (last accessed 
25th January 2010) from the UK National Institute of Health Research Medicines for Children 
Research Network. Topical anaesthetics are not relevant for preterm infants. 
Volume of Blood:  As noted in Section 6.13, we will work within limits for blood volume for 
neonates proposed by the European Medicines Agency  [5]  and Medicines for Children 
Research Network Guidance [42]. Additional routine clinical samples will be scavenged at 
various time points to minimize study specific procedures. These may occur at suboptimal time 
points for PK analysis. Therefore specific sampling time points are also be required.  
Observational data exists to support the idea that the parents and professional carers of at least 
some neonates rate the pain and distress of study-specific blood sampling episodes to be 
minimal [43]. Fifty four of 90 parents (60%) reported that their term neonates was “not at all 
upset” by a non-clinically indicated study-specific blood sampling episode [43]. PK studies that 
require additional samples from neonates, to the clinically indicated sampling episodes have 
previously received favorable opinions from UK Research Ethics Committees.   
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Cerebrospinal Fluid PK Sample – will only be collected if the baby requires the sample for 
clinical purposes and when a further 0.5 ml can be collected from the same sampling episode.  
Access to Personal Identifiable Data  (section 7.6) relating to the study will all be collected in 
the course of routine clinical practice and so there are no risk issues beyond loss of 
confidentiality. Confidentiality will be maintained in accord with standard practice in the health 
care setting. Data that leaves the health care setting will be protected by “linked anonymisation” 
so that the data will not be associated with any personal identifiers once it leaves the health 
care setting. In this way, the risks relating to data will be no greater than routine clinical practice. 
Data up to the time of withdrawal will be included unless parents request that data is discarded 
(consent form will state this). 
Baseline Assessments following recruitment:  
a clinical assessment will consist of a standard physical examination conducted by a health 
care professional with appropriate clinical training and experience and study-specific training 
who appears on the delegation log. Blood Results from haematology, biochemistry and blood 
gas analysis that are required for clinical care.  
Biochemistry2: Plasma creatinine, Na+, K+, Cl-, AST, ALT, alkaline phosphatase, total bilirubin, 
conjugated bilirubin, albumin, total calcium, corrected calcium, magnesium 
C-reactive protein 
Full Blood Count3: Hb, total white cell count, differential white cell count, MCV. MCH, MCHC 
and  platelets. 
Blood gas4: glucose, lactate, ionized calcium2 
Microbiological 5- clinically indicated samples including blood cultures and lumbar punctures 
carried out for patient’s care before the start of ciprofloxacin therapy will be reported. 
A faeces sample will be taken after recruitment when available.  
Dosage and Administration  
Dosing schedule:  10mg/kg 12 hourly infused intravenously over 30 - 60 minutes   
                                               
 
 
 
2 To be measured using near-patient testing on participating units 
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The dose selected for our study is based on previous studies in neonates and infants and is 
consistent with UK BNF for Children[44]. Although only few PK data are available in neonates 
for this drug, we can assume that neonates have reduced clearance and increased volume of 
distribution compared with the adult population due to their profound changes in term of 
physiology and organ maturation. (cf 5.4). Previous studies have demonstrated that plasma 
AUC0-24h/MIC ratio (AUIC) was a good predictor of efficacy in adults in the treatment of serious 
gram-negative infections. As we are not aware of any evidence that ciprofloxacin 
pharmacodynamic in neonates will differ from those in adults, the AUC/MIC target of 100 was 
chosen as efficacy predictor (cf 5.2.2).The only data available in preterm neonates are from 
Aggarwal et al. [23] but this study did not evaluate AUCs. Lipman et al. [21] determined the 
pharmacokinetic profile of ciprofloxacin (10mg/kg administered 12 hourly) in 10 patients from 3 
months to 1 years.  By dividing the AUC0-24h by a MIC of 0.25 mg/l, the AUC/MIC is close to 
120 in this group of patients. In cases where MIC would be higher (e.g. 0.8 mg/L), the AUC/MIC 
would be only 37, which is much lower than the target value for Gram negative pathogens. 
However, systemic exposure may be higher in neonates < 3 months. 
Dose Adjustment 
Data from a recent study of the Minimum Inhibitory Concentration of Ciprofloxacin for Gram 
negative isolates in the participating Neonatal Unit suggests the current dosage is sufficient to 
achieve the EUCAST sensitivity breakpoint in the majority of cases.  
 
Interim analysis of PK samples will be performed.  
An increased dose will be envisaged if AUC/MIC is below the expected target of 100. As the 
PK is linear, we would propose a “rule of proportionality”. 
If an adjustment is required the nature of the adjustment will depend on the spread of results. 
In the absence of extreme variation we will follow the following rule: 
“If more than 25% of patients exhibit an AUC/MIC < 80, the dose will be increased by 20%. If 
AUC/MIC<50 the dose will be doubled.”  
The choice of dose adjustment would be guided by review of the data by the TINN consortium. 
Dose decrease would only be supported if acute side effects occur but this is not expected. In 
such a case, the safety monitoring board would decide what to do. 
Drug Administration  
A commercial, generic preparation will be used containing 2 mg/ml of ciprofloxacin. 
Ciprofloxacin provided from the hospital pharmacy supplies will be administered at a dose of 10 
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mg/kg 12 hourly. Infusion will be prepared and administered according to routine clinical practice 
by central or peripheral intravenous infusion according to the vascular access available for that 
child over 30 - 60 minutes.  
Pharmacokinetic Samples and Assessment  
(see Standard Operating Procedure for storage, labelling and couriering of samples) 
The maximum number of study specific blood samples is limited to 3 per baby 
and per period (Day 1 and on one day between Day 5- 7) (2 samples per day for 
babies less than 1000g). In order to completely cover the distribution and 
elimination phase in the whole population, babies will be assigned to 1 of the 2 
predefined 3-time (or 2-time) point schedules.  
Sample time schedule - babies will be assigned to one of the two groups of 
sampling times (A and B) as follows: 
 
Group Weight Sampling times on day 1 and day 5 -7 or last 
day of ciprofloxacin treatment*: 
Maximum blood volume 
for all study samples 
A > 1000g  T1  T3  T8  1.2 ml 
 
< 1000g** 
Ai 
 
T1  T3     
0.8 ml 
Aii T1    T8  
Aiii   T3  T8  
B > 1000g   T2  T6  T12 1.2 ml 
 
< 1000g** 
Bi  T2  T6    
0.8 ml Bii  T2    T12 
Biii    T6  T12 
 
* The sampling times are calculated from the start of the first infusion of ciprofloxacin except 
for T1 when the sample must be taken immediately after the end of the first infusion i.e at the 
end of the 30 minute infusion or the end of the 60 minute infusion.    
Samples are required on day 1 of starting ciprofloxacin and completed on one day between 
days  5-7 of ciprofloxacin treatment to allow some flexibility but day 7 is preferred when possible.    
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** Babies less than 1000g will have samples taken on alternate times to minimise blood loss 
but allocated to one of three subgroups and 2 specific times to ensure representation of each 
period.    
Sample Time Window: The T1 sample will be taken within 3 minutes of the end of 
the infusion. The infusion is either given over 30 minutes or 60 minutes according 
the local practice. All other sample times (T) periods represent are the number of 
hours after the infusion started.   
To ensure the samples provide accurate data all other samples are required within a 20 minute 
interval of the allocated sampling time (10 minutes before or after the allocated time).   
The research team will discuss the timing of samples required with the clinical team and parents 
to ensure cares are co-ordinated at this time and with minimal disruption to the baby's routine. 
However, some additional blood sampling episodes will be required and this will be made clear 
during the consent process. 
Scavenged samples: Additional, opportunistic samples will add to the precision of 
the pilot PK model. Blood that has been taken for clinical monitoring will be 
scavenged throughout ciprofloxacin treatment and up to 24-48 hours following 
treatment to monitor liver and renal clearance.  
Blood Sample volume:  The assay requires 200 microlitres of blood collected in an 
EDTA bottle. The sampling schema requires a total of 0.4 - 0.6 mls of blood on 
the first and last day of treatment a total per patient maximum of 0.8 - 1.2 mls of 
blood within 7 days depending on the babies weight. For infants < 1000g we will 
use alternate sampling time points and each infant < 1000g will contribute 
randomly two among the three time points a maximum of 0.8 ml of blood within 
7 days. For a 500g infant with estimated circulating volume of 90 ml/kg or a 
circulating volume of 45mls, 3% would be 1.35 ml). This is consistent with the 
EMEA and Medicines for Children Research Network sampling of neonates in 
clinical trials, that recommends 1% of blood loss on each occasion and 3% over 
28 days. 
Blood Sample Collection and Source: All blood sampling episodes will be 
undertaken by clinicians with neonatal skills and experience. Efforts to minimise 
pain and distress will be tailored to the individual child by clinical staff with the 
involvement of parents. Sample source - Blood will be sampled from one of the 
following sources in the light of clinical circumstances as judged by the health 
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care team and investigators. Samples will be taken from a different vascular 
access route to the one used for administration.  This list provides the order of 
preference for site of blood sampling. 
Umbilical arterial line 
Peripheral arterial line 
Umbilical venous line 
Surgical central line (Broviac) 
Capillary sampling 
Venepuncture  
Venous cannula 
When venepuncture or capillary sampling is required each sampling episode will involve a 
maximum of 2 (two) attempts to obtain the sample, when each attempt is defined as a break of 
the skin of the participant. 
When a sample is taken via an indwelling line (surgical, umbilical or peripheral) sufficient 
serosanguinous fluid will be taken to account for dead space. 
Cerebrospinal fluid (CSF) Pharmacokinetic Sample:  
If the baby requires a clinically indicated CSF sample and consent is obtained for the CSF sub-
study, a further 0.5ml will be taken after the CSF required for clinical tests has been collected. 
CSF may be obtained by the following methods  
a. Lumbar puncture b. Ventricular tap c. CSF reservoir tap  
The sample will be collected in a sterile polypropylene tube in one of 2 ways; either at the time 
that CSF is collected for diagnostic purposes or a scavenged sample from the clinical 
microbiology laboratory  
Pharmacokinetic Analysis  
(see Standard Operating Procedure)  
An analytical Liquid Chromatography-mass Spectrometry (LC-MS) method for ciprofloxacin 
detection in human plasma suitable for assaying the small plasma volumes obtainable in 
neonates has been developed and implemented in the pharmacology laboratory (University 
Hospital of Tours, France). 
 Pharmacogenetic samples:   
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For pharmacogenetic analyses, DNA will be extracted from the cells left over after centrifugation 
of the plasma EDTA samples to reduce the amount of blood taken from the neonate therefore 
no additional sample will be required.  The Quieten method for DNA extraction will be used. 
DNA will be extracted at University of Liverpool laboratory based at Liverpool Women’s Hospital.  
Following a blood transfusion - No further blood samples may be used for DNA.  In this 
situation buccal samples will be collected using a swab in the baby’s mouth.  
Pharmacogenetic analysis will be undertaken at the Institute of Pharmacology of Natural 
Products and Clinical Pharmacology University of Ulm Germany where they will be stored for a 
maximum of 10 years.  
 Microbiological Samples  
The results of all blood cultures and CSF cultures will be recorded. Microbiological Analysis will 
be carried out in the Clinical Microbiology laboratory at Royal Liverpool University according to 
their Standard Operating Procedures. The MIC values will be obtained for all positive gram 
negative cultures. Each faeces sample will be inoculated onto 4 plates (1 plain and 3 
incorporating CIP at 0.1, 1.0 & 4.0mg/l). Only organisms that grow above 0.1mg will be 
characterized.  
Faeces Samples - A basal sample of faeces will be collected to assess colonization at anytime 
following consent (requested by PDCO). A further sample will be collected at the end of 
treatment with ciprofloxacin and between weeks 4 – 6 following completion of the antibiotic to 
test for gram negative insensitivity. If the patient has been discharged then the families will be 
asked to bring a sample to clinic, or the family may post the sample to the laboratory in an 
approved container (consistent with Health and Safety Executive Regulations).   
 Test-of-cure 
Clinical Cure will be defined as CRP < 10mg/L three days after the cessation of ciprofloxacin. 
Data will be collected on the duration of ciprofloxacin therapy including whether ciprofloxacin 
was stopped because of incompatibility. Three days after the cessation of ciprofloxacin 
treatment a detailed assessment of clinical outcome will be conducted, comprising: 
 
Clinical: a physical examination conducted by a health care professional with appropriate 
clinical training and experience and study-specific training who appears on the delegation log. 
Laboratory: C Reactive Protein 
Microbiological: results of any repeat blood cultures. 
STUDY SAFETY MONITORING  
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During ciprofloxacin therapy the study team will conduct a systematic daily review of patient 
records until 3 days following the last dose using electronic patient data system and consult 
carers and parents in order to identify adverse events.  Pharmacovigilance reporting will 
commence will continue until 6 weeks following the treatment.    
Clinical Blood Samples - All Biochemistry / Haematology analyses carried out during the 
course of ciprofloxacin for routine care will be assessed for safety parameters. No study-specific 
blood sampling episodes will be undertaken for safety purposes. 
Laboratory Reference Ranges (all clinical samples are processed at Alder Hey 
Children's NHS FT for both recruiting sites).   
Haematology - Full Blood Count   
Value: Range for age group: 
 Day 1 Day 3 Day 7  Day 14  1 month  2 month 6 month 
Hb 14   - 22 14   -22 13  -21 12.5 -
20.5 
10  -17   9   -13.5 10  -14.1 
MCV 96   -130 94   -130 88  -120 86    -
120 
85  -120 77   -115 72  -95 
MCH 31   -39 30   -37 28  -37 28    -37 27  -36 29   -34 25  -33 
MCHC 30   -36 30   -36 28  -36 28    -36  29  -36.5 29   -
36.5 
30  -36 
Platelets  150 -400 150-400 150-400 150-400 150-400 150-400 150-400 
Total WCC 9     -1.84  9    -
18.4 
 5   -18.4  5    -18 5    -18  5   -18  5   -17 
Haematocrit 45   -67 45   -67 42  -66 39   -63 31  -55 28  -42 30  -41 
Differential 
WCC: 
Neutrophil  
Lymphocyte 
Monocyte 
Eosinophil 
Basophil 
Myelocytes 
 
4.8   - 17.1 
2      - 7.3 
0.06 - 1.9 
0      - 0.8 
0      - 0.2 
0      - 0.1 
 
2      -94 
2      -7.3 
0.06 -1.9 
0      -0.8 
0      -0.2 
0      -0.1 
 
1.8   -8 
2.8   -9.1 
0.06 -1.7 
0      -0.9 
0      -0.2 
0      -0.1 
 
1.7    -
6.0 
2.8    -
9.1 
0.06  -
1.7 
0       -0.8 
0       -0.2 
 
1     -9.0 
3     -13.5 
0.06 -1.7 
0      -0.6 
0      -0.2 
 
1      -9 
3      -
13.5 
0.06 -1.7 
0      -0.8 
0      -0.2. 
 
 
1     -8.5 
4     -13.5 
0.06 -1.3 
0      -0.8 
0      -0.2 
 
 
Biochemistry 
Blood Sample: Age: Range: 
Creatinine 2 weeks 
2-26 weeks 
30 -58 μmol/L 
20 -48 μmol/L 
Sodium 0-1month 
> 1month 
132 – 142 mmol/L 
135 – 145 mmol/L 
Potassium 0-1month 
> 1 month 
4.0 – 6.2 mmol/L 
3.5 – 5.5 mmol/L 
Chloride  95 – 105 mmol/L 
AST 0-1month 
> 1 month 
23 – 73 IU/L 
15 – 58 IU/L 
ALT 0-1month 9  -  44    IU/L  
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> 1 month 9  -  36  IU/L 
ALK Phosphate 0-1month 
>1month  
<1600 IU/L 
187 - 1197 IU/L 
Total bilirubin 0-1 month 
> 1month 
 <340 μmol/L  
 <15  μmol/L  
Conjugated bilirubin 0-1month 
>1 month 
<10 μmol/L 
<10 μmol/L 
Albumin 0-2 months 
> 2 months 
30  - 45 g/L 
37  - 53 g/L 
Total Calcium 0-1week 
1 week - 2 years 
1.75 – 2.99 mmol/L 
2.20 – 2.79 mmol/L 
Corrected calcium  For albumin <40 g/L :  = measured Ca + 0.02(40-alb) 
For albumin >40 g/L :  = measured Ca – 0.02(Alb-40)  
Magnesium  0.78 – 1.02 mmol/L 
C Reactive Protein  0 – 8 mg/L 
 
Blood Gas 
PH 
 
PO2 
 
 
PCO2 
 
 
0-1month  
> 1month 
 
0-1month 
> 1 month  
 
0-1 month 
> 1 month 
 
7.33 – 7.49  
7.35 – 7.46 
 
60 – 76 mmHg 
80 - 105 mmHg 
 
27 – 40 mmHg 
36 – 46 mmHg  
                       (To convert to kPa = mmHg x 0.133) 
Glucose Neonate (term) 
Neonate pre term 
Fasting child 
>1.6  mmol/L 
>1.1  mmol/L 
2.8 – 6.1 mmol/L 
Lactate   0.7 – 2.1 mmol/L 
 
Peripheral Infusion Site – An injection site reaction is described as an uncommon reaction in 
the SPC (between 1 in 1000 patients and 1 in 100 patients). However, we are not aware of any 
studies in neonates. We will pilot measures to assess injection site reaction.  
Tolerance to intravenous ciprofloxacin at the site of peripheral infusion will be monitored 
immediately before and after the infusion using a validated scale. The Infusions Standards by 
the Royal College of Nursing (UK) [45] recommend the Visual Infusion Phlebitis Scale 
developed by Jackson [46] the validation of which is unpublished but cited by Gallant and 
Schultz [47]. The scale of 0- 5 assesses phlebitis by monitoring pain, redness, swelling and 
palpable venous cord. The babies may receive other infusions of drugs or fluids through the 
same intravenous site therefore the site will be assessed using this scale immediately before 
the infusion and on completion of the 30 - 60 minute infusion and approximately 6 hours later 
(in-between the doses (appendix 5). Further information on other intravenous drugs 
administered by the peripheral venous line will be recorded with the pH. Data regarding the 
intravenous site such as removal of the cannula due to phlebitis or infiltration will be recorded 
and compared to the incidence neonates receiving other intravenous drugs.  
Regulatory Compliance  
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This trial will be conducted in accord with the principles of the Helsinki Declaration and Good 
Clinical Practice according to the ICH document adopted in the European Union as 
http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf (last accessed 25th January 2010) and 
applied to English law. Medicines for Human Use Clinical Trial  Regulations (2004) 1031, as 
amended [48].  The trial will be conducted in accord with the opinion of the National Research 
Ethics Committee and NHS approval from Liverpool Women’s NHS Foundation Trust including 
the Research and Development Manager and Clinical Director. 
Regulatory Safety Reporting 
All serious adverse events and non serious adverse events /reactions specified in the protocol 
whether or not they are attributable to the study intervention will be reported on case report 
forms. The reporting will commence when the patient has been consented and has become 
eligible for study monitoring. These will be reviewed by the investigators monthly to determine 
if there is reasonable suspected causal relationship to the intervention.  
If there is evidence that there may be a novel causal relationship with the intervention, then the 
procedure for expedited reporting of suspected unexpected serious adverse reactions will be 
followed (section 7.4) All adverse events will be followed until satisfactory resolution or until the 
investigator responsible for the care of the participant deems the event to be chronic or the 
patient to be stable. 
All expected Serious Adverse Events (SAE) will be recorded in the case report forms (CRF) but 
will not require expedited reporting [4] but will be reviewed by the DMC at regular intervals 
throughout the trial. The trial sponsor will collate and submit annual safety reports to MHRA and 
the appointed NRES committee. However, the MHRA, the trial sponsor and the chair of the 
MREC may also be informed about severe adverse events by the DMC chair if considered 
appropriate.  
A standard reporting procedure will be provided on the reverse side of all SAE forms. A Trial 
Standard Operating Procedure with detailed information on reporting procedures will also be 
kept in site files at each ‘trial station’ in each centre. Copies of all correspondence relating to 
reporting will be maintained in the Investigator’s files. 
Regulatory adverse event or reaction reporting will commence once consent has been given 
and the baby has been determined as eligible to participate in the study and until the last study 
related procedure for that baby.  (systematic data collection for non serious adverse 
events/reactions will continue until 3 days after the last dose).    
Pharmacovigilance Definitions: 
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Adverse event (AE) -Any untoward medical occurrence in a subject recruited to a clinical trial, 
including occurrences which are not necessarily caused by or related with the treatment.  An 
adverse event can be any unfavourable and unintended sign or symptom associated with the 
use of a medicinal product whether or not related to that product.   
Adverse reaction (AR)-Any untoward and unintended response in a subject to an 
investigational medicinal product which is related to any dose administered to that subject. 
Serious adverse event (SAE), serious adverse reaction (SAR) or unexpected serious adverse 
reaction (see 5.3) 
Any adverse event, adverse reaction or unexpected adverse reaction, respectively, that 
a) results in death, 
b) is life-threatening, 
c) requires hospitalisation or prolongation of existing hospitalisation, 
d) results in persistent or significant disability or incapacity,  
Expected Serious Adverse Events NOT Requiring Expedited Reporting  
Expected serious adverse events defined as follows will be recorded and reported but are 
exempt from expedited reporting to the sponsor and regulatory bodies as they are expected in 
this high risk populations [4]. 
Among extremely premature babies born at less than 34 weeks, the following are serious 
adverse events and incidence rates which could be reasonably expected for this group of babies 
during the course of the study.  
Adverse event Estimated   
  Incidence < 28 
weeks gestation 
Estimated 
incidence 28 – 34 
weeks gestation 
a) death  20%* 8%* 
b) necrotising enterocolitis or focal intestinal perforation 
diagnosed on clinical grounds, or at surgery 
15%* 3%* 
c) intracranial abnormality (parenchymal haemorrhage or focal 
white matter damage) on cranial ultrasound 
15%* 6%* 
d) requirement for supplementary oxygen 28 days after birth 55%* 6%* 
e) patent ductus arteriosus requiring medical or surgical 
management 
25%* 8%* 
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f)  retinal surgery for retinopathy of prematurity 5%* 0.14* 
g) pulmonary haemorrhage 5%** 0.5%** 
h) persistent weight loss after 14 days after birth in the absence 
of infection. 
10%** 1** 
* based on incidence of these complications at Liverpool Women’s Hospital 1980 - 2004 (Prof. 
RWI. Cooke, personal communication, and Cooke RW51)  
** based on incidences estimated by the investigators 
Based on data for those under 34 weeks the serious adverse events listed as expected will be 
exempt from expedited reporting for all babies in the study including those up to 52 weeks 
post menstrual age unless the Chief Investigator or DMC determine the incidence has 
increased.  
 Suspected Unexpected Serious Adverse Reactions 
All serious adverse events will be reviewed by the Chief Investigator Dr. Mark Turner or another 
senior clinician nominated by the Sponsor. For each death or other serious adverse event, the 
CI, or his deputy, will make a judgment about whether the nature or severity of the 
circumstances surrounding the death is consistent with adverse events associated with the 
underlying conditions, or with ciprofloxacin (including literature cited in the protocol). In the event 
of a serious adverse event that has a causal relationship to ciprofloxacin and is not consistent 
with the information contained in this protocol or the Summary of Product Characteristics the 
event will be labelled as a Suspected Unexpected Serious Adverse Reaction (SUSAR). All 
events labelled as SUSARs will be reported to the sponsor within 24 hours of the decision being 
made. All SUSARs will be reported to the competent regulatory authority (MHRA) in accord with 
the Sponsor’s Standard Operating Procedures.  
 Data Monitoring Committee (DMC) 
An independent data monitoring committee has been established for this study: 
Chairperson:   Professor David Field, University of Leicester, UK.  
Members:        Professor Stephanie Laer, University of Düsseldorf, Germany. 
                           Professor Neil Morton, University of Glasgow, UK. 
The DMC will determine the frequency and the form in which they meet (personal meeting/ 
teleconference), which data they would like to see and how frequently. The investigators and 
Ethics Work Package of TINN will support the DMC to follow the DAMOCLES statement for 
DMC charters [49] [50]. The trial investigators will ensure that all the requested data is received 
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by the DMC during the trial.  The DMC will assess safety aspects and inform the trial 
investigators who will then respond to their recommendations. 
Data Management 
The case report form (CRF) will not contain patient identifiable data. On recruitment each 
participant will be assigned a unique study number. The data in the CRF will be linked to clinical 
source documents by the unique study number. The tables linking unique study numbers to 
patients will be retained by the Research and Development Department at Liverpool Women’s 
Hospital or Alder Hey Children’s NHS Foundation Trust for 21 years to ensure data is available 
as the child develops and will not be passed on to other organizations. The investigators and 
institutions will permit trial-related monitoring, audits, REC review, and regulatory inspection(s). 
This will include direct access to source data/documents. 
At LWH, the clinical source documents will be the electronic patient record contained within the 
unit’s patient data management system. At the PICU the clinical source documents will be the 
written patient record and other aspects of the clinical record. The source document for PK 
assays will be the meditech system for blood results or nursing notes, patient charts and medical 
records.  
Quality Control and Quality Assurance 
The study will be monitored by LWFT R&D. 
Drug Product Quality Issues 
Ciprofloxacin will be stored and administered in accordance with the Marketing Authorisation Summary 
of Product Characteristics and Trust Drug Administration Protocol. The drug will be labelled during the 
infusion in accordance with Eudralex Annex 13 [51]. 
Ethics 
The TINN Consortium includes Ethics and Safety work package co-ordinated by The University of 
Nottingham – Ethics Advisory Board (EAB) who will provide independent Ethics and Safety Monitoring 
of the program with European representatives who will liaise with the DMC. The PK study will be 
approved by the UK regulatory National Research Ethics Service.  
The lack of benefit to participants does not preclude including procedures such as blood sampling 
episodes that are extra to clinical requirements (section 6.10). Some authors have written of the “Moral 
responsibility to attain thorough pediatric drug labelling” [52]. 
Statistical Methods 
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Pharmacokinetic data will be made available by clinical investigation center (CIC, Inserm 9202, Hôpital 
Robert Debré) on a standard Microsoft Office Excel spreadsheet For subsequent modeling using 
NONMEM version 6.2 (Globomax, USA). 
A detailed statistical analysis plan will be developed. The principles underlying this plan are as follows: 
Model selection criteria will include: (i) successful minimisation, (ii) standard error of estimates, (iii) 
number of significant digits, (iv) termination of the covariance step, (v) correlation between model 
parameters and (vi) acceptable gradients at the last iteration.  
Continuous and categorical covariates will be tested during the primary analysis. For univariate 
analyses, additional parameters leading to a decrease in the objective function of 3.84 will be 
considered significant (p<0.05).  During the final steps of the model building, only the covariates 
which resulted in a difference of objective function 7.88 (p<0.005) will be kept in the final 
model. 
Validation of the final model will be based on graphical and statistical methods. A suitable 
model is defined as including approximately 90% of data points within the 5th-95th prediction 
interval (approximately 5% above 95th and 5% below 5th). The final model will also be assessed 
by visual predictive check (VPC) and metric normalized prediction distribution errors (NPDE). 
The following graphs will be plotted by NPDE R package: (i) QQ-plot of the NPDE; (ii) histogram 
of the NPDE; (iii) NPDE versus time and (iv) NPDE versus predicted concentrations. The NPDE is 
expected to follow the N (0, 1) distribution.  
Optimal dosing regimens PK parameters and their variability estimates from the preliminary model will 
be used to define the optimal dosing regimens to be used in neonates and infants. The optimised dosing 
regimen will take consideration of the PK-PD relationship published in adults, indicating that the 
AUC/MIC should be > 100. Hence, the model will be used to simulate various dosing regimens in various 
kinds of children (i.e. according to covariates), provided they allow attaining this PK-PD endpoint for the 
most relevant bacterial species concerned by this treatment (mean MIC for each strain). A secondary 
model with covariates will also be tested.  
The optimised dosage regimen will be evaluated in subsequent PK studies (particularly as a component 
of the TINN registry study). 
Safety outcomes will be tabulated. No statistical analysis will be performed on safety data. 
Financing and Insurance 
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Funding: The study is funded by TINN European Research Network (collaborative Project) supported by 
the European Commission under the Health Co-operation Work Program of the 7th Framework Program, 
project .  
Financial disclaimer - The drug products used for the PK study are generic products currently purchased 
through the NHS pharmacy.  
The TINN consortium will liaise with the pharmaceutical industry regarding improved ciprofloxacin 
formulations for future work packages. 
The TINN consortium includes a pharmaceutical small-medium-sized enterprise (SME), EPMC. 
(http://www.epmc-pharma.com/index.html) EPMC may become the PUMA holder or may license the 
PUMA to a different company. None of the investigators have any financial interest relating to EPMC.  
Sponsorship Arrangements 
The trial will have two co-sponsors: University of Liverpool and Liverpool Women’s NHS Foundation 
Trust (LWFT). There will be a written agreement about the division of sponsorship responsibilities 
between these two organizations. In brief the University of Liverpool will be responsible for funding the 
trial (based on its contract with the European Commission as a participant in TINN). LWFT will undertake 
all other sponsorship responsibilities (this will be funded by a subcontract between the University of 
Liverpool and LWFT). 
Insurance  
Cover for negligent harm arising from trial-related activities conducted on NHS premises by staff with 
substantive or honorary NHS contracts will be provided by the NHS Litigation Authority (NHSLA) since 
the trial will be co-sponsored by Liverpool Women’s NHS Foundation Trust. Indemnity for Dr. Turner’s 
actions as an employee of the University of Liverpool will be provided by the University.     
Publication Policy 
This study will be published in accord with TINN ‘Treat Infection in Neonates’ policy. The study aims to 
licensing ciprofloxacin for neonates by contributing to a specific neonatal Marketing Authorisation 
therefore will be required to report all data to the EMEA. The study has been registered on the EUDRACT 
data base EudraCT: 2010-019955-23. For the primary published report of the study, the first author will 
be Hill and the last author will be Turner.  
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All data fields on EudraCT will be completed (including protocol and results fields) as indicated in the 
most recent guidance 3. Raw data from the blood and CSF PK samples will be made available to other 
investigators subject to the agreement of the TINN Executive and the EC. 
 
                                               
 
 
 
3 http://ec.europa.eu/health/files/eudralex/vol-10/2009_02_04_guidelines_paed_en.pdf (last accessed 
28th August 2010). 
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Appendix 1 PK Studies Ciprofloxacin 
 
N'  Publication N Dosing 
schedule 
Duration of  
infusion 
Time of 
Cmax 
Cmax Trough 
level 
Plasma 
half-life 
Evidence 
of 
accumulati
on 
Volume of 
distribution 
Plasma 
protein 
binding 
CSF 
concentration 
Excretion 
 Chapter 29 of 
Antibiotic and 
Chemotherapy, 
Finch et al. 2003 
[ADULTS] 
n.r. 200mg IV 15 minutes End of 
infusion 
3.5mg/L  n.r. 3 – 4h *n.r. 3 – 4 L/kg 20-40% 50% of 
simultaneous 
plasma values 
75% of IV 
dose 
appear in 
the urine 
over 24 h 
[6] Lipman 
[1 – 5 years old] 
10 10mg/kg/do
se twice 
daily 
1 hour End of 
infusion 
7.38 (1.35) 
d0, 7.78 
(1.56) d2, 
6.38 (1.35) d7 
0.14 (2.03) 
d0, 0.21 
(2.75) d2, 
0.10 (1.74) 
d7 
2.84 (1.18) 
d0, 3.13 
(1.41) d2, 
2.82 (1.18) 
d7 
No 1.44 (1.17) d0, 
1.43 (1.19) d2, 
1.76 (1.23) d7 
*n.r. *n.r. *n.r. 
[6] Lipman 
[INFANTS] 
10 10mg/kg/do
se twice 
daily 
1 hour End of 
infusion 
6.08 (1.23) 
day 0, 9.03 
(1.85) day 2, 
5.81 (1.35) 
day 7 
0.21 (2.39) 
day 0, 0.21 
(2.77) day 
2, 0.16 
(1.86) day 7 
3.67 (1.51) 
day 0, 3.32 
(1.90) day 
2, 4.23 
(1.32) day 7 
No 2.06 (1.33) 
day 0, 1.49 
(1.53) day 2, 
2.05 (1.32) 
day 7 
*n.r. *n.r. *n.r. 
[21] Bannon 6 5 
mg/kg/day 
twice daily 
*n.r. 30minutes 
after IV 
injection 
3.1 mg/L 
(range 1.45 to 
5.7 mg/L) 
after the third 
dose 
1.25 mg/L 
(range 0.04 
to 2.6 
mg/L). 
*n.r. *n.r. *n.r. *n.r. 64% of 
simultaneous 
serum values 
*n.r. 
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[32] Aggarwal et al., 
2004 
24 10mg/kg/do
se twice 
daily 
30 minutes 15 minutes 
after dose 
2.3 mg/L 
(range 0.2 to 
6.8 mg/L) day 
1 
 
3.0 mg/L 
(range 0.1 to 
7.1 mg/L) day 
3 
 
2.7 mg/L 
(range 0.5 to 
7.1 mg/L) day 
7 
 
0.7 mg/L 
(range 0 to 
2.1 mg/L) 
day 1 
 
0.8 mg/L 
(range 0 to 
2.1 mg/L) 
day 3 
 
1.0 mg/L 
(range 0.1 
to 3.5 mg/L) 
day 7 
 
*n.r. No *n.r. *n.r. *n.r. *n.r. 
[33] Goepp, et al 1 infant 
with 
ventriculiti
s 
35 
mg/kg/day 
twice daily 
2 hours 15 minutes 
after end of 
infusion 
11.6 mg/L 0.9 mg/L 2.89h for 
eighth dose 
 
3.79 h for 
twenty-
fourth dose 
*nr *nr *nr 12.1% -175% of 
simultaneous 
serum values 
 
[34] Wessalowski et 
al. 
1 infant 
with brain 
abscess 
*nr  *nr *nr 0.1 to 2.8 
mg/L 
      
[35] Van den Oever 
et al.  
1 infant 20 
mg/kg/day 
twice daily 
30 minutes *nr *nr *nr *nr *nr *nr *nr *nr *nr 
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[53] Payen et al. 
 
Some were cystic 
fibrosis patients. 
These data were 
excluded from 
our review 
-53 
pediatric 
patients 
aged 1 day 
to 17 years 
and 2 
young 
adults 
- 3 
neonates 
 
Neonate: 5 
to 17 mg/kg  
 
30 min *nr *nr *nr Mean: 16.6 
Min: 10.5 
Max: 24.5 
*nr Mean: 7.19 
Min: 3.8” 
Max: 12.4 
*nr *nr *nr 
n.r. not reported 
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SUMMARY OF PRODUCT CHARACTERISTICS  
1 NAME OF THE MEDICINAL PRODUCT  
Ciprofloxacin 2mg/ml, Solution for Infusion  
2 QUALITATIVE AND QUANTITATIVE COMPOSITION  
Each presentation of Ciprofloxacin 2mg/ml infusion contains the following:  
Ciprofloxacin 100 mg/50 ml, Solution for Infusion  
1 ml of Solution for Infusion contains 2mg Ciprofloxacin as 2.544mg Ciprofloxacin lactate.  
Each 50 ml vial contains 100 mg Ciprofloxacin (as Ciprofloxacin Lactate).  
Excipient: Each 50ml contains 7.7 mmol (177 mg) Sodium.  
Ciprofloxacin 200 mg/100 ml, Solution for Infusion  
1 ml of Solution for Infusion contains 2mg Ciprofloxacin as 2.544mg Ciprofloxacin lactate  
Each 100 ml vial contains 200 mg Ciprofloxacin. (as Ciprofloxacin Lactate).  
Excipient: Each 100ml contains 15.4 mmol (354 mg) Sodium.  
Ciprofloxacin 400 mg/200 ml, Solution for Infusion  
1 ml of Solution for Infusion contains 2mg Ciprofloxacin as 2.544mg Ciprofloxacin lactate.  
Each 200 ml bottle contains 400 mg Ciprofloxacin. (as Ciprofloxacin Lactate).  
Excipient: Each 200 ml contains 30.8 mmol (708 mg) Sodium.  
For a full list of excipients see section 6.1  
3 PHARMACEUTICAL FORM  
Solution for infusion  
Clear, colourless to slightly yellow solution.  
4 CLINICAL PARTICULARS  
4.1 Therapeutic indications  
Ciprofloxacin is indicated for the treatment of serious and/or life-threatening infections 
caused by ciprofloxacin-susceptible pathogens. The following indications can be 
considered for treatment with Ciprofloxacin when oral therapy is not possible or not 
reliable:  
• complicated urinary tract infections  
• infections of the lower respiratory tract including pneumonia caused by aerobic gram-
negative bacteria, in case of Streptococcus pneumoniae infections ciprofloxacin is 
not the substance of first choice.  
• complicated skin and soft tissue infections  
• osteomyelitis  
 
Children and adolescents:  
Ciprofloxacin may be used for 2nd and 3rd line treatment of complicated urinary tract 
infections and pyelonephritis in children and adolescents of 1-17 years of age and for the 
treatment of acute pulmonary exacerbation of cystic fibrosis associated with 
Pseudomonas aeruginosa in children and adolescents of 5-17 years of age. The use of 
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ciprofloxacin in paediatric patients with complicated urinary tract infections and 
pyelonephritis should be restricted to infections caused by organisms for which 
ciprofloxacin is the drug of choice, based on the results of antimicrobial susceptibility 
testing. Treatment should be initiated by a physician who is experienced in the treatment 
of severe infections in children and adolescents and after careful benefit/risk evaluation, 
due to possible adverse events related to joints and / or surrounding tissues (see sections 
4.4 and 5.1)  
In case of mixed infections with anaerobes ciprofloxacin must be combined with other 
antibiotics effective against anaerobes.  
Consideration should be given to official guidance on the appropriate use of antibacterial 
agents.  
4.2 Posology and method of administration  
The solution for infusion should be administered over an infusion period of 60 minutes.  
Due to the increased risk of local reactions, higher intravenous doses in particular should 
only be administered via a large vein or a central line. Mixing with other solutions: see 
sections 6.2 and 6.6.  
The duration of treatment depends upon the severity of infection, clinical response and 
bacteriological findings. Generally, acute and chronic infections (e.g. osteomyelitis and 
prostatitis, etc), where the causative organism is known to be sensitive to ciprofloxacin, 
should be treated for at least three days after the signs and symptoms of the infection 
have disappeared.  
Adults:  
The adult dosage is 200 – 400 mg ciprofloxacin twice daily.  
In case of very serious, life-threatening or recurrent infections the dosage can be 
increased to 400 mg three times daily. The maximum daily dose is 1200 mg.  
Osteomyelitis:  
Prior to initiation of therapy, bacteriological sensitivity tests should be conducted. As with 
all other antibiotics, the patient should be monitored during therapy for the development 
of resistant strains of initially sensitive bacteria, especially P. aeruginosa and S. aureus 
(see the relevant statements in section 5.1). Average duration of treatment can be 4-6 
weeks. If a prolonged treatment is necessary, a reassessment of treatment should be 
done at 2 months at the latest.  
Impaired renal function:  
In patients with a creatinine clearance in the range 31 – 60 ml/minute/1.73 m2 or a serum 
creatinine concentration in the range 124 – 174 μmol/l, the maximum daily intravenous 
dose is 800 mg.  
If creatinine clearance is ≤ 30 ml/minute/1.73 m2 or the serum creatinine concentration is 
≥ 175 μmol/l, the maximum daily intravenous dose is 400 mg.  
In patients on haemodialysis or CAPD, the maximum daily intravenous dose is also 400 
mg. On the dialysis days, the dose is given after the haemodialysis session.  
Impaired hepatic function:  
In case of impaired hepatic function it is not necessary to adjust the dosage.  
Impaired renal and hepatic function:  
Dose adjustment according to renal function. Monitoring the level of active substance in 
the blood provides the most reliable basis for dose adjustment.  
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Elderly:  
Due to the higher plasma levels in the elderly it is advisable to administer doses based 
on creatinine clearance and severity of disease.  
Paediatric patients:  
Acute lower respiratory tract infections caused by Pseudomonas aeruginosa in children 
and adolescents (5-17years) with cystic fibrosis: Twice daily intravenous administration 
of 15 mg/kg bodyweight, or 10 mg/kg bodyweight three times daily (maximum of 1200 mg 
per day).  
Complicated urinary tract infections and pyelonephritis:  
For complicated urinary tract infections or pyelonephritis the dose is 6 to 10 mg/kg IV 
every 8 hours with a maximum of 400 mg per dose or 10 to 20 mg/kg orally every 12 
hours with a maximum of 750 mg per dose.  
For complicated urinary tract infections or pyelonephritis the duration of treatment is 10-
21 days.  
The dosage in children with impaired renal and/or hepatic function has not been 
investigated.  
4.3 Contraindications  
Ciprofloxacin is contraindicated in:  
• patients with a hypersensitivity to ciprofloxacin, chinolin carboxylic acid derivatives or 
to any of the excipients  
• children under 5 years of age. With regard to the safety and use of ciprofloxacin in 
children, see also section 4.4  
• Children and growing adolescents except for the treatment of acute pulmonary 
exacerbations of cystic fibrosis in children aged 5 to 17 years.  
• pregnancy and lactation  
• patients with a history of tendon disorder related to fluoroquinolone administration  
• Concurrent administration of ciprofloxacin and tizanidine  
 
4.4 Special warnings and precautions for use  
Renal and urinary system:  
Crystalluria related to the use of ciprofloxacin has been reported. Patients receiving 
ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be 
avoided.  
Hepatic disorders:  
Cases of hepatic necrosis up to life threatening hepatic failure have been reported with 
ciprofloxacin (see section 4.8). In the event of any signs and symptoms of hepatic disease 
(such as anorexia, jaundice, dark urine, pruritus or tender abdomen), treatment should be 
discontinued.  
Blood and lymphatic system:  
Patients with a family history of or actual defects in glucose-6-phosphate dehydrogenase 
activity are prone to haemolytic reactions with quinolones, and so ciprofloxacin should be 
used with caution in these patients.  
Central nervous system:  
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As with other fluoroquinolones, specific undesirable effects with regard to the central 
nervous system must be taken into account when using Ciprofloxacin . In patients with 
epilepsy or other lesions of the central nervous system (e.g. reduced convulsion 
threshold, a history of epileptic seizures, diminished cerebral blood flow, changes in brain 
structure or stroke), ciprofloxacin is only to be used after carefully weighing the benefits 
against the risk, because the possibility of central nervous side effects puts these patients 
at increased risk.  
Anaphylactic/anaphylactoid reactions can in very rare cases develop into life-threatening 
shock, sometimes even after the first administration of ciprofloxacin. In that case, the 
ciprofloxacin treatment must be discontinued, and medical treatment for shock should be 
given.  
Local reaction:  
Local reactions have been reported after intravenous administration of ciprofloxacin. 
These reactions occur more frequently when the infusion time is 30 minutes or less. These 
may be manifested as local skin reactions, which rapidly disappear after the infusion has 
been completed.  
Further intravenous administration is not contraindicated unless the reactions reoccur or 
worsen.  
Because ciprofloxacin has some activity against Mycobacerium tuberculosis, false-
negative cultures may occur when the specimens are obtained during ciprofloxacin 
treatment.  
Ciprofloxacin contains 15.4 mmol (354 mg) sodium per 100 ml solution for infusion. This 
has to be taken into consideration for patients on a controlled sodium diet.  
 
The undesirable effects sometimes occur already after the first administration of 
ciprofloxacin. Depression or psychoses lead to self-endangering behaviour in some 
cases. If such reactions occur, treatment with ciprofloxacin must be discontinued 
immediately and the treating physician informed.  
Cardiac disorders:  
Since ciprofloxacin is associated with very rare cases of QT prolongation (see section 
4.8) caution should be exercised when treating patients at risk for torsade de pointes 
arrhythmia.  
Pediatric use:  
Ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature 
animals. Safety data from a randomized double blind study on ciprofloxacin use in 
children (Ciprofloxacin: n=335, mean age = 6.3 years; comparators: n=349, mean age = 
6.2 years; age range = 1 to 17 years) revealed an incidence of suspected drug related 
arthropathy (discerned from joint-related clinical signs and symptoms) by Day +42 of 7.2% 
and 4.6%. Respectively, an incidence of drug-related arthropathy by 1-year follow-up was 
9.0% and 5.7%. The increase of suspected drug related arthropathy over the time was 
not statistically significant between groups. Treatment should only be initiated after a 
careful benefit/risk evaluation, due to possible adverse events related to joints and/or 
surrounding tissue.  
The use of ciprofloxacin for indications other than the treatment of acute pulmonary 
exacerbation of cystic fibrosis caused by P. aeruginosa infection (children aged 5 – 17 
years), complicated urinary tract infections and pyelonephritis (children aged 1 – 17 years) 
and for the use in inhalational anthrax (post-exposure) has not been evaluated in clinical 
trials and the clinical experience is limited. The use of ciprofloxacin should follow the 
official guidance.  
Gastrointestinal tract:  
When during or after the treatment with ciprofloxacin or another fluoroquinolone severe 
and persistent diarrhoea occurs, pseudomembranous colitis must be taken into account 
(life-threatening with possibly fatal outcome). In that case the ciprofloxacin therapy must 
immediately be discontinued and an appropriate treatment initiated. Antiperistaltics are 
contraindicated. The transaminase or alkaline phosphatase concentrations may 
 325                                Helen Hill University of Liverpool 2010 
temporarily increase or cholestatic icterus might occur, especially in patients with previous 
liver damage.  
Musculoskeletal system:  
If there is any indication of tendinitis (e.g. painful swelling) the administration of 
ciprofloxacin or other fluoroquinolones must immediately be discontinued, the affected 
extremity should not be strained and a physician must be consulted. Very rarely, a partial 
or total rupture (in particular of the Achilles tendon) has been reported, especially in 
elderly patients who were previously treated systemically with glucocorticoids.  
Ciprofloxacin may cause an exacerbation of Myastenia gravis symptoms. Therefore, in 
case of any symptom indicating an exacerbation of Myastenia gravis a physician must be 
consulted.  
Photosensitivity:  
Ciprofloxacin and other fluoroquinolones may cause photosensitivity. Therefore, it is 
recommended to avoid prolonged exposure to sunlight or UV light during treatment with 
ciprofloxacin. However, if this is not possible the patient is recommended to use a sun-
protection cream. When photosensitivity occurs the treatment must be discontinued.  
Hypersensitivity:  
Hypersensitivity reactions and allergic reactions occurred in some cases after the first 
administration of ciprofloxacin. If such reactions occur, a physician must immediately be 
consulted.  
4.5 Interaction with other medicinal products and other forms of interaction  
Probenecid  
Probenecid inhibits the renal excretion of ciprofloxacin resulting in an increase in the 
plasma concentration of ciprofloxacin.  
CYP1A2  
Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of 
concomitantly administered substances metabolised by this enzyme (e.g. theophylline, 
clozapine, tacrine, ropinirol, tizanidine). Therefore, patients taking these substances 
concomitantly with ciprofloxacin should be monitored closely for clinical signs of overdose. 
Determination of serum concentrations, especially of theophylline, and dose adjustments 
may be necessary. The interaction between theophylline and ciprofloxacin is potentially 
life-threatening.  
Other xanthine derivatives  
On concurrent administration of ciprofloxacin and caffeine or pentoxifylline 
(oxpentifylline), raised serum concentrations of these xanthine derivatives were reported.  
Phenytoin  
Simultaneous administration of ciprofloxacin and phenytoin may result in increased or 
reduced serum levels of phenytoin such that monitoring of drug levels is recommended.  
Methotrexate  
Renal tubular transport of methotrexate may be inhibited by concomitant administration 
of ciprofloxacin potentially leading to increased plasma levels of methotrexate. This may 
increase the risk of methotrexate associated toxic reactions. Therefore, patients receiving 
methotrexate therapy should be carefully monitored when concomitant ciprofloxacin 
therapy is indicated.  
Ciclosporin  
Following concomitant administration of ciprofloxacin and ciclosporin a transient increase 
of the serum creatinine concentration has been observed in separate cases. Therefore, 
the serum creatinine concentration must be checked regularly (twice per week) in these 
patients.  
Oral anticoagulants (e.g. warfarin)  
Ciprofloxacin, like other quinolones, may enhance the effect of coumarin derivates 
including warfarin. In the case of concomitant administration of these products, 
prothrombin time (PT) or other suitable coagulation tests should be monitored. If 
necessary, the oral anticoagulant dose should be adjusted as appropriate.  
 
Glibenclamide  
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When used simultaneously, ciprofloxacin may, in certain cases, increase the effect of 
glibenclamide (hypoglycaemia).  
NSAIDs  
Animal trials have shown that the concurrent administration of very high doses of 
fluoroquinolones and certain NSAIDs (but not acetylsalicylic acid) may provoke 
convulsions.  
Mexiletine  
Simultaneous administration of ciprofloxacin and mexiletine can lead to increased plasma 
concentrations of mexiletine.  
4.6 Pregnancy and lactation  
Pregnancy  
Use during pregnancy is contraindicated. There are limited data on the use of 
ciprofloxacin during pregnancy. Up to now, no evidence has been found of an increased 
risk of congenital abnormalities or other undesirable effects following use of ciprofloxacin 
or other quinolones during the first trimester. Teratogenic effects have not been observed 
in animal experimental research. In juvenile and prenatal animals exposed to quinolones 
effects on immature cartilage have been observed. Since the risks for humans are 
unknown Ciprofloxacin must not be administered during pregnancy (see section 4.3).  
Lactation  
Ciprofloxacin is excreted in breast milk. Due to the risk of arthropathy and other potentially 
severe toxicity in the infant, ciprofloxacin is contraindicated during lactation (see section 
4.3).  
4.7 Effects on ability to drive and use machines  
Ciprofloxacin has minor or moderate influence on the ability to drive and use machines. 
When undesirable effects on the central nervous system, like dizziness, occur, it is 
prohibited to drive a vehicle or to operate machines.  
4.8 Undesirable effects  
Adverse reactions have been reported in 5-14% of patients receiving ciprofloxacin. Most 
frequent adverse reactions involve the gastro-intestinal tract and the central nervous 
system.  
The following adverse reactions have been observed:  
In this section undesirable effects are defined as follows: 
very common  
(≥1/10)  
common  (≥1/100 to <1/10)  
uncommon  (≥1/1,000 to <1/100)  
rare  (≥1/10,000 to <1/1,000)  
very rare  (<1/10,000), not known (cannot be 
estimated from the available data)  
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Information Sheet for Parents/Guardians 
A study about the antibiotic 'Ciprofloxacin' used to prevent or treat infection in 
neonates and young infants.     
We would like to invite you to allow your baby to participate in a research study. Take enough 
time to decide whether or not you wish to take part. It is important for you to understand why 
the research is being done and what it will involve before deciding.  Please read the following 
information carefully and discuss it with others if you wish, or ask us if you would like more 
information.   
The purpose of this study is to monitor the effects of Ciprofloxacin an antibiotic. This drug has 
been used in babies for a long time. It has been tested extensively in adults and children but less 
so in neonates. By monitoring babies who are prescribed this medicine as part of their clinical 
care will help us to work out the most effective dose to treat infections, the time to wait between 
dose and which, if any, side effects are important.  
Why has my baby been chosen?  
You have been asked to consider taking part as your baby is less than 3 months of age and during 
the time they are in hospital they may require the antibiotic 'Ciprofloxacin' to prevent or treat 
infection. Your baby's doctor (not the research team) may make a decision to start this antibiotic 
(it would be given through a drip as part of their clinical care).  We would like to monitor babies 
as soon as the treatment is started therefore would like to ask for your consent at this stage.   
We would like to include 50 babies for this study. Some of the babies will be treated at Liverpool 
Women’s Hospital and some will be treated at Alder Hey Children’s Hospital.        
Does my baby have to take part?  
No - It is up to you to decide whether your baby can take part and which part of the study you 
would be willing to consent to. This decision will not affect the care your baby receives. If you do 
decide to take part then change your mind you are free to withdraw at any time without giving 
a reason. You may request that any information already collected can also be withdrawn.  
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What will happen to my baby if s/he takes part in the drug level and safety study?  
o The research team will collect details from the baby’s medical notes and complete a 
physical assessment. 
o To monitor the level of the antibiotic in the baby’s blood we will collect 2-3 blood 
samples (0.2 ml approximately 4 – 6 drops for each sample or less in very small babies) 
on the first and last day of treatment.  
o A sample of faeces from the baby’s nappy will be collected whilst in hospital and 
between 4-6 weeks later (may be posted from home if no longer in hospital).  
o We will monitor your baby carefully for any potential side effects to the antibiotic.  
Additional consent for further samples:  
o CSF Sample - in some situations when a baby shows signs of infection their doctor may 
decide to test a sample of the fluid that surrounds the brain and spinal cord ‘CSF’ 
(cerebrospinal fluid) to see if they need to treat infection in this area. If your baby 
needs this test for their clinical care we would like to use a few extra drops (0.5ml) to 
see if the antibiotic is effective in treating infection in this part of the body.  
o ‘Genetics’ –some babies may respond better to this antibiotic than others, this could 
be because different genes have a better response than others. We would like to asses 
this by analysing DNA obtained from blood already taken for your baby’s care or by 
wiping a cotton bud in the baby’s mouth. The genetic sample will only be used for the 
purpose of collecting information on babies, response to infection or this medicine. 
 
If you choose to consent to the study you will be asked to sign the appropriate boxes on the 
consent form stating which samples you have agreed to.   
What are the possible benefits of taking part?  
There are no direct benefits to your baby but the study may help the clinical team to know more 
about the best way to treat babies in the future. Many studies of different treatments over the 
years have enabled us to develop the care of babies.   
Studies involving children only provide expenses to families if they are required to travel, 
therefore there will be no financial compensation.    
Are there any side effects?  
The study involves closely monitoring the effects of ciprofloxacin therefore there are no side 
effects to the monitoring.  Ciprofloxacin would be given as part of the clinical care not as part of 
the study. This study will check in more detail the effects of this drug by closely observing the 
effects of this treatment.   
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What are the disadvantages or risks of this procedure when taking part?  
Taking blood samples may lead to some discomfort for the baby.  Blood samples will be taken 
by staff experienced in taking blood from premature or new born babies. The team will make an 
effort to minimise any distress with involvement of parents. 
When babies require this antibiotic they often require other blood samples for their clinical care, 
whenever possible we will plan to take these at the same time as the study sample to minimise 
disturbing your baby.  Some babies will already have a line into a blood vessel to give fluid, other 
medicines or for monitoring, when possible we will aim to take the sample from this line. In some 
cases when this is not possible then we may take a small amount of blood from a vein or a heel 
prick. If we are unable to take the sample or if the baby is too distressed then we will stop.   
What happens after the study?  
With your permission the researcher may contact you to ask a few questions about your baby at 
a later stage.  Also, if you would like to receive a summary of the results of the study this will be 
sent to you. (If you agree you will be asked to initial the appropriate box on the consent form).   
What if something concerns me?  
If you have any concern about the study you may speak to the researcher or the baby's doctor 
or nurse who will discuss this with you and try to provide an answer.  If you wish to complain, or 
have concerns about any aspect of the study the National Health Service complaints mechanisms 
may be followed.   
Will my taking part in this study be kept confidential?  
If you do consent to the research, your baby's medical records may be read by the research team 
or inspected by regulatory authorities to check that the study is being carried out correctly.  With 
your permission we will write to your GP to let them know that your baby has been part of the 
study (this is routine for any research).  Your baby's name or other personal details will not be 
given to anyone else outside the hospital.  All information will be stored confidentially.  
If you have agreed to a DNA sample this will be given a code so that it is confidential then stored 
in the TINN Genetics Laboratory in European for a maximum of 10 years.  
What will happen to the results of the research study?  
 330                                Helen Hill University of Liverpool 2010 
The results will contribute to the information on the use of medicines for children and may be 
used to guide the dosage and administration of this drug specifically for neonates. We will 
publish the results of the study in medical journals, present to other relevant staff and put a 
summary of the results onto the hospital web site.  The results will not be available until after 
the research has finished.  We plan to get a license for this medicine in newborn babies. If you 
would like us to send you a summary of the results please initial the appropriate section on the 
consent form.  
Who is organising and funding this research?  
The study is a European research network project supported by the European Commission 
(Health Co-operation Work Programme of the 7th Framework Programme).      
Who has reviewed the study other than the research team?   
The study has been reviewed by the UK National Research Ethics Service, the Medicines for 
Children Research Network including nurses and doctors who are experts in the care of new born 
babies and by the Research Governance Group at Liverpool Women's Hospital and Alder Hey 
Children's NHS Foundation Trust.  
Contact for further information?  Dr Mark Turner Consultant Neonatologist 0151 708 9988 or 
24 hour access via switch board Email: mark.turner@liverpool.ac.uk  
Helen Hill Research Fellow 0151 702 4111 Email: Hhill@liv.ac.uk  Email: TINN@lwh.nhs.uk  
The clinical team support this study, including the Neonatal Consultants or Consultants at the 
Childrens’s Hospital.  
Thank you for reading this information sheet.          Version number1            EudraCT number  
2010-019955-23  
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PARENTAL CONSENT FORM 
To study the antibiotic Ciprofloxacin used to prevent or treat infection  
in neonates and young infants Researchers: Chief Investigator Dr Mark Turner, Research 
Fellow Helen Hill  
Name of baby………………………………………       
 
1. I confirm that I have read and understood the information sheet and have  
      had the opportunity to ask questions and these have been answered satisfactorily. 
2. I understand that my baby's participation is voluntary and that we are free to withdraw at 
any time, without giving reason, without my babies medical care  
      or legal rights being affected.  
3. I understand that sections of any of my baby's medical notes may be looked at by  
the research team or the  regulatory authorities for this research. I give permission for these 
individuals to have access to my baby's records.  
4. I understand that my family doctor will be informed that my child is taking part in this 
study. 
5. I agree for my baby to take part in the ciprofloxacin safety and drug level study 
6. I agree for my baby's DNA to be analysed for the genetic part of this study   
7. I agree that if my baby’s doctor decides to test cerebrospinal fluid they may take 
       an additional sample at the same time for this study.       
8. I would like a summary of the results of the study when the research is completed.  
9. I agree to be contacted at a later stage regarding the study.   
Name of parent:………………………………  Relationship to baby……………………………… 
Signature………………………………………….          Date…………………………………    
Researcher.......................................Signature ..................................Date:....................   
Photocopy and give 1 copy to the parent, 1 for research file, original in the medical notes 
EudraCT number  2010-019955-23      Patient's study number:                        Version 
number 1 
 
Please Initial 
Box 
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Leaflet /Flyer 
 
Treat Infections in Neonates 
INFORMATION FOR PARENTS OF BABIES UNDER 3 MONTHS AGE 
Ciprofloxacin Study 
for babies less than 3 months age at 
 Liverpool Women’s Hospital  
&  
Alder Hey Children’s Hospital 
Ciprofloxacin, it is an ‘antibiotic’ used to treat or prevent infection in neonates 
and young infants. It is often used when the infection has not responded to 
other antibiotics 
We would like to ask your permission for your baby to take part in the study. 
Then if at any time during their hospital stay they are prescribed this medicine 
as part of their care the research team will be able to monitor the baby as soon 
as they start the treatment. 
The antibiotic has been used for many years in newborn babies and infants. We 
believe ciprofloxacin is a safe medicine in newborn babies.                            
 
The study will allow us to update prescribing guidelines by checking the most 
effective dose to treat infections and the time we should wait between doses. 
By collecting details from the baby's medical records, drug levels from blood 
tests, stool sample from the nappy and by completing a physical assessment (as 
the clinical team do routinely) we can monitor possible side-effects very 
carefully. 
We would like to give you an information sheet to explain this in more detail 
then allow you to ask questions about the study.  
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This information will be offered to families of babies who are in hospital and 
under 3 months of age.  
If you then choose to take part you will be asked to sign a consent form, this will 
allow us to monitor your baby if they are prescribed ciprofloxacin for their 
clinical care. 
 
  
 Contact details: 
If you have any questions at any time the doctors, nurses and researchers will be 
pleased to provide more information. Please contact us or ask any of the clinical 
staff to contact us on your behalf:  
Liverpool Women’s NHS Foundation Trust  
Dr Mark Turner, Consultant Neonatologist Tel: 0151 702 4029 (Secretary)  
        0151 702 4193 (Neonatal Unit)   
Helen Hill Research Fellow  
Tel: 0151 702 4111  
Alder Hey Children’s NHS Foundation Trust 
Dr Sarah Mahoney  
Consultant Intensivist  
Alder Hey NHS Foundation Trust  
Tel: 0151 228 4811 
Email: TINN@lwh.nhs.uk 
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Information for Parents of all Babies under 3 
months of Age   
What is Ciprofloxacin? It is an antibiotic we use to treat infections. It is often 
used when the infection has not responded to other antibiotics. Ciprofloxacin has 
been used for many years in new born babies and infants.  
  
We are leading a European study about an antibiotic called 
Ciprofloxacin used to treat infection in babies.   
Many studies of different treatments over the years have enabled us to 
develop the care of babies.  
 
 
Please contact us: Tel: 0151 702 4193 
Alder Hey Hospital: Dr Sarah Mahoney Consultant  Paediatrician  Tel: 0151 228 4811 
                        Dr Stephane Paulus Consultant  Paediatrician Tel: 0151 228 4811  
Both sites: Helen Hill Research Fellow 0151 702 4111 
Email TINN@lwh.nhs.uk. 
We would like to provide information to families about the study then 
allow you time to ask questions and consider whether your baby may take part in the 
monitoring. The medicine would be prescribed by your baby’s doctor as part of your baby’s 
clinical care  not as part of the research. The researchers would like to ask for your consent 
so that if your baby needs this medicine at any time we may monitor them as soon as the 
treatment is started.  
 
Why are we studying this medicine? By monitoring babies who are 
prescribed this medicine will help us to work out the most effective dose to treat 
infections, the time to wait between doses and which, if any, side effects are 
important.  
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TINN  TREAT INFECTIONS IN NEONATES 
Pharmacokinetics, tolerability and short-term safety of ciprofloxacin in 
neonates with suspected (or proven) Gram Negative infection 
Case Report Form  
1st letter of patient name:                |__| 
1st letter of patient surname:       |__|  
Center Number:    |__|__|  (centre LWH 1 AHH 2)  
Inclusion number in the study:  |__|__|__| 
Date of Inclusion  
Date of Birth:    |__|__|/|__|__|/|__|__|__|__| (dd/mm/yyyy) 
INCLUSION CRITERIA 
 Yes No 
Information Leaflet Provided to Parents   
24– 52 weeks post menstrual age   
Receiving ciprofloxacin as part of clinical care   
Parental consent   
EXCLUSION CRITERIA 
 Yes No 
Likely not to survive 48 hours in the judgement of attending 
physician 
  
Ciprofloxacin administered before day 5 of life   
 ECMO or Haemofiltration   
 
Person(s) with parental responsibility has consented to:  
      Cerebrospinal fluid      
     DNA sample       
     Contacted by Study Team at a later stage  
     Request a copy of the study results    
Appendix II 
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Consent form signed by the parents (or legal representative): 
(According to the local law, at least 1 parent has to sign consent in the UK. Both parents 
have to sign the consent in France)  
 Date |__|__|/|__|__|/|__|__|__|__| (dd/mm/yyyy):  
 
1 copy given to parents Yes 
  1 copy case report form  Yes 
1 copy medical notes  Yes 
 
Eligibility: 
Patient commenced ciprofloxacin and is now eligible signed………………… (medically 
qualified)   Date……….. 
Record eligibility in is determined by a medically qualified)    
 Demographics 
Gender:    Male   Female 
Maternal race 
Caucasian   African    Asian   other (specify):   
Post menstrual age at birth:  ___ ___ weeks ___ ___ days 
Post menstrual age when starting study weeks ………..days………………. 
Birth weight: ___ ___ g 
Fetal growth restriction*  yes   no 
*According to the local curve:  
In UK, birth weight below 9TH CENTILE  
In France: Audipog (http://www.audipog.net/crois-foet.php) 
Apgar score at 5 minutes   ------- 
Surfactant:        yes   no 
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Indication of ciprofloxacin treatment (at the start of treatment) 
Suspected gram negative infection       
Proven (microbiologically documented) gram negative infection*  
Proven multi-resistant gram negative infection    
With proven Meningitis        
With suspected Meningitis        
Renal sparing         
*Blood culture 
Summary of ciprofloxacin administration (since birth to 42 days after the study start) 
Study period 
Start of treatment  |__|__|/|__|__|/|__|__|__|__| (dd/mm/yyyy) 
End of treatment  |__|__|/|__|__|/|__|__|__|__| (dd/mm/yyyy) 
Everyday from the start to the end of treatment   
Dose 
number 
Not 
administered*  
 
  
 
dose 
mg 
Date 
(day/ 
month/ 
year) 
Start 
time of 
infusion  
 
Stop 
time of 
infusion 
** 
 
Line primed 
with 
ciprofloxacin 
Yes or no 
 
State if given via a 
broviac  
1        
2        
3        
4        
5        
6        
7        
8        
9        
10        
11        
12        
13        
14        
15        
16        
17        
18        
19        
20        
21        
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*If the ciprofloxacin was not administrated code reason a) no intravenous access b) 
absent due to other procedure (theatre etc),  c) other describe (includes stopped due 
to end of treatment) 
**if the stop time has not been completed then check the nursing notes for any record 
of a delay in the infusion then make a note in the comments to say there is /is not a 
record of a delay and the planned infusion time (30 or 60 minutes) .  
Summary of all treatment episodes from birth to 42 days after study start 
Episode 1  
Ciprofloxacin administered from …………………………………….to………………………Dose 
administered……………. 
Episode 2 
Ciprofloxacin administered from …………………………………….to………………………Dose 
administered…………….. 
Episode 3  
Ciprofloxacin administered from …………………………………….to………………………Dose 
administered…………….. 
Comments: 
 
 
 
 
 
Important if administered via a Broviac the time the drug reaches the vein may 
need adjusting please state here the date and time doses were given via a 
broviac 
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Co-administration  
Record all antimicrobials, steroids, vasoactive, proton pump inhibitors, antiepileptics, inotrope, 
cox inhibitors (non-steroidal), albumin , Selective decontamination of the digestive tract 
and caffeine from the first dose of study drug and through the last dose of study drug therapy. 
Class Drug name 
Date of inclusion or 
start date if after 
inclusion 
 
 
 
Stop date up to the end of study 
drug or state ‘continuing’  
Antimicrobials                                                                                                                                                            
    
Steroids    
    
Inotropic drugs    
    
Proton pump inhibitor ( antacids)    
    
Antiepileptics    
    
Warfarin    
Cox inhibitors (non-steroidal)    
    
Albumin    
    
Selective decontamination of the 
digestive tract 
   
Indomethacin     
Diuretics     
 Caffeine 
Date of  
inclusion  
Stop Date or 
last day of 
study drug  
Mode of 
administration 
Loading 
Dose 
Maintenance 
dose 
Interval 
between doses 
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PK Blood Sample Planner and Record of Collection Times 
1st Day of PK : |__|__|/|__|__|/|__|__|__|__| (dd/mm/yyyy) 
Last day of PK |__|__|/|__|__|/|__|__|__|__| (dd/mm/yyyy) 
Weight start of ciprofloxacin.........................tinn 
Weight Last day of PK sampling ............................... 
Day of ciprofloxacin treatment: day 1 or  day 2,,   then   day 5,    day 6  or  day 7,      
Most recent weight (start of ciprofloxacin) :                              weight drug calculated on:   
Weight (day of PK (if available) 
Sample group (allocation):  A   B   C   D 
Q 12 h 
A T1 T3h T8h 
B T2h T6h T12h 
Q8 h 
C T1h T3h T6h 
D T2h T4h T8h 
 
For weight< 1000g, 2 samples will be randomly selected from 3 predefined samples 
times (web site) 
 
Q 12 h 
Ai T1h T3h  
Aii T1h  T8h 
Aiii  T3h T8h 
BI T2h T6h  
 Bii T2h  T12h 
 Biii  T6h T12h 
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PK Blood Samples  
 
Planned  Sample 
Schedule 
(according to 
allocated group) 
Planned 
Sample 
Time   
Actual Time 
sample 
collected 
Date and time 
sample frozen at -
20°C 
(must be within 
24 hours of 
collection)* 
Sample source 
capillary /central 
venous/ arterial 
Sample 
number** 
PK Day 1 or 2  
T….   
 
   
T….   
 
   
T…. 
 
  
 
   
PK  Last day  
T….   
 
   
T….   
 
   
T….   
 
   
Christine Chesters Biochemistry will provide this data 
** this does not allow letters so just put 1, 2 , 3 etc 
T1  sample is required within 3 minutes of the end of the 1st infusion; other sample 
times allow 10 minutes before or after the set time.  
 
PK Scavenged Samples - Blood samples (centrifugation before storage) 
 
Date Time 
collected  
Date and Time 
frozen 
sample number 
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CSF Sample  
Date Time 
collected  
Time frozen sample number 
    
    
 
 DNA sample (buccal smears) 
 
 
 
 
 
DNA sample (blood sample)  
Received in batches from the lab so check lab have collected surplus FBC and state this 
date  
 
 
 
 
 
 
Microbiological data - Culture Results 
Data reported 72 hours prior to start of ciprofloxacin until day 10  
Include most recent gram negative blood culture if earlier than this period. MIC reported 
at the end of the study 
Site of collection 
using code list 
Date  Organism (state if no 
growth) 
Sensitivity 
/Resistance  to 
ciprofloxacin 
MIC Ciprofloxacin  
     
     
     
     
     
     
Code list :  
1 Peripheral (blood)  2 Central line (blood) 3 Peritoneal fluid 4 Endotracheal tube suction 
5 Other sterile (specify)  
Date 
collected 
Date 
completed 
*Extracted 
sample 
number 
   
Dates 
collected 
Date 
completed 
* extracted 
sample 
number 
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Faeces  
Sample date Date obtained 
/received: 
Results:* 
 
MIC 
 
1st Sample  
(immediately prior to 
ciprofloxacin or before 
day 2) 
 
 
  
Colonisation: 
 
 
 
 
 
2nd Sample  
 
Date packaging sent to 
family 
 
……………………. 
Required 4-6 weeks 
following ciprofloxacin 
 
  
Gram negative 
insensitivity: 
 
Results will be added at the end of the study so leave blank and do not freeze this form 
yet
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Articular Phlebitis Assessment 
Date Examination 
Assessment 
 (indicate specially if it’s related with 
ciprofloxacin)* 
Or enter not applicable 
Prior to ciprofloxacin start Normal or no clinical sign    ⁮  
Pain                                      ⁮  
Redness                                ⁮  
Immobility                              
 
Day 5  Normal or no clinical sign    ⁮  
Pain                                      ⁮  
Redness                                ⁮  
Immobility                                
 
Day 7 
 
Normal or no clinical sign    ⁮  
Pain                                      ⁮  
Redness                                ⁮  
Immobility                                
 
End of ciprofloxacin Normal or no clinical sign    ⁮  
Pain                                      ⁮  
Redness                                ⁮  
Immobility                               ⁮  
 
End of hospitalisation 
 
Normal or no clinical sign    ⁮  
Pain                                      ⁮  
Redness                                ⁮  
Immobility                                
 
Any additional day if 
abnormal 
Normal or no clinical sign    ⁮  
Pain                                      ⁮  
Redness                                ⁮  
Immobility                                
 
Assessment of Phlebitis - Peripheral Infusion Site - VIP Score every day until the end of 
ciprofloxacin treatment – record the highest score for the vein that day.  
Day of 
ciprofloxacin 
treatment  
Date 
Planned 
Duration of 
infusion (30 
minutes or 60 
minutes) 
Pre 
dose 
Mid 
infusion 
1 hour 
post 
dose 
6 hours 
post 
dose 
Central 
line 
infusion* 
       
       
       
       
       
       
       
*IMPORTANT - If given via a broviac please make a comment in the summary as the drug 
may take longer to enter the vein. 
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Lab results 
If more than one blood sample has been taken in the day record the value that is furthest 
from the normal range   Do not record decimal places for haemoglobin or CRP.    
 
 72 hours prior to 
ciprofloxacin 
Date: 
1st day of 
ciprofloxacin 
Date: 
Last study day of 
ciprofloxacin 
(day 5,6 or 7)  
Date: 
3 days 
after last 
dose  
Date 
Full Blood Count     
Haemoglobin     
WBC     
Platelets     
Haematocrit     
Biochemistry     
Creatinine     
Albumin     
Blood Gas     
pH     
PCO2     
PO2     
Glucose     
Ionized Calcium     
Lactate     
 
Liver function and CRP need to be recorded only on the days assessed for clinical care 
 Within  
72 hours 
prior to 
ciprofloxacin 
1st day of 
ciprofloxaci
n 
Day 
2 
Day 
3 
Day 
4 
Day 
5 
Day 
6 
Day 7 3 days after 
last dose 
Liver Function           
Total Bilirubin          
Conjugated 
Bilirubin 
         
AST          
ALT          
ALK Phosphate          
Amylase          
CRP          
 
 346                                Helen Hill University of Liverpool 2010 
Summary of clinical history 
Date of hospitalization in the NICU ……………………….  
End of hospitalization ……………………..  
Status at admission: Inpatient/in born or transferred from another hospital  
Weight: end of cipro treatment or on 10th day (if available):  
Weight end of hospitalization:    
Status 6 weeks following commencement of ciprofloxacin date ……………………… : 
Inpatient   Transferred to another hospital   Discharged Home:          
Death date…………………….. 
Ventilation  
 1st day ventilation from birth …………………………. Last Day of ventilation 
*…………………………… 
Ventilation  Mode on Day 1 
PK samples 
Last Day PK 
samples  
HFO   
Pressure support /BIPAP   
CPAP   
Non invasive CPAP   
Not ventilated   
 If ventilation has stopped and started as part of weaning  record the last day 
ventilated 
Record transfusions from the 1st day of ciprofloxacin until day 10   
Include Blood Product: Packed Red Cells      Fresh Frozen Plasma     Cryo    Human Albumin 
Solution      Platelets  
Date administered Blood Product  Volume (ml) 
   
   
   
PDA Yes  or No 
Surgery  Date: 
Indomethacin  Start date: End date: 
Ibuprofen    
Prostin    
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Intervention 1st Day PK 
Samples 
Last Day PK Samples  
(day 5, 6, or 7) 
Nutrition  
Parenteral  
Breast Milk 
Formula  
       
   
   
   
            
 
  
  
Gastroesophageal reflux                                                             
Phototherapy                                                              
Haemofiltration *                                                             
ECMO*                                                             
Cooling                                                              
*Patients on ECMO or Haemofiltration are excluded from the study but this is recorded if 
started after inclusion 
Outcome record from 1st dose until 42 days (if the outcome occurs out with this 
time period then please add details to the comments box)  
   
Outcome  Yes or No  Details Date (within 
monitoring 
period) 
Surgery –any surgical 
procedure 
  
 
 
Necrotising 
Enterocolitis  
 Surgical                    
Medical                     
 
Tolerability:–  
state if ciprofloxacin 
was stopped due to a 
clinical concern 
 Reason stopped:  
Fitting     
Intra ventricular 
Haemorrhage 
 
 
 Grade  I        
             II      
             III     
             IV     
Grade not recorded  
  
 
 
Comments  
 
Include if any information: 
To explain a deviation from the protocol 
Chronic clinical condition that may affect drug metabolism such as Downs, Cystic 
fibrosis, hydrops 
Include significant adverse events such as NEC, Death etc that occurred after the 42 
day reporting period  
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Section 4  
Pharmacovigilance Reporting commences on the 1st day of ciprofloxacin until 42 days 
afterwards (last study procedure) see Protocol Section 7 and SOP Section 7 
Serious Adverse Events Reactions or Suspected Serious Adverse Events or Reactions 
require expedited reporting  except for the Expected Serious Adverse Events listed in the 
protocol. These are classed as:  
  Result in death (excluded from expedited reporting in this patient group*)   
Life-threatening ** 
Requires hospitalisation or prolongation of existing hospitalization 
Results in persistent or significant disability or incapacity  
*(the subject was at risk of death at the time of the event it does not refer to an event which 
hypothetically might have caused death if it were more severe).  
*Expected events that are relevant in this context will be collected systematically in the 
CRF (Death NEC, PDA) but do not require further reporting.  
 
**Adverse events that have been identified as more likely in the risk assessment of the 
drug will be collected systematically in the case report form. Additional 
pharmacovigilance reporting will only be required if the investigator assesses the event 
as serious including: 
Arthropathy /Phlebitis / Liver Function /pancreatitis/Renal Function/Deranged 
Blood cells   
Adverse events have been identified in the risk assessment as uncommon and should 
also be included: 
Anaphylaxis /Allergy 
Skin: Rash/photosensitivity 
Cardiac Arrhythmias: ventricular arrhythmia, QT interval prolongation 
Syndromes: Stevens Johnson /Lyell 
Neurological: convulsions 
Adverse event categorie: 
Adverse event details 
Start date: 
Stop date: 
Action taken with study drug: 
Outcome: 
Intensity:  
Severity: 
 
General comments  
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Consent Withdrawn by Parent  
Date of Withdrawn : |__|__|/|__|__|/|__|__|__|__| (dd/mm/yyyy) 
 
Name of Parent:      Date consent withdrawn: 
Describe whether consent is withdrawn from the PK safety /sampling study, from 
CSF, DNA or all. Confirm with parent if the data already collected may still be used.  
 
Name of Person that discussed withdrawal of consent with the parent 
……………………………………………………..  
-------------------------------------------------------------------------------------------------------------------- 
 
Case report From Completed by: 
 
Name:      Signature:   Date: 
  
  
 
 
 
PMA  CL  
(L/h) 
V1 
(L) 
V2 
(L) 
Q 
(L/h) 
AUC 
0-24 
(mg*h/L) 
T1/2 
beta 
(h) 
Dose (mg/ 
dose) 
Dose 
(mg /kg 
/dose) 
PMA 
week 
PNA 
(day) 
Current 
weight (g) 
 
24-27 N 9 9 9 9 9 9 9 9 9 9 9 
Mean 0.10 0.82 0.85 1.32 179 15.64 7.3 8.7 27 14 831 
Median 0.08 0.84 0.85 1.34 167 12.60 7.7 9.6 27 12 850 
Min 0.04 0.54 0.64 1.16 85 5.70 4.5 5.0 25 3 700 
Max 0.22 1.08 1.15 1.42 289 33.80 9.2 10.0 28 27 915 
Std.  0.06 0.18 0.18 0.10 78 9.07 1.7 1.7 1 8 84 
28-31 N 11 11 11 11 11 11 11 11 11 11 11 
Mean 0.17 1.24 1.33 1.69 130 13.06 10.0 8.7 30 24 1154 
Median 0.15 1.18 1.24 1.64 115 12.65 9.3 9.5 30 24 1090 
Min 0.11 0.58 0.73 1.34 65 5.60 5.4 4.4 28 6 850 
Max 0.30 2.0 3.12 2.31 291 23.20 18.0 10.6 31 43 1755 
Std.  0.06 0.44 0.66 0.27 60 5.85 3.4 2.0 1 9 243 
32-35 N 8 8 8 8 8 8 8 8 8 8 8 
Mean 0.24 1.40 1.44 2.04 132 12.09 12.5                                              8.3 33 31 1492 
Median 0.18 1.44 1.48 1.95 136 9.10 12.7 9.6 33 30 1400 
Min 0.08 0.30 0.26 1.66 73 2.80 5.7 5.0 31 3 1130 
Max 0.46 3.22 2.82 2.63 207 32.10 20.0 10.1 35 56 2090 
Std.  0.16 0.89 0.70 0.30 43 9.77 4.6 2.3 1 19 300 
36-39 N 13 13 13 13 13 13 13 13 13 13 13 
Mean 0.54 2.61 2.54 2.88 114 7.91 22.0 9.4 38 46 2362 
Median 0.48 2.25 2.39 2.92 113 7.10 23.0 10.0 37 45 2400 
Min 0.26 1.75 1.57 2.34 46 4.10 18.0 6.3 36 4 1790 
Max 1.04 4.44 5.02 3.61 178 14.00 27.0 11.0 41 105 3190 
Std.  0.24 0.82 0.86 0.38 39 3.14 3.2 1.2 1 35 420 
40-43 N 11 11 11 11 11 11 11 11 11 11 11 
Mean 1.01 3.04 2.76 3.44 95 4.89 27.3 9.3 42 52 2962 
Median 1.09 3.13 2.74 3.53 64 4.90 28.5 9.9 42 30 3053 
Min 0.44 1.15 1.68 2.64 41 2.70 15.0 5.8 41 9 2100 
Max 1.45 4.38 4.35 4.16 201 9.00 35.0 11.0 44 122 3850 
 Std.  0.39 0.95 0.75 0.49 51 2.00 6.3 1.7 1 42 545 
44-48 N 8 8 8 8 8 8 8 8 8 8 8 
 Mean 1.36 3.85 3.42 3.81 88 4.66 32.3 9.3 46 58 3448 
 Median 1.20 4.25 3.34 3.99 73 5.10 31.5 9.4 46 52 3650 
 Min 0.49 2.21 2.16 2.81 35 2.10 20.0 8.3 43 31 2280 
 Max 3.42 5.44 5.51 4.44 184 6.60 40.0 10.0 48 108 4200 
 Std.  0.88 1.28 1.11 0.60 44 1.46 7.5 0.6 2 28 712 
Total  N 60 
0.56 
60 60 60 60 60 60 60 60 60 60 
 Mean 2.17 2.08 2.54 122  18.9 9.1 35.7 38  
 Median 0.38 1.92 1.99 2.51 110  18.7 
 
9.7 36.5 27  
 Min 0.04 0.30 0.26 1.16 35 2.10 4.5 
 
4.4 
 
24.9 5 700 
 Max 3.42 5.44 5.51 4.44 291 33.8 40 
 
11 47.8 121 4200 
 Std.  0.58 1.31 1.14 0.96 60  10.1 1.6 6.5 30  
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Appendix IV Clinical Outcome Protocol   
The minimum inhibitory concentration of Ciprofloxacin and its clinical utility in 
neonates with Gram Negative septicaemia MT 201108 
MA Turner, S Thiesen, S Foulkes, A Hart, C Parry, T Neal 
 
Background 
Ciprofloxacin is a fluoroquinolone antibiotic with useful activity against Gram Negative 
bacteria [Andriole 2005]. 
It has been used as a second line antibiotic on the Neonatal Unit at Liverpool 
Women’s Hospital for 20 years [Bannon 1989]. This Neonatal Unit admits over 1000 
newborn babies a year of whom 60 – 70 are given ciprofloxacin. Organisms isolated 
from neonatal blood cultures are retained in the Clinical Microbiology laboratories at 
Royal Liverpool University Hospital. Most ciprofloxacin is administered because of 
clinical suspicion of sepsis but there have been about 150 cases of proven Gram 
Negative sepsis during the past 15 years. Most of these cases have been given 
ciprofloxacin. The use of ciprofloxacin on this large neonatal unit has avoided 
problems relating to cephalosporin resistance that have been experienced by other 
units. 
Ciprofloxacin is off-patent and is used off-label in neonates. As such the European 
Medicines Agency (EMEA) identified it as a priority medicine for work to develop a 
“Paediatric Marketing Use Authorisation” (PUMA). A consortium involving Liverpool 
Women’s Hospital has been funded by the European Commission to prepare an 
application for a PUMA. Dr. Turner is leading the development and implementation of 
a paediatric investigation plan (PIP) for ciprofloxacin. As part of the work towards the 
PIP and PUMA we wish to examine our use of ciprofloxacin in some detail. 
An important aspect of the evaluation of any antibiotic is the extent of resistance to 
the antibiotic among the target organisms. Resistance can be quantified as the 
“Minimum Inhibitory Concentration” (MIC) which is measured under standardised 
conditions and indicates how much antibiotic is required to inhibit visible growth of a 
APPENDIX IV 
  
 
 
micro-organism. A low MIC indicates a susceptible, or sensitive, micro-organism. A 
high MIC indicates that a micro-organism is resistant to a particular antibiotic. Recent 
work on the mechanisms of resistance to ciprofloxacin has identified several types of 
resistance [Robicsek 2006]. Some of these are associated with a clear signal of 
resistance on routine laboratory testing, with a high MIC. We have examined 
resistance to ciprofloxacin for isolates obtained from blood culture from neonates in 
Liverpool. The results are shown in Table 1. We found that the extent of resistance 
appears to differ according to year of isolate (Figure 1).  
Table 1: sensitivity to ciprofloxacin of Gram Negative organisms isolated from blood 
cultures in neonates in Liverpool 1994 – 2007. 
Organism 
Total Sensitive 
(N) 
Sensitive 
(%) 
Resistant 
(N) 
Resistant 
(%) 
Acineobacter baumannii 2 1 50 1 50 
Acinetobacter 1 1 100 0 0 
Acineobacter lwoffii 5 4 80 1 20 
Enterobacter amnigenus 2 2 100 0 0 
Enterobacter cloacae 19 19 100 0 0 
Enterobacter spp 6 6 100 0 0 
E coli 56 54 96 2 4 
Klebsiella oxytoca 10 10 100 0 0 
Klebsiella pneumoniae 10 8 80 2 20 
Proteus mirabilis 3 3 100 0 0 
Pseudomonas 
aeruginosa 
31 
29 94 2 6 
Pseudomonas 
versicularis 
1 
0 0 1 100 
Serratia marcescens 11 11 100 0 0 
Stenotrophomonas 
maltophilia 
2 1 50 1 50 
      
Total 159 149 94 10 6 
 
 
  
 
 
Figure 1. Number of Gram Negative organisms resistant to ciprofloxacin in Liverpool 
Neonatal Units by time. 
 
 
 
Some types of resistance are associated with more subtle changes in the 
susceptibility to ciprofloxacin and these are associated with smaller changes in MIC 
[Robicsek 2006]. This low level resistance may be more easily detected by testing the 
isolate against the lower class quinolone agent; nalidixic acid. In other populations it 
has been suggested that subtle changes in MIC may predispose to resistance and 
possibly to a reduced effectiveness of fluoroquinolones [Chau 2007]. However, this 
issue has not yet been examined in neonates.  
 
The value of an antibiotic can be examined in two ways. The “effectiveness” describes 
whether it is better than a comparator (another antibiotic or placebo). The “utility” 
describes what happens when an antibiotic is used in individual patients. The ethical 
and scientific complexities inherent to randomising an infant with a life-threatening 
infection that may be due to a multiply-resistant micro-organism mean that it is not 
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feasible to examine the effectiveness of ciprofloxacin for this patient population. 
Accordingly, we are concerned here with the utility of ciprofloxacin in neonates. 
The overall objective of this study is to examine how subtle changes in MIC are related 
to the utility of ciprofloxacin in neonates with Gram Negative septicaemia. We will also 
examine the clinical course of infants who have had a Gram Negative septicaemia.  
The storage of isolates is incomplete, particularly for the earlier years of this series. 
Sixty five isolates are available. This means that a limited number of infants will 
contribute to studies of the relationship between MIC and clinical outcome. 
Nevertheless, descriptive data for infants with Gram Negative isolates on blood 
cultures will inform the design of further studies. Thus, for infants whose isolates have 
not been retained, we will examine the clinical data. For these reasons we will 
consider the cohort in two ways: a) those who have complete data for both 
microbiological and clinical aspects and are eligible for consideration in the primary 
hypothesis (these are identified by a “Case Definition”); b) all infants with clinical data 
available (these are identified by “Inclusion criteria”). This is in accord with guidance 
from the European Medicines Agency about the evaluation of antibiotics [EMEA, 
2004]. 
Aims 
1. To examine the relationship between MIC of ciprofloxacin with respect to Gram 
Negative organisms and the rate of clinical cure of Gram Negative septicaemia.  
2. To determine whether MIC of ciprofloxacin is related to other indicators of utility 
including the number of days during which the infant had evidence of inflammation, 
the duration of ciprofloxacin therapy, microbiological cure rates and the use of other 
antibiotics.  
3. To describe the clinical course of Gram Negative septicaemia in all available cases.  
Hypotheses 
1. Among neonates who receive ciprofloxacin to treat a Gram Negative organism a 
higher MIC to nalidixic acid is associated with less likelihood of clinical cure.  
2. Among neonates who receive ciprofloxacin to treat a Gram Negative organism a 
higher MIC to nalidixic acid is associated with longer duration of an inflammatory state, 
longer administration of ciprofloxacin, lower microbiological cure rates and increased 
use of other antibiotics. 
  
 
 
The third aim will yield descriptive data and a hypothesis will not be tested. 
Outcomes and other variables to be assessed 
Primary exposure variable: 
MIC of ciprofloxacin to Gram Negative organism 
Primary outcome variable: 
Clinical cure: survival to the end of an episode of sepsis during which a Gram Negative 
bacterium was isolated where the episode of sepsis ended within 10 days of starting 
ciprofloxacin 
The end of the episode of sepsis during which the Gram Negative organism was 
isolated will be defined as the day on which the C-reactive protein (CRP) is first < 
10mg/l. CRP is measured daily on sick neonates on the neonatal unit. The cut-off of 
10 days has been selected on the basis of clinical experience. The time to recovery 
for each infant will be assessed as a secondary outcome. 
Important covariates 
These have been selected to capture factors that are associated with poor clinical 
outcomes and which could thus mask the effect of ciprofloxacin on the primary 
outcome. Not all of these covariates will be included in the final model, but in this 
exploratory study we need to collect data in order to find the best summary of the 
situation. 
Gestational age at birth. Justification: infants born at lower gestational ages are more 
likely to die from sepsis and more likely to have co-morbidities. 
Sex. Justification: male infants generally do worse than females. 
Nature of illness at start of ciprofloxacin treatment (septicaemia, meningitis, NEC, 
other). Justification: infants with co-morbidity are more likely to require longer courses 
of ciprofloxacin. 
Illness severity at start of ciprofloxacin treatment (assessed using Neonatal 
Therapeutic Intervention Scoring System – NTISS – see Appendix 1). Justification: 
infants with co-morbidity are more likely to require longer courses of ciprofloxacin. 
Year of blood culture 
Secondary outcomes: 
  
 
 
Demographics (including assessment of relationship between year of isolate and 
MIC) will be done on all eligible isolates and descriptive statistics relating to the clinical 
course of episodes of Gram Negative sepsis will be prepared.  
For each infant: 
Number of days of the inflammatory state (CRP > 9.9 mg/L; platelet count < 100 x 
1012), i.e. time to recovery. 
Number of days of ciprofloxacin treatment 
Prescription of other antibiotics targeted at Gram Negative bacteria 
Persistence of the same organism in blood cultures taken more than 72 hours after 
start of ciprofloxacin treatment 
Recurrence of the same organism in blood cultures after the end of treatment 
Blood culture positive to another Gram Negative organism. 
Survival to discharge 
Condition at discharge: presence of Grade 3/4 IVH or periventricular leucomalacia; 
oxygen requirement at 36 weeks corrected gestational age. 
Inclusion criteria for data collection 
Infants who were in-patients in a Liverpool Neonatal Unit between 1994 and 2008 
who were reported to have Gram Negative isolates by the Microbiology laboratories 
at Royal Liverpool University Hospital. 
Case definition for inclusion in models analysis relating to the primary 
hypothesis 
Blood culture positive for a Gram Negative organsism. 
Methods 
1. Laboratory records will be used to prepare a list of Gram Negative isolates 
obtained from blood cultures performed on infants who were in-patients at a 
Liverpool Neonatal Unit and who have isolates stored in the microbiology 
laboratory 
2. The relevant infant will be identified. Each infant will only contribute once to 
the analysis of the primary hypothesis, using the first episode of Gram 
Negative sepsis if there is more than one episode. 
3. Descriptive data about subsequent episodes of sepsis will also be gathered 
and summarised. 
4. MIC to ciprofloxacin and susceptibility to nalidixic acid will be measured 
using standard methods by Dr Foulkes. 
  
 
 
5. Clinical notes will be obtained and data extracted using a standardised 
proforma by Dr. Thiessen. 
6. A dataset with no identifying data will be prepared for analysis. Each patient 
will be assigned a unique study number and a code-break sheet will be 
retained (linked anonymised data). 
7. Cases that are evaluable for the primary hypothesis will be idendified. 
8. Data analysis will be performed by Dr. Thiessen and Dr. Turner with input 
from Mrs. Hart. 
Sample size 
This is a sample of convenience. 
Whole sample 
Up to 150 cases of Gram Negative septicaemia are available.  
Evaluable cases 
We anticipate that 65 isolates will be eligible. Of these 30 are likely to have died, have 
an episode of sepsis that lasts more than 10 days or be prescribed another antibiotic 
targeted at Gram Negative bacteria. This gives an estimate of 30 neonates who will 
have a clinical cure.  
a) For a logistic regression model the dataset is likely to be sufficient to 
construct a model with 3 covariates 
b) Using standard assumptions about regression models this dataset is likely to 
be sufficient to construct a model with 5 covariates. 
Analytic plan 
Characterisation of the whole sample 
Summary statistics of demographic variables and course of Gram Negative infections. 
Course of Gram negative infections will be assessed using a) C-reactive protein; b) 
platelet count; c) NTISS; d) a selection of markers from NTISS: mechanical 
ventilation, inotrope therapy,  
Univariate correlations between MIC and year of isolate, gestational age at birth, 
number of days CRP > 9.9mg/l. 
Primary analyses 
Aim 1.  
Dependent variable: death / administration of ciprofloxacin for more than 10 days 
Possible independent variables: Year of isolate; MIC; Gestational age at birth; Sex; 
Presence of NEC; illness severity score at start of treatment. 
  
 
 
Statistical approach: Logistic regression 
Aim 2. 
Dependent variable: number of days with CRP > 9.9 mg/l after starting ciprofloxacin. 
Possible independent variables: Year of isolate; MIC; Gestational age at birth; Sex; 
Presence of NEC; illness severity score at start of treatment. 
Regression analysis for all possible independent variables. 
Survival analysis for continuous variables: MIC; Gestational age at birth; illness 
severity score at start of treatment. 
For Aims 1 and 2 we will construct a range of models and make a clinically informed 
decision about which model best addresses our hypothesis about the relationship 
between MIC and the explanatory variables. 
We will explore the relative importance of independent variables using bootstrapping 
to systematically examine which variables contribute to models of samples of the 
dataset. 
Aim 3 (all cases).  
Summary of clinical course for all available cases with point estimate and summary 
of variation for each primary outcome, covariate and secondary outcome. 
These summaries will be tabulated according to subgroups: 
Gestational age at birth: 23 – 25 weeks; 26 – 28 weeks; 29 – 32 weeks; 33 – 36 
weeks; ≥ 37 weeks 
Secondary analyses 
These are designed to summarise the data in order to inform the design of future 
studies. 
Aim 2  Descriptive data of the incidence of cure / failure rates according to different 
definitions of cure /failure 
Sensitivity analysis of regression models using different variables. 
Aim 3  Univariate analysis to explore whether covariates are associated with 
outcomes including: 
Correlation between gestational age and each outcome. 
  
 
 
Ethical issues 
This analysis will not alter the care given to babies included in the study since they 
have either died or been discharged from the Unit. 
This analysis will use data that was routinely collected in clinical practice. Identifiable 
data will be used to construct and clean the dataset but will not be used in the analysis. 
Participants will have been born over a large time range (1994 – 2008) and many will 
have died. 
Accordingly we believe that consent is not necessary, feasible or proportionate. 
We will not seek individual consent. 
Resource issues 
Measurement of MIC will be done by Microbiology trainees using the time and 
resources set aside for research within their training programme. 
Extraction of clinical data will be done by a Neonatal trainee using the time and 
resources set aside for research within her training programme. 
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